

References

1. Abate F, Ambrosio MR, Mundo L, et al. Distinct viral and mutational spectrum of endemic Burkitt lymphoma. *PLoS Pathog.* 2015 Oct;11(10):e1005158. PMID:26468873
2. Abdalla HM, Sakr MA. Predictive factors of local recurrence and survival following primary surgical treatment of phyllodes tumors of the breast. *J Egypt Natl Canc Inst.* 2006 Jun;18(2):125–33. PMID:17496937
3. Abdel-Fatah TM, Powe DG, Hodi Z, et al. High frequency of coexistence of columnar lesions, lobular neoplasia, and low grade tubular carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. *Am J Surg Pathol.* 2007 Mar;31(3):417–26. PMID:17325484
4. Abdel-Fatah TM, Powe DG, Hodi Z, et al. Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. *Am J Surg Pathol.* 2008 Apr;32(4):513–23. PMID:18223478
5. Abraham SC, Reynolds C, Lee JH, et al. Fibromatosis of the breast and mutations involving the APC/beta-catenin pathway. *Hum Pathol.* 2002 Jan;33(1):39–46. PMID:11823972
6. Abrams HL, Spiro R, Goldstein N. Metastases in carcinoma: analysis of 1000 autopsied cases. *Cancer.* 1950 Jan;3(1):74–85. PMID:15405683
7. Acevedo F, Armengol VD, Deng Z, et al. Pathologic findings in reduction mammoplasty specimens: a surrogate for the population prevalence of breast cancer and high-risk lesions. *Breast Cancer Res Treat.* 2019 Jun;173(1):201–7. PMID:30238276
8. Achatz MI, Olivier M, Le Calvez F, et al. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. *Cancer Lett.* 2007 Jan;245(1-2):96–102. PMID:16494995
9. Acs G, Lawton TJ, Rebbeck TR, et al. Differential expression of E-cadherin in tubular and ductal neoplasms of the breast and its biologic and diagnostic implications. *Am J Clin Pathol.* 2001 Jan;115(1):85–98. PMID:11190811
10. Acs G, Simpson JF, Bleiweiss IJ, et al. Microglandular adenosis with transition into stromal cystic carcinoma of the breast. *Am J Surg Pathol.* 2003 Aug;27(8):1052–60. PMID:12883237
11. Adams SJ, Kanthan R. Paget's disease of the male breast in the 21st century: a systematic review. *Breast.* 2016 Oct;29:14–23. PMID:27394005
12. Adank MA, Jonker MA, Kluitj I, et al. CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women. *Am J Med Genet.* 2011 Dec;48(12):860–3. PMID:22058428
13. Adegbola T, Connolly CE, Mortimer G. Small cell neuroendocrine carcinoma of the breast: a report of three cases and review of the literature. *J Clin Pathol.* 2005 Jul;58(7):775–8. PMID:15976350
14. Adem C, Reynolds C, Ingle JN, et al. Primary breast sarcoma: clinicopathologic series from the Mayo Clinic and review of the literature. *Br J Cancer.* 2004 Jul;19(12):237–41. PMID:15187996
15. Adeniran A, Al-Ahmadie H, Mahoney MC, et al. Granular cell tumor of the breast: a series of 17 cases and review of the literature. *Breast J.* 2004 Nov-Dec;10(6):528–31. PMID:15569210
16. Adrada B, Arribas E, Gilcrease M, et al. Invasive micropapillary carcinoma of the breast: mammographic, sonographic, and MRI features. *AJR Am J Roentgenol.* 2009 Jul;193(1):W58–63. PMID:19542384
17. Adrada BE, Miranda RN, Rauch GM, et al. Breast implant-associated anaplastic large cell lymphoma: sensitivity, specificity, and findings of imaging studies in 44 patients. *Breast Cancer Res Treat.* 2014 Aug;147(1):1–14. PMID:25073777
18. Ahmed AA, Heller DS. Malignant adenomyoepithelioma of the breast with malignant proliferation of epithelial and myoepithelial elements: a case report and review of the literature. *Arch Pathol Lab Med.* 2000 Apr;124(4):632–6. PMID:10747327
19. Ahmed S, Thomas G, Ghousaini M, et al. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. *Nat Genet.* 2009 May;41(5):585–90. PMID:19330027
20. Aida Y, Takeuchi E, Shinagawa T, et al. Fine needle aspiration cytology of lipid-secreting carcinoma of the breast. A case report. *Acta Cytol.* 1993 Jul-Aug;37(4):547–51. PMID:8328251
21. Akbulut M, Zekioglu O, Ozdemir N, et al. Fine needle aspiration cytology of mammary carcinoma with choriocarcinomatous features: a report of 2 cases. *Acta Cytol.* 2008 Jan-Feb;52(1):99–104. PMID:18323284
22. Al Sarakbi W, Worku D, Escobar PF, et al. Breast papillomas: current management with a focus on a new diagnostic and therapeutic modality. *Int Semin Surg Oncol.* 2006 Jan 17;3:1. PMID:16417642
23. Al-Abbadia MA, Almasri NM, Al-Quran S, et al. Cytokeratin and epithelial membrane antigen expression in angiosarcomas: an immunohistochemical study of 33 cases. *Arch Pathol Lab Med.* 2007 Feb;131(2):288–92. PMID:17284115
24. Aladily TN, Medeiros LJ, Amin MB, et al. Anaplastic large cell lymphoma associated with breast implants: a report of 13 cases. *Am J Surg Pathol.* 2012 Jul;36(7):1000–8. PMID:22613996
25. Al-Ahmadie H, Hasselgren PO, Yassin R, et al. Colocalized granular cell tumor and infiltrating ductal carcinoma of the breast. *Arch Pathol Lab Med.* 2002 Jun;126(6):731–3. PMID:12033967
26. Allassiri AH, Ali RH, Shen Y, et al. ETV6-NTRK3 is expressed in a subset of ALK-negative inflammatory myofibroblastic tumors. *Am J Surg Pathol.* 2016 Aug;40(8):1051–61. PMID:27259007
27. Alawad AA. Multiple parenchymal leiomyomas of the breast in a Sudanese female. *Breast Dis.* 2014 Jan 1;34(4):165–7. PMID:24898199
28. Albonico G, Querzoli P, Ferretti S, et al. Biological profile of *in situ* breast cancer investigated by immunohistochemical technique. *Cancer Detect Prev.* 1998;22(4):313–8. PMID:9674874
29. Alenda C, Aranda FI, Segui FJ, et al. Secretory carcinoma of the male breast: correlation of aspiration cytology and pathology. *Diagn Cytopathol.* 2005 Jan;32(1):47–50. PMID:15584046
30. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. *Nature.* 2013 Aug 22;500(7463):415–21. PMID:23945592
31. Ali RH, Hayes MM. Combined epithelial-myoepithelial lesions of the breast. *Surg Pathol Clin.* 2012 Sep;5(3):661–99. PMID:26838284
32. Ali RH, Taraboanta C, Mohammad T, et al. Metastatic non-small cell lung carcinoma a mimic of primary breast carcinoma-case series and literature review. *Virchows Arch.* 2018 May;472(5):771–7. PMID:29105026
33. Ali SN, Jayasena CN, Sam AH. Which patients with gynaecomastia require more detailed investigation? *Clin Endocrinol (Oxf).* 2018 Mar;88(3):360–3. PMID:29193251
34. Ali-Fehmi R, Carolin K, Wallis T, et al. Clinicopathologic analysis of breast lesions associated with multiple papillomas. *Hum Pathol.* 2003 Mar;34(3):234–9. PMID:12673557
35. Alkaied H, Harris K, Brenner A, et al. Does hormonal therapy have a therapeutic role in metastatic primary small cell neuroendocrine breast carcinoma? Case report and literature review. *Clin Breast Cancer.* 2012 Jun;12(3):226–30. PMID:22424945
36. Allen S, Levine EA, Lesko N, et al. Is excisional biopsy and chemoprevention warranted in patients with atypical lobular hyperplasia on core biopsy? *Am Surg.* 2015 Sep;81(9):876–8. PMID:26350664
37. Allison KH. Ancillary prognostic and predictive testing in breast cancer: focus on discordant, unusual, and borderline results. *Surg Pathol Clin.* 2018 Mar;11(1):147–76. PMID:29413654
38. Allison KH, Abraham LA, Weaver DL, et al. Trends in breast biopsy pathology diagnoses among women undergoing mammography in the United States: a report from the Breast Cancer Surveillance Consortium. *Cancer.* 2015 May 1;121(9):1369–78. PMID:25603785
39. Allison KH, Eby PR, Kohr J, et al. Atypical ductal hyperplasia on vacuum-assisted breast biopsy: suspicion for ductal carcinoma *in situ* can stratify patients at high risk for upgrade. *Hum Pathol.* 2011 Jan;42(1):41–50. PMID:20970167
40. Allison KH, Mohsin SK, Dabbs DJ. Gross examination of breast specimens. In: Dabbs DJ, editor. *Breast pathology.* 2nd ed. Philadelphia (PA): Elsevier; 2017. pp. 76–102.
41. Allison KH, Reisch LM, Carney PA, et al. Understanding diagnostic variability in breast pathology: lessons learned from an expert consensus review panel. *Histopathology.* 2014 Aug;65(2):240–51. PMID:24511905
42. Allison KH, Rendi MH, Peacock S, et al. Histological features associated with diagnostic agreement in atypical ductal hyperplasia of the breast: illustrative cases from the B-Path study. *Histopathology.* 2016 Dec;69(6):1028–46. PMID:27398812
43. Allred DC, Anderson SJ, Paik S, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma *in situ*: a study based on NSABP protocol B-24. *J Clin Oncol.* 2012 Apr 20;30(12):1268–73. PMID:22393101
44. Allred DC, Wu Y, Mao S, et al. Ductal carcinoma *in situ* and the emergence of diversity during breast cancer evolution. *Clin Cancer Res.* 2008 Jan 15;14(2):370–8. PMID:18223211
45. Alman BA, Li C, Pajerski ME, et al. Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatosis (desmoid tumors). *Am J Pathol.* 1997 Aug;151(2):329–34. PMID:9250146
46. Alsadi A, Lin D, Alnajar H, et al. Hematologic malignancies discovered on investigation of breast abnormalities. *South Med J.* 2017 Oct;110(10):614–20. PMID:28973700
47. Alsadoun N, MacGrogan G, Truntzer C, et al. Solid papillary carcinoma with reverse polarity of the breast harbors specific morphologic, immunohistochemical and molecular profile in comparison with other benign or malignant papillary lesions of the breast: a comparative study of 9 additional cases. *Mod Pathol.* 2018 Sep;31(9):1367–80. PMID:29785016
48. Alsaedi M, Shoimer I, Kurwa HA. Basal cell carcinoma of the nipple-areola complex. *Dermatol Surg.* 2017 Jan;43(1):142–6. PMID:27571043
49. Alsharif S, Daghistani R, Kamberoglu EA, et al. Mammographic, sonographic and MR imaging features of invasive micropapillary breast cancer. *Eur J Radiol.* 2014 Aug;83(8):1375–80. PMID:24913934
50. AlSharif S, Tremblay F, Omeroglu A, et al. Infiltrating syringomatous adenoma of the nipple: sonographic and mammographic features with pathologic correlation. *J Clin Ultrasound.* 2014 Sep;42(7):427–9. PMID:24648330
51. Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. *J Clin Oncol.* 2012 Jul 20;30(21):2654–63. PMID:22711857
52. Alvarado-Cabrero I, Picón Coronel G, Valencia Cedillo R, et al. Florid lobular intraepithelial neoplasia with signet ring cells, central necrosis and calcifications: a clinicopathological and immunohistochemical analysis of ten cases associated with invasive lobular carcinoma. *Arch Med Res.* 2010 Aug;41(6):436–41. PMID:21044747
53. Alvarenga CA, Paravidino PI, Alvarenga M, et al. Reappraisal of immunohistochemical profiling of special histological types of breast carcinomas: a study of 121 cases of eight different subtypes. *J Clin Pathol.* 2012 Dec;65(12):1066–71. PMID:22944625
54. Alvarez RH, Gong Y, Ueno NT, et al. Metastasis in the breast mimicking inflammatory breast cancer. *J Clin Oncol.* 2012 Aug 1;30(22):e202–6. PMID:22734030
55. Amadou A, Waddington Achatz MI, Hainaut P. Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome. *Curr Opin Oncol.* 2018 Jan;30(1):23–9. PMID:29076966
56. Amary MF, Pauwels P, Meulemans E, et al. Detection of beta-catenin mutations in paraffin-embedded sporadic desmoid-type fibromatosis by mutation-specific restriction enzyme

- digestion (MSRED): an ancillary diagnostic tool. *Am J Surg Pathol.* 2007 Sep;31(9):1299–309. PMID:17721184
57. Amato T, Abate F, Piccaluga P, et al. Clonality analysis of immunoglobulin gene rearrangement by next-generation sequencing in endemic Burkitt lymphoma suggests antigen drive activation of BCR as opposed to sporadic Burkitt lymphoma. *Am J Clin Pathol.* 2016 Jan;145(1):116–27. PMID:26712879
58. Ambrosio MR, Lazzi S, Bello GL, et al. MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients. *Haematologica.* 2019 Jan;104(1):e25–8. PMID:29954940
59. Ambrosio MR, Navari M, Di Lisio L, et al. The Epstein Barr-encoded BART-6-3p microRNA affects regulation of cell growth and immune response in Burkitt lymphoma. *Infect Agent Cancer.* 2014 Apr 14;9:12. PMID:24731550
60. Ambrosio MR, Piccaluga PP, Ponzoni M, et al. The alteration of lipid metabolism in Burkitt lymphoma identifies a novel marker: adipophilin. *PLoS One.* 2012;7(8):e44315. PMID:22952953
- 60A. American Society of Clinical Oncology, College of American Pathologists. Estrogen and progesterone receptor testing in breast cancer: American Society of Clinical Oncology / College of American Pathologists Clinical Practice Guideline Update. Forthcoming 2019. Available from: <https://www.cap.org/protocols-and-guidelines/cap-guidelines/current-cap-guidelines/guideline-recommendations-for-immunohistochemical-testing-of-estrogen-and-progesterone-receptors-in-breast-cancer>.
61. Amin MB, Edge S, Greene F, et al., editors. AJCC cancer staging manual. 8th ed. New York (NY): Springer; 2017.
62. Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. *CA Cancer J Clin.* 2017 Mar;67(2):93–9. PMID:28094848
63. Andersen JA. Lobular carcinoma in situ of the breast. An approach to rational treatment. *Cancer.* 1977 Jun;39(6):2597–602. PMID:872058
64. Anderson C, Ricci A Jr, Pedersen CA, et al. Immunocytochemical analysis of estrogen and progesterone receptors in benign stromal lesions of the breast. Evidence for hormonal etiology in pseudoangiomatous hyperplasia of mammary stroma. *Am J Surg Pathol.* 1991 Feb;15(2):145–9. PMID:1989462
65. Anderson JM, Ariga R, Govil H, et al. Assessment of Her-2/Neu status by immunohistochemistry and fluorescence in situ hybridization in mammary Paget disease and underlying carcinoma. *Appl Immunohistochem Mol Morphol.* 2003 Jun;11(2):120–4. PMID:12777994
66. Anderson KN, Schwab RB, Martinez ME. Reproductive risk factors and breast cancer subtypes: a review of the literature. *Breast Cancer Res Treat.* 2014 Feb;144(1):1–10. PMID:24477977
67. Anderson WF, Chu KC, Chang S, et al. Comparison of age-specific incidence rate patterns for different histopathologic types of breast carcinoma. *Cancer Epidemiol Biomarkers Prev.* 2004 Jul;13(7):1128–35. PMID:15247123
68. Anderson WF, Rosenberg PS, Prat A, et al. How many etiological subtypes of breast cancer: two, three, four, or more? *J Natl Cancer Inst.* 2014 Aug 12;106(8):dju165. PMID:25118203
69. Andrade VP, Morrogh M, Qin LX, et al. Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasion. *Mol Oncol.* 2015 Apr;9(4):772–82. PMID:25601220
- 69A. André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. *N Engl J Med.* 2019 May 16;380(20):1929–40. PMID:31091374
70. Andreasen S, Tan Q, Agander TK, et al. Adenoid cystic carcinomas of the salivary gland, lacrimal gland, and breast are morphologically and genetically similar but have distinct microRNA expression profiles. *Mod Pathol.* 2018 Aug;31(8):1211–25. PMID:29467480
71. Ansquer Y, Delaney S, Santulli P, et al. Risk of invasive breast cancer after lobular intraepithelial neoplasia: review of the literature. *Eur J Surg Oncol.* 2010 Jul;36(7):604–9. PMID:20541352
72. Antonescu C. Malignant vascular tumors—an update. *Mod Pathol.* 2014 Jan;27 Suppl 1:S30–8. PMID:24384851
73. Antonescu CR, Suurmeijer AJ, Zhang L, et al. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement. *Am J Surg Pathol.* 2015 Jul;39(7):957–67. PMID:25723109
74. Antonescu CR, Yoshida A, Guo T, et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. *Cancer Res.* 2009 Sep 15;69(18):7175–9. PMID:19723655
75. Antoniou AC, Casadei S, Heikkinen T, et al. Breast-cancer risk in families with mutations in PALB2. *N Engl J Med.* 2014 Aug 7;371(6):497–506. PMID:25099575
76. Antoniou AC, Wang X, Fredericksen ZS, et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nat Genet.* 2010 Oct;42(10):885–92. PMID:20852631
77. Apostolou P, Papasotiriou I. Current perspectives on CHEK2 mutations in breast cancer. *Breast Cancer (Dove Med Press).* 2017 May 12;9:331–5. PMID:28553140
78. Arber DA, Simpson JF, Weiss LM, et al. Non-Hodgkin's lymphoma involving the breast. *Am J Surg Pathol.* 1994 Mar;18(3):288–95. PMID:8116797
79. Arce C, Cortes-Padilla D, Huntsman DG, et al. Secretory carcinoma of the breast containing the ETV6-NTRK3 fusion gene in a male: case report and review of the literature. *World J Surg Oncol.* 2005 Jun 17;3:35. PMID:15963235
80. Aroner SA, Collins LC, Schnitt SJ, et al. Columnar cell lesions and subsequent breast cancer risk: a nested case-control study. *Breast Cancer Res.* 2010;12(4):R61. PMID:20691043
81. Arpino G, Allred DC, Mohsin SK, et al. Lobular neoplasia on core-needle biopsy—clinical significance. *Cancer.* 2004 Jul 15;101(2):242–50. PMID:15241819
82. Arpino G, Bardou VJ, Clark GM, et al. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. *Breast Cancer Res.* 2004;6(3):R149–56. PMID:15084238
83. Arpino G, Clark GM, Mohsin S, et al. Adenoid cystic carcinoma of the breast: molecular markers, treatment, and clinical outcome. *Cancer.* 2002 Apr 15;94(8):2119–27. PMID:12001107
84. Arslan A, Güldoğan N, Kapucuoglu N, et al. A rare case of pleomorphic adenoma of the breast: ultrasonography and pathology findings. *Breast J.* 2018 Nov;24(6):1069–70. PMID:30240069
85. Arvey A, Ojesina AI, Pedamallu CS, et al. The tumor virus landscape of AIDS-related lymphomas. *Blood.* 2015 May 14;125(20):e14–22. PMID:25827832
86. Ashikari R, Huvo AG, Urban JA, et al. Infiltrating lobular carcinoma of the breast. *Cancer.* 1973 Jan;31(1):110–6. PMID:4345605
87. Ashikari R, Park K, Huvo AG, et al. Paget's disease of the breast. *Cancer.* 1970 Sep;26(3):680–5. PMID:4318756
88. Ascoli S, Marucci G, Ficarra G, et al. Polymorphous adenocarcinoma of the breast. Report of three cases. *Virchows Arch.* 2006 Jan;448(1):29–34. PMID:16220292
89. Asirvatham JR, Falcone MM, Kleer CG. Atypical apocrine adenosis: diagnostic challenges and pitfalls. *Arch Pathol Lab Med.* 2016 Oct;140(10):1045–51. PMID:27684975
90. Astvatsaturyan K, Yue Y, Walts AE, et al. Androgen receptor positive triple negative breast cancer: clinicopathologic, prognostic, and predictive features. *PLoS One.* 2018 Jun 8;13(6):e0197827. PMID:29883487
91. Atkins KA, Cohen MA, Nicholson B, et al. Atypical lobular hyperplasia and lobular carcinoma in situ at core breast biopsy: use of careful radiologic-pathologic correlation to recommend excision or observation. *Radiology.* 2013 Nov;269(2):340–7. PMID:23901123
92. Aubelé MM, Cummings MC, Mattis AE, et al. Accumulation of chromosomal imbalances from intraductal proliferative lesions to adjacent *in situ* and invasive ductal breast cancer. *Diagn Mol Pathol.* 2000 Mar;9(1):14–9. PMID:10718208
93. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. *Lancet.* 2010 Jul 24;376(9737):245–51. PMID:20609468
94. Auger M, Hüthner I. Fine-needle aspiration cytology of pleomorphic lobular carcinoma of the breast. Comparison with the classic type. *Cancer.* 1997 Feb 25;81(1):29–32. PMID:9100538
95. Aulmann S, Elsawaf Z, Penzel R, et al. Invasive tubular carcinoma of the breast frequently is clonally related to flat epithelial atypia and low-grade ductal carcinoma *in situ*. *Am J Surg Pathol.* 2009 Nov;33(11):1646–53. PMID:19675453
96. Austin RM, Dupree WB. Liposarcoma of the breast: a clinicopathologic study of 20 cases. *Hum Pathol.* 1986 Sep;17(9):906–13. PMID:3019868
- 96A. Avigdor BE, Beierl K, Gocke CD, et al. Whole-exome sequencing of metaplastic breast carcinoma indicates monoclonality with associated ductal carcinoma component. *Clin Cancer Res.* 2017 Aug 15;23(16):4875–884. PMID:28424200
97. Azzopardi JG, Eusebi V. Melanocyte colonization and pigmentation of breast carcinoma. *Histopathology.* 1977 Jan;1(1):21–30. PMID:615831
98. Azzopardi JG, Muretto P, Goddeeris P, et al. ‘Carcinoid’ tumours of the breast: the morphological spectrum of argyrophil carcinomas. *Histopathology.* 1982 Sep;6(5):549–69. PMID:6183185
99. Bacchi CE, Wludarski SC, Ambaye AB, et al. Metastatic melanoma presenting as an isolated breast tumor: a study of 20 cases with emphasis on several primary mimickers. *Arch Pathol Lab Med.* 2013 Jan;137(1):41–9. PMID:23276173
100. Bacchi CE, Wludarski SC, Lamovic J, et al. Lipophyllodes of the breast. A reappraisal of fat-rich tumors of the breast based on 22 cases integrated by immunohistochemical study, molecular pathology insights, and clinical follow-up. *Ann Diagn Pathol.* 2016 Apr;21:1–6. PMID:27040923
101. Bachmeier BE, Nerlich AG, Mirisola V, et al. Lineage infidelity and expression of melanocytic markers in human breast cancer. *Int J Oncol.* 2008 Nov;33(5):1171–4. PMID:18949364
102. Baddoura FK, Judd RL. Apocrine carcinoma of the breast: report of a case with investigation of lectin binding patterns in apocrine lesions. *Mod Pathol.* 1990 May;3(5):393–6. PMID:2362943
103. Badve S, Sloane JP. Pseudoglandular hyperplasia of male breast. *Histopathology.* 1995 May;26(5):463–6. PMID:7547574
104. Badyal RK, Bal A, Das A, et al. Micropapillary carcinoma of the breast: immunohistochemical analysis and role of adhesion molecules (CD44 and E-cadherin) in nodal metastasis. *Appl Immunohistochem Mol Morphol.* 2016 Mar;24(3):240–5. PMID:26200840
105. Bagaria SP, Shamoni J, Kimball J, et al. The florid subtype of lobular carcinoma *in situ*: marker or precursor for lobular carcinoma? *Ann Surg Oncol.* 2001 Jul;18(7):1845–51. PMID:12187281
106. Bailer JC 3rd. Diagnostic reporting of cancer incidence. *J Natl Inst.* 1998 Jun 3;90(11):863–4. PMID:9610000
107. Baird AD, Higgins RJ, Hume E. Cyclosporin A and multiple fibroadenomas of the breast. *Br J Surg.* 1996 Dec;83(12):1705–7. PMID:9038560
108. Baker GM, Schnitt SJ. Vasculitis of the breast. *Semin Diagn Pathol.* 1996 Sep;13(4):410–9. PMID:8878174
109. Bal A, Joshi K, Sharma S, et al. Prognostic significance of mucinous pattern in pure mucinous carcinoma of the breast. *Int J Surg Pathol.* 2008 Jun;16(3):233–7. PMID:18387988
110. Balasubramanian I, Fleming DA, Cooper MA, et al. Meta-analysis of the accuracy of ultrasound-guided fine-needle aspiration and core needle biopsy for axillary lymph node metastasis. *Br J Surg.* 2002 Sep;105(10):1244–53. PMID:12372220
111. Balleine RL, Murali R, Elston CW, et al. Histopathological features of breast cancer carriers of ATM gene variants. *Hum Pathol.* 2006 Nov;49(5):523–32. PMID:17104230
112. Bamps S, Oyen T, Legius E, et al. Multiple granular cell tumors in a patient with Noonan syndrome. *Eur J Pediatr.* 2006 Jun;165(3):257–9. PMID:16729571
113. Bane AL, Tjan S, Parker BL, et al. Invasive lobular carcinoma: its grade. *Mod Pathol.* 2005 May;18(5):560–5. PMID:15605082
114. Banev SG, Filipovski VA. Classification of the breast—case report and a review of the literature. *Breast.* 2006 Jun;13(3):233–7. PMID:16131470
115. Banneau G, Guedj M, Miquel S, et al. Molecular apocrine differentiation: a common feature of breast carcinomas with germline PTEN mutations. *Breast Cancer Res.* 2010;12(4):R63. PMID:20771382
116. Baraban E, Zhang PJ, Corbin KE, et al. MYB rearrangement and immunohistochemical expression in adenocarcinomas of the breast: a comparison with cystic carcinomas. *Histopathology.* 2004 Dec;45(6):897–903. PMID:15576000
117. Barbashina V, Corbin KE, et al. Mucinous microcarcinoma of the breast: an aggressive tumor compared to conventional pure mucinous carcinoma. *Hum Pathol.* 2013 Aug;44(8):1443–50. PMID:23517923
118. Barber M, Murrell A, et al. Mechanisms and sequelae of silencing in hereditary breast cancer. *J Pathol.* 2008 Nov;215(5):611–20. PMID:18803530

- PMID:18788075
 119. Barbosa ML, Ribeiro EM, Silva GF, et al. Cytogenetic findings in phyllodes tumor and fibroadenomas of the breast. *Cancer Genet Cytofogenet*. 2004 Oct 15;154(2):156–9. PMID:15474152
 120. Barco I, Vidal M, Fraile M, et al. MOHS micrographic surgery for treating erosive adenoma of the nipple: a case report and review of the literature. *Int J Dermatol*. 2017 Dec;56(12):1451–4. PMID:28960299
 121. Barco Nebreda I, Vidal MC, Fraile M, et al. Lactating adenoma of the breast. *J Hum Lact*. 2016 Aug;32(3):559–62. PMID:27197575
 122. Bareche Y, Venet D, Ignatiadis M, et al. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. *Ann Oncol*. 2018 Apr 29;29(4):895–902. PMID:29365031
 123. Barreta Z, Mocellin S, Goldin E, et al. Effect of BRCA germline mutations on breast cancer prognosis: a systematic review and meta-analysis. *Medicine (Baltimore)*. 2016 Oct;95(40):e4975. PMID:27749552
 124. Bari VB, Bholay SU, Sane KC. Invasive tubular carcinoma of the breast with extracellular mucin - a new rare variant. *J Clin Diagn Res*. 2015 Apr;9(4):ED05–06. PMID:26023557
 125. Barkley CR, Ligibel JA, Wong JS, et al. Mucinous breast carcinoma: a large contemporary series. *Am J Surg*. 2008 Oct;196(4):549–51. PMID:18809061
 126. Barnard ME, Boeke CE, Tamimi RM. Established breast cancer risk factors and of intrinsic tumor subtypes. *Biochim Biophys Acta*. 2015 Aug;1856(1):73–85. PMID:26071880
 127. Barth TF, Müller S, Pawlita M, et al. Homogeneous immunophenotype and paucity of secondary genomic aberrations are distinctive features of endemic but not of sporadic Burkitt's lymphoma and diffuse large B-cell lymphoma with MYC rearrangement. *J Pathol*. 2004 Aug;203(4):940–5. PMID:15258997
 128. Bartuma H, Hallor KH, Panagopoulos I, et al. Assessment of the clinical and molecular impact of different cytogenetic subgroups in a series of 272 lipomas with abnormal karyotype. *Genes Chromosomes Cancer*. 2007 Jun;46(6):594–606. PMID:17370328
 129. Basbug M, Akbulut S, Arikanoğlu Z, et al. Mucoepidermoid carcinoma in a breast affected by sun scars: comprehensive literature review and case report. *Breast Care (Basel)*. 2011 Aug;6(4):293–7. PMID:22135628
 130. Basham VM, Lipscombe JM, Ward J, et al. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. *Breast Cancer Res*. 2002;4(1):R2. PMID:11879560
 131. Bataillon G, Fuhrmann L, Girard E, et al. High rate of PIK3CA mutations but no TP53 mutations in low-grade adenosquamous carcinoma of the breast. *Histopathology*. 2018 Aug;73(2):273–83. PMID:29537649
 132. Battistella M, Cribier B, Feugeas JP, et al. Tumour invasion and other invasive features in basal cell tumours of the skin: a multicentre study of 119 cases. *J Clin Pathol*. 2014 Jun;67(1):19–25. PMID:23908453
 133. Bauermeister DE, Hall MH. Specimen radiography—a mandatory adjunct to mammography. *Am J Clin Pathol*. 1973 Jun;59(6):782–9. PMID:4709078
 134. Bean GR, Krings G, Otis CN, et al. CTC1-MAML2 fusion in mucoepidermoid carcinoma of the breast. *Histopathology*. 2019 Feb;74(3):463–73. PMID:30380176
 135. Beck AH, Lee CH, Witten DM, et al. Discovery of molecular subtypes in myosarcoma through integrative molecular profiling. *Oncogene*. 2010 Feb 11;29(6):845–54. PMID:19901961
 136. Beert E, Brems H, Daniëls B, et al. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. *Genes Chromosomes Cancer*. 2011 Dec;50(12):1021–32. PMID:21987445
 137. Begg CB, Ostrovnaya I, Geyer FC, et al. Contralateral breast cancers: independent cancers or metastases? *Int J Cancer*. 2018 Jan 15;142(2):347–56. PMID:28921573
 138. Beguinot M, Dauplat MM, Kwiatkowski F, et al. Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ. *BMC Cancer*. 2018 Feb 3;18(1):129. PMID:29394917
 139. Behjati S, Tarpey PS, Sheldon H, et al. Recurrent PTEN and PLCG1 mutations in angiosarcoma. *Nat Genet*. 2014 Apr;46(4):376–9. PMID:24633157
 140. Benusiglio PR, Malka D, Rouleau E, et al. CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study. *J Med Genet*. 2013 Jul;50(7):486–9. PMID:23709761
 141. Ben-Yehuda A, Steiner-Saltz D, Libson E, et al. Plasmacytoma of the breast. Unusual initial presentation of myeloma: report of two cases and review of the literature. *Blut*. 1989 Mar;58(3):169–70. PMID:2649190
 142. Berg AN, Soma L, Clark BZ, et al. Evaluating breast lymphoplasmacytic infiltrates: a multiparameter immunohistochemical study, including assessment of IgG4. *Hum Pathol*. 2015 Aug;46(8):1162–70. PMID:26026200
 143. Berg JC, Scheithauer BW, Spinner RJ, et al. Plexiform schwannoma: a clinicopathologic overview with emphasis on the head and neck region. *Hum Pathol*. 2008 May;39(5):633–40. PMID:18439936
 144. Berg JW, Hutter RV. Breast cancer. *Cancer*. 1995 Jan 1;75(1) Suppl:257–69. PMID:8001000
 145. Berg WA, Mrose HE, Ioffe OB. Atypical lobular hyperplasia or lobular carcinoma in situ at core-needle breast biopsy. *Radiology*. 2001 Feb;218(2):503–9. PMID:11161169
 146. Berna JD, Arcas I, Ballester A, et al. Adenomyoepithelioma of the breast in a male. *AJR Am J Roentgenol*. 1997 Sep;169(3):917–8. PMID:9275934
 147. Bernardello F, Caneva A, Bresaola E, et al. Breast solitary schwannoma: fine-needle aspiration biopsy and immunocytochemical analysis. *Diagn Cytopathol*. 1994;10(3):221–3. PMID:8050328
 148. Bernstein JL, Haile RW, Stovall M, et al. Radiation exposure, the ATM gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study. *J Natl Cancer Inst*. 2010 Apr 7;102(7):475–83. PMID:20305132
 149. Bernstein JL, Teraoka S, Southey MC, et al. Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry. *Hum Mutat*. 2006 Nov;27(11):1122–8. PMID:16958054
 150. Bernstein JL, WE CARE Study Collaborative Group, Concannon P. ATM, radiation, and the risk of second primary breast cancer. *Int J Radiat Biol*. 2017 Oct;93(10):1121–7. PMID:28627265
 151. Bernstein L, Deapen D, Ross RK. The descriptive epidemiology of malignant cystosarcoma phyllodes tumors of the breast. *Cancer*. 1993 May 15;71(10):3020–4. PMID:8387873
 152. Bertani E, Testori A, Chiappa A, et al. Recurrence and prognostic factors in patients with aggressive fibromatosis. The role of radical surgery and its limitations. *World J Surg Oncol*. 2012 Sep 10;10:184. PMID:22963172
 153. Berx G, Van Roy F. The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. *Breast Cancer Res*. 2001;3(5):289–93. PMID:11597316
 154. Beumer IJ, Persoon M, Witteven A, et al. Prognostic value of MammaPrint® in invasive lobular breast cancer. *Biomark Insights*. 2016 Dec 11;11:139–46. PMID:27980389
 155. Beute BJ, Kalisher L, Hutter RV. Lobular carcinoma in situ of the breast: clinical, pathologic, and mammographic features. *AJR Am J Roentgenol*. 1991 Aug;157(2):257–65. PMID:1853802
 156. Bezić J, Forempoher G, Poljicanin A, et al. Apocrine adenoma of the breast coexistent with invasive carcinoma. *Pathol Res Pract*. 2007;203(11):809–12. PMID:17936522
 157. Bezić J, Karaman I, Šundov D. Combined fibroadenoma and tubular adenoma of the breast: rare presentation that confirms common histogenesis. *Breast J*. 2015 May-Jun;21(3):309–11. PMID:25775939
 158. Bhagavan BS, Patchefsky A, Koss LG. Florid subareolar duct papillomatosis (nipple adenoma) and mammary carcinoma: report of three cases. *Hum Pathol*. 1973 Jun;4(2):289–95. PMID:4350340
 159. Bhargava R, Dabbs DJ. Use of immunohistochemistry in diagnosis of breast epithelial lesions. *Adv Anat Pathol*. 2007 Mar;14(2):93–107. PMID:17471116
 160. Bhargava R, Esposito NN, Dabbs DJ. Intracystic papillary carcinomas of the breast are more similar to in situ carcinomas than to invasive carcinoma. *Am J Surg Pathol*. 2011 May;35(5):778–9, author reply 779–81. PMID:21451361
 161. Bhargava R, Florea AV, Pelius M, et al. Breast tumor resembling tall cell variant of papillary thyroid carcinoma: a solid papillary neoplasm with characteristic immunohistochemical profile and few recurrent mutations. *Am J Clin Pathol*. 2017 Apr 1;147(4):399–410. PMID:28375433
 162. Bhasin SD, Vyas JJ. Angiomatosis of the breast—a case report with review of literature. *Indian J Pathol Microbiol*. 1991 Oct;34(4):296–8. PMID:1818036
 163. Bhattacharya B, Dilworth HP, Iacobuzio-Donahue C, et al. Nuclear beta-catenin expression distinguishes deep fibromatosis from other benign and malignant fibroblastic and myofibroblastic lesions. *Am J Surg Pathol*. 2005 May;29(5):653–9. PMID:15832090
 164. Bhattachary S, Kapila K, Verma K. Phyllodes tumor of the breast. A cytohistologic study of 80 cases. *Acta Cytol*. 2000 Sep-Oct;44(5):790–6. PMID:11015981
 165. Bhutani N, Kajal P, Singla S. Adenoid cystic carcinoma of the breast: experience at a tertiary care centre of Northern India. *Int J Surg Case Rep*. 2018;51:204–9. PMID:30189404
 166. Bianchi S, Vezzosi V. Microinvasive carcinoma of the breast. *Pathol Oncol Res*. 2008 Jun;14(2):105–11. PMID:18493870
 167. Bianchini L, Birtwistle L, Saâda E, et al. Identification of PPAP2B as a novel recurrent translocation partner gene of HMG2A in lipomas. *Genes Chromosomes Cancer*. 2013 Jun;52(6):580–90. PMID:23508853
 168. Bibbo M, Hanau C. Cytopathology of the breast. In: Tavassoli FA, editor. *Pathology of the breast*. 2nd ed. Stamford (CT): Appleton & Lange; 1999. pp. 82–3.
 169. Biesma HD, Schouten PC, Lacle MM, et al. Copy number profiling by array comparative genomic hybridization identifies frequently occurring BRCA2-like male breast cancer. *Genes Chromosomes Cancer*. 2015 Dec;54(12):734–44. PMID:26355282
 170. Bijkler N, Peterse JL, Duchateau L, et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. *J Clin Oncol*. 2001 Apr 15;19(8):2263–71. PMID:11304780
 171. Billings SD, McKenney JK, Folpe AL, et al. Cutaneous angiosarcoma following breast-conserving surgery and radiation: an analysis of 27 cases. *Am J Surg Pathol*. 2004 Jun;28(6):781–8. PMID:15166670
 172. Binh MB, Sastre-Garau X, Guillou L, et al. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. *Am J Surg Pathol*. 2005 Oct;29(10):1340–7. PMID:16160477
 173. Binokay F, Balal M, Demir E, et al. Risk of developing fibroadenoma with the use of cyclosporine A in renal transplant recipients. *Ren Fail*. 2005;27(6):721–5. PMID:16350824
 174. Birch JM, Alston RD, McNally RJ, et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. *Oncogene*. 2001 Aug 2;20(34):4621–8. PMID:11498785
 175. Biserni GB, Di Oto E, Moskovszky LE, et al. Preferential expression of NY-BR-1 and GATA-3 in male breast cancer. *J Cancer Res Clin Oncol*. 2018 Feb;144(2):199–204. PMID:29116378
 176. Bishop JA, Taube JM, Su A, et al. Secretory carcinoma of the skin harboring ETV6 gene fusions: a cutaneous analogue to secretory carcinomas of the breast and salivary glands. *Am J Surg Pathol*. 2017 Jan;41(1):62–6. PMID:27631515
 177. Black J, Metcalf C, Wylie EJ. Ultrasonography of breast hamartomas. *Australas Radiol*. 1996 Nov;40(4):412–5. PMID:8996902
 178. Blair SL, Emerson DK, Kulkarni S, et al. Breast surgeon's survey: no consensus for surgical treatment of pleomorphic lobular carcinoma in situ. *Breast J*. 2013 Jan-Feb;19(1):116–8. PMID:23231019
 179. Blombery P, Thompson ER, Jones K, et al. Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma and anaplastic large cell lymphoma. *Haematologica*. 2016 Sep;101(9):e387–90. PMID:27198716
 180. Bodian CA, Perzin KH, Lattes R. Lobular neoplasia. Long term risk of breast cancer and relation to other factors. *Cancer*. 1996 Sep 1;78(5):1024–34. PMID:8780540
 181. Bodian CA, Perzin KH, Lattes R, et al. Reproducibility and validity of pathologic classifications of benign breast disease and implications for clinical applications. *Cancer*. 1993 Jun 15;71(12):3908–13. PMID:8508356
 182. Boecker W, Buerger H, Schmitz K, et al. Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high-molecular-weight cytokeratin expression patterns. *J Pathol*. 2001 Nov;195(4):415–21. PMID:11745672
 183. Boecker W, Buerger H. Usual and atypical ductal hyperplasia—members of the same family? *Diagn Histopathol (Oxf)*. 2004 Jun;10(3):175–82. doi:10.1016/j.

cdip.2004.03.010.

184. Boecker W, Junkers T, Reusch M, et al. Origin and differentiation of breast nipple syringoma. *Sci Rep.* 2012;2:226. PMID:22355740
185. Boecker W, Moll R, Dervan P, et al. Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma *in situ*. *J Pathol.* 2002 Dec;198(4):458–67. PMID:12434415
186. Boecker W, Stenman G, Loening T, et al. Differentiation and histogenesis of syringomatous tumour of the nipple and low-grade adenosquamous carcinoma: evidence for a common origin. *Histopathology.* 2014 Jul;65(1):9–23. PMID:24382117
187. Boelens MC, Nethe M, Klarenbeek S, et al. PTEN loss in E-cadherin-deficient mouse mammary epithelial cells rescues apoptosis and results in development of classical invasive lobular carcinoma. *Cell Rep.* 2016 Aug 23;16(8):2087–101. PMID:27524621
188. Bogina G, Munari E, Brunelli M, et al. Neuroendocrine differentiation in breast carcinoma: clinicopathological features and outcome. *Histopathology.* 2016 Feb;68(3):422–32. PMID:26114478
189. Bojesen SE, Pooley KA, Johnatty SE, et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nat Genet.* 2013 Apr;45(4):371–84, e1–2. PMID:23537531
190. Boldt V, Stacher E, Halbwedl I, et al. Positioning of necrotic lobular intraepithelial neoplasias (LIN, grade 3) within the sequence of breast carcinoma progression. *Genes Chromosomes Cancer.* 2010 May;49(5):463–70. PMID:20155841
191. Bombonati A, Lerwill MF. Metastases to and from the breast. *Surg Pathol Clin.* 2012 Sep;5(3):719–47. PMID:26838286
192. Bombonati A, Sgroi DC. The molecular pathology of breast cancer progression. *J Pathol.* 2011 Jan;223(2):307–17. PMID:21125683
193. Bomeisl PE, Thompson CL, Harris LN, et al. Comparison of Oncotype DX recurrence score by histologic types of breast carcinoma. *Arch Pathol Lab Med.* 2015 Dec;139(12):1546–9. PMID:26619027
194. Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. *J Clin Oncol.* 1998 Jan;16(1):93–100. PMID:9440728
195. Bondeson L, Lindholm K. Aspiration cytology of tubular breast carcinoma. *Acta Cytol.* 1990 Jan-Feb;34(1):15–20. PMID:2296836
196. Bongiorno MR, Doukaki S, Ariò M. Neurofibromatosis of the nipple-areolar area: a case series. *J Med Case Rep.* 2010 Jan 25;4:22. PMID:20205809
197. Bonnier P, Romain S, Giacalone PL, et al. Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. *Obstet Gynecol.* 1995 Jan;85(1):11–7. PMID:7800305
198. Bonvalot S, Eldwyne H, Haddad V, et al. Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients. *Eur J Surg Oncol.* 2008 Apr;34(4):462–8. PMID:17709227
199. Borda LJ, Mervis JS, Romanelli P, et al. Clear cell acanthoma on the areola. *Dermatol Online J.* 2018 Jul 15;24(7):13030/qt9q47d056. PMID:30261576
200. Borden EC, Baker LH, Bell RS, et al. Soft tissue sarcomas of adults: state of the translational science. *Clin Cancer Res.* 2003 Jun;9(6):1941–56. PMID:12796356
201. Borst MJ, Ingold JA. Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast. *Surgery.* 1993 Oct;114(4):637–41, discussion 641–2. PMID:8211676
202. Bosse K, Ott C, Biegner T, et al. 23-year-old female with an inflammatory myofibroblastic tumour of the breast: a case report and a review of the literature. *Geburtshilfe Frauenheilkd.* 2014 Feb;74(2):167–70. PMID:24741129
203. Bossuyt V. Processing and reporting of breast specimens in the neoadjuvant setting. *Surg Pathol Clin.* 2018 Mar;11(1):213–30. PMID:29413658
204. Bossuyt V, Provenzano E, Symmans WF, et al. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. *Ann Oncol.* 2015 Jul;26(7):1280–91. PMID:26019189
205. Boto A, Harigopal M. Strong androgen receptor expression can aid in distinguishing GATA3+ metastases. *Hum Pathol.* 2018 May;75:63–70. PMID:29408697
206. Botta G, Fessia L, Ghiringhelli B. Juvenile milk protein secreting carcinoma. *Virchows Arch A Pathol Anat Histol.* 1982;395(2):145–52. PMID:7101723
207. Bottles K, Chan JS, Holly EA, et al. Cytologic criteria for fibroadenoma. A step-wise logistic regression analysis. *Am J Clin Pathol.* 1988 Jun;89(6):707–13. PMID:2835896
208. Bouaoun L, Sonkin D, Ardin M, et al. TP53 variations in human cancers: new lessons from the IARC TP53 Database and genomics data. *Hum Mutat.* 2016 Sep;37(9):865–76. PMID:27328919
209. Boudova L, Kazakov DV, Sima R, et al. Cutaneous lymphoid hyperplasia and other lymphoid infiltrates of the breast nipple: a retrospective clinicopathologic study of fifty-six patients. *Am J Dermatopathol.* 2005 Oct;27(5):375–86. PMID:16148405
210. Bougeard G, Renaux-Petel M, Flaman JM, et al. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. *J Clin Oncol.* 2015 Jul 20;33(21):2345–52. PMID:26014290
211. Boujelbene N, Khabir A, Boujelbene N, et al. Clinical review—breast adenoid cystic carcinoma. *Breast.* 2012 Apr;21(2):124–7. PMID:22154460
212. Boukhechba M, Kadiri H, El Khanoussi B. Invasive lobular carcinoma of the breast with extracellular mucin: case report of a new variant of lobular carcinoma of the breast. *Case Rep Pathol.* 2018 Apr 5;2018:5362951. PMID:29850340
213. Boulos FI, Dupont WD, Simpson JF, et al. Histologic associations and long-term cancer risk in columnar cell lesions of the breast: a retrospective cohort and a nested case-control study. *Cancer.* 2008 Nov 1;113(9):2415–21. PMID:18816618
214. Boulos FI, Granja NM, Simpson JF, et al. Intranodal papillary epithelial proliferations: a local process with a spectrum of morphologies and frequent association with papillomas in the breast. *Am J Surg Pathol.* 2014 Mar;38(3):383–8. PMID:24525508
215. Bourgeois JM, Knezevich SR, Mathers JA, et al. Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors. *Am J Surg Pathol.* 2000 Jul;24(7):937–46. PMID:10895816
216. Bowman E, Oprea G, Okoli J, et al. Pseudoangiomatous stromal hyperplasia (PASH) of the breast: a series of 24 patients. *Breast J.* 2012 May-Jun;18(3):242–7. PMID:22583194
217. Bozovic-Spašojević I, Zardavas D, Brohée S, et al. The prognostic role of androgen receptor in patients with early-stage breast cancer: a meta-analysis of clinical and gene expression data. *Clin Cancer Res.* 2017 Jun 1;23(11):2702–12. PMID:28151718
218. Brain E, Garrido C, Misser JL, et al. Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy. *Br J Cancer.* 1997;75(9):1360–7. PMID:9155059
219. Brankov N, Nino T, Hsiang D, et al. Utilizing Mohs surgery for tissue preservation in erosive adenomatosis of the nipple. *Dermatol Surg.* 2016 May;42(5):684–6. PMID:27045746
220. Brathauer GL, Tavassoli FA. Lobular intraepithelial neoplasia: previously unexplored aspects assessed in 775 cases and their clinical implications. *Virchows Arch.* 2002 Feb;440(2):134–8. PMID:11964042
221. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018 Nov;68(6):394–424. PMID:30207593
222. Bray F, McCarron P, Parkin DM. The changing global patterns of female breast cancer incidence and mortality. *Breast Cancer Res.* 2004;6(6):229–39. PMID:15535852
223. Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. *J Natl Cancer Inst.* 1999 Aug 4;91(15):1310–6. PMID:10433620
224. Brenn T, Fletcher CD. Radiation-associated cutaneous atypical vascular lesions and angiosarcoma: clinicopathologic analysis of 42 cases. *Am J Surg Pathol.* 2005 Aug;29(8):983–96. PMID:16006792
225. Brennan MF, Antonescu CR, Moraco N, et al. Lessons learned from the study of 10,000 patients with soft tissue sarcoma. *Ann Surg.* 2014 Sep;260(3):416–21, discussion 421–2. PMID:25115417
226. Brents M, Hancock J. Ductal carcinoma in situ of the male breast. *Breast Care (Basel).* 2016 Aug;11(4):288–90. PMID:27721718
227. Breuer A, Kandel M, Fisseler-Eckhoff A, et al. BRCA1 germline mutation in a woman with metaplastic squamous cell breast cancer. *Onkologie.* 2007 Jun;30(6):316–8. PMID:17551255
228. Brieher WM, Yap AS. Cadherin junctions and their cytoskeleton(s). *Curr Opin Cell Biol.* 2013 Feb;25(1):39–46. PMID:23127608
229. Brierly JD, Gospodarowicz MK, Wittekind C, editors. *TNM classification of malignant tumours.* 8th ed. Oxford (UK): Wiley Blackwell; 2017.
230. Bright CJ, Rea DW, Francis A, et al. Comparison of quadrant-specific breast cancer incidence trends in the United States and England between 1975 and 2013. *Cancer Epidemiol.* 2016 Oct;44:186–94. PMID:27632243
231. Brinton LA, Cook MB, McCormack V, et al. Anthropometric and hormonal risk factors for male breast cancer: male breast cancer pooling project results. *J Natl Cancer Inst.* 2014 Mar;106(3):dj465. PMID:24552677
232. Briski LM, Jorns JM. Primary breast atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma. *Arch Pathol Lab Med.* 2018 Feb;142(2):268–74. PMID:29372852
233. Britton P, Duffy SW, Sinnatamby R, et al. One-stop diagnostic breast clinics: How often are breast cancers missed? *Br J Cancer.* 2009 Jun 16;100(12):1873–8. PMID:19455145
234. Brooks A, Urbanus JH, Floore AN, et al. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. *Am J Hum Genet.* 2000 Feb;66(2):494–500. PMID:10677309
235. Broët P, de la Rochebrochardière A, Scholl SM, et al. Contralateral breast cancer: annual incidence and risk parameters. *J Clin Oncol.* 1995 Jul;13(7):1578–83. PMID:7602346
236. Brogi E, Oyama T, Koerner FC. Atypical cystic lobules in patients with lobular neoplasia. *Int J Surg Pathol.* 2001 Jul;9(3):209–14. PMID:11584316
237. Brookes MJ, Bourke AG. Radiological appearances of papillary breast lesions. *Clin Radiol.* 2008 Nov;63(11):1265–71. PMID:18929044
238. Brosens LA, van Hattem WA, Jansen R, et al. Gastrointestinal polyposis syndrome. *Curr Mol Med.* 2007 Feb;7(1):12–4. PMID:17311531
239. Brosens LA, Wood LD, Offerhaus GJ, et al. Pathology and genetics of syndromic intestinal polyyps. *Int J Surg Pathol.* 2016 May;24(3):98–99. PMID:26721304
240. Brown AC, Audisio RA, Regimbal C, et al. Granular cell tumour of the breast. *Surg Oncol.* 2011 Jun;20(2):97–105. PMID:21074890
241. Brown DC, Theaker JM, Banks PM, et al. Cytokeratin expression in smooth muscle and smooth muscle tumours. *Histopathology.* 1997 May;11(5):477–86. PMID:92440790
242. Brustein S, Filippa DA, Kimmerle A, et al. Malignant lymphoma of the breast. A report of 53 patients. *Ann Surg.* 1987 Feb;205(2):202–10. PMID:3545107
243. Bubien V, Bonnet F, Brouste V, et al. Cumulative risks of cancer in patients with hamartoma tumour syndrome. *J Natl Cancer Inst.* 2013 Apr;105(4):255–63. PMID:23550550
244. Buchanan CL, Flynn LW, Murray J, et al. Is pleomorphic lobular carcinoma a distinct clinical entity? *J Surg Oncol.* 2001;1:98(5):314–7. PMID:16668643
245. Buckle G, Maranda L, Sklarin S, et al. Factors influencing survival among children diagnosed with endemic Burkitt lymphoma between 2003 and 2010: a historical cohort study. *Int J Cancer.* 2015 Jul;139(6):1231–40. PMID:27135587
246. Budczies J, Bockmayr M, Denkert C, et al. Classical pathology and molecular pathology of breast cancer - integration of techniques. *J Pathol Clin Res.* 2015 Jul;23(1):1–10. PMID:27499907
247. Buerger H, Otterbach F, Smolarek S, et al. Comparative genomic hybridization analysis of carcinomas in situ of the breast reveals multiple genetic pathways. *J Pathol.* 2002 Mar;187(4):396–402. PMID:12000557
248. Buerger H, Otterbach F, Smolarek S, et al. Different genetic pathways in the development of invasive breast cancer are associated with distinct morphological subtypes. *J Pathol.* 2002 Dec;189(4):521–6. PMID:12028272
249. Buijsman FE, van Geel C, Pluijmers MB, et al. Non-melanomatous cutaneous malignancies: a single institution's experience of a diagnostic challenge with therapeutic consequences—a study. *World J Surg Oncol.* 2013 Mar;14(1):166. PMID:27337544
250. Buley ID, Gatter KC, et al. Granular cell tumour: immunohistochemical and ultrastructural study. *Histopathology.* 1988 Mar;12(3):251–6. PMID:2452781
251. Bur ME, Zimarowski WL, et al. Estrogen receptor immunohistochemistry in carcinoma *in situ* of the breast. *Cancer.* 2000 Mar;169(5):1174–81. PMID:10736377
252. Burdick C, Rinehart RM, et al. Nipple adenoma and Paget's disease. *Cancer.* 2000 Mar;169(5):1174–81. PMID:10736377

- 21. Burkitt D.** A sarcoma involving the breast in African children. *Br J Surg.* 1958 Dec;45(17):218-23. PMID:13628987
- 22. Burstein MD, Tsimelzon A, Poage GM, et al.** Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. *Clin Cancer Res.* 2015 Apr 1;21(7):1688-98. PMID:25208879
- 23. Bussolati G, Gugliotta P, Sapino A, et al.** Chromogranin-reactive endocrine cells in neuroendocrine carcinomas ("carcinoids") and normal tissue of the breast. *Am J Pathol.* 1985 Aug;110(2):186-92. PMID:4025508
- 24. Butler RS, Venta LA, Wiley EL, et al.** Sonographic evaluation of infiltrating lobular carcinoma. *AJR Am J Roentgenol.* 1999 Feb;172(2):325-30. PMID:9930776
- 25. Buttitta F, Felicioni L, Barassi F, et al.** PIK3CA mutation and histological type of breast carcinoma: high frequency of mutations in lobular carcinoma. *J Pathol.* 2006 Feb;208(3):350-5. PMID:16353168
- 26. Cabibi D, Cipolla C, Maria Florena A, et al.** Solid variant of mammary "adenoid cystic carcinoma with basaloid features" merging with "small cell carcinoma". *Pathol Res Pract.* 2011 May;210(10):705-11. PMID:16325513
- 27. Cabras MG, Amichetti M, Nagliati M, et al.** Primary non-Hodgkin's lymphoma of the breast: a report of 11 cases. *Haematologica.* 2004 Dec;89(12):1527-8. PMID:15590406
- 28. Cai Q, Long J, Lu W, et al.** Genome-wide association study identifies breast cancer risk variant at 10q21.2: results from the Asia Breast Cancer Consortium. *Hum Mol Genet.* 2011 Dec 20(24):4991-9. PMID:21908515
- 29. Cai RZ, Tan PH.** Adenomyoepithelioma of the breast with squamous and sebaceous metaplasia. *Pathology.* 2005 Dec;37(6):557-9. PMID:16373236
- 30. Cai Z, Chehab NH, Pavletich NP.** Structure and activation mechanism of the CHK2 DNA damage checkpoint kinase. *Mol Cell.* 2009 Sep 24;35(6):818-29. PMID:19782031
- 31. Cakir A, Gonul II, Uluoglu O.** A comprehensive morphological study for basal-like breast carcinomas with comparison to luminal-like carcinomas. *Diagn Pathol.* 2012 Oct 20;7:145. PMID:23082819
- 32. Calhoun BC.** Core needle biopsy of the breast: an evaluation of contemporary data. *Surg Pathol Clin.* 2018 Mar;11(1):1-16. PMID:29413652
- 33. Calhoun BC, Booth CN.** Atypical apocrine adenosis diagnosed on breast core biopsy: implications for management. *Hum Pathol.* 2014 Oct;45(10):2130-5. PMID:25106711
- 34. Calhoun BC, Collie AM, Lott-Limbach AA, et al.** Lobular neoplasia diagnosed on breast core biopsy: frequency of carcinoma on excision and implications for management. *Ann Diagn Pathol.* 2016 Dec;25:20-5. PMID:27806840
- 35. Calhoun BC, Collins LC.** Recommendations for excision following core needle biopsy of the breast: a contemporary evaluation of the literature. *Histopathology.* 2016 Jan;68(1):138-51. PMID:26768035
- 36. Caliskan M, Gatti G, Sosnovskaikhi I, et al.** Paget's disease of the breast: the experience of the European Institute of Oncology and review of the literature. *Breast Cancer Res Treat.* 2008 Dec;112(3):513-21. PMID:18240020
- 37. Callari M, Cappelletti V, De Cecco L, et al.** Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer. *Breast Cancer Res Treat.* 2011 Jun;127(3):601-10. PMID:20625818
- 38. Camelo-Piragua SI, Habib C, Kanumuri P, et al.** Mucoepidermoid carcinoma of the breast shares cytogenetic abnormality with mucoepidermoid carcinoma of the salivary gland: a case report with molecular analysis and review of the literature. *Hum Pathol.* 2009 Jun;40(6):887-92. PMID:19200580
- 39. Cameselle-Teijeiro J, Abdulkader I, Barreiro-Morandeira F, et al.** Breast tumor resembling the tall cell variant of papillary thyroid carcinoma: a case report. *Int J Surg Pathol.* 2006 Jan;14(1):79-84. PMID:16501842
- 40. Canas-Marques R, Schnitt SJ.** E-cadherin immunohistochemistry in breast pathology: uses and pitfalls. *Histopathology.* 2016 Jan;68(1):57-69. PMID:26768029
- 41. Cancello G, Maisonneuve P, Rotmensz N, et al.** Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. *Breast Cancer Res Treat.* 2011 Jun;127(3):713-20. PMID:21452022
- 42. Cancer Genome Atlas Network.** Comprehensive molecular portraits of human breast tumours. *Nature.* 2012 Oct 4;490(7418):61-70. PMID:23000897
- 43. Cangiarella J, Guth A, Axelrod D, et al.** Is surgical excision necessary for the management of atypical lobular hyperplasia and lobular carcinoma in situ diagnosed on core needle biopsy? A report of 38 cases and review of the literature. *Arch Pathol Lab Med.* 2008 Jun;132(6):979-83. PMID:18517282
- 44. Cantile M, Di Bonito M, Cerrone M, et al.** Primary breast angiosarcoma in young women from the same geographic region in a short period of time: only a coincidence or an increased risk? *Breast J.* 2018 Jan;24(1):91-3. PMID:28597488
- 45. Capella C, Eusebi V, Mann B, et al.** Endocrine differentiation in mucoid carcinoma of the breast. *Histopathology.* 1980 Nov;4(6):613-30. PMID:6254868
- 46. Capella C, Usellini L, Papotti M, et al.** Ultrastructural features of neuroendocrine differentiated carcinomas of the breast. *Ultrastruct Pathol.* 1990 Jul-Aug;14(4):321-34. PMID:2200185
- 47. Caplain A, Drouet Y, Peyron M, et al.** Management of patients diagnosed with atypical ductal hyperplasia by vacuum-assisted core biopsy: a prospective assessment of the guidelines used at our institution. *Am J Surg.* 2014 Aug;208(2):260-7. PMID:24680949
- 48. Carbone L, Sperduti I, Fabi A, et al.** Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: cut-off analysis of Ki67 according to histology and clinical validation. *Breast.* 2017 Oct;35:21-6. PMID:28628772
- 49. Cardoso F, Bartlett JMS, Slaets L, et al.** Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. *Ann Oncol.* 2018 Feb 1;29(2):405-17. PMID:29092024
- 50. Cardoso F, van't Veer LJ, Bogaerts J, et al.** 70-gene signature as an aid to treatment decisions in early-stage breast cancer. *N Engl J Med.* 2016 Aug 25;375(8):717-29. PMID:27557300
- 51. Carey LA, Metzger R, Dees EC, et al.** American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. *J Natl Cancer Inst.* 2005 Aug 3;97(15):1137-42. PMID:16077072
- 52. Carey LA, Perou CM, Livasy CA, et al.** Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. *JAMA.* 2006 Jun 7;295(21):2492-502. PMID:16757721
- 53. Carley AM, Chivukula M, Carter GJ, et al.** Frequency and clinical significance of simultaneous association of lobular neoplasia and columnar cell alterations in breast tissue specimens. *Am J Clin Pathol.* 2008 Aug;130(2):254-8. PMID:18628095
- 54. Carlson JW, Fletcher CD.** Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature. *Histopathology.* 2007 Oct;51(4):509-14. PMID:17711447
- 55. Carney JA.** The Carney complex (myxomas, spotty pigmentation, endocrine overactivity, and schwannomas). *Dermatol Clin.* 1995 Jan;13(1):19-26. PMID:7712644
- 56. Carney JA, Stratakis CA.** Ductal adenoma of the breast and the Carney complex. *Am J Surg Pathol.* 1996 Sep;20(9):1154-5. PMID:8764753
- 57. Carney JA, Toorkey BC.** Myxoid fibroadenoma and allied conditions (myxomatosis) of the breast. A heritable disorder with special associations including cardiac and cutaneous myxomas. *Am J Surg Pathol.* 1991 Aug;15(8):713-21. PMID:2069209
- 58. Carreira C, Romero C, Rodriguez R, et al.** A cavernous haemangioma of breast in male: radiological-pathological correlation. *Eur Radiol.* 2001;11(2):292-4. PMID:11218030
- 59. Carter BA, Jensen RA, Simpson JF, et al.** Benign transport of breast epithelium into axillary lymph nodes after biopsy. *Am J Clin Pathol.* 2000 Feb;113(2):259-65. PMID:10664628
- 60. Carter BA, Page DL, Schuyler P, et al.** No elevation in long-term breast carcinoma risk for women with fibroadenomas that contain atypical hyperplasia. *Cancer.* 2001 Jul 1;92(1):30-6. PMID:11443606
- 61. Carter CS, Skala SL, Chinnaian AM, et al.** Immunohistochemical characterization of fumarate hydratase (FH) and succinate dehydrogenase (SDH) in cutaneous leiomyomas for detection of familial cancer syndromes. *Am J Surg Pathol.* 2017 Jun;41(6):801-9. PMID:28288038
- 62. Carter D.** Intraductal papillary tumors of the breast: a study of 78 cases. *Cancer.* 1977 Apr;39(4):1689-92. PMID:851947
- 63. Carter MR, Hornick JL, Lester S, et al.** Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immunohistochemical analysis of 29 cases. *Am J Surg Pathol.* 2006 Mar;30(3):300-9. PMID:16538049
- 64. Casadei S, Norquist BM, Walsh T, et al.** Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. *Cancer Res.* 2011 Mar 15;71(6):2222-9. PMID:21285249
- 65. Castillo JJ, Winer ES, Olszewski AJ.** Population-based prognostic factors for survival in patients with Burkitt lymphoma: an analysis from the Surveillance, Epidemiology, and End Results database. *Cancer.* 2013 Oct 15;119(20):3672-9. PMID:23913575
- 66. Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, et al.** A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. *EMBO Mol Med.* 2018 Dec;10(12):e9172. PMID:30377213
- 67. Catalina-Fernández I, Sáenz-Santamaría J.** Lipid-rich carcinoma of breast: a case report with fine needle aspiration cytology. *Diagn Cytopathol.* 2009 Dec;37(12):935-6. PMID:19795489
- 68. Catena F, Santini D, Di Saverio S, et al.** Adenomyoepithelioma of the breast: an intricate diagnostic problem. *Breast Care (Basel).* 2008;3(2):125-7. PMID:21373216
- 69. Catucci I, Milgrom R, Kushner A, et al.** Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families. *Fam Cancer.* 2012 Sep;11(3):483-91. PMID:22692731
- 70. Cavallaro U, Dejana E.** Adhesion molecule signalling: not always a sticky business. *Nat Rev Mol Cell Biol.* 2011 Mar;12(3):189-97. PMID:21346732
- 71. Cawson JN, Law EM, Kavanagh AM.** Invasive lobular carcinoma: sonographic features of cancers detected in a BreastScreen program. *Australas Radiol.* 2001 Feb;45(1):25-30. PMID:11259968
- 72. Cesarman E, Knowles DM.** Kaposi's sarcoma-associated herpesvirus: a lymphotropic human herpesvirus associated with Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. *Semin Diagn Pathol.* 1997 Feb;14(1):54-66. PMID:9044510
- 73. Chang CK, Jacobs IA, Calilao G, et al.** Metastatic infiltrating syringomatous adenoma of the breast. *Arch Pathol Lab Med.* 2003 Mar;127(3):e155-6. PMID:12653606
- 74. Chang HL, Lerwill MF, Goldstein AM.** Breast hamartomas in adolescent females. *Breast J.* 2009 Sep-Oct;15(5):515-20. PMID:19624414
- 75. Chang SY, Fleiszer DM, Mesurolle B, et al.** Breast tumor resembling the tall cell variant of papillary thyroid carcinoma. *Breast J.* 2009 Sep-Oct;15(5):531-5. PMID:19594763
- 76. Charfi L, Driss M, Mrad K, et al.** Primary well differentiated liposarcoma: an unusual tumor in the breast. *Breast J.* 2009 Mar-Apr;15(2):206-7. PMID:19292812
- 77. Charpin C, Mathoulin MP, Andrac L, et al.** Reappraisal of breast hamartomas. A morphological study of 41 cases. *Pathol Res Pract.* 1994 Apr;190(4):362-71. PMID:8078805
- 78. Charu V, Cimino-Mathews A.** Peripheral nerve sheath tumors of the breast. *Semin Diagn Pathol.* 2017 Sep;34(5):420-6. PMID:28647116
- 79. Chaudhury A, Williams S, Cook J, et al.** The real-time intra-operative evaluation of sentinel lymph nodes in breast cancer patients using One Step Nucleic Acid Amplification (OSNA) and implications for clinical decision-making. *Eur J Surg Oncol.* 2014 Feb;40(2):150-7. PMID:24378008
- 80. Chavez-Macgregor M, Clarke CA, Lichtensztajn D, et al.** Male breast cancer according to tumor subtype and race: a population-based study. *Cancer.* 2013 May 1;119(9):1611-7. PMID:23341341
- 81. Cheung MC, Chia SK, Voduc D, et al.** Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. *J Natl Cancer Inst.* 2009 May 20;101(10):736-50. PMID:19436038
- 82. Chehab NH, Malikzay A, Appel M, et al.** Chk2/hCds1 functions as a DNA damage checkpoint in G1 by stabilizing p53. *Genes Dev.* 2000 Feb 1;14(3):278-88. PMID:10673500
- 83. CHEK2 Breast Cancer Case-Control Consortium.** CHEK2*1100delC and susceptibility to breast cancer: a collaborative

- analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. *Am J Hum Genet.* 2004 Jun;74(6):1175–82. PMID:15122511
- 319.** Chen AC, Paulino AC, Schwartz MR, et al. Population-based comparison of prognostic factors in invasive micropapillary and invasive ductal carcinoma of the breast. *Br J Cancer.* 2014 Jul 29;111(3):619–22. PMID:24921921
- 320.** Chen AM, Meric-Bernstam F, Hunt KK, et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson Cancer Center experience. *J Clin Oncol.* 2004 Jun 15;22(12):2303–12. PMID:15197191
- 321.** Chen BJ, Mariño-Enríquez A, Fletcher CD, et al. Loss of retinoblastoma protein expression in spindle cell/pleomorphic lipomas and cytogenetically related tumors: an immunohistochemical study with diagnostic implications. *Am J Surg Pathol.* 2012 Aug;36(8):1119–28. PMID:22790852
- 322.** Chen CY, Sun LM, Anderson BO. Paget disease of the breast: changing patterns of incidence, clinical presentation, and treatment in the U.S. *Cancer.* 2006 Oct 1;107(7):1448–58. PMID:16933329
- 323.** Chen H, Wu J, Zhang Z, et al. Association between BRCA status and triple-negative breast cancer: a meta-analysis. *Front Pharmacol.* 2018 Aug 21;9:909. PMID:30186165
- 324.** Chen H, Wu K, Wang M, et al. Invasive micropapillary carcinoma of the breast has a better long-term survival than invasive ductal carcinoma of the breast in spite of its aggressive clinical presentations: a comparison based on large population database and case-control analysis. *Cancer Med.* 2017 Dec;6(12):2775–86. PMID:29072365
- 324A.** Chen HL, Zhou MQ, Tian W, et al. Effect of age on breast cancer patient prognoses: a population-based study using the SEER 18 database. *PLoS One.* 2016 Oct 31;11(10):e0165409. PMID:27798652
- 325.** Chen L, Li CI, Tang MT, et al. Reproductive factors and risk of luminal, HER2-overexpressing, and triple-negative breast cancer among multiethnic women. *Cancer Epidemiol Biomarkers Prev.* 2016 Sep;25(9):1297–304. PMID:27307466
- 326.** Chen QX, Li JJ, Wang XX, et al. Similar outcomes between adenoid cystic carcinoma of the breast and invasive ductal carcinoma: a population-based study from the SEER 18 database. *Oncotarget.* 2017 Jan 24;8(4):6206–15. PMID:28008158
- 327.** Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. *J Clin Oncol.* 2007 Apr 10;25(11):1329–33. PMID:17416853
- 328.** Chen Y, Thompson W, Semenciw R, et al. Epidemiology of contralateral breast cancer. *Cancer Epidemiol Biomarkers Prev.* 1999 Oct;8(10):855–61. PMID:10548312
- 329.** Chen YL, Chen JJ, Chang C, et al. Sclerosing adenosis: ultrasonographic and mammographic findings and correlation with histopathology. *Mol Clin Oncol.* 2017 Feb;6(2):157–62. PMID:28357084
- 330.** Chen YY, Hwang ES, Roy R, et al. Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast. *Am J Surg Pathol.* 2009 Nov;33(11):1683–94. PMID:19701073
- 331.** Chen Z, Yang J, Li S, et al. Invasive lobular carcinoma of the breast: a special histological type compared with invasive ductal carcinoma. *PLoS One.* 2017 Sep 1;12(9):e0182397. PMID:28863134
- 332.** Chene A, Donati D, Orem J, et al. Endemic Burkitt's lymphoma as a polymicrobial disease: new insights on the interaction between *Plasmodium falciparum* and Epstein-Barr virus. *Semin Cancer Biol.* 2009 Dec;19(6):411–20. PMID:19897039
- 333.** Chenevix-Trench G, Spurdle AB, Gatei M, et al. Dominant negative ATM mutations in breast cancer families. *J Natl Cancer Inst.* 2002 Feb 6;94(3):205–15. PMID:11830610
- 334.** Cheng CW, Wu PE, Yu JC, et al. Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene. *Oncogene.* 2001 Jun 28;20(29):3814–23. PMID:11439345
- 335.** Cheng DT, Mitchell TN, Zehir A, et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. *J Mol Diagn.* 2015 May;17(3):251–64. PMID:25801821
- 336.** Cheng M, Geng C, Tang T, et al. Mucoepidermoid carcinoma of the breast: four case reports and review of the literature. *Medicine (Baltimore).* 2017 Dec;96(51):e9385. PMID:29390541
- 337.** Chesebro AL, Rives AF, Shaffer K. Male breast disease: what the radiologist needs to know. *Curr Probl Diagn Radiol.* 2018 Jul 29;S0363-0188(18)30061-6. PMID:30122313
- 338.** Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. *J Clin Oncol.* 2014 Sep 20;32(27):3059–68. PMID:25113753
- 339.** Cheung KL, Wong AW, Parker H, et al. Pathological features of primary breast cancer in the elderly based on needle core biopsies—a large series from a single centre. *Crit Rev Oncol Hematol.* 2008 Sep;67(3):263–7. PMID:18524618
- 340.** Chia Y, Thike AA, Cheok PY, et al. Stromal keratin expression in phyllodes tumours of the breast: a comparison with other spindle cell breast lesions. *J Clin Pathol.* 2012 Apr;65(4):339–47. PMID:22259180
- 341.** Chiacchio R, Panico L, D'Antonio A, et al. Mammary hamartomas: an immunohistochemical study of ten cases. *Pathol Res Pract.* 1999;195(4):231–6. PMID:10337660
- 342.** Chiang S, Weigelt B, Wen HC, et al. IDH2 mutations define a unique subtype of breast cancer with altered nuclear polarity. *Cancer Res.* 2016 Dec 15;76(24):7118–29. PMID:27913435
- 343.** Chibon F, Lagarde P, Salas S, et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. *Nat Med.* 2010 Jul;16(7):781–7. PMID:20581836
- 344.** Chng TW, Gudi M, Lim SH, et al. Validation of the Singapore nomogram for outcome prediction in breast phyllodes tumours in a large patient cohort. *J Clin Pathol.* 2018 Feb;71(2):125–8. PMID:28751520
- 345.** Chng TW, Lee JY, Lee CS, et al. Validation of the Singapore nomogram for outcome prediction in breast phyllodes tumours: an Australian cohort. *J Clin Pathol.* 2016 Dec;69(12):1124–6. PMID:27466383
- 346.** Cho KS, Choi HY, Lee SW, et al. Sonographic findings in solitary schwannoma of the breast. *J Clin Ultrasound.* 2001 Feb;29(2):99–101. PMID:11425095
- 347.** Cho WK, Choi DH, Lee J, et al. Comparison of failure patterns between tubular breast carcinoma and invasive ductal carcinoma (KROG 14–25). *Breast.* 2018 Apr;38:165–70. PMID:29413404
- 348.** Choi M, Kipps T, Kurzrock R. ATM mutations in cancer: therapeutic implications. *Mol Cancer Ther.* 2016 Aug;15(8):1781–91. PMID:27413114
- 349.** Choi N, Kim K, Shin KH, et al. Malignant and borderline phyllodes tumors of the breast: a multicenter study of 362 patients (KROG 16–08). *Breast Cancer Res Treat.* 2018 Sep;171(2):335–44. PMID:29808288
- 350.** Chou WYY, Veis DJ, Aft R. Radial scar on image-guided breast biopsy: Is surgical excision necessary? *Breast Cancer Res Treat.* 2018 Jul;170(2):313–20. PMID:29532340
- 351.** Christgen M, Steinemann D, Kühnle E, et al. Lobular breast cancer: clinical, molecular and morphological characteristics. *Pathol Res Pract.* 2016 Jul;212(7):583–97. PMID:27233940
- 352.** Christie M, Chin-Lenn L, Watts MM, et al. Primary small cell carcinoma of the breast with TTF-1 and neuroendocrine marker expressing carcinoma in situ. *Int J Clin Exp Pathol.* 2010 Jun 30;3(6):629–33. PMID:20661411
- 353.** Christou CM, Kyriacou K. BRCA1 and its network of interacting partners. *Biology (Basel).* 2013 Jan 2;2(1):40–63. PMID:24832651
- 354.** Chu KC, Anderson WF. Rates for breast cancer characteristics by estrogen and progesterone receptor status in the major racial/ethnic groups. *Breast Cancer Res Treat.* 2002 Jun;74(3):199–211. PMID:12206512
- 355.** Chuua CL, Thomas A, Ng BK. Cystosarcoma phyllodes—Asian variations. *Aust N Z J Surg.* 1988 Apr;58(4):301–5. PMID:2855393
- 356.** Chuba PJ, Hamre MR, Yap J, et al. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of Surveillance, Epidemiology, and End Results data. *J Clin Oncol.* 2005 Aug 20;23(24):5534–41. PMID:16110014
- 357.** Chulakadabba A, Denariyakoon S, Chakkabat P, et al. Preoperative radiation in large angiomyomatosis of the breast, attempting breast conserving surgery: multidisciplinary approach. *J Surg Case Rep.* 2018 Feb 14;2018(2):rjy024. PMID:29479420
- 358.** Chun KA, Cohen PR. Basal cell carcinoma of the nipple-areola complex: a comprehensive review of the world literature. *Dermatol Ther (Heidelberg).* 2016 Sep;6(3):379–95. PMID:27363851
- 359.** Ciatto S, Bonardi R, Cataliotti L, et al. Sarcomas of the breast: a multicenter series of 70 cases. *Neoplasma.* 1992;39(6):375–9. PMID:1491728
- 360.** Cimino-Mathews A, Hicks JL, Sharma R, et al. A subset of malignant phyllodes tumors harbors alterations in the Rb/p16 pathway. *Hum Pathol.* 2013 Nov;44(11):2494–500. PMID:23916291
- 361.** Cimino-Mathews A, Sharma R, Illei PB, et al. A subset of malignant phyllodes tumors express p63 and p40: a diagnostic pitfall in breast core needle biopsies. *Am J Surg Pathol.* 2014 Dec;38(12):1689–96. PMID:25046342
- 362.** Cimino-Mathews AM. Peripheral nerve sheath tumors. *Surg Pathol Clin.* 2011 Sep;4(3):761–82. PMID:26837647
- 363.** Cirolli G, Gatzka ML, Beck AH, et al. Comprehensive molecular portraits of invasive lobular breast cancer. *Cell.* 2015 Oct 8;163(2):506–19. PMID:26451490
- 364.** Ciurea A, Dudea SM, Lebovici A, et al. Diffuse angiomyomatosis of the breast—sonographic appearance. *J Clin Ultrasound.* 2014 Oct;42(8):498–501. PMID:24965677
- 365.** Clark SL, Rodriguez AM, Snyder RR, et al. Structure-function of the tumor suppressor BRCA1. *Comput Struct Biotechnol J.* 2012 Apr 1;1(1):e20120405. PMID:22737296
- 366.** Claus EB, Petruzzella S, Matloff E, et al. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. *JAMA.* 2005 Feb 23;293(8):964–9. PMID:15728167
- 367.** Claus EB, Stowe M, Carter D. Breast carcinoma in situ: risk factors and screening patterns. *J Natl Cancer Inst.* 2001 Dec 5;93(23):1811–7. PMID:11734598
- 368.** Claus EB, Stowe M, Carter D. Family history of breast and ovarian cancer and the risk of breast carcinoma in situ. *Breast Cancer Res Treat.* 2003 Mar;78(1):7–15. PMID:12611462
- 369.** Clemens MW, Horwitz SM. NCCN consensus guidelines for the diagnosis and management of breast implant-associated anaplastic large cell lymphoma. *Aesthet Surg J.* 2017 Mar 1;37(3):285–9. PMID:28184418
- 370.** Clemens MW, Medeiros LI, Eberle CE, et al. Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma. *J Clin Oncol.* 2016 Jun 10;34(2):160–8. PMID:26628470
- 371.** Cloyd JM, Yang RL, Allison KH, et al. Impact of histological subtype on long-term outcomes of neuroendocrine carcinoma in situ of the breast. *Breast Cancer Res Treat.* 2016 Dec;148(3):637–44. PMID:25399232
- 372.** Co M, Chen C, Tsang JY, et al. Malignant phyllodes tumour: a 15-year multicentre review. *J Clin Pathol.* 2018 Jun;71(E):1–6. PMID:29146885
- 373.** Co M, Tse GM, Chen C, et al. Characteristics of ductal carcinoma within malignant phyllodes tumor: a review of 557 cases from a Chinese region-wide database in Hong Kong and southern China. *Clin Breast Cancer.* 2018 Jun;18(3):e421–5. PMID:28689071
- 374.** Cocco E, Scaltriti M, Dilon A. NTRK positive cancers and TRK inhibitor therapy. *Rev Clin Oncol.* 2018 Dec;15(2):33–41. PMID:30335156
- 375.** Coffin CM, Hornick JL, Reuter VE, et al. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, immunohistochemical features including expression in atypical and aggressive forms. *Am J Surg Pathol.* 2007 Apr;31(4):461–70. PMID:17414097
- 376.** Coffin CM, Watterson J, Priest JR, et al. Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor): clinicopathologic and immunohistochemical study of 84 cases. *Am J Surg Pathol.* 1998 Aug;19(8):859–72. PMID:7615233
- 377.** Cohen JM, Nazarian RM, Fife C, et al. Rare presentation of secondary malignant lymphoma: report of a case and review of the literature. *Am J Dermatopathol.* 2001 Jan;37(1):e1–4. PMID:25238446
- 378.** Cohen MA, Newell MS. Radiologic imaging of the breast encountered at core biopsy: of histologic, imaging, and management considerations. *AJR Am J Roentgenol.* 2008 Nov;209(5):1168–77. PMID:28873188
- 379.** Coindre JM. Grading of soft tissue sarcomas: review and update. *Ann Lab Med.* 2006 Oct;130(10):651–6. PMID:17090186
- 380.** Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. *Am J Epidemiol.* 2000 May;151(10):950–64. PMID:11092437
- 381.** Colella R, Guerriero A, Gennari L, et al. An additional case of breast carcinoma resembling the tall cell variant of papillary thyroid carcinoma. *Int J Surg Pathol.* 2018 May;23(3):217–20. PMID:24868074
- 382.** Collins LC. Precursor lesions of the grade breast neoplasia pathway. *Surg Clin North Am.* 2018 Mar;98(1):177–97. PMID:29462000
- 383.** Collins LC, Achacoso N, Hwang ES, et al. Risk prediction for local recurrence and distant metastasis in women with early-stage breast cancer. *Cancer.* 2018 Mar;111(1):177–87. PMID:29462000

- in community practice: a nested, case-control study. *Ann Surg Oncol.* 2015 Dec;22 Suppl 3:S502–8. PMID:26059650
384. Collins LC, Aroner SA, Connolly JL, et al. Breast cancer risk by extent and type of atypical hyperplasia: an update from the Nurses' Health Study. *Cancer.* 2016 Feb 15;122(4):515–20. PMID:26565738
385. Collins LC, Baer HJ, Tamimi RM, et al. Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia: results from the Nurses' Health Study. *Cancer.* 2007 Jan 15;109(2):180–7. PMID:17154175
386. Collins LC, Baer HJ, Tamimi RM, et al. The influence of family history on breast cancer risk in women with biopsy-confirmed benign breast disease: results from the Nurses' Health Study. *Cancer.* 2006 Sep 15;107(6):1240–7. PMID:16902983
387. Collins LC, Carlo VP, Hwang H, et al. Invasive papillary carcinomas of the breast: reevaluation using a panel of myoepithelial markers. *Am J Surg Pathol.* 2006 Jun;30(8):1002–7. PMID:16861972
388. Collins LC, Cole KS, Marotti JD, et al. Estrogen receptor expression in breast cancer: correlation to molecular phenotype: results from the Nurses' Health Study. *Mod Pathol.* 2011 Jul;24(7):924–31. PMID:21552212
389. Collins LC, Connolly JL, Page DL, et al. Diagnostic agreement in the evaluation of image-guided breast core needle biopsies: results from a randomized clinical trial. *Am J Surg Pathol.* 2004 Jan;28(1):126–31. PMID:14707874
390. Collins LC, Martyniak A, Kandel MJ, et al. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers. *Am J Surg Pathol.* 2005 Jul;33(7):1093–7. PMID:1590427
391. Collins LC, Tamimi RM, Baer HJ, et al. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study. *Cancer.* 2005 May 1;103(9):1778–84. PMID:15770688
392. Colombo C, Miceli R, Lazar AJ, et al. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study. *Cancer.* 2013 Oct 15;119(20):3696–702. PMID:23913621
393. Comer JD, Cui X, Eisen CS, et al. Fibroblastoma of the male breast: a rare entity with radiologic-pathologic correlation. *Am J Imaging.* 2017 Mar-Apr;42:109–12. PMID:27936420
394. Concannon P, Gatti RA. Diversity of ATM mutations detected in patients with ataxiatelangiectasia. *Hum Mutat.* 1997;10(2):100–7. PMID:9259193
395. Conlon N, Ross DS, Howard J, et al. Is there a role for Oncotype DX testing in invasive lobular carcinoma? *Breast J.* 2015 Sep;21(5):514–9. PMID:26271749
396. Conlon N, Sadri N, Corben AD, et al. Acinic cell carcinoma of breast: morphologic and immunohistochemical review of a rare breast cancer subtype. *Hum Pathol.* 2016 May;51:16–22. PMID:27067778
397. Cook JR, Dehner LP, Collins MH, et al. Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. *Am J Surg Pathol.* 2001 Nov;25(11):1364–71. PMID:11684952
398. Coopay SB, Mazzola E, Buckley JM, et al. The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions. *Breast Cancer Res Treat.* 2012 Dec;136(3):627–33. PMID:23117858
399. Copson ER, Maishman TC, Tapper WJ, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. *Lancet Oncol.* 2018 Feb;19(2):169–80. PMID:29337092
400. Coriat R, Mozer M, Caux F, et al. Endoscopic findings in Cowden syndrome. *Endoscopy.* 2011 Aug;43(8):723–6. PMID:21437855
401. Corso G, Figueiredo J, La Vecchia C, et al. Hereditary lobular breast cancer with an emphasis on E-cadherin genetic defect. *J Med Genet.* 2018 Jul;55(7):431–41. PMID:29929997
402. Costanzo PR, Pacenza NA, Aszpis SM, et al. Clinical and etiological aspects of gynecomastia in adult males: a multicenter study. *Biomed Res Int.* 2018 May 29;2018:8364824. PMID:30003107
403. Couch FJ, Hart SN, Sharma P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. *J Clin Oncol.* 2015 Feb 1;33(4):304–11. PMID:25452441
404. Couch FJ, Kuchenbaecker KB, Michailidou K, et al. Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. *Nat Commun.* 2016 Apr 27;7:11375. PMID:27117709
405. Couch FJ, Shimelis H, Hu C, et al. Associations between cancer predisposition testing panel genes and breast cancer. *JAMA Oncol.* 2017 Sep 1;3(9):1190–6. PMID:28418444
406. Couch FJ, Wang X, McGuffog L, et al. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. *PLoS Genet.* 2013;9(3):e1003212. PMID:23544013
407. Couch FJ, Weber BL. Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. *Breast Cancer Information Core. Hum Mutat.* 1996;8(1):8–18. PMID:8807330
408. Cowan ML, Argani P, Cimino-Mathews A. Benign and low-grade fibroepithelial neoplasms of the breast have low recurrence rate after positive surgical margins. *Mod Pathol.* 2016 Mar;29(3):259–65. PMID:26743469
409. Cowell CF, Weigelt B, Sakr RA, et al. Progression from ductal carcinoma in situ to invasive breast cancer: revisited. *Mol Oncol.* 2013 Oct;7(5):859–69. PMID:23890733
410. Crago AM, Chmielecki J, Rosenberg M, et al. Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis. *Genes Chromosomes Cancer.* 2015 Oct;54(10):606–15. PMID:26171757
411. Crisi GM, Mandavilli S, Cronin E, et al. Invasive mammary carcinoma after immediate and short-term follow-up for lobular neoplasia on core biopsy. *Am J Surg Pathol.* 2003 Mar;27(3):325–33. PMID:12604888
412. Cross AS, Azzopardi JG, Krausz T, et al. A morphological and immunocytochemical study of a distinctive variant of ductal carcinoma in-situ of the breast. *Histopathology.* 1985 Jan;9(1):21–37. PMID:2579885
413. Crozat A, Aman P, Mandahl N, et al. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. *Nature.* 1993 Jun 17;363(6430):640–4. PMID:8510758
414. Cserni G. Benign apocrine papillary lesions of the breast lacking or virtually lacking myoepithelial cells—potential pitfalls in diagnosing malignancy. *APMIS.* 2012 Mar;120(3):249–52. PMID:22339683
415. Cserni G. Lack of myoepithelium in apocrine glands of the breast does not necessarily imply malignancy. *Histopathology.* 2008 Jan;52(2):253–5. PMID:18184276
416. Cserni G. Presence of basement membrane material around the tubules of tubulolobular carcinoma. *Breast Care (Basel).* 2008;3(6):423–5. PMID:21048914
417. Cserni G. What is a positive sentinel lymph node in a breast cancer patient? A practical approach. *Breast.* 2007 Apr;16(2):152–60. PMID:17081752
418. Cserni G, Chmielik E, Cserni B, et al. The new TNM-based staging of breast cancer. *Virchows Arch.* 2018 May;472(5):697–703. PMID:29380126
419. Cserni G, Floris G, Koufopoulos N, et al. Invasive lobular carcinoma with extracellular mucin production—a novel pattern of lobular carcinomas of the breast. *Clinico-pathological description of eight cases.* *Virchows Arch.* 2017 Jul;471(1):3–12. PMID:28528509
420. Cserni G, Wells CA, Kaya H, et al. Consistency in recognizing microinvasion in breast carcinomas is improved by immunohistochemistry for myoepithelial markers. *Virchows Arch.* 2016 Apr;468(4):473–81. PMID:26818833
421. Curigliano G, Burstein HJP, P Winer E, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. *Ann Oncol.* 2017 Aug 1;28(8):1700–12. PMID:28838210
422. Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. *Ann Oncol.* 2018 Oct 1;29(10):2153. PMID:29733336
423. Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature.* 2012 Apr 18;486(7403):346–52. PMID:22522925
424. Cutress RI, McDowell A, Gabriel FG, et al. Observational and cost analysis of the implementation of breast cancer sentinel node intraoperative molecular diagnosis. *J Clin Pathol.* 2010 Jun;63(6):522–9. PMID:20439323
425. Cutuli B, Dilhuud JM, De Lafontan B, et al. Ductal carcinoma in situ of the male breast: Analysis of 31 cases. *Eur J Cancer.* 1997 Jan;33(1):35–8. PMID:9071896
426. Cuzick J, Dowsett M, Pineda S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. *J Clin Oncol.* 2011 Nov 10;29(32):4273–8. PMID:21990413
427. Cuzick J, Sestak I, Pinder SE, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. *Lancet Oncol.* 2011 Jan;12(1):21–9. PMID:21145284
428. Cybulski C, Huzarski T, Byrski T, et al. Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention. *Clin Genet.* 2009 Jan;75(1):72–8. PMID:19021634
429. Da Silva L, Parry S, Reid L, et al. Aberrant expression of E-cadherin in lobular carcinomas of the breast. *Am J Surg Pathol.* 2008 May;32(5):773–83. PMID:18379416
430. Dabbs DJ, Bhargava R, Chivukula M. Lobular versus ductal breast neoplasms: the diagnostic utility of p120 catenin. *Am J Surg Pathol.* 2007 Mar;31(3):427–37. PMID:17325485
431. Dabbs DJ, Carter G, Fudge M, et al. Molecular alterations in columnar cell lesions of the breast. *Mod Pathol.* 2006 Mar;19(3):344–9. PMID:16400324
432. Dabbs DJ, Grenko RT, Silverman JF. Fine needle aspiration cytology of pleomorphic lobular carcinoma of the breast. *Duct carcinoma as a diagnostic pitfall.* *Acta Cytol.* 1994 Nov-Dec;38(6):923–8. PMID:7992580
433. Dabbs DJ, Schnitt SJ, Geyer FC, et al. Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. *Am J Surg Pathol.* 2013 Jul;37(7):e1–11. PMID:23759937
434. Dadmanesh F, Fan X, Dastane A, et al. Comparative analysis of size estimation by mapping and counting number of blocks with ductal carcinoma in situ in breast excision specimens. *Arch Pathol Lab Med.* 2009 Jan;133(1):26–30. PMID:19123732
435. Daemen A, Manning G. HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumors. *Breast Cancer Res.* 2018 Jan 30;20(1):8. PMID:29382369
436. Dahlén AM, Wibom C, Ghasimi S, et al. Relation between established glioma risk variants and DNA methylation in the tumor. *PLoS One.* 2016 Oct 25;11(10):e0163067. PMID:27780202
437. Dahlstrom JE, Tait N, Cranney BG, et al. Fine needle aspiration cytology and core biopsy histology in infiltrating syringomatous adenoma of the breast: A case report. *Acta Cytol.* 1999 Mar-Apr;43(2):303–7. PMID:10097731
438. Dal Cin P, Wunschura S, Christiaens MR, et al. Hamartoma of the breast with involvement of 6p21 and rearrangement of HMGY1. *Genes Chromosomes Cancer.* 1997 Sep;20(1):90–2. PMID:9290959
439. Dalal KM, Kattan MW, Antonescu CR, et al. Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. *Ann Surg.* 2006 Sep;244(3):381–91. PMID:16926564
440. Dalberg K, Hellborg H, Wärnberg F. Paget's disease of the nipple in a population based cohort. *Breast Cancer Res Treat.* 2008 Sep;111(2):313–9. PMID:17952590
441. D'Alfonso TM, Ginter PS, Liu YF, et al. Cystic hypersecretory (in situ) carcinoma of the breast: a clinicopathologic and immunohistochemical characterization of 10 cases with clinical follow-up. *Am J Surg Pathol.* 2014 Jan;38(1):45–53. PMID:24121179
442. D'Alfonso TM, Mosquera JM, MacDonald TY, et al. MYB-NFIB gene fusion in adenoid cystic carcinoma of the breast with special focus paid to the solid variant with basaloid features. *Hum Pathol.* 2014 Nov;45(11):2270–80. PMID:25217885
443. D'Alfonso TM, Shin SJ. Small glandular proliferations of the breast. *Surg Pathol Clin.* 2012 Sep;5(3):591–643. PMID:26838282
444. D'Alfonso TM, Wang K, Chiu YL, et al. Pathologic upgrade rates on subsequent excision when lobular carcinoma in situ is the primary diagnosis in the needle core biopsy with special attention to the radiographic target. *Arch Pathol Lab Med.* 2013 Jul;137(7):927–35. PMID:23808465
445. Daling JR, Malone KE, Doody DR, et al. Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. *Cancer.* 2002 Dec 15;95(12):2455–64. PMID:12467057
446. Damiani S, Eusebi V. Gynecomastia in type-1 neurofibromatosis with features of pseudoangiomatous stromal hyperplasia with giant cells. Report of two cases. *Virchows Arch.* 2001 May;438(5):513–6. PMID:11407482
447. Damiani S, Pasquinelli G, Lamovcic J,

- et al. Acinic cell carcinoma of the breast: an immunohistochemical and ultrastructural study. *Virchows Arch.* 2000 Jul;437(1):74–81. PMID:10963383
- 448.** D'Angelo P, Carli M, Ferrari A, et al. Breast metastases in children and adolescents with rhabdomyosarcoma: experience of the Italian Soft Tissue Sarcoma Committee. *Pediatr Blood Cancer.* 2010 Dec 15;55(7):1306–9. PMID:20730885
- 449.** Dangoor A, Seddon B, Gerrard C, et al. UK guidelines for the management of soft tissue sarcomas. *Clin Sarcoma Res.* 2016 Nov 15;6:20. PMID:27891213
- 450.** Daniel BL, Gardner RW, Birdwell RL, et al. Magnetic resonance imaging of intraductal papilloma of the breast. *Magn Reson Imaging.* 2003 Oct;21(8):887–92. PMID:14599539
- 451.** Daniels BH, Ko JS, Rowe JJ, et al. Radiation-associated angiosarcoma in the setting of breast cancer mimicking radiation dermatitis: a diagnostic pitfall. *J Cutan Pathol.* 2017 May;44(5):456–61. PMID:28169467
- 452.** Darabi H, Beesley J, Droit A, et al. Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGS). *Sci Rep.* 2016 Sep 7;6:32512. PMID:27600471
- 453.** Darabi H, McCue K, Beesley J, et al. Polymorphisms in a putative enhancer at the 10q21.2 breast cancer risk locus regulate NRBF2 expression. *Am J Hum Genet.* 2015 Jul 2;97(1):22–34. PMID:26073781
- 454.** Daroca PJ Jr, Reed RJ, Love GL, et al. Myoid hamartomas of the breast. *Hum Pathol.* 1985 Mar;16(3):212–9. PMID:3972402
- 455.** Das Gupta TK, Brasfield RD, Strong EW, et al. Benign solitary schwannomas (neurilemmomas). *Cancer.* 1969 Aug;24(2):355–66. PMID:5796779
- 456.** Da Silva L, Lakhani SR. Pathology of hereditary breast cancer. *Mod Pathol.* 2010 May;23 Suppl 2:S46–51. PMID:20436502
- 457.** Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma. *N Engl J Med.* 2006 Jun 8;354(23):2431–42. PMID:16760443
- 458.** Davies H, Glodzik D, Morganella S, et al. HRDdetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. *Nat Med.* 2017 Apr;23(4):517–25. PMID:28288110
- 459.** Davis WG, Hennessy B, Babiera G, et al. Metaplastic sarcomatoid carcinoma of the breast with absent or minimal overt invasive carcinomatous component: a misnomer. *Am J Surg Pathol.* 2005 Nov;29(11):1456–63. PMID:16224212
- 460.** Daya D, Trus T, D'Souza TJ, et al. Hamartoma of the breast, an underrecognized breast lesion. A clinicopathologic and radiographic study of 25 cases. *Am J Clin Pathol.* 1995 Jun;103(6):685–9. PMID:7785651
- 461.** de Bock GH, Schutte M, Krol-Warmerdam EM, et al. Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant. *J Med Genet.* 2004 Oct;41(10):731–5. PMID:15466005
- 462.** de Boer M, van Leeuwen FE, Hauptmann M, et al. Breast implants and the risk of anaplastic large-cell lymphoma in the breast. *JAMA Oncol.* 2018 Mar 1;4(3):335–41. PMID:29302687
- 463.** De Brot M, Koslow Mautner S, Muhsen S, et al. Pleomorphic lobular carcinoma in situ of the breast: a single institution experience with clinical follow-up and centralized pathology review. *Breast Cancer Res Treat.* 2017 Sep;165(2):411–20. PMID:28612228
- 464.** De Chiara A, Losito S, Terracciano L, et al. Primary plasmacytoma of the breast. *Arch Pathol Lab Med.* 2001 Aug;125(8):1078–80. PMID:11473462
- 465.** de Groot JS, Ratze MA, van Amersfoort M, et al. αE-catenin is a candidate tumor suppressor for the development of E-cadherin-expressing lobular-type breast cancer. *J Pathol.* 2018 Aug;245(4):456–67. PMID:29774524
- 466.** De Leeuw WJ, Berx G, Vos CB, et al. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. *J Pathol.* 1997 Dec;183(4):404–11. PMID:9496256
- 467.** de Leng WW, Jansen M, Carvalho R, et al. Genetic defects underlying Peutz-Jeghers syndrome (PJS) and exclusion of the polarity-associated MARK/Par1 gene family as potential PJS candidates. *Clin Genet.* 2007 Dec;72(6):568–73. PMID:17924967
- 468.** de Moraes Schenka NG, Schenka AA, de Souza Queiroz L, et al. p63 and CD10: reliable markers in discriminating benign sclerosing lesions from tubular carcinoma of the breast? *Appl Immunohistochem Mol Morphol.* 2006 Mar;14(1):71–7. PMID:16540734
- 469.** Deb S, Do H, Byrne D, et al. PIK3CA mutations are frequently observed in BRCA1 but not BRCA2-associated male breast cancer. *Breast Cancer Res.* 2013;15(4):R69. PMID:23971979
- 470.** Deb S, Jene N, Fox SB, et al. Genotypic and phenotypic analysis of familial male breast cancer shows underrepresentation of the HER2 and basal subtypes in BRCA-associated carcinomas. *BMC Cancer.* 2012 Nov 9;12:510. PMID:23146383
- 471.** Deb S, Johansson I, Byrne D, et al. Nuclear HIF1A expression is strongly prognostic in sporadic but not familial male breast cancer. *Mod Pathol.* 2014 Sep;27(9):1223–30. PMID:24457463
- 472.** Deen SA, McKee GT, Kissin MW. Differential cytologic features of fibroepithelial lesions of the breast. *Diagn Cytopathol.* 1999 Feb;20(2):53–6. PMID:9951596
- 473.** Degnim AC, Dupont WD, Radisky DC, et al. Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women. *Cancer.* 2016 Oct;122(19):2971–8. PMID:27352219
- 474.** Degnim AC, Visscher DW, Berman HK, et al. Stratification of breast cancer risk in women with atypia: a Mayo cohort study. *J Clin Oncol.* 2007 Jul 1;25(19):2671–7. PMID:17563394
- 475.** Del Castillo M, Chibon F, Arnould L, et al. Secretory breast carcinoma: a histopathologic and genomic spectrum characterized by a joint specific ETV6-NTRK3 gene fusion. *Am J Surg Pathol.* 2015 Nov;39(11):1458–67. PMID:26291510
- 476.** DeLair DF, Corben AD, Catalano JP, et al. Non-mammary metastases to the breast and axilla: a study of 85 cases. *Mod Pathol.* 2013 Mar;26(3):343–9. PMID:23174933
- 477.** de la Torre M, Lindholm K, Lindgren A. Fine needle aspiration cytology of tubular breast carcinoma and radial scar. *Acta Cytol.* 1994 Nov-Dec;38(6):884–90. PMID:7992574
- 478.** Dellapasqua S, Maisonneuve P, Viale G, et al. Immunohistochemically defined subtypes and outcome of apocrine breast cancer. *Clin Breast Cancer.* 2013 Apr;13(2):95–102. PMID:23245877
- 479.** Demicco EG, Torres KE, Ghadimi MP, et al. Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma. *Mod Pathol.* 2012 Feb;25(2):212–21. PMID:22020193
- 480.** Deng G, Lu Y, Zlotnikov G, et al. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. *Science.* 1996 Dec 20;274(5295):2057–9. PMID:8953032
- 481.** Deng Y, Xue D, Wang X, et al. Mucinous cystadenocarcinoma of the breast with a basal-like immunophenotype. *Pathol Int.* 2012 Jun;62(6):429–32. PMID:22612513
- 482.** Denkert C, von Minckwitz G, Darbs-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. *Lancet Oncol.* 2018 Jan;19(1):40–50. PMID:29233559
- 483.** Derkens PW, Braumüller TM, van der Burg E, et al. Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice. *Dis Model Mech.* 2011 May;4(3):347–58. PMID:21282721
- 484.** Derkens PW, Liu X, Saridin F, et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. *Cancer Cell.* 2006 Nov;10(5):437–49. PMID:17097565
- 485.** De Santis CE, Bray F, Ferlay J, et al. International variation in female breast cancer incidence and mortality rates. *Cancer Epidemiol Biomarkers Prev.* 2015 Oct;24(10):1495–506. PMID:26359465
- 486.** Desmedt C, Haibe-Kains B, Wirapati P, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. *Clin Cancer Res.* 2008 Aug 15;14(16):5158–65. PMID:18698033
- 487.** Desmedt C, Salgado R, Fornili M, et al. Immune infiltration in invasive lobular breast cancer. *J Natl Cancer Inst.* 2018 Jul 1;110(7):768–76. PMID:29471435
- 488.** Desmedt C, Zoppoli G, Gundem G, et al. Genomic characterization of primary invasive lobular breast cancer. *J Clin Oncol.* 2016 Jun 1;34(16):1872–81. PMID:26926684
- 489.** Desouki MM, Li Z, Hameed O, et al. Incidental atypical proliferative lesions in reduction mammoplasty specimens: analysis of 2498 cases from 2 tertiary women's health centers. *Hum Pathol.* 2013 Sep;44(9):1877–81. PMID:23656973
- 490.** Destounis SV, Murphy PF, Seifert PJ, et al. Management of patients diagnosed with lobular carcinoma in situ at needle core biopsy at a community-based outpatient facility. *AJR Am J Roentgenol.* 2012 Feb;198(2):281–7. PMID:22268169
- 491.** de-Thé G, Geser A, Day NE, et al. Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study. *Nature.* 1978 Aug 24;274(5673):756–61. PMID:210392
- 492.** Devouassoux-Shisheboran M, Schammel MD, Man YG, et al. Fibromatosis of the breast: age-correlated morphofunctional features of 33 cases. *Arch Pathol Lab Med.* 2000 Feb;124(2):276–80. PMID:10656738
- 493.** Deyrup AT, Lee VK, Hill CE, et al. Epstein-Barr virus-associated smooth muscle tumors are distinctive mesenchymal tumors reflecting multiple infection events: a clinicopathologic and molecular analysis of 29 tumors from 19 patients. *Am J Surg Pathol.* 2006 Jan;30(1):75–82. PMID:16330945
- 494.** Di Cristofano C, Mrad K, Zavaglia K, et al. Papillary lesions of the breast: a molecular progression? *Breast Cancer Res Treat.* 2005 Mar;90(1):71–6. PMID:15770529
- 495.** Di Filippo F, Di Filippo S, Ferrari AM, et al. Elaboration of a nomogram to predict non-sentinel node status in breast cancer patients with positive sentinel node, intraoperatively assessed with one step nucleic amplification: retrospective and validation phase. *J Exp Clin Cancer Res.* 2016 Dec 8;35(1):193. PMID:27931238
- 496.** Di Napoli A, De Cecco L, Piccaluga PP, et al. Transcriptional analysis distinguishes breast implant-associated anaplastic large cell lymphoma from other peripheral T-cell lymphomas. *Mod Pathol.* 2019 Feb;32(2):296–30. PMID:30206415
- 497.** Di Oto E, Biserni GB, Varga Z, et al. X chromosome gain is related to increased androgen receptor expression in male breast cancer. *Virchows Arch.* 2018 Aug;473(2):155–63. PMID:29802469
- 498.** Di Oto E, Monti V, Cucchi MC, et al. X chromosome gain in male breast cancer. *Hum Pathol.* 2015 Dec;46(12):1930–1. PMID:26475094
- 499.** Di Tommaso L, Foschini MP, Rapaccini T, et al. Mucoepidermoid carcinoma of the breast. *Virchows Arch.* 2004 Jan;444(1):101–5. PMID:14634807
- 500.** Di Tommaso L, Franchi G, Desmedt C, et al. Toker cells of the breast. Morphological and immunohistochemical characterization of 40 cases. *Hum Pathol.* 2008 Sep;39(9):1285–90. PMID:18614197
- 501.** Diab SG, Clark GM, Osborne CK, et al. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. *J Clin Oncol.* 1999 May;17(5):1400–5. PMID:10334529
- 502.** Dialani V, Venkataraman S, Freudenthal S, et al. Does isolated flat epithelial atypia on vacuum-assisted breast core biopsy need surgical excision? *Breast J.* 2014 Dec;20(6):606–14. PMID:25264188
- 503.** Diallo R, Schaefer KL, Bankfalvi A, et al. Secretory carcinoma of the breast: a clinicopathologic variant of invasive ductal carcinoma by comparative genomic hybridization and immunohistochemistry. *Hum Pathol.* 2005 Dec;36(12):1299–305. PMID:16591916
- 504.** Diaz LK, Wiley EL, Venta LA, et al. Mucinous carcinoma cells displaced by large-gauge needle core biopsy of the breast? *AJR Am J Roentgenol.* 1999 Nov;173(5):1303–13. PMID:10547711
- 505.** Diaz NM, McDermott WM, et al. Pleomorphic adenoma of the breast: a clinicopathologic and immunohistochemical study of 10 cases. *Hum Pathol.* 2000 Dec;31(12):1206–14. PMID:11063550
- 506.** Diaz-Arias AA, Hurt MA, Ley TE, et al. Leiomyoma of the breast. *Hum Pathol.* 1999 Apr;20(4):396–9. PMID:2467872
- 507.** Diaz-Casajao C, Borghi S, Weyers A, et al. Benign lymphangiomyoma of the skin following radiotherapy: a report of five new cases and review of the literature. *Histopathology.* 1999 Oct;35(4):425–30. PMID:10564386
- 508.** DiCostanzo D, Rosen PP, et al. Prognosis in infiltrating lobular carcinoma: An analysis of "classical" and variant forms. *Am J Surg Pathol.* 1990 Jan;14(1):1–7. PMID:2153007
- 509.** Dieci MV, Smutná V, Scott L, et al. Exome sequencing of rare aggressive breast cancer histologies. *Breast Cancer Res Treat.* 2016 Feb;156(1):21–32. PMID:26583650
- 510.** Dietrich CU, Pandis N, Kotsopoulos J, et al. Chromosome aberrations in adenolipomas of the breast: evidence that the mesenchymal component constitutes the neoplastic parenchyma. *Genet Cytogenet.* 1994 Feb;16(1):1–10. PMID:8143274
- 511.** Dietzel M, Baltzer PA, Nagy T, et al. Magnetic resonance mammography of infiltrating lobular versus ductal carcinoma: comparison of 811 patients with diagnostic accuracy irrespective of tumor grade. *Comput Assist Tomogr.* 2010 Jul;34(5):433–40. PMID:20657229
- 512.** Dillon DA, Lester SC, Lester SC, et al. Lesions of the breast nipple. *Surg Pathol Clin.* 2005 Jun;28(3):393–410. PMID:15937020
- 513.** Dillon MF, McDermott WM, et al. Primary plasmacytoma of the breast. *Arch Pathol Lab Med.* 2001 Aug;125(8):1078–80. PMID:11473462

- Predictive value of breast lesions of "uncertain malignant potential" and "suspicious for malignancy" determined by needle core biopsy. *Am J Surg Oncol.* 2007 Feb;14(2):704–11. PMID:17151788
514. Dimitriadis G, Papadopoulos V, Mimidis K. Eplerenone reverses spironolactone-induced painful gynaecomastia in cirrhotics. *Hepatol Int.* 2011 Jun;5(2):738–9. PMID:21484105
515. Din NU, Idrees R, Fatima S, et al. Secretory carcinoma of breast: clinicopathologic study of cases. *Ann Diagn Pathol.* 2013 Feb;17(1):54–7. PMID:22832018
516. Disanto MG, Ambrosio MR, Rocca E, et al. Optimal minimal panels of immunohistochemistry for diagnosis of B-cell lymphoma for application in countries with limited resources and for triaging cases before referral to specialist centers. *Am J Clin Pathol.* 2016 May;145(5):687–95. PMID:27247372
517. Di Saverio S, Gutierrez J, Avisar E. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. *Breast Cancer Res Treat.* 2008 Oct;111(3):541–7. PMID:18026874
518. Dischinger PS, Tovar EA, Essenburg CJ, et al. NF1 deficiency correlates with estrogen receptor signaling and diminished survival in breast cancer. *NPJ Breast Cancer.* 2018 Aug 29. PMID:30182054
519. Dite GS, MacLennan RJ, Bickerstaffe A, et al. Breast cancer risk prediction using clinical models and 77 independent risk-associated SNPs for women aged under 50 years: Australian Breast Cancer Family Registry. *Cancer Epidemiol Biomarkers Prev.* 2016 Feb;25(2):359–65. PMID:26677205
520. Di Tommaso L, Rosai J. The capillary tumor: a deceptively benign feature of post-radiation angiosarcoma of the skin: report of three cases. *Am J Dermatopathol.* 2005 Aug;27(4):301–5. PMID:16121049
521. Dixon JM, Anderson TJ, Page DL, et al. Infiltrating lobular carcinoma of the breast. *Histopathology.* 1982 Mar;6(2):149–61. PMID:7076138
522. Doane AS, Danso M, Lal P, et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. *Oncogene.* 2006 Jun;25(28):3994–4008. PMID:16491124
523. Doctor VM, Sirsat MV. Florid papillomatosis (adenoma) and other benign tumors of the nipple and areola. *Br J Cancer.* 1971 Mar;25(1):1–9. PMID:5581295
524. Doobar SC, Krol NM, van Marion R, et al. Progression of ductal carcinoma in situ to invasive breast cancer: comparative genomic sequencing. *Virchows Arch.* 2019 Feb;474(2):247–51. PMID:30284611
525. Doobar SC, Slaets L, Cardoso F, et al. Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/WABC International Male Breast Cancer Program. *Mod Pathol.* 2017 Apr;30(4):509–18. PMID:28084333
526. Dogan S, Wang L, Ptashkin RN, et al. Mammary analog secretory carcinoma of the thyroid gland: a primary thyroid adenocarcinoma harboring ETV6-NTRK3 fusion. *Mod Pathol.* 2016 Sep;29(9):985–95. PMID:27282352
527. Dolgin E. Olaparib keeps hereditary breast tumors in check. *Cancer Discov.* 2017 Aug;7(8):OF10. PMID:28583909
528. Domagala P, Wokolorczyk D, Cybulski C, et al. Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer. *Breast Cancer Res Treat.* 2012 Apr;132(3):937–45. PMID:21701879
529. Domagala W, Harezga B, Szadowska A, et al. Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas. *Am J Pathol.* 1993 Mar;142(3):669–74. PMID:8384406
530. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. *JAMA.* 2010 Sep 1;304(9):967–75. PMID:20810374
531. Domchek SM, Hecht JL, Fleming MD, et al. Lymphomas of the breast: primary and secondary involvement. *Cancer.* 2002 Jan 1;94(1):6–13. PMID:11815954
532. Domfeh AB, Carley AL, Striebel JM, et al. WT1 immunoreactivity in breast carcinoma: selective expression in pure and mixed mucinous subtypes. *Mod Pathol.* 2008 Oct;21(10):1217–23. PMID:18469795
533. Dömont J, Salas S, Lacroix L, et al. High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management. *Br J Cancer.* 2010 Mar 16;102(6):1032–6. PMID:20197769
534. Domoto H, Tsuda H, Miyakawa K, et al. Invasive ductal carcinoma associated with tubular adenoma of the breast. *Pathol Int.* 2002 Mar;52(3):244–8. PMID:11972869
535. Donaldson AR, Sieck L, Booth CN, et al. Radial scars diagnosed on breast core biopsy: frequency of atypia and carcinoma on excision and implications for management. *Breast.* 2016 Dec;30:201–7. PMID:27371970
536. Donnell RM, Rosen PP, Lieberman PH, et al. Angiosarcoma and other vascular tumors of the breast. *Am J Surg Pathol.* 1981 Oct;5(7):629–42. PMID:7199829
537. Doren EL, Miranda RN, Selber JC, et al. U.S. epidemiology of breast implant-associated anaplastic large cell lymphoma. *Plast Reconstr Surg.* 2017 May;139(5):1042–50. PMID:28157769
538. Dores GM, Qubaiah O, Mody A, et al. A population-based study of incidence and patient survival of small cell carcinoma in the United States, 1992–2010. *BMC Cancer.* 2015 Mar 27;15:185. PMID:25885914
539. Downs-Kelly E, Bell D, Perkins GH, et al. Clinical implications of margin involvement by pleomorphic lobular carcinoma in situ. *Arch Pathol Lab Med.* 2011 Jun;135(6):737–43. PMID:21631266
540. Downs-Kelly E, Nayeeemuddin KM, Albaracin C, et al. Matrix-producing carcinoma of the breast: an aggressive subtype of metaplastic carcinoma. *Am J Surg Pathol.* 2009 Apr;33(4):534–41. PMID:19047898
541. Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. *J Clin Oncol.* 2010 Apr 10;28(11):1829–34. PMID:20212256
542. Dowsett M, Nielsen TO, A'Hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. *J Natl Cancer Inst.* 2011 Nov 16;103(22):1656–64. PMID:21960707
543. Doyle LA, Hornick JL. Mesenchymal tumors of the gastrointestinal tract other than GIST. *Surg Pathol Clin.* 2013 Sep;6(3):425–73. PMID:26839096
544. Dreyer G, Vandorpe T, Smeets A, et al. Triple negative breast cancer: clinical characteristics in the different histological subtypes. *Breast.* 2013 Oct;22(5):761–6. PMID:23416046
545. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. *N Engl J Med.* 2018 Feb 22;378(8):731–9. PMID:29466156
546. Droufakou S, Deshmeh V, Roylance R, et al. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. *Int J Cancer.* 2001 May 1;92(3):404–8. PMID:11291078
547. du Toit RS, Locker AP, Ellis IO, et al. Invasive lobular carcinomas of the breast—the prognosis of histopathological subtypes. *Br J Cancer.* 1989 Oct;60(4):605–9. PMID:2803932
548. El Aouni N, Laurent I, Terrier P, et al. Granular cell tumor of the breast. *Diagn Cytopathol.* 2007 Nov;35(11):725–7. PMID:17924412
549. El Hag IA, Aodah A, Kollur SM, et al. Cytological clues in the distinction between phyllodes tumor and fibroadenoma. *Cancer Cytopathol.* 2010 Feb 25;118(1):33–40. PMID:20094997
550. Duffy MJ, Harbeck N, Nap M, et al. Clinical use of biomarkers in breast cancer: updated guidelines from the European Group on Tumor Markers (EGTM). *Eur J Cancer.* 2017 Apr;75:284–98. PMID:28259011
551. Duman BB, Sahin B, Güvenç B, et al. Lymphoma of the breast in a male patient. *Med Oncol.* 2011 Dec;28 Suppl 1:S490–3. PMID:20830532
552. Dunning AM, Michailidou K, Kuchenbaecker KB, et al. Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. *Nat Genet.* 2016 Apr;48(4):374–86. PMID:26928228
553. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. *N Engl J Med.* 1985 Jan 17;312(3):146–51. PMID:3965932
554. Dupont WD, Page DL, Parl FF, et al. Long-term risk of breast cancer in women with fibroadenoma. *N Engl J Med.* 1994 Jul 7;331(1):10–5. PMID:8202095
555. Duprez R, Wilkerson PM, Lacroix-Triki M, et al. Immunophenotypic and genomic characterization of papillary carcinomas of the breast. *J Pathol.* 2012 Feb;226(3):427–41. PMID:22025283
556. Dursun F, Su Dur SM, Şahin C, et al. A rare cause of prepubertal gynecomastia: Sertoli cell tumor. *Case Rep Pediatr.* 2015;2015:439239. PMID:26366315
557. Dye K, Saucedo M, Raju D, et al. A common cancer in an uncommon location: a case report of squamous cell carcinoma of the nipple. *Int J Surg Case Rep.* 2017;36:94–7. PMID:28551484
558. Dyrtstad SW, Yan Y, Fowler AM, et al. Breast cancer risk associated with benign breast disease: systematic review and meta-analysis. *Breast Cancer Res Treat.* 2015 Feb;149(3):569–75. PMID:25636589
559. Correa C, McGale P, Taylor C, et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. *J Natl Cancer Inst Monogr.* 2010;2010(41):162–77. PMID:20956824
560. Easton DF, Pharoah PD, Antoniou AC, et al. Gene-panel sequencing and the prediction of breast-cancer risk. *N Engl J Med.* 2015 Jun 4;372(23):2243–57. PMID:26014596
561. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. *Nature.* 2007 Jun 28;447(7148):1087–93. PMID:17529967
562. Ebrahim L, Parry J, Taylor DB. Fibromatosis of the breast: a pictorial review of the imaging and histopathology findings. *Clin Radiol.* 2014 Oct;69(10):1077–83. PMID:24990452
563. Eby PR, Ochsner JE, DeMartini WB, et al. Frequency and upgrade rates of atypical ductal hyperplasia diagnosed at stereotactic vacuum-assisted breast biopsy: 9- versus 11-gauge. *AJR Am J Roentgenol.* 2009 Jan;192(1):229–34. PMID:19098204
564. Edelweiss M, Corben AD, Liberman L, et al. Focal extravasated mucin in breast core needle biopsies: Is surgical excision always necessary? *Breast J.* 2013 May-Jun;19(3):302–9. PMID:23534893
565. Efared B, Sidibé IS, Abdoulaziz S, et al. Tubular adenoma of the breast: a clinicopathologic study of a series of 9 cases. *Clin Med Insights Pathol.* 2018 Feb 5;11:1179555718757499. PMID:29449780
566. El Aouni N, Laurent I, Terrier P, et al. Granular cell tumor of the breast. *Diagn Cytopathol.* 2007 Nov;35(11):725–7. PMID:17924412
567. El Hag IA, Aodah A, Kollur SM, et al. Cytological clues in the distinction between phyllodes tumor and fibroadenoma. *Cancer Cytopathol.* 2010 Feb 25;118(1):33–40. PMID:20094997
568. Elayat G, Selim AG, Wells CA. Cell turnover in apocrine metaplasia and apocrine adenosis of the breast. *Ann Diagn Pathol.* 2010 Feb;14(1):1–7. PMID:20123450
569. Elbendary A, Xue R, Valdebran M, et al. Diagnostic criteria in intraepithelial pagetoid neoplasms: a histopathologic study and evaluation of select features in Paget disease, Bowen disease, and melanoma in situ. *Am J Dermatopathol.* 2017 Jun;39(6):419–27. PMID:28525420
570. Elghobashy M, Basu N, Warner R, et al. Metaplastic breast cancer masquerading as liposarcoma of the breast: a case report following oncoplastic treatment. *Pathobiology.* 2018;85(4):261–5. PMID:29788010
571. Ellingjord-Dale M, Vos L, Hjerkind KV, et al. Alcohol, physical activity, smoking, and breast cancer subtypes in a large, nested case-control study from the Norwegian Breast Cancer Screening Program. *Cancer Epidemiol Biomarkers Prev.* 2017 Dec;26(12):1736–44. PMID:28877889
572. Ellingjord-Dale M, Vos L, Tretli S, et al. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program. *Breast Cancer Res.* 2017 Jan 23;19(1):10. PMID:28114999
573. Ellis IO, Al-Sam S, Anderson N, et al. Pathology reporting of breast disease in surgical excision specimens incorporating the dataset for histological reporting of breast cancer. London (UK): The Royal College of Pathologists; June 2016.
574. Ellis IO, Galea M, Broughton N, et al. Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. *Histopathology.* 1992 Jun;20(6):479–89. PMID:1607149
- 574A. Ellis MJ, Perou CM. The genomic landscape of breast cancer as a therapeutic roadmap. *Cancer Discov.* 2013 Jan;3(1):27–34. PMID:23319768
575. Ellsworth RE, Ellsworth DL, Love B, et al. Correlation of levels and patterns of genomic instability with histological grading of DCIS. *Ann Surg Oncol.* 2007 Nov;14(11):3070–7. PMID:17549568
576. Elmí M, Sequeira S, Azin A, et al. Evolving surgical treatment decisions for male breast cancer: an analysis of the National Surgical Quality Improvement Program (NSQIP) database. *Breast Cancer Res Treat.* 2018 Sep;171(2):427–34. PMID:29808286
577. Elmore JG, Longton GM, Carney PA, et al. Diagnostic concordance among pathologists interpreting breast biopsy specimens. *JAMA.* 2015 Mar 17;313(11):1122–32. PMID:25781441
578. Elmore JG, Nelson HD, Pepe MS, et al. Variability in pathologists' interpretations of individual breast biopsy slides: a population perspective. *Ann Intern Med.* 2016 May

- 17;164(10):649–55. PMID:26999810
579. Elmore JG, Tosteson AN, Pepe MS, et al. Evaluation of 12 strategies for obtaining second opinions to improve interpretation of breast histopathology: simulation study. *BMJ*. 2016 Jun 22;353:i3069. PMID:27334105
580. El-Naggar AK, Chan JKC, Grandis JR, et al., editors. WHO classification of head and neck tumours. Lyon (France): International Agency for Research on Cancer; 2017. (WHO classification of tumours series, 4th ed.; vol. 9). <http://publications.iarc.fr/548>.
581. El Sharouni MA, Postma EL, van Diest PJ. Correlation between E-cadherin and p120 expression in invasive ductal breast cancer with a lobular component and MRI findings. *Virchows Arch.* 2017 Dec;471(6):707–12. PMID:28779344
582. Elsheikh TM, Silverman JF. Follow-up surgical excision is indicated when breast core needle biopsies show atypical lobular hyperplasia or lobular carcinoma in situ: a correlative study of 33 patients with review of the literature. *Am J Surg Pathol.* 2005 Apr;29(4):534–43. PMID:15767810
583. Elshof LE, Schmidt MK, Rutgers EJT, et al. Cause-specific mortality in a population-based cohort of 9799 women treated for ductal carcinoma in situ. *Ann Surg.* 2018 May;267(5):952–8. PMID:28375855
584. Elshof LE, Tryfonidis K, Slaets L, et al. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - the LORD study. *Eur J Cancer.* 2015 Aug;51(12):1497–510. PMID:26025767
585. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. *Histopathology.* 1991 Nov;19(5):403–10. PMID:1757079
586. Elston CW, Sloane JP, Amendoeira I, et al. Causes of inconsistency in diagnosing and classifying intraductal proliferations of the breast. *Eur J Cancer.* 2000 Sep;36(14):1769–72. PMID:10974624
587. Elzahaby IA, Saleh S, Metwally IH, et al. Huge lactating adenoma of the breast: case report. *Breast Dis.* 2017;37(1):37–42. PMID:28269736
588. Ende L, Mercado C, Axelrod D, et al. Intraparenchymal leiomyoma of the breast: a case report and review of the literature. *Ann Clin Lab Sci.* 2007 Summer;37(3):268–73. PMID:17709693
589. Eng C. PTEN hamartoma tumor syndrome. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. *GeneReviews.* Seattle (WA): University of Washington, Seattle; 2001 Nov 29 [updated 2016 Jun 2]. PMID:20301661
590. Engström MJ, Opdahl S, Vatten LJ, et al. Invasive lobular breast cancer: the prognostic impact of histopathological grade, E-cadherin and molecular subtypes. *Histopathology.* 2015 Feb;66(3):409–19. PMID:25283075
591. Eren E, Edgunlu T, Korkmaz HA, et al. Genetic variants of estrogen beta and leptin receptors may cause gynecomastia in adolescent. *Gene.* 2014 May 15;541(2):101–6. PMID:24625355
592. Erhan Y, Erhan Y, Zekioğlu O. Pure invasive micropapillary carcinoma of the male breast: report of a rare case. *Can J Surg.* 2005 Apr;48(2):156–7. PMID:15887800
593. Erickson-Johnson MR, Chou MM, Evers BR, et al. Nodular fasciitis: a novel model of transient neoplasia induced by MYH9-USP6 gene fusion. *Lab Invest.* 2011 Oct;91(10):1427–33. PMID:21826056
594. Erinanc H, Türk E. The rare benign lesion that mimics a malignant tumor in breast parenchyma: nodular fasciitis of the breast. *Case Rep Pathol.* 2018 Apr 30;2018:1612587. PMID:29854526
595. Ersahin C, Bandyopadhyay S, Bhargava R. Thyroid transcription factor-1 and “basal marker”—expressing small cell carcinoma of the breast. *Int J Surg Pathol.* 2009 Oct;17(5):368–72. PMID:19578049
596. Espinosa I, Gallardo A, D’Angelo E, et al. Simultaneous carcinomas of the breast and ovary: utility of Pax-8, WT-1, and GATA3 for distinguishing independent primary tumors from metastases. *Int J Gynecol Pathol.* 2015 May;34(3):257–65. PMID:25844549
597. Esposito NN, Dabbs DJ, Bhargava R. Are encapsulated papillary carcinomas of the breast in situ or invasive? A basement membrane study of 27 cases. *Am J Clin Pathol.* 2009 Feb;131(2):228–42. PMID:19141383
598. Etzell JE, Devries S, Chew K, et al. Loss of chromosome 16q in lobular carcinoma in situ. *Hum Pathol.* 2001 Mar;32(3):292–6. PMID:11274638
599. Eusebi V, Casadei GP, Bussolati G, et al. Adenomyoepithelioma of the breast with a distinctive type of apocrine adenosis. *Histopathology.* 1987 Mar;11(3):305–15. PMID:2828217
- 599A. Eusebi V, Damiani S, Ellis IO, et al. Breast tumor resembling the tall cell variant of papillary thyroid carcinoma: report of 5 cases. *Am J Surg Pathol.* 2003 Aug;27(8):1114–8. PMID:12883243
600. Eusebi V, Feudale E, Foschini MP, et al. Long-term follow-up of in situ carcinoma of the breast. *Semin Diagn Pathol.* 1994 Jan;19(1):115–21. PMID:16357842
601. Eusebi V, Foschini MP, Bussolati G, et al. Myoblastomatoid (histiocytoid) carcinoma of the breast. A type of apocrine carcinoma. *Am J Surg Pathol.* 1995 May;19(5):553–62. PMID:7726365
602. Eusebi V, Lamovec J, Cattani MG, et al. Acantholytic variant of squamous-cell carcinoma of the breast. *Am J Surg Pathol.* 1986 Dec;10(12):855–61. PMID:2431630
603. Eusebi V, Magalhaes F, Azzopardi JG. Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation. *Hum Pathol.* 1992 Jun;23(6):655–62. PMID:1592388
604. Eusebi V, Millis RR. Epitheliosis, infiltrating epitheliosis, and radial scar. *Semin Diagn Pathol.* 2010 Feb;27(1):5–12. PMID:20306826
605. Eusebi V, Millis RR, Cattani MG, et al. Apocrine carcinoma of the breast. A morphologic and immunocytochemical study. *Am J Pathol.* 1986 Jun;123(3):532–41. PMID:3717305
606. Evans DG, O’Hara C, Wilding A, et al. Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989. *Eur J Hum Genet.* 2011 Nov;19(11):1187–91. PMID:21694737
607. Evans N, Lyons K. The use of ultrasound in the diagnosis of invasive lobular carcinoma of the breast less than 10 mm in size. *Clin Radiol.* 2000 Apr;55(4):261–3. PMID:10767184
608. Evers B, Speksnijder EN, Schut E, et al. A tissue reconstitution model to study cancer cell-intrinsic and -extrinsic factors in mammary tumourigenesis. *J Pathol.* 2010 Jan;220(1):34–44. PMID:19927317
609. Fackenthal JD, Marsh DJ, Richardson AL, et al. Male breast cancer in Cowden syndrome patients with germline PTEN mutations. *J Med Genet.* 2001 Mar;38(3):159–64. PMID:11238682
610. Fadare O, Dadmanesh F, Alvarado-Cabrero I, et al. Lobular intraepithelial neoplasia (lobular carcinoma in situ) with comedo-type necrosis: a clinicopathologic study of 18 cases. *Am J Surg Pathol.* 2006 Nov;30(11):1445–53. PMID:17063087
611. Fadare O, Wang SA, Hileeto D. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset? *Hum Pathol.* 2008 Mar;39(3):331–6. PMID:18261623
612. Falconieri G, Delta Libera D, Zanconati F, et al. Leiomyosarcoma of the female breast: report of two new cases and a review of the literature. *Am J Clin Pathol.* 1997 Jul;108(1):19–25. PMID:9208974
613. Falomo E, Adejumo C, Carson KA, et al. Variability in the management recommendations given for high-risk breast lesions detected on image-guided core needle biopsy at U.S. academic institutions. *Curr Probl Diagn Radiol.* 2018 Jun 27;S0363-0188(18)30067-7. PMID:30075881
614. Fanburg-Smith JC, Majidi M, Miettinen M. Keratin expression in schwannoma: a study of 115 retroperitoneal and 22 peripheral schwannomas. *Mod Pathol.* 2006 Jan;19(1):115–21. PMID:16357842
615. Fanburg-Smith JC, Meis-Kindblom JM, Fante R, et al. Malignant granular cell tumor of soft tissue: diagnostic criteria and clinicopathologic correlation. *Am J Surg Pathol.* 1998 Jul;22(7):779–94. PMID:9669341
616. Fang Y, Wu J, Wang W, et al. Biologic behavior and long-term outcomes of breast ductal carcinoma in situ with microinvasion. *Oncotarget.* 2016 Sep 27;7(39):64182–90. PMID:27577080
617. Farinha P, André S, Cabeçadas J, et al. High frequency of MALT lymphoma in a series of 14 cases of primary breast lymphoma. *Appl Immunohistochem Mol Morphol.* 2002 Jun;10(2):115–20. PMID:12051628
618. Farinha P, Gascogne RD. Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. *J Clin Oncol.* 2005 Sep 10;23(26):6370–8. PMID:16155022
619. Farkash EA, Ferry JA, Harris NL, et al. Rare lymphoid malignancies of the breast: a report of two cases illustrating potential diagnostic pitfalls. *J Hematop.* 2009 Aug 20;2(4):237–44. PMID:20309431
620. Farmer P, Bonnefond H, Becette V, et al. Identification of molecular apocrine breast tumours by microarray analysis. *Oncogene.* 2005 Jul 7;24(29):4660–71. PMID:15897907
621. Farrow JH, Ashikari H. Breast lesions in young girls. *Surg Clin North Am.* 1969 Apr;49(2):261–9. PMID:5813207
622. Farshid G, Edwards S, Kollias J, et al. Active surveillance of women diagnosed with atypical ductal hyperplasia on core needle biopsy may spare many women potentially unnecessary surgery, but at the risk of undertreatment for a minority: 10-year surgical outcomes of 114 consecutive cases from a single center. *Mod Pathol.* 2018 Mar;31(3):395–405. PMID:29099502
623. Fasola CE, Chen JJ, Jensen KC, et al. Characteristics and clinical outcomes of pleomorphic lobular carcinoma in situ of the breast. *Breast J.* 2018 Jan;24(1):66–9. PMID:28929550
624. Fassan M, Baffa R, Palazzo JP, et al. MicroRNA expression profiling of male breast cancer. *Breast Cancer Res.* 2009;11(4):R58. PMID:19664288
625. Faverly DR, Burgers L, Bult P, et al. Three dimensional imaging of mammary ductal carcinoma in situ: clinical implications. *Semin Diagn Pathol.* 1994 Aug;11(3):193–8. PMID:7831530
626. Fechner RE. Histologic variants of infiltrating lobular carcinoma of the breast. *Hum Pathol.* 1975 May;6(3):373–8. PMID:16357842
627. Fechner RE. Infiltrating lobular carcinoma without lobular carcinoma in situ. *Cancer.* 1977 Jun;39(6):1539–45. PMID:4337952
628. Fedko MG, Scow JS, Shah SS, et al. Pure tubular carcinoma and axillary metastases. *Ann Surg Oncol.* 2010 Suppl 3:338–42. PMID:20853056
629. Felts JL, Zhu J, Han B, et al. An analysis of Oncotype DX recurrence scores and clinicopathologic characteristics in invasive lobular breast cancer. *Breast.* 2007 Nov;23(6):677–86. PMID:18097781
630. Ferlay J, Colombet M, Bray F, et al. Incidence in Five Continents. Clermont-Ferrand (France): International Agency for Research on Cancer; 2018. Available from: <http://ci5.iarc.fr>
631. Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today [Internet]. Lyon (France): International Agency for Research on Cancer; 2018. Available from: <https://gco.iarc.fr/>
632. Ferlicot S, Vincent-Salomon A, et al. Wide metastatic spreading in invasive lobular carcinoma of the breast. *Eur J Cancer.* 2004 Feb;40(3):336–41. PMID:14748855
633. Fernandez AP, Sun Y, Tuttis RR, et al. FISH for MYC amplification and anti-MYC immunohistochemistry: useful diagnostic tools in the assessment of secondary and atypical vascular proliferations. *Cutan Pathol.* 2012 Feb;35(2):194–200. PMID:22121953
634. Ferrier RE. Neurofibromatosis 1 and neurofibromatosis 2: a twenty-first century perspective. *Lancet Neurol.* 2007 Apr;6(4):51–6. PMID:17362838
635. Ferreira AI, Borges S, Souza M, et al. Radial scar of the breast: Is it necessary to avoid surgery? *Eur J Surg Oncol.* 2007 Jul;43(7):1265–72. PMID:17815516
636. Ferrufino-Schmidt MC, Medeiros LF, et al. Clinicopathologic features and impact of lymph node involvement associated with breast implant-associated large cell lymphoma. *Am J Surg Pathol.* 2012 Mar;42(3):293–305. PMID:22914202
637. Ferzoco RM, Ruddy KJ. The epidemiology of male breast cancer. *Curr Oncol Rev.* 2009 Jan;18(1):1. PMID:26694922
638. Fillion MM, Glass KE, Hayes DF, et al. Healthcare costs reduced after implementation of the results of the American College of Surgeons Oncology Group Z0011 trial into clinical practice. *Breast J.* 2017 May;23(3):230–7. PMID:27900818
639. Fineberg S, Rosen PP. The biology of angiosarcoma and atypical vascular proliferations of the skin and breast after radiation therapy for breast carcinoma. *Am J Clin Pathol.* 2000 Dec;162(6):757–63. PMID:11078080
640. Fiore M, Rimareix F, Marin L, et al. Desmoid-type fibromatosis: a conservative approach to select patients with surgical treatment. *Ann Surg Oncol.* 2009 Sep;16(9):2587–93. PMID:19758875
641. Fisher B, Costantino JP, Redmond C, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. *Cancer Inst.* 1999 Nov 3;91(21):1631–9. PMID:10547399
642. Fisher B, Land S, Mamounas E, et al. Prevention of invasive breast cancer with tamoxifen in women with ductal carcinoma in situ: report of the National Surgical Adjuvant Breast and Bowel Project experience. *Semin Oncol.* 2000 Aug;28(4):400–18. PMID:11049882
643. Fisher C. Unusual myxoid, perineurial, and postradiation lesions, with emphasis on atypical vascular lesions. *Am J Clin Pathol.* 2000 Jun;163(6):833–40. PMID:10883220

- cutaneous angiosarcoma, myoepithelial tumors, myopericytoma, and perivascular epithelioid cell tumor. *Semin Diagn Pathol.* 2013 Feb;30(1):73–84. PMID:23327731
644. Fisher C, Magnusson B, Hardarson S, et al. Myxoid variant of follicular dendritic cell sarcoma arising in the breast. *Ann Diagn Pathol.* 1999 Apr;3(2):92–8. PMID:10196389
645. Fisher CJ, Hanby AM, Robinson L, et al. Mammary hamartoma—a review of 35 cases. *Histopathology.* 1992 Feb;20(2):99–106. PMID:1559675
646. Fisher ER, Costantino J, Fisher B, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Five-year observations concerning lobular carcinoma in situ. *Cancer.* 1996 Oct 178(7):1403–16. PMID:8839545
647. Fisher ER, Gregorio RM, Redmond C, et al. Tubulolobular invasive breast cancer: a variant of lobular invasive cancer. *Hum Pathol.* 1977 Nov;8(6):679–83. PMID:924431
648. Fisher ER, Land SR, Fisher B, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ. *Cancer.* 2004 Jan 15;100(2):238–44. PMID:14716756
649. Fisher ER, Wang J, Bryant J, et al. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. *Cancer.* 2002 Aug 15;95(4):681–95. PMID:12209710
650. Fitzgibbons PL, Henson DE, Hutter RL. Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. *Arch Pathol Lab Med.* 1998 Dec;122(12):1053–5. PMID:9870852
651. Flaherty DC, Bawa R, Burton C, et al. Breast cancer in male adolescents and young adults. *Ann Surg Oncol.* 2017 Jan;24(1):84–90. PMID:27650826
652. Flanagan MR, Rendi MH, Calhoun E, et al. Pleomorphic lobular carcinoma in situ: radiologic-pathologic features and clinical management. *Ann Surg Oncol.* 2015 Dec;22(13):4263–9. PMID:25893410
653. Fletcher CD, Beham A, Bekir S, et al. Epithelioid angiosarcoma of deep soft tissue: a distinctive tumor readily mistaken for an epithelial neoplasm. *Am J Surg Pathol.* 1991 Oct;15(10):915–24. PMID:1718176
654. Fletcher CDM, Bridge JA, Hogendoorn PCW, et al., editors. WHO classification of tumours of soft tissue and bone. Lyon (France): International Agency for Research on Cancer; 2013. (WHO classification of tumours series, 4th ed; vol. 5). <http://publications.iarc.fr/15>
655. Fletcher O, Johnson N, Dos Santos Silva I, et al. Family history, genetic testing, and clinical prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls. *Cancer Epidemiol Biomarkers Prev.* 2009 Jan;18(1):230–4. PMID:19124502
656. Fletcher O, Johnson N, Orr N, et al. Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. *J Natl Cancer Inst.* 2011 Mar 2;103(5):425–35. PMID:21263130
657. Flint A, Oberman HA. Infarction and squamous metaplasia of intraductal papilloma: a benign breast lesion that may simulate carcinoma. *Hum Pathol.* 1984 Aug;15(8):764–7. PMID:6745916
658. Flucke U, Requena L, Mentzel T. Radiation-induced vascular lesions of the skin: an overview. *Adv Anat Pathol.* 2013 Nov;20(6):407–15. PMID:24113311
659. Folpe AL, Chand EM, Goldblum JR, et al. Expression of Fli-1, a nuclear transcription factor, distinguishes vascular neoplasms from potential mimics. *Am J Surg Pathol.* 2001 Aug;25(8):1061–6. PMID:11474291
660. Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. *J Clin Oncol.* 2010 May 20;28(15):2512–9. PMID:20406929
661. Foote FW Jr, Stewart FW. A histologic classification of carcinoma of the breast. *Surgery.* 1946 Jan;19:74–99. PMID:21022022
662. Foote FW, Stewart FW. Lobular carcinoma in situ: a rare form of mammary cancer. *Am J Pathol.* 1941 Jul;17(4):491–63. PMID:19970575
663. Fortuno C, James PA, Spurdle AB. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome. *Hum Mutat.* 2018 Dec;39(12):1764–73. PMID:30240537
664. Foschini MP, Asioli S, Foreid S, et al. Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms: a unique invasive tumor with indolent behavior. *Am J Surg Pathol.* 2017 Jul;41(7):887–95. PMID:28418993
665. Foschini MP, Eusebi V. Microglandular adenosis of the breast: a deceptive and still mysterious benign lesion. *Hum Pathol.* 2018 Dec;82:1–9. PMID:29949742
666. Foschini MP, Krausz T. Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including “triple negative carcinomas” of low malignant potential. *Semin Diagn Pathol.* 2010 Feb;27(1):77–90. PMID:20306833
667. Foschini MP, Marucci G, Eusebi V. Low-grade mucoepidermoid carcinoma of salivary glands: characteristic immunohistochemical profile and evidence of striated duct differentiation. *Virchows Arch.* 2002 May;440(5):536–42. PMID:12021929
668. Foschini MP, Morandi L, Asioli S, et al. The morphological spectrum of salivary gland type tumours of the breast. *Pathology.* 2017 Feb;49(2):215–27. PMID:28043647
669. Foschini MP, Pizzicannella G, Peterse JL, et al. Adenomyoepithelioma of the breast associated with low-grade adenosquamous and sarcomatoid carcinomas. *Virchows Arch.* 1995;427(3):243–50. PMID:7496592
670. Foschini MP, Rizzo A, De Leo A, et al. Solid variant of adenoid cystic carcinoma of the breast: a case series with proposal of a new grading system. *Int J Surg Pathol.* 2016 Apr;24(2):97–102. PMID:26378056
671. Foster MC, Helvie MA, Gregory NE, et al. Lobular carcinoma in situ or atypical lobular hyperplasia at core-needle biopsy: Is excisional biopsy necessary? *Radiology.* 2004 Jun;231(3):813–9. PMID:15105449
672. Foulkes WD, Knoppers BM, Turnbull C. Population genetic testing for cancer susceptibility: founder mutations to genomes. *Nat Rev Clin Oncol.* 2016 Jan;13(1):41–54. PMID:26483301
673. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. *J Natl Cancer Inst.* 2003 Oct 1;95(19):1482–5. PMID:14519755
674. Fraga-Guedes C, Gobbi H, Mastropasqua MG, et al. Clinicopathological and immunohistochemical study of 30 cases of post-radiation atypical vascular lesion of the breast. *Breast Cancer Res Treat.* 2014 Jul;146(2):347–54. PMID:24943869
675. Franceschini G, Terribile D, Scafetta I, et al. Conservative treatment of a rare case of multifocal adenoid cystic carcinoma of the breast: case report and literature review. *Med Sci Monit.* 2010 Mar;16(3):CS33–9. PMID:20190690
676. Francis A, Thomas J, Fallowfield L, et al. Addressing overtreatment of screen detected DCIS: the LORIS trial. *Eur J Cancer.* 2015 Nov;51(16):2296–303. PMID:26296293
677. Franco F, González-Rincón J, Lavernia J, et al. Mutational profile of primary breast diffuse large B-cell lymphoma. *Oncotarget.* 2017 Oct 24;8(61):102888–97. PMID:29262531
678. Franco Pérez F, Lavernia J, Aguiar-Bujanda D, et al. Primary breast lymphoma: analysis of 55 cases of the Spanish Lymphoma Oncology Group. *Clin Lymphoma Myeloma Leuk.* 2017 Mar;17(3):186–91. PMID:27847267
679. Frayling IM, Mautner VF, van Minckelen R, et al. Breast cancer risk in neurofibromatosis type 1 is a function of the type of NF1 gene mutation: a new genotype-phenotype correlation. *J Med Genet.* 2019 Apr;56(4):209–19. PMID:30530636
680. Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. *Cancer.* 1972 Jan;29(1):252–60. PMID:5007387
681. French JD, Ghousaini M, Edwards SL, et al. Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. *Am J Hum Genet.* 2013 Apr 4;92(4):489–503. PMID:23540573
682. Friebel TM, Domchek SM, Rebbeck TR. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. *J Natl Cancer Inst.* 2014 Jun;106(6):dju091. PMID:24824314
683. Frykberg ER. Lobular carcinoma in situ of the breast. *Breast J.* 1999 Sep;5(5):296–303. PMID:11348305
684. Fu W, Lobocki CA, Silberberg BK, et al. Molecular markers in Paget disease of the breast. *J Surg Oncol.* 2001 Jul;77(3):171–8. PMID:11455553
685. Fuehrer N, Hartmann L, Degnim A, et al. Atypical apocrine adenosis of the breast: long-term follow-up in 37 patients. *Arch Pathol Lab Med.* 2012 Feb;136(2):179–82. PMID:22288965
686. Fujii T, Yajima R, Morita H, et al. Adenoma of the nipple projecting out of the nipple: curative resection without excision of the nipple. *World J Surg Oncol.* 2014 Apr 10;12:91. PMID:24716784
687. Fukami M, Miyado M, Nagasaki K, et al. Aromatase excess syndrome: a rare autosomal dominant disorder leading to pre- or peri-pubertal onset gynecomastia. *Pediatr Endocrinol Rev.* 2014 Mar;11(3):298–305. PMID:24716396
688. Fukamizu H, Yamanaka K, Takemoto S, et al. An acquired giant vascular tumour of the breast. *Scand J Plast Reconstr Surg Hand Surg.* 2002;36(1):53–5. PMID:11925831
689. Fukunaga M, Ushigome S. Myofibroblastoma of the breast with diverse differentiations. *Arch Pathol Lab Med.* 1997 Jun;121(6):599–603. PMID:9199625
690. Fukuoka K, Hirokawa M, Shimizu M, et al. Basaloid type adenoid cystic carcinoma of the breast. *APMIS.* 1999 Aug;107(8):762–6. PMID:10515126
691. Fukuoka K, Kanahara T, Tamura M, et al. Basement membrane substance in adenomyoepithelioma of the breast. *Acta Cytol.* 2001 Mar-Apr;45(2):282–3. PMID:11284321
692. Fusco N, Geyer FC, De Filippo MR, et al. Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer. *Mod Pathol.* 2016 Nov;29(11):1292–305. PMID:27491809
693. Gall TM, Frampton AE. Gene of the month: E-cadherin (CDH1). *J Clin Pathol.* 2013 Nov;66(11):928–32. PMID:23940132
694. Gamallo C, Palacios J, Suarez A, et al. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. *Am J Pathol.* 1993 Apr;142(4):987–93. PMID:7682767
695. Ganjoo K, Advani R, Mariappan MR, et al. Non-Hodgkin lymphoma of the breast. *Cancer.* 2007 Jul 1;110(1):25–30. PMID:17541937
696. Gao F, Carter G, Tseng G, et al. Clinical importance of histologic grading of lobular carcinoma in situ in breast core needle biopsy specimens: current issues and controversies. *Am J Clin Pathol.* 2010 May;133(5):767–71. PMID:20395524
697. Gao FF, Khalbuss WE, Austin RM, et al. Cytomorphology of crystal storing histiocytosis in the breast associated with lymphoma: a case report. *Acta Cytol.* 2011;55(3):302–6. PMID:21525745
698. Gao Y, Niu Y, Wang X, et al. Genetic changes at specific stages of breast cancer progression detected by comparative genomic hybridization. *J Mol Med (Berl).* 2009 Feb;87(2):145–52. PMID:18936904
699. Garcia-Closas M, Couch FJ, Lindstrom S, et al. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. *Nat Genet.* 2013 Apr;45(4):392–8, e1–2. PMID:23535733
700. Gatalica Z. Immunohistochemical analysis of apocrine breast lesions. Consistent overexpression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ. *Pathol Res Pract.* 1997;193(11–12):753–8. PMID:9521507
701. Gatalica Z, Xiu J, Swensen J, et al. Molecular characterization of cancers with NTRK gene fusions. *Mod Pathol.* 2019 Jan;32(1):147–53. PMID:30171197
702. Gatta G, van der Zwan JM, Casali PG, et al. Rare cancers are not so rare: the rare cancer burden in Europe. *Eur J Cancer.* 2011 Nov;47(17):2493–511. PMID:22033323
703. Gatti RA, Tward A, Concannon P. Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations. *Mol Genet Metab.* 1999 Dec;68(4):419–23. PMID:10607471
704. Gaudet MM, Gapstur SM, Sun J, et al. Active smoking and breast cancer risk: original cohort data and meta-analysis. *J Natl Cancer Inst.* 2013 Apr 17;105(8):515–25. PMID:23449445
705. Gaudet MM, Kuchenbaecker KB, Vijai J, et al. Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. *PLoS Genet.* 2013;9(3):e1003173. PMID:23544012
706. Gengler C, Coindre JM, Leroux A, et al. Vascular proliferations of the skin after radiation therapy for breast cancer: clinicopathologic analysis of a series in favor of a benign process: a study from the French Sarcoma Group. *Cancer.* 2007 Apr 15;109(8):1584–98. PMID:17357996
707. Georgiannos SN, Chin J, Goode AW, et al. Secondary neoplasms of the breast: a survey of the 20th century. *Cancer.* 2001 Nov 1;92(9):2259–66. PMID:11745279
708. Gersell DJ, Katzenstein AL. Spindle cell carcinoma of the breast. A clinicopathologic and ultrastructural study. *Hum Pathol.* 1981 Jun;12(6):550–61. PMID:7275095
709. Gervais MK, Burtneshaw SM, Maxwell J, et al. Clinical outcomes in breast angiosarcoma patients: a rare tumor with unique challenges. *J Surg Oncol.* 2017 Dec;116(8):1056–61. PMID:29205355
710. Geyer FC, Berman SH, Marchiò C,

- et al. Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family. *Mod Pathol.* 2017 Jan;30(1):69–84. PMID:27713419
- 711.** Geyer FC, de Biase D, Lambros MB, et al. Genomic profiling of mitochondrion-rich breast carcinoma: chromosomal changes may be relevant for mitochondria accumulation and tumour biology. *Breast Cancer Res Treat.* 2012 Feb;132(1):15–28. PMID:21509527
- 712.** Geyer FC, Lacroix-Triki M, Colombo PE, et al. Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis. *Histopathology.* 2012 May;60(6):E115–30. PMID:22486256
- 713.** Geyer FC, Lacroix-Triki M, Savage K, et al. β -Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. *Mod Pathol.* 2011 Feb;24(2):209–31. PMID:21076461
- 714.** Geyer FC, Lambros MB, Natrajan R, et al. Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast. *Mod Pathol.* 2010 Jul;23(7):951–60. PMID:20453835
- 715.** Geyer FC, Li A, Papanastasiou AD, et al. Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas. *Nat Commun.* 2018 May;9(1):1816. PMID:29739933
- 716.** Geyer FC, Pareja F, Weigelt B, et al. The spectrum of triple-negative breast disease: high- and low-grade lesions. *Am J Pathol.* 2017 Oct;187(10):2139–51. PMID:28736315
- 717.** Geyer FC, Weigelt B, Natrajan R, et al. Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. *J Pathol.* 2010 Apr;220(5):562–73. PMID:20099298
- 718.** Ghabach B, Anderson WF, Curtis RE, et al. Adenoid cystic carcinoma of the breast in the United States (1977 to 2006): a population-based cohort study. *Breast Cancer Res.* 2010;12(4):R54. PMID:20653964
- 719.** Ghadimi MP, Liu P, Peng T, et al. Pleomorphic liposarcoma: clinical observations and molecular variables. *Cancer.* 2011 Dec 1;117(23):5359–69. PMID:21598240
- 720.** Gherehdagi M, Hassani M, Khooei AR, et al. Multicentric myxoid liposarcoma: a case report and literature review. *Arch Bone Jt Surg.* 2014 Mar;2(1):79–81. PMID:25207321
- 721.** Gherardi G, Bernardi C, Marveggio C. Microglandular adenosis of the breast: fine-needle aspiration biopsy of two cases. *Diagn Cytopathol.* 1993;9(1):72–6. PMID:8458288
- 722.** Ghosh K, Vierkant RA, Frank RD, et al. Association between mammographic breast density and histologic features of benign breast disease. *Breast Cancer Res.* 2017 Dec 19;19(1):134. PMID:29258587
- 723.** Ghoussaini M, Edwards SL, Michalidou K, et al. Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. *Nat Commun.* 2014 Sep 23;4:4999. PMID:25248036
- 724.** Ghoussaini M, Fletcher O, Michalidou K, et al. Genome-wide association analysis identifies three new breast cancer susceptibility loci. *Nat Genet.* 2012 Jan 22;44(3):312–8. PMID:22267197
- 725.** Giacinti L, Claudio PP, Lopez M, et al. Epigenetic information and estrogen receptor alpha expression in breast cancer. *Oncologist.* 2006 Jan;11(1):1–8. PMID:16401708
- 726.** Giacomazzi J, Graudenz MS, Osorio CA, et al. Prevalence of the TP53 p.R337H mutation in breast cancer patients in Brazil. *PLoS One.* 2014 Jun 17;9(6):e99893. PMID:24936644
- 727.** Giardello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. *Gastroenterology.* 2000 Dec;119(6):1447–53. PMID:11113065
- 728.** Giardello FM, Welsh SB, Hamilton SR, et al. Increased risk of cancer in the Peutz-Jeghers syndrome. *N Engl J Med.* 1987 Jun 11;316(24):1511–4. PMID:3587280
- 729.** Gibbons D, Leitch M, Coscia J, et al. Fine needle aspiration cytology and histologic findings of granular cell tumor of the breast: review of 19 cases with clinical/radiologic correlation. *Breast J.* 2000 Jan;6(1):27–30. PMID:11348331
- 730.** Ginter PS, McIntire PJ, Shin SJ. Vascular tumors of the breast: a comprehensive review with focus on diagnostic challenges encountered in the core biopsy setting. *Pathology.* 2017 Feb;49(2):197–214. PMID:28049578
- 731.** Ginter PS, Mosquera JM, MacDonald TY, et al. Diagnostic utility of MYC amplification and anti-MYC immunohistochemistry in atypical vascular lesions, primary or radiation-induced mammary angiomas, and primary angiomas of other sites. *Hum Pathol.* 2014 Apr;45(4):709–16. PMID:24457083
- 732.** Ginter PS, Scognamiglio T, Tauchi-Nishi P, et al. Pleomorphic adenoma of breast: a radiological and pathological study of a common tumor in an uncommon location. *Case Rep Pathol.* 2015;2015:172750. PMID:25830053
- 733.** Giovanella L, Marelli M, Ceriani L, et al. Evaluation of chromogranin A expression in serum and tissues of breast cancer patients. *Int J Biol Markers.* 2001 Oct-Dec;16(4):268–72. PMID:11820723
- 734.** Giovannelli P, Di Donato M, Galasso G, et al. The androgen receptor in breast cancer. *Front Endocrinol (Lausanne).* 2018 Aug 28;9:492. PMID:30210453
- 735.** Giuliano AE, Connolly JL, Edge SB, et al. Breast cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. *CA Cancer J Clin.* 2017 Jul 8;67(4):290–303. PMID:28294295
- 736.** Giulino-Roth L, Wang K, MacDonald TY, et al. Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes. *Blood.* 2012 Dec 20;120(26):5181–4. PMID:23091298
- 737.** Gleason BC, Hornick JL. Inflammatory myofibroblastic tumours: Where are we now? *J Clin Pathol.* 2008 Apr;61(4):428–37. PMID:17938159
- 738.** Gleason BC, Nascimento AF. HMB-45 and Melan-A are useful in the differential diagnosis between granular cell tumor and malignant melanoma. *Am J Dermatopathol.* 2007 Feb;29(1):22–7. PMID:17284958
- 739.** Glubb DM, Maranian MJ, Michailidou K, et al. Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. *Am J Hum Genet.* 2015 Jan 8;96(1):5–20. PMID:25529635
- 740.** Grant M, Harbeck N, Thomassen C. St. Gallen/Vienna 2017: a brief summary of the consensus discussion about escalation and de-escalation of primary breast cancer treatment. *Breast Care (Basel).* 2017 May;12(2):102–7. PMID:28559767
- 741.** Gobbi H, Jensen RA, Simpson JF, et al. Atypical ductal hyperplasia and ductal carcinoma in situ of the breast associated with perineural invasion. *Hum Pathol.* 2001 Aug;32(8):785–90. PMID:11521220
- 741A.** Gobbi H, Simpson JF, Borowsky A, et al. Metaplastic breast tumors with a dominant fibromatosis-like phenotype have a high risk of local recurrence. *Cancer.* 1999 May 15;85(10):2170–82. PMID:10326695
- 742.** Gobbi H, Simpson JF, Jensen RA, et al. Metaplastic spindle cell breast tumors arising within papillomas, complex sclerosing lesions, and nipple adenomas. *Mod Pathol.* 2003 Sep;16(9):893–901. PMID:13679453
- 743.** Gojon H, Fawunmi D, Valachis A. Sentinel lymph node biopsy in patients with microinvasive breast cancer: a systematic review and meta-analysis. *Eur J Surg Oncol.* 2014 Jan;40(1):5–11. PMID:24238761
- 744.** Goldgar DE, Healey S, Dowty JG, et al. Rare variants in the ATM gene and risk of breast cancer. *Breast Cancer Res.* 2011 Jul 25;13(4):R73. PMID:21787400
- 745.** Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. *Ann Oncol.* 2013 Sep;24(9):2206–23. PMID:23917950
- 746.** Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. *Ann Oncol.* 2011 Aug;22(8):1736–47. PMID:21709140
- 747.** Gomes DS, Balabram D, Porto SS, et al. Lobular neoplasia: frequency and association with other breast lesions. *Diagn Pathol.* 2011 Aug 9;6:74. PMID:21827679
- 748.** Gomes DS, Porto SS, Balabram D, et al. Inter-observer variability between general pathologists and a specialist in breast pathology in the diagnosis of lobular neoplasia, columnar cell lesions, atypical ductal hyperplasia and ductal carcinoma in situ of the breast. *Diagn Pathol.* 2014 Jun 19;9:121. PMID:24948027
- 749.** Gómez Macías GS, Pérez Saucedo JE, Cardona Huerta S, et al. Invasive lobular carcinoma of the breast with extracellular mucin: a case report. *Int J Surg Case Rep.* 2016;25:33–6. PMID:27315432
- 750.** Gong G, DeVries S, Chew KL, et al. Genetic changes in paired atypical and usual ductal hyperplasia of the breast by comparative genomic hybridization. *Clin Cancer Res.* 2001 Aug;7(8):2140–4. PMID:11489820
- 751.** Gong S, Crane GM, McCall CM, et al. Expanding the spectrum of EBV-positive marginal zone lymphomas: a lesion associated with diverse immunodeficiency settings. *Am J Surg Pathol.* 2018 Oct;42(10):1306–16. PMID:29957733
- 752.** Gonzalez KD, Noltner KA, Buzin CH, et al. Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. *J Clin Oncol.* 2009 Mar 10;27(8):1250–6. PMID:19204208
- 753.** Gonzalez-Angulo AM, Barlow WE, Gralow J, et al. SWOG S1007: a phase III, randomized clinical trial of standard adjuvant endocrine therapy with or without chemotherapy in patients with one to three positive nodes, hormone receptor (HR)-positive, and HER2-negative breast cancer with recurrence score (RS) of 25 or less [abstract]. *J Clin Oncol.* 2016 Sep 22;29(15 suppl):TPS104. Abstract no. TPS104. doi:10.1200/jco.2011.29.15_suppl.tps104.
- 754.** González-Rivera M, Lobo M, López-Tarruella S, et al. Erratum to: Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial. *Breast Cancer Res Treat.* 2017 Sep;165(2):471. PMID:28721639
- 755.** Goodman ZD, Taxay JB. Fibroadenomas of the breast with prominent smooth muscle. *Am J Surg Pathol.* 1981 Jan;5(1):99–101. PMID:7246853
- 756.** Gooren LJ, van Trotsenburg MA, Giltay EJ, et al. Breast cancer development in transsexual subjects receiving cross-sex hormone treatment. *J Sex Med.* 2013 Dec;10(12):3125–34. PMID:24010586
- 757.** Gospodarowicz MK, Sutcliffe SE. The extranodal lymphomas. *Semin Radiat Oncol.* 1995 Oct;5(4):281–300. PMID:10717152
- 758.** Gow AM, Fulton RS, Kandafti R. Markers of metastatic carcinoma of breast origin. *Histopathology.* 2016 Jan;58(1):95–103. PMID:26768031
- 759.** Gradishar WJ, Anderson BO, Balabram R, et al. NCCN Guidelines Insights: Breast Cancer, Version 1.2017. *J Natl Compr Canc Netw.* 2017 Apr;15(4):433–51. PMID:28414755
- 760.** Grady I, Gorsuch H, Wilburn-Bailey S. Long-term outcome of benign fibroadenomas treated by ultrasound-guided percutaneous excision. *Breast J.* 2008 May-Jun;14(3):270–4. PMID:18397185
- 761.** Grady WM, Willis J, Guilford PJ, et al. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse glioma cancer. *Nat Genet.* 2000 Sep;25(1):111–4. PMID:10973239
- 762.** Grant RC, Al-Sukhni W, Borgida AE, et al. Exome sequencing identifies nonsense and non-sense ATM and PALB2 variants in pancreatic cancer. *Hum Genomics.* 2015;5:7–11. PMID:23561644
- 763.** Green I, McCormick B, Carter H, et al. A comparative study of pure tubular and tubulolobular carcinoma of the breast. *Am J Surg Pathol.* 1997 Jun;21(6):561–7. PMID:9199642
- 764.** Greenberg ML, Camaris C, Pannier S, et al. Is there a role for fine-needle aspiration in radial scar/complex sclerosing lesions of the breast? *Diagn Cytopathol.* 1997 Jun;17(6):42–52. PMID:9181322
- 765.** Gresik CM, Godellas C, Arana B, et al. Pseudoangiomatous stromal hyperplasia of the breast: a contemporary approach to diagnosis and radiologic features and ideal management. *Surgery.* 2010 Oct;148(4):752–7. PMID:20708765
- 766.** Grimm EE, Schmidt RA, Schuetz J, et al. Achieving 95% cross-method concordance in HER2 testing: implications of discordant results. *J Clin Pathol.* 2010 Aug;63(8):734–7. PMID:20660333
- 767.** Grimm LJ, Bookhout CE, Bentzen SM, et al. Concordant, non-atypical breast lesions do not require surgical excision: a 10-institution study and review of the literature. *Clin Imaging.* 2018 Sep;52:102–7. PMID:29859481
- 768.** Grin A, Horne G, Emri M, et al. Measuring extent of ductal carcinoma in situ in breast excision specimens: a comparison of 4 methods. *Arch Pathol Lab Med.* 2000 Jan;133(1):31–7. PMID:10725732
- 769.** Grin A, O'Malley FP, Liao J, et al. Cytokeratin 5 and estrogen receptor immunohistochemistry as a useful panel for identifying atypical papillary lesions on needle core biopsy. *Am J Surg Pathol.* 2000 Nov;33(11):1615–23. PMID:10957943
- 770.** Gronchi A, Casali PG, Mazzoni E, et al. Quality of surgery and outcome in abdominal aggressive fibromatosis: patients surgically treated at a single institution. *J Clin Oncol.* 2003 Apr 1;21(9):1727–33. PMID:12663732
- 771.** Gronchi A, Miceli R, Shiu E, et al. Outcome prediction in primary retroperitoneal soft tissue sarcomas: specific overall survival and progression-free survival nomograms built on major center data sets. *J Clin Oncol.* 2006 Jun 10;24(17):4271–7. PMID:16785322

- 1:31(13):1649–55. PMID:23530096
772. Gronwald J, Byrski T, Huzarski T, et al. Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. *Breast Cancer Res Treat.* 2006 Jan;95(2):105–9. PMID:16261399
773. Grossman RA, Pedrosa FE, Byrne MM, et al. Does surgery or radiation therapy impact survival for patients with extrapulmonary small cell cancers? *J Surg Oncol.* 2011 Nov 1;104(6):604–12. PMID:21618245
774. Gruel N, Benhamo V, Bhalshankar J, et al. Polarity gene alterations in pure invasive micropapillary carcinomas of the breast. *Breast Cancer Res.* 2014 May 8;16(3):R46. PMID:24887297
775. Gruel N, Fuhrmann L, Lodillinsky C, et al. LIN7A is a major determinant of cell-polarity defects in breast carcinomas. *Breast Cancer Res.* 2016 Feb 17;18(1):23. PMID:26887652
776. Gruel N, Lucchesi C, Raynal V, et al. Lobular invasive carcinoma of the breast is a molecular entity distinct from luminal invasive ductal carcinoma. *Eur J Cancer.* 2010 Sep;46(13):2399–407. PMID:20570624
777. Gualco G, Bacchi CE. B-cell and T-cell lymphomas of the breast: clinical-pathological features of 53 cases. *Int J Surg Pathol.* 2008 Oct;16(4):407–13. PMID:18480397
778. Gualco G, Weiss LM, Harrington WJ Jr, et al. BCL6, MUM1, and CD10 expression in mantle cell lymphoma. *Appl Immunohistochem Mol Morphol.* 2010 Mar;18(2):103–8. PMID:19826251
779. Guan B, Wang H, Cao S, et al. Lipid-rich carcinoma of the breast clinicopathologic analysis of 17 cases. *Ann Diagn Pathol.* 2011 Aug;15(4):225–32. PMID:21396871
780. Gudjónsdóttir A, Hägerstrand I, Ostberg E. Adenoma of the nipple with carcinomatous development. *Acta Pathol Microbiol Scand A.* 1971;79(6):676–80. PMID:5123518
781. Guerini-Rocco E, Piscuoglio S, Ng CK, et al. Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations. *J Pathol.* 2016 Apr;238(5):677–88. PMID:26806567
782. Guidi AJ, Tworek JA, Mais DD, et al. Breast specimen processing and reporting with an emphasis on margin evaluation: a College of American Pathologists survey of 666 laboratories. *Arch Pathol Lab Med.* 2018 Apr;142(4):496–506. PMID:29328775
783. Gullett NP, Rizzo M, Johnstone PA. National surgical patterns of care for primary surgery and axillary staging of phyllodes tumors. *Breast J.* 2009 Jan-Feb;15(1):41–4. PMID:19141133
784. Gumi-Pause F, Wacker P, Sappino AP. ATM gene and lymphoid malignancies. *Leukemia.* 2004 Feb;18(2):238–42. PMID:14628072
785. Günhan-Bilgen I, Oktay A. Tubular carcinoma of the breast: mammographic, sonographic, clinical and pathologic findings. *Eur J Radiol.* 2007 Jan;61(1):158–62. PMID:16987629
786. Guo Q, Schmidt MK, Kraft P, et al. Identification of novel genetic markers of breast cancer survival. *J Natl Cancer Inst.* 2015 Apr 18;107(5):djv081. PMID:25890600
787. Guo S, Wang Y, Rohr J, et al. Solid papillary carcinoma of the breast: a special entity needs to be distinguished from conventional invasive carcinoma avoiding over-treatment. *Breast.* 2016 Apr;26:67–72. PMID:27017244
789. Guo T, Wang Y, Shapiro N, et al. Pleomorphic lobular carcinoma in situ diagnosed by breast core biopsy: clinicopathologic features and correlation with subsequent excision. *Clin Breast Cancer.* 2018 Aug;18(4):e449–54. PMID:29102711
790. Guo T, Zhang L, Chang NE, et al. Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. *Genes Chromosomes Cancer.* 2011 Jan;50(1):25–33. PMID:20949568
791. Guo X, Chen L, Lang R, et al. Invasive micropapillary carcinoma of the breast: association of pathologic features with lymph node metastasis. *Am J Clin Pathol.* 2006 Nov;126(5):740–6. PMID:17050071
792. Gupta D, Croitoru CM, Ayala AG, et al. E-cadherin immunohistochemical analysis of histiocytoid carcinoma of the breast. *Ann Diagn Pathol.* 2002 Jun;6(3):141–7. PMID:12089723
793. Guss CE, Divasta AD. Adolescent gynecomastia. *Pediatr Endocrinol Rev.* 2017 Jun;14(4):371–7. PMID:28613047
794. Gustafson P. Soft tissue sarcoma. Epidemiology and prognosis in 508 patients. *Acta Orthop Scand Suppl.* 1994 Jun;259:1–31. PMID:8042499
795. Gutierrez Barrera AM, Fouad TM, Song J, et al. BRCA mutations in women with inflammatory breast cancer. *Cancer.* 2018 Feb 1;124(3):466–74. PMID:29044548
796. Gutmann DH, Fenner RE, Listernick RH, et al. Neurofibromatosis type 1. *Nat Rev Dis Primers.* 2017 Feb 23;3:17004. PMID:28230061
797. Ha D, Dialani V, Mehta TS, et al. Mucocele-like lesions in the breast diagnosed with percutaneous biopsy: Is surgical excision necessary? *AJR Am J Roentgenol.* 2015 Jan;204(1):204–10. PMID:25539258
798. Ha SM, Cha JH, Shin HJ, et al. Radial scars/complex sclerosing lesions of the breast: radiologic and clinicopathologic correlation. *BMC Med Imaging.* 2018 Nov 3;18(1):39. PMID:30390667
799. Ha SM, Chae EY, Cha JH, et al. Association of BRCA mutation types, imaging features, and pathologic findings in patients with breast cancer with BRCA1 and BRCA2 mutations. *AJR Am J Roentgenol.* 2017 Oct;209(4):920–8. PMID:28796549
800. Haagensen CD, editor. Diseases of the breast. 3rd ed. Philadelphia (PA): Saunders; 1986.
801. Haagensen CD, Lane N, Lattes R, et al. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. *Cancer.* 1978 Aug;42(2):737–69. PMID:209887
802. HaDuong JH, Martin AA, Skapek SX, et al. Sarcomas. *Pediatr Clin North Am.* 2015 Feb;62(1):179–200. PMID:25435119
803. Haiman CA, Chen GK, Vachon CM, et al. A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. *Nat Genet.* 2011 Oct 30;43(12):1210–4. PMID:22037553
804. Haj M, Weiss M, Loberant N, et al. Inflammatory pseudotumor of the breast: case report and literature review. *Breast J.* 2003 Sep-Oct;9(5):423–5. PMID:12968967
805. Hajdu SI, Urban JA. Cancers metastatic to the breast. *Cancer.* 1972 Jun;29(6):1691–6. PMID:4337956
806. Hall J, Marcel V, Bolin C, et al. The associations of sequence variants in DNA-repair and cell-cycle genes with cancer risk: genotype-phenotype correlations. *Biochem Soc Trans.* 2009 Jun;37(Pt 3):527–33. PMID:19442246
807. Haltas H, Bayrak R, Yenidunya S, et al. Invasive lobular carcinoma with extracellular mucin as a distinct variant of lobular carcinoma: a case report. *Diagn Pathol.* 2012 Aug 6;7:91. PMID:22867429
808. Halteh P, Patel A, Eskreis-Winkler S, et al. Schwannoma of the breast: a common tumor in an uncommon location. *Breast J.* 2018 Mar;24(2):206–7. PMID:28707768
809. Hamdi H, Soucy P, Kuchenbaecker KB, et al. Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. *Breast Cancer Res Treat.* 2017 Jan;161(1):117–34. PMID:27796716
810. Hameed O, Perry A, Banerjee R, et al. Papillary carcinoma of the breast lacks evidence of RET rearrangements despite morphological similarities to papillary thyroid carcinoma. *Mod Pathol.* 2009 Sep;22(9):1236–42. PMID:19543246
811. Hamele-Bena D, Cranor ML, Rosen PP. Mammary mucocele-like lesions. Benign and malignant. *Am J Surg Pathol.* 1996 Sep;20(9):1081–5. PMID:8764744
812. Hamele-Bena D, Cranor ML, Sciotti C, et al. Uncommon presentation of mammary myofibroblastoma. *Mod Pathol.* 1996 Jul;9(7):786–90. PMID:8832563
813. Hamilton-Dutoit SJ, Raphael M, Audouin J, et al. In situ demonstration of Epstein-Barr virus small RNAs (EBER 1) in acquired immunodeficiency syndrome-related lymphomas: correlation with tumor morphology and primary site. *Blood.* 1993 Jul 15;82(2):619–24. PMID:8392401
814. Hammer P, White K, Mengden S, et al. Nipple leiomyoma: a rare neoplasm with a broad spectrum of histologic appearances. *J Cutan Pathol.* 2019 May;46(5):343–6. PMID:30663114
815. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). *Arch Pathol Lab Med.* 2010 Jul;134(7):e48–72. PMID:20586616
816. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. *Arch Pathol Lab Med.* 2010 Jun;134(6):907–22. PMID:20524868
817. Hamperl H. The myothelia (myoepithelial cells). Normal state; regressive changes; hyperplasia; tumors. *Curr Top Pathol.* 1970;53:161–220. PMID:4323195
818. Han B, Mori I, Nakamura M, et al. Myoepithelial carcinoma arising in an adenomyoepithelioma of the breast: case report with immunohistochemical and mutational analysis. *Pathol Int.* 2006 Apr;56(4):211–6. PMID:16634967
819. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, et al. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. *J Clin Oncol.* 2007 Nov 1;25(31):4952–60. PMID:17971593
820. Hansford S, Kaurah P, Li-Chang H, et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. *JAMA Oncol.* 2015 Apr;1(1):23–32. PMID:26182300
821. Haralambieva E, Schuring E, Rosati S, et al. Interphase fluorescence in situ hybridization for detection of 8q24/MYC breakpoints on routine histologic sections: validation in Burkitt lymphomas from three geographic regions. *Genes Chromosomes Cancer.* 2004 May;40(1):10–8. PMID:15034863
822. Hare F, Giri S, Patel JK, et al. A population-based analysis of outcomes for small cell carcinoma of the breast by tumor stage and the use of radiation therapy. *Springerplus.* 2015 Mar 21;4:138. PMID:25853028
823. Harigopal M, Park K, Chen X, et al. Pathologic quiz case: a rapidly increasing breast mass in a postmenopausal woman. Malignant adenomyoepithelioma. *Arch Pathol Lab Med.* 2004 Feb;128(2):235–6. PMID:14736274
824. Harris LN, Ismaila N, McShane LM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary. *J Oncol Pract.* 2016 Apr;12(4):384–9. PMID:26957642
825. Harris M, Howell A, Chrischou M, et al. A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. *Br J Cancer.* 1984 Jul;50(1):23–30. PMID:6331484
826. Hart J, Gardner JM, Edgar M, et al. Epithelioid schwannomas: an analysis of 58 cases including atypical variants. *Am J Surg Pathol.* 2016 May;40(5):704–13. PMID:26752543
827. Hartley RL, Stone JP, Temple-Oberle C. Breast cancer in transgender patients: a systematic review. Part 1: Male to female. *Eur J Surg Oncol.* 2018 Oct;44(10):1455–62. PMID:30087072
828. Hartmann LC, Degnim AC, Santen RJ, et al. Atypical hyperplasia of the breast—risk assessment and management options. *N Engl J Med.* 2015 Jan 1;372(1):78–89. PMID:25551530
829. Hartmann LC, Radisky DC, Frost MH, et al. Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study. *Cancer Prev Res (Phila).* 2014 Feb;7(2):211–7. PMID:24480577
830. Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. *N Engl J Med.* 2005 Jul 21;353(3):229–37. PMID:16034008
831. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. *J Clin Oncol.* 1999 May;17(5):1474–81. PMID:10334533
832. Hasebe T, Tsuda H, Hirohashi S, et al. Fibrotic focus in invasive ductal carcinoma: an indicator of high tumor aggressiveness. *Jpn J Cancer Res.* 1996 Apr;87(4):385–94. PMID:8641970
833. Hasebe T, Tsuda H, Tsubono Y, et al. Fibrotic focus in invasive ductal carcinoma of the breast: a histopathological prognostic parameter for tumor recurrence and tumor death. *Jpn J Cancer Res.* 1997 Jun;88(6):590–9. PMID:9263537
834. Hashmi AA, Ajiaz S, Mahboob R, et al. Clinicopathologic features of invasive metaplastic and micropapillary breast carcinomas: comparison with invasive ductal carcinoma of breast. *BMC Res Notes.* 2018 Jul 31;11(1):531. PMID:30064485
835. Hauke J, Horvath J, Groß E, et al. Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer. *Cancer Med.* 2018 Apr;7(4):1349–58. PMID:29522266
836. Hayes MM. Adenomyoepithelioma of the breast: a review stressing its propensity for malignant transformation. *J Clin Pathol.* 2011 Jun;64(6):477–84. PMID:21307156

- 837.** Hayes MM, Lesack D, Girardet C, et al. Carcinoma ex-pleomorphic adenoma of the breast. Report of three cases suggesting a relationship to metaplastic carcinoma of matrix-producing type. *Virchows Arch*. 2005 Feb;446(2):142–9. PMID:15583933
- 838.** Hearle N, Schumacher V, Menko FH, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. *Clin Cancer Res*. 2006 May 15;12(10):3209–15. PMID:16707622
- 839.** Hechtman JF, Benayad R, Hyman DM, et al. Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions. *Am J Surg Pathol*. 2017 Nov;41(11):1547–51. PMID:28719467
- 840.** Hegyi L, Thway K, Newton R, et al. Malignant myoepithelioma arising in adenomyoepithelioma of the breast and coincident multiple gastrointestinal stromal tumours in a patient with neurofibromatosis type 1. *J Clin Pathol*. 2009 Jul;62(7):653–5. PMID:19561236
- 841.** Heller SL, Elias K, Gupta A, et al. Outcome of high-risk lesions at MRI-guided 9-gauge vacuum-assisted breast biopsy. *AJR Am J Roentgenol*. 2014 Jan;202(1):237–45. PMID:24370150
- 842.** Hendry S, Pang JB, Byrne DJ, et al. Relationship of the breast ductal carcinoma in situ immune microenvironment with clinicopathological and genetic features. *Clin Cancer Res*. 2017 Sep 1;23(17):5210–7. PMID:28611201
- 843.** Hennessy BT, Giordano S, Broglio K, et al. Biphasic metaplastic sarcomatoid carcinoma of the breast. *Ann Oncol*. 2006 Apr;17(4):605–13. PMID:16469754
- 844.** Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. *Cancer Res*. 2009 May 15;69(10):4116–24. PMID:19435916
- 845.** Hennessy BT, Krishnamurthy S, Giordano S, et al. Squamous cell carcinoma of the breast. *J Clin Oncol*. 2005 Nov 1;23(31):7827–35. PMID:16258085
- 846.** Henry NL, Braun TM, Breslin TM, et al. Variation in the use of advanced imaging at the time of breast cancer diagnosis in a statewide registry. *Cancer*. 2017 Aug 1;123(15):2975–83. PMID:28301680
- 847.** Herbert M, Sandbank J, Liokumovich P, et al. Breast hamartomas: clinicopathological and immunohistochemical studies of 24 cases. *Histopathology*. 2002 Jul;41(1):30–4. PMID:12121234
- 848.** Herbert M, Schwimer M, Zehavi S, et al. Breast hamartoma: fine-needle aspiration cytologic finding. *Cancer*. 2003 Aug 29;94(4):255–8. PMID:12925988
- 849.** Herrington CS, Tarin D, Buley I, et al. Osteosarcomatous differentiation in carcinoma of the breast: a case of 'metaplastic' carcinoma with osteoclasts and osteoclast-like giant cells. *Histopathology*. 1994 Mar;24(3):282–5. PMID:8200630
- 850.** Herz H, Cooke B, Goldstein D. Metastatic secretory breast cancer. Non-responsiveness to chemotherapy: case report and review of the literature. *Ann Oncol*. 2000 Oct;11(10):1343–7. PMID:11106125
- 851.** Heslin MJ, Lewis JJ, Woodruff JM, et al. Core needle biopsy for diagnosis of extremity soft tissue sarcoma. *Ann Surg Oncol*. 1997 Jul-Aug;4(5):425–31. PMID:9259971
- 852.** Heymann JJ, Halligan AM, Hoda SA, et al. Fine needle aspiration of breast masses in pregnant and lactating women: experience with 28 cases emphasizing Thinprep findings. *Diagn Cytopathol*. 2015 Mar;43(3):188–94. PMID:24976078
- 853.** Hill CB, Yeh IT. Myoepithelial cell staining patterns of papillary breast lesions: from intraductal papillomas to invasive papillary carcinomas. *Am J Clin Pathol*. 2005 Jan;123(1):36–44. PMID:15762278
- 854.** Hilleren DJ, Andersson IT, Lindholm K, et al. Invasive lobular carcinoma: mammographic findings in a 10-year experience. *Radiology*. 1991 Jan;178(1):149–54. PMID:1984294
- 855.** Hilson JB, Schnitt SJ, Collins LC. Phenotypic alterations in ductal carcinoma in situ-associated myoepithelial cells: biologic and diagnostic implications. *Am J Surg Pathol*. 2009 Feb;33(2):227–32. PMID:18936688
- 856.** Hilson JB, Schnitt SJ, Collins LC. Phenotypic alterations in myoepithelial cells associated with benign sclerosing lesions of the breast. *Am J Surg Pathol*. 2010 Jun;34(6):896–900. PMID:20463570
- 857.** Hirose T, Scheithauer BW, Sano T. Giant plexiform schwannoma: a report of two cases with soft tissue and visceral involvement. *Mod Pathol*. 1997 Nov;10(11):1075–81. PMID:9388056
- 858.** Hisaoka M, Takamatsu Y, Hirano Y, et al. Sebaceous carcinoma of the breast: case report and review of the literature. *Virchows Arch*. 2006 Oct;449(4):484–8. PMID:16944238
- 859.** Hittmair AP, Lininger RA, Tavassoli FA. Ductal carcinoma in situ (DCIS) in the male breast: a morphologic study of 84 cases of pure DCIS and 30 cases of DCIS associated with invasive carcinoma—a preliminary report. *Cancer*. 1998 Nov 15;83(10):2139–49. PMID:9827718
- 860.** Ho SK, Thike AA, Cheok PY, et al. Phyllodes tumours of the breast: the role of CD34, vascular endothelial growth factor and β-catenin in histological grading and clinical outcome. *Histopathology*. 2013 Sep;63(3):393–406. PMID:23772632
- 861.** Hobert JA, Eng C. PTEN hamartoma tumor syndrome: an overview. *Genet Med*. 2009 Oct;11(10):687–94. PMID:19668082
- 862.** Hock AK, Vousten KH. Tumor suppression by p53: fall of the triumvirate? *Cell*. 2012 Jun 8;149(6):1183–5. PMID:22682240
- 863.** Hock YL, Mohamid W. Myxoid neurofibroma of the male breast: fine needle aspiration cydiagnosis. *Cytopathology*. 1995 Feb;6(1):44–7. PMID:7734701
- 864.** Hoda SA, Brogi E, Koerner FC, et al., editors. *Rosen's breast pathology*. 4th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2014.
- 865.** Hodges KB, Abdul-Karim FW, Wang M, et al. Evidence for transformation of fibroadenoma of the breast to malignant phyllodes tumor. *Appl Immunohistochem Mol Morphol*. 2009 Jul;17(4):345–50. PMID:19276971
- 866.** Hofvander J, Arbajian E, Stenkula KG, et al. Frequent low-level mutations of protein kinase D2 in angioliopoma. *J Pathol*. 2017 Apr;241(5):578–82. PMID:28139834
- 867.** Holm-Rasmussen EV, Jensen MB, Balslev E, et al. The use of sentinel lymph node biopsy in the treatment of breast ductal carcinoma in situ: a Danish population-based study. *Eur J Cancer*. 2017 Dec;87:1–9. PMID:29096155
- 868.** Hoogerbrugge N, Jongmans MC. Finding all BRCA pathogenic mutation carriers: best practice models. *Eur J Hum Genet*. 2016 Sep;24 Suppl 1:S19–26. PMID:27514840
- 869.** Hopper JL, Dite GS, MacLennan RJ, et al. Age-specific breast cancer risk by body mass index and familial risk: prospective family study cohort (ProF-SC). *Breast Cancer Res*. 2018 Nov 3;20(1):132. PMID:30390716
- 870.** Horii R, Akiyama F, Ikenaga M, et al. Mucoepidermoid carcinoma of the breast. *Pathol Int*. 2006 Sep;56(9):549–53. PMID:16930336
- 871.** Horlings HM, Weigelt B, Anderson EM, et al. Genomic profiling of histological special types of breast cancer. *Breast Cancer Res Treat*. 2013 Nov;142(2):257–69. PMID:24162157
- 872.** Horne CH, Reid IN, Milne GD. Prognostic significance of inappropriate production of pregnancy proteins by breast cancers. *Lancet*. 1976 Aug 7;2(7980):279–82. PMID:59853
- 873.** Hornick JL, Bosenberg MW, Mentzel T, et al. Pleomorphic liposarcoma: clinicopathologic analysis of 57 cases. *Am J Surg Pathol*. 2004 Oct;28(10):1257–67. PMID:15371941
- 874.** Hornick JL, Fletcher CD. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. *Am J Clin Pathol*. 2002 Feb;167(2):188–93. PMID:11865845
- 875.** Hornick JL, Sholl LM, Dal Cin P, et al. Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors. *Mod Pathol*. 2015 May;28(5):732–9. PMID:25612511
- 876.** Horowitz DP, Sharma CS, Connolly E, et al. Secretory carcinoma of the breast: results from the Survival, Epidemiology and End Results database. *Breast*. 2012 Jun;21(3):350–3. PMID:22494666
- 877.** Hosein PJ, Maragulia JC, Salzberg MP, et al. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. *Br J Haematol*. 2014 May;165(3):358–63. PMID:24467658
- 878.** Hou Y, Chaudhary S, Gao FF, et al. Surgical follow-up results for apocrine adenosis and atypical apocrine adenosis diagnosed on breast core biopsy. *Ann Diagn Pathol*. 2016 Oct;24:4–6. PMID:27649945
- 879.** Hou Y, Shen R, Chaudhary S, et al. Utility of different immunostains for diagnosis of metastatic breast carcinomas in both surgical and cytological specimens. *Ann Diagn Pathol*. 2017 Oct;30:21–7. PMID:28965624
- 880.** Hou Y, Zynger DL, Li X, et al. Comparison of Oncotype DX with modified Magee equation recurrence scores in low-grade invasive carcinoma of breast. *Am J Clin Pathol*. 2017 Aug 1;148(2):167–72. PMID:28898988
- 881.** Houssami N, Macaskill P, Marinovich ML, et al. The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis. *Ann Surg Oncol*. 2014 Mar;21(3):717–30. PMID:24473640
- 882.** Howat AJ, Campbell PE. Angiomatosis: a vascular malformation of infancy and childhood. Report of 17 cases. *Pathology*. 1987 Oct;19(4):377–82. PMID:3444663
- 883.** Hoyer J, Vasileiou G, Uebe S, et al. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria. *BMC Cancer*. 2018 Sep 26;18(1):926. PMID:30257646
- 884.** Hu H, Johani K, Almatroud A, et al. Bacterial biofilm infection detected in breast implant-associated anaplastic large-cell lymphoma. *Plast Reconstr Surg*. 2016 Jun;137(6):1659–69. PMID:26890506
- 885.** Hu S, Song Y, Sun X, et al. Primary breast diffuse large B-cell lymphoma in the rituximab era: therapeutic strategies and patterns of failure. *Cancer Sci*. 2018 Dec;109(12):3943–52. PMID:30302857
- 886.** Huang HC, Hang JF, Wu MH, et al. Lung adenocarcinoma with ipsilateral breast metastasis: a simple coincidence? *J Thorac Oncol*. 2013 Jul;8(7):974–9. PMID:23774384
- 887.** Huang K, Fu H, Shi YQ, et al. Prognostic factors for extra-abdominal and abdominal wall desmoids: a 20-year experience at a single institution. *J Surg Oncol*. 2009 Dec 1;100(7):563–9. PMID:19722232
- 888.** Huang SC, Zhang L, Sung BC, et al. Recurrent CIC gene abnormalities in angiosarcomas: a molecular study of 100 cases with concurrent investigation of CD34, KDR, MYC, and FLT4 gene alterations. *J Surg Pathol*. 2016 May;40(5):594–601. PMID:26735859
- 889.** Huang Y, Zhang H, Zhou Q, et al. Tubular adenoma of the accessory breast in the anterior chest wall occurred in a pregnant woman. *Diagn Pathol*. 2015 Jun 4;10(1):15. PMID:26040320
- 890.** Hugh J, Hanson J, Cheang MC, et al. Breast cancer subtypes and resistance to docetaxel in node-positive breast cancer: use of an immunohistochemical test in the BCIRG 001 trial. *J Clin Oncol*. 2009 Oct;27(8):1168–76. PMID:19204255
- 891.** Hugh JC, Jackson FI, Hanson J, et al. Primary breast lymphoma. An immunohistochemical study of 20 new cases. *Cancer*. 1993 Dec 15;66(12):2602–11. PMID:8129000
- 891A.** Hui Y, Wang Y, Nam E, et al. Differentiating breast carcinoma from signet ring features from gastrointestinal signet ring carcinoma: immunohistochemical markers. *Hum Pathol*. 2018 Jul;77:11–9. PMID:29317255
- 892.** Huijts PE, Hollestelle A, Balooch M, et al. CHEK2*1100delC homozygosity in Netherlands—prevalence and risk of breast and lung cancer. *Eur J Hum Genet*. 2011 Jan;22(1):46–51. PMID:23652375
- 893.** Hulsebos TJ, Plomp AS, Wolters M, et al. Germline mutation of *INI1/SMARCB1* in familial schwannomatosis. *Am J Hum Genet*. 2007 Apr;80(4):805–10. PMID:17478088
- 894.** Holtbom R, Hanson C, Kortes M, et al. Prevalence of Klinefelter's syndrome in breast cancer patients. *Anticancer Res*. 2009 Nov-Dec;17(6D):4293–7. PMID:19446202
- 895.** Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiles. *Engl J Med*. 2006 Jun 8;354(23):2409–17. PMID:16760442
- 896.** Humphries MP, Jordan WC, et al. Obesity and male breast cancer: parallels? *BMC Med*. 2015 Jun 10;13(1):10. PMID:26044503
- 897.** Humphries MP, Sundaram R, Honarpisheh H, et al. Characteristics of male breast cancer: a descriptive biomarker study from a large patient series. *Sci Rep*. 2017;7:45293. PMID:28350011
- 898.** Hungermann D, Buerger H, Debatin CM, et al. Adenomyoepithelial tumor of the breast: a spectrum of monophasic and biphasic tumors dominated by immature myoepithelial cells. *BMC Cancer*. 2005 Jul 20;5:105. PMID:16050957
- 899.** Hussien M, Sivananthan S, Arora S, et al. Primary leiomyosarcoma of the breast: diagnosis, management and outcome of a new case and review of literature. *Br J Cancer*. 2001 Dec;85(10):530–4. PMID:11750204
- 900.** Hutter S, Piro RM, Reuss DE, et al. Exome sequencing reveals that the majority of schwannomatosis cases remain undiagnosed after excluding *SMARCB1* and other germline variants. *Acta Neuropathol Commun*. 2018 Sep;12(8):449–52. PMID:25006757
- 901.** Huynh DP, Mautner V, Bauer ME, et al. Immunohistochemical analysis of schwannomin and neurofibromin in vestibular schwannomas, epidermal meningiomas, and meningiomas. *J Neuropathol Exp Neurol*. 2018 Apr;56(4):382–90. PMID:9100668
- 902.** Huzarski T, Cybulski C, et al. et al. Pathology of breast cancer in men

- with constitutional CHEK2 mutations. *Breast Cancer Res Treat.* 2005 Mar;90(2):187–9. PMID:15803365
903. Huzarski T, Cybulski C, Wokolorczyk D, et al. Survival from breast cancer in patients with CHEK2 mutations. *Breast Cancer Res Treat.* 2014 Apr;144(2):397–403. PMID:24557336
904. Hwang ES, DeVries S, Chew KL, et al. Patterns of chromosomal alterations in breast ductal carcinoma in situ. *Clin Cancer Res.* 2004 Aug 1;10(15):5160–7. PMID:15297420
905. Hwang ES, Nyante SJ, Yi Chen Y, et al. Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma. *Cancer.* 2004 Jun 15;100(12):2562–72. PMID:15197797
906. Hwang H, Barke LD, Mendelson EB, et al. Atypical lobular hyperplasia and classic lobular carcinoma in situ in core biopsy specimens: routine excision is not necessary. *Mod Pathol.* 2008 Oct;21(10):1208–16. PMID:18660792
907. IARC TP53 Database [Internet]. Lyon (France): International Agency for Research on Cancer; 2018. Version R19, August 2018. Available from: <http://p53.iarc.fr/>.
908. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Pharmaceuticals. Volume 100 A. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt A):1–401. PMID:23189749
909. Iaria G, Pisani F, De Luca L, et al. Prospective study of switch from cyclosporine to tacrolimus for fibroadenomas of the breast in kidney transplantation. *Transplant Proc.* 2010 May;42(4):1169–70. PMID:20534252
910. Ibrahim AE, Bateman AC, Theaker JM, et al. The role and histological classification of needle core biopsy in comparison with fine needle aspiration cytology in the preoperative assessment of impalpable breast lesions. *J Clin Pathol.* 2001 Feb;54(2):121–5. PMID:11215280
911. Ibrahim N, Bessissoff A, Lalonde L, et al. Surgical outcome of biopsy-proven lobular neoplasia: Is there any difference between lobular carcinoma in situ and atypical lobular hyperplasia? *AJR Am J Roentgenol.* 2012 Feb;198(2):288–91. PMID:22268170
912. Ichihara S, Fujimoto T, Hashimoto K, et al. Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast. *Pathol Int.* 2007 Mar;57(3):126–32. PMID:17295644
913. Ichinokawa Y, Ohtuki A, Hattori M, et al. A case of syringomatous adenoma of the nipple. *Case Rep Dermatol.* 2012 Jan;4(1):98–103. PMID:22649338
914. Ihrler S, Guntinas-Lichius O, Agaimy A, et al. Histological, immunohistological and molecular characteristics of intraductal precursor of carcinoma ex pleomorphic adenoma support a multistep carcinogenic process. *Virchows Arch.* 2017 Jun;470(6):601–9. PMID:28353089
915. Ilkay TM, Gozde K, Ozgur S, et al. Diagnosis of adenoid cystic carcinoma of the breast using fine-needle aspiration cytology: a case report and review of the literature. *Diagn Cytopathol.* 2015 Sep;43(9):722–6. PMID:26183224
917. Imamovic D, Bilalovic N, Skenderi F, et al. A clinicopathologic study of invasive apocrine carcinoma of the breast: a single-center experience. *Breast J.* 2018 Nov;24(6):1105–8. PMID:30240079
918. Inno A, Bogina G, Turazza M, et al. Neuroendocrine carcinoma of the breast: current evidence and future perspectives. *Oncologist.* 2016 Jan;21(1):28–32. PMID:26659223
919. Inoue M, Nakagomi H, Nakada H, et al. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer. *Breast Cancer.* 2017 Sep;24(5):667–72. PMID:28108967
920. Institute of Medicine (US) Committee on the Safety of Silicone Breast Implants; Bondurant S, Ernster V, Herdman R, editors. Safety of silicone breast implants. Washington, DC: National Academies Press (US); 1999. PMID:20669503
921. International Association of Cancer Registries (IACR) [Internet]. Lyon (France): International Agency for Research on Cancer; 2019. ICD-O-3.2; updated 2019 Apr 23. Available from: http://www.iacr.com.fr/index.php?option=com_content&view=article&id=149:icd-o-3-2&catid=80&Itemid=545
922. International Immuno-Oncology Biomarker Working Group on Breast Cancer [Internet]. 2018. Available from: <https://www.tilis-inbreastcancer.org/>.
923. Inyang A, Thomas DG, Jorns J. Heterologous liposarcomatous differentiation in malignant phyllodes tumor is histologically similar but immunohistochemically and molecularly distinct from well-differentiated liposarcoma of soft tissue. *Breast J.* 2016 May;22(3):282–6. PMID:26843318
924. Iorfida M, Maiorano E, Orvieto E, et al. Invasive lobular breast cancer: subtypes and outcome. *Breast Cancer Res Treat.* 2012 Jun;133(2):713–23. PMID:22399188
925. Iqbal J, Ginsburg O, Rochon PA, et al. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. *JAMA.* 2015 Jan 13;313(2):165–73. PMID:25585328
926. Itagaki H, Yamamoto T, Hiroi A, et al. Synchronous and bilateral oncocytic carcinoma of the breast: a case report and review of the literature. *Oncol Lett.* 2017 Mar;13(3):1714–8. PMID:28454314
927. Jabi M, Dardick I, Cardigos N. Adenomyoepithelioma of the breast. *Arch Pathol Lab Med.* 1988 Jan;112(1):73–6. PMID:2447854
928. Jacobs PA, Maloney V, Cooke R, et al. Male breast cancer, age and sex chromosome aneuploidy. *Br J Cancer.* 2013 Mar 5;108(4):959–63. PMID:23299533
929. Jacoby LB, MacCollin M, Barone R, et al. Frequency and distribution of NF2 mutations in schwannomas. *Genes Chromosomes Cancer.* 1996 Sep;17(1):45–55. PMID:8889506
930. Jahn SW, Kashofer K, Thüringer A, et al. Mutation profiling of usual ductal hyperplasia of the breast reveals activating mutations predominantly at different levels of the PI3K/AKT/mTOR pathway. *Am J Pathol.* 2016 Jan;186(1):15–23. PMID:26718977
931. Jain RK, Mehta R, Dimitrov R, et al. Atypical ductal hyperplasia: interobserver and intraobserver variability. *Mod Pathol.* 2011 Jul;24(7):917–23. PMID:21532546
932. Jain S, Fisher C, Smith P, et al. Patterns of metastatic breast cancer in relation to histological type. *Eur J Cancer.* 1993;29A(15):2155–7. PMID:8297656
933. Janatova M, Kleibl Z, Strbrna J, et al. The PALB2 gene is a strong candidate for clinical testing in BRCA1- and BRCA2-negative hereditary breast cancer. *Cancer Epidemiol Biomarkers Prev.* 2013 Dec;22(12):2323–32. PMID:24136930
934. Jansen M, de Leng WW, Baas AF, et al. Mucosal prolapse in the pathogenesis of Peutz-Jeghers polyposis. *Gut.* 2006 Jan;55(1):1–5. PMID:16344569
935. Jassar A, Pathania K. Tubular variant of mammary adenomyoepithelioma: diagnostic challenges and cytomorphological correlation in two cases. *Cytotechnology.* 2017 Dec 27;14:29. PMID:29333189
936. Javed A, Jenkins SM, Labow B, et al. Intermediate and long-term outcomes of fibroadenoma excision in adolescent and young adult patients. *Breast J.* 2019 Jan;25(1):91–5. PMID:30444280
937. Javid SH, Smith BL, Mayer E, et al. Tubular carcinoma of the breast: results of a large contemporary series. *Am J Surg.* 2009 May;197(5):674–7. PMID:18789411
938. Jayaram G, Jayalakshmi P, Yip CH. Leiomyosarcoma of the breast: report of a case with fine needle aspiration cytologic, histologic and immunohistochemical features. *Acta Cytol.* 2005 Nov-Dec;49(6):656–60. PMID:16450908
939. Jayaram G, Swain M, Chew MT, et al. Cytology of mucinous carcinoma of breast: a report of 28 cases with histological correlation. *Malays J Pathol.* 2000 Dec;22(2):65–71. PMID:16329537
940. Jensen KC, Kong CS. Cytologic diagnosis of columnar-cell lesions of the breast. *Diagn Cytopathol.* 2007 Feb;35(2):73–9. PMID:17230565
941. Jensen ML, Johansen P, Noer H, et al. Ductal adenoma of the breast: the cytological features of six cases. *Diagn Cytopathol.* 1994;10(2):143–5. PMID:8187593
942. Jernström H, Lubinski J, Lynch HT, et al. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. *J Natl Cancer Inst.* 2004 Jul 21;96(14):1094–8. PMID:15265971
943. Jeruss JS, Mittendorf EA, Tucker SL, et al. Staging of breast cancer in the neoadjuvant setting. *Cancer Res.* 2008 Aug 15;68(16):6477–81. PMID:18701468
944. Jesinger RA, Lattin GE Jr, Ballard EA, et al. Vascular abnormalities of the breast: arterial and venous disorders, vascular masses, and mimic lesions with radiologic-pathologic correlation. *Radiographics.* 2011 Nov-Dec;31(7):E117–36. PMID:22084191
945. Jeyaretna DS, Oriolovo A, Smith ME, et al. Solitary neurofibroma in the male breast. *World J Surg Oncol.* 2007 Feb 27;5:23. PMID:17324294
946. Jia Y, Sun C, Liu Z, et al. Primary breast diffuse large B-cell lymphoma: a population-based study from 1975 to 2014. *Oncotarget.* 2017 Dec 8;9(3):3956–67. PMID:29423097
947. Jiao YF, Nakamura S, Oikawa T, et al. Sebaceous gland metaplasia in intraductal papilloma of the breast. *Virchows Arch.* 2001 May;438(5):505–8. PMID:11407480
948. Jo VY, Fletcher CDM. SMARCB1/INI1 loss in epithelial schwannoma: a clinicopathologic and immunohistochemical study of 65 cases. *Am J Surg Pathol.* 2017 Aug;41(8):1013–22. PMID:28368924
949. João C, Farinha P, da Silva MG, et al. Cytogenetic abnormalities in MALT lymphomas and their precursor lesions from different organs. A fluorescence in situ hybridization (FISH) study. *Histopathology.* 2007 Jan;50(2):217–24. PMID:17222250
950. Johansson I, Nilsson C, Berglund P, et al. Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker. *Breast Cancer Res.* 2012 Feb 14;14(1):R31. PMID:22333393
951. Johansson I, Ringnér M, Hedenfalk I. The landscape of candidate driver genes differs between male and female breast cancer. *PLoS One.* 2013 Oct 23;8(10):e78299. PMID:24149416
952. John BJ, Griffiths C, Ebbs SR. Pleomorphic adenoma of the breast should be excised with a cuff of normal tissue. *Breast J.* 2007 Jul-Aug;13(4):418–20. PMID:17593049
953. Johnson JB, Emory TH. Intracystic papillary carcinoma in a man with gynecomastia. *Radiol Case Rep.* 2015 Dec 7;3(4):214. PMID:27303554
954. Johnston WT, Mutualima N, Sun D, et al. Relationship between Plasmodium falciparum malaria prevalence, genetic diversity and endemic Burkitt lymphoma in Malawi. *Sci Rep.* 2014 Jan 17;4:3741. PMID:24434689
955. Jones AM, Mitter R, Springall R, et al. A comprehensive genetic profile of phyllodes tumours of the breast detects important mutations, intra-tumoral genetic heterogeneity and new genetic changes on recurrence. *J Pathol.* 2008 Apr;214(5):533–44. PMID:18288784
956. Jones C, Damiani S, Wells D, et al. Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast. *Am J Pathol.* 2001 Jan;158(1):207–14. PMID:11141494
957. Jones C, Merrett S, Thomas VA, et al. Comparative genomic hybridization analysis of bilateral hyperplasia of usual type of the breast. *J Pathol.* 2003 Feb;199(2):152–6. PMID:12533827
958. Jones EL. Primary squamous-cell carcinoma of breast with pseudosarcomatous stroma. *J Pathol.* 1969 Feb;97(2):383–5. PMID:5352811
959. Jones MW, Norris HJ, Snyder RC. Infiltrating syringomatous adenoma of the nipple. A clinical and pathological study of 11 cases. *Am J Surg Pathol.* 1989 Mar;13(3):197–201. PMID:2919717
960. Jones MW, Norris HJ, Wargotz ES. Hamartomas of the breast. *Surg Gynecol Obstet.* 1991 Jul;173(1):54–6. PMID:1866672
961. Jones MW, Tavassoli FA. Coexistence of nipple duct adenoma and breast carcinoma: a clinicopathologic study of five cases and review of the literature. *Mod Pathol.* 1995 Aug;8(6):633–6. PMID:8532696
962. Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. *Science.* 2009 Apr 10;324(5924):217. PMID:19264984
963. Joshi D, Singh P, Zounounfawni Y, et al. Metaplastic carcinoma of the breast: cytological diagnosis and diagnostic pitfalls. *Acta Cytol.* 2011;55(4):313–8. PMID:21791899
964. Jozefczyk MA, Rosen PP. Vascular tumors of the breast. II. Peribulbar hemangiomas and hemangiomas. *Am J Surg Pathol.* 1985 Jul;9(7):491–503. PMID:4091183
965. Jung SY, Kim HY, Nam BH, et al. Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. *Breast Cancer Res Treat.* 2010 Apr;120(3):627–37. PMID:20143153
966. Kabat GC, Jones JG, Olson N, et al. A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer. *Cancer Causes Control.* 2010 Jun;21(6):821–8. PMID:20084540
967. Kader HA, Jackson J, Mates D, et al. Tubular carcinoma of the breast: a population-based study of nodal metastases at presentation and of patterns of relapse. *Breast J.* 2001 Jan-Feb;7(1):8–13. PMID:11348409
968. Kadin ME, Deva A, Xu H, et al. Biomarkers provide clues to early events in the pathogenesis of breast implant-associated anaplastic large cell lymphoma. *Aesthet Surg J.* 2016 Jul;36(7):773–81. PMID:26979456
969. Kadin ME, Morgan J, Xu H, et al. IL-13 is produced by tumor cells in breast implant-associated anaplastic large cell lymphoma: implications for pathogenesis. *Hum Pathol.* 2018 Aug;78:54–62. PMID:29689246
970. Kalambo M, Adriana BE, Adeyefa MM, et al. Phyllodes tumor of the breast: ultrasound-pathology correlation. *AJR Am J Roentgenol.*

- 2018 Apr;210(4):W173-9. PMID:29412020
- 971.** Kambouchner M, Godmer P, Guillemin L, et al. Low grade marginal zone B cell lymphoma of the breast associated with localised amyloidosis and corpora amylacea in a woman with long standing primary Sjögren's syndrome. *J Clin Pathol*. 2003 Jan;56(1):74-7. PMID:12499440
- 972.** Kamihara J, Rana HQ, Garber JE. Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome. *Hum Mutat*. 2014 Jun;35(6):654-62. PMID:24706533
- 973.** Kamitani T, Matsuo Y, Yabuuchi H, et al. Differentiation between benign phyllodes tumors and fibroadenomas of the breast on MR imaging. *Eur J Radiol*. 2014 Aug;83(8):1344-9. PMID:24856515
- 974.** Kang A, Kumar JB, Thomas A, et al. A spontaneously resolving breast lesion: imaging and cytological findings of nodular fasciitis of the breast with FISH showing USP6 gene rearrangement. *BMJ Case Rep*. 2015 Dec 23;2015. PMID:26698206
- 975.** Kang H, Tam M, Bishop JA, et al. Whole-exome sequencing of salivary gland mucoepidermoid carcinoma. *Clin Cancer Res*. 2017 Jan 1;23(1):283-8. PMID:27340278
- 976.** Kanhai RC, Hage JJ, van Diest PJ, et al. Short-term and long-term histologic effects of castration and estrogen treatment on breast tissue of 14 male-to-female transsexuals in comparison with two chemically castrated men. *Am J Surg Pathol*. 2000 Jan;24(1):74-80. PMID:10632490
- 977.** Kanojia D, Nagata Y, Garg M, et al. Genomic landscape of liposarcoma. *Oncotarget*. 2015 Dec 15;6(40):42429-44. PMID:26463872
- 978.** Karabakhtsian RG, Johnson R, Sumkin J, et al. The clinical significance of lobular neoplasia on breast core biopsy. *Am J Surg Pathol*. 2007 May;31(5):717-23. PMID:17460455
- 979.** Karamchandani JR, Nielsen TO, van de Rijn M, et al. Sox10 and S100 in the diagnosis of soft-tissue neoplasms. *Appl Immunohistochem Mol Morphol*. 2012 Oct;20(5):445-50. PMID:22495377
- 980.** Karim RZ, O'Toole SA, Scolyer RA, et al. Recent insights into the molecular pathogenesis of mammary phyllodes tumours. *J Clin Pathol*. 2013 Jun;66(6):496-505. PMID:23404800
- 981.** Kas K, Voz ML, Röijer E, et al. Promoter swapping between the genes for a novel zinc finger protein and beta-catenin in pleiomorphic adenomas with t(3;8)(p21;q12) translocations. *Nat Genet*. 1997 Feb;15(2):170-4. PMID:9020842
- 982.** Kasper B, Baumgarten C, Garcia J, et al. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). *Ann Oncol*. 2017 Oct 1;28(10):2399-408. PMID:28961825
- 983.** Kast K, Krause M, Schuler M, et al. Late onset Li-Fraumeni syndrome with bilateral breast cancer and other malignancies: case report and review of the literature. *BMC Cancer*. 2012 Jun 6;12:217. PMID:22672556
- 984.** Kawaguchi K, Shin SJ. Immunohistochemical staining characteristics of low-grade adenosquamous carcinoma of the breast. *Am J Surg Pathol*. 2012 Jul;36(7):1009-20. PMID:22446941
- 985.** Kawase K, Dimaria DJ, Tucker SL, et al. Paget's disease of the breast: there is a role for breast-conserving therapy. *Ann Surg Oncol*. 2005 May;12(5):391-7. PMID:15915373
- 986.** Kazakov DV, Bisceglia M, Mukensnabl P, et al. Pseudoangiomatous stromal hyperplasia in lesions involving anogenital mammary-like glands. *Am J Surg Pathol*. 2005 Sep;29(9):1243-6. PMID:16096415
- 987.** Kebudi R, Koc BS, Gorgun O, et al. Breast metastases in children and adolescents with rhabdomyosarcoma: a large single-institution experience and literature review. *J Pediatr Hematol Oncol*. 2017 Jan;39(1):67-71. PMID:27820124
- 988.** Kehr EL, Jorns JM, Ang D, et al. Mucinous breast carcinomas lack PIK3CA and AKT1 mutations. *Hum Pathol*. 2012 Dec;43(12):2207-12. PMID:22705004
- 989.** Kelly GL, Stylianou J, Rasaiyaah J, et al. Different patterns of Epstein-Barr virus latency in endemic Burkitt lymphoma (BL) lead to distinct variants within the BL-associated gene expression signature. *J Virol*. 2013 Mar;87(5):2882-94. PMID:23269792
- 990.** Kelten Talu C, Leblebici C, Kilicaslan Ozturk T, et al. Primary breast carcinomas with neuroendocrine features: clinicopathological features and analysis of tumor growth patterns in 36 cases. *Ann Diagn Pathol*. 2018 Jun;34:122-30. PMID:29661717
- 991.** Kensler KH, Regan MM, Heng YJ, et al. Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98. *Breast Cancer Res*. 2019 Feb 22;21(1):30. PMID:30795773
- 992.** Kerlikowske K. Epidemiology of ductal carcinoma in situ. *J Natl Cancer Inst Monogr*. 2010;2010(41):139-41. PMID:20956818
- 993.** Kerlikowske K, Barclay J, Grady D, et al. Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. *J Natl Cancer Inst*. 1997 Jan 1;89(1):76-82. PMID:8978410
- 994.** Keung EZ, Chiang YJ, Voss RK, et al. Defining the incidence and clinical significance of lymph node metastasis in soft tissue sarcoma. *Eur J Surg Oncol*. 2018 Jan;44(1):170-7. PMID:29208319
- 995.** Khalifeh IM, Albaracín C, Diaz LK, et al. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma. *Am J Surg Pathol*. 2008 Apr;32(4):544-52. PMID:18300793
- 996.** Khan HN, Rampaul R, Blamey RW. Management of physiological gynaecomastia with tamoxifen. *Breast*. 2004 Feb;13(1):61-5. PMID:14759718
- 997.** Khanafshar E, Phillipson J, Schammel DP, et al. Inflammatory myofibroblastic tumor of the breast. *Am J Diagn Pathol*. 2005 Jun;9(3):123-9. PMID:15944952
- 998.** Khanna KK, Chenevix-Trench G. ATM and genome maintenance: defining its role in breast cancer susceptibility. *J Mammary Gland Biol Neoplasia*. 2004 Jul;9(3):247-62. PMID:15557798
- 999.** Kheder ES, Hong DS. Emerging targeted therapy for tumors with NTRK fusion proteins. *Clin Cancer Res*. 2018 Dec 1;24(23):5807-14. PMID:29986850
- 1000.** Khouri T, Chen X, Wang D, et al. Nomogram to predict the likelihood of upgrade of atypical ductal hyperplasia diagnosed on a core needle biopsy in mammographically detected lesions. *Histopathology*. 2015 Jul;67(1):106-20. PMID:25529860
- 1001.** Khouri T, Karabakhtsian RG, Mattson D, et al. Pleiomorphic lobular carcinoma in situ of the breast: clinicopathological review of 47 cases. *Histopathology*. 2014 Jun;64(7):981-93. PMID:24372322
- 1002.** Khouri T, Kumar PR, Li Z, et al. Lobular neoplasia detected in MRI-guided core biopsy carries a high risk for upgrade: a study of 63 cases from four different institutions. *Mod Pathol*. 2016 Jan;29(1):25-33. PMID:26564004
- 1003.** Khoury T, Li Z, Sanati S, et al. The risk of upgrade for atypical ductal hyperplasia detected on magnetic resonance imaging-guided biopsy: a study of 100 cases from four academic institutions. *Histopathology*. 2016 Apr;68(5):713-21. PMID:26291517
- 1004.** Khurana KK, Wilbur D, Dawson AE. Fine needle aspiration cytology of invasive micropapillary carcinoma of the breast. A report of two cases. *Acta Cytol*. 1997 Jul-Aug;41(4 Suppl):1394-8. PMID:9990283
- 1005.** Kiae H, Nielsen B, Paulsen S, et al. Adenomyoepithelial adenosis and low-grade malignant adenomyoepithelioma of the breast. *Virchows Arch A Pathol Anat Histopathol*. 1984;405(1):55-67. PMID:6438900
- 1006.** Kiesewetter B, Lukas J, Dolak W, et al. Gender aspects in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue: Does sex matter? *Oncology*. 2016;91(5):243-50. PMID:27548082
- 1007.** Kilpivaara O, Vahtero P, Falck J, et al. CHEK2 variant I157T may be associated with increased breast cancer risk. *Int J Cancer*. 2004 Sep 10;111(4):543-7. PMID:15239132
- 1007A.** Kim A, Heo SH, Kim YA, et al. An examination of the local cellular immune response to examples of both ductal carcinoma in situ (DCIS) of the breast and DCIS with microinvasion, with emphasis on tertiary lymphoid structures and tumor infiltrating lymphocytes. *Am J Clin Pathol*. 2016 Jul;146(1):137-44. PMID:27402610
- 1008.** Kim DJ, Sun WY, Ryu DH, et al. Microglandular adenosis. *J Breast Cancer*. 2011 Mar;14(1):72-5. PMID:21847399
- 1009.** Kim HM, Park BW, Han SH, et al. Infiltrating syringomatous adenoma presenting as microcalcification in the nipple on screening mammogram: case report and review of the literature of radiologic features. *Clin Imaging*. 2010 Nov-Dec;34(6):462-5. PMID:21092877
- 1010.** Kim J, Geyer FC, Martelotto LG, et al. MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene. *J Pathol*. 2018 Feb;244(2):143-50. PMID:29149504
- 1011.** Kim JY, Moon HG, Kang YJ, et al. The effect of reproductive factors on breast cancer presentation in women who are BRCA mutation carrier. *J Breast Cancer*. 2017 Sep;20(3):279-85. PMID:28970854
- 1012.** Kim M, Kim HJ, Chung YR, et al. Microinvasive carcinoma versus ductal carcinoma in situ: a comparison of clinicopathological features and clinical outcomes. *J Breast Cancer*. 2018 Jun;21(2):197-205. PMID:29963116
- 1013.** Kim MJ, Gong G, Joo HJ, et al. Immunohistochemical and clinicopathologic characteristics of invasive ductal carcinoma of breast with micropapillary carcinoma component. *Arch Pathol Lab Med*. 2005 Oct;129(10):1277-82. PMID:16196516
- 1014.** Kim S, Kim JY, Kim DH, et al. Analysis of phyllodes tumor recurrence according to the histologic grade. *Breast Cancer Res Treat*. 2013 Oct;141(3):353-63. PMID:24062207
- 1015.** Kim S, Moon BI, Lim W, et al. Expression patterns of GATA3 and the androgen receptor are strongly correlated in patients with triple-negative breast cancer. *Hum Pathol*. 2016 Sep;55:190-5. PMID:27184484
- 1016.** Kim SE, Koo JS, Jung WH. Immunophenotypes of glycogen rich clear cell carcinoma. *Yonsei Med J*. 2012 Nov 1;53(6):1142-6. PMID:23074114
- 1017.** Kim SE, Park JH, Hong S, et al. Primary mucinous cystadenocarcinoma of the breast: cytologic finding and expression of MUC5 are different from mucinous carcinoma. *Korean J Pathol*. 2012 Dec;46(6):611-6. PMID:23290000
- 1018.** Kim SM, Kim HH, Shim JH, et al. Cavernous haemangioma of the breast. *Br J Radiol*. 2006 Nov;79(917):777-80. PMID:17065282
- 1019.** Kindblom LG, Meis-Kindblom JM, Westermark P, et al. Benign epithelioid schwannoma. *Am J Surg Pathol*. 1998 Jun;22(6):709-14. PMID:9630185
- 1020.** King MC, Levy-Lahad E, Watson MA, et al. Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award. *JAMA*. 2014;311(17):1731-8. PMID:25198332
- 1021.** King TA, Pilewskie M, Mutter L, et al. Lobular carcinoma in situ: a 29-year longitudinal experience evaluating clinicopathologic features and breast cancer risk. *J Clin Oncol*. 2015 Nov 20;33(33):3945-52. PMID:26370700
- 1022.** Kirova YM, Vilcoq JR, Asselmann H, et al. Radiation-induced sarcomas: a scale single-institution review. *Cancer*. 2008 Aug 15;104(4):856-63. PMID:18652201
- 1023.** Kirschner LS, Carney JA, Parsons JT, et al. Mutations of the gene encoding the kinase A type I-alpha regulatory subunit in patients with the Carney complex. *Nature*. 2000 Sep;26(1):89-92. PMID:10972050
- 1024.** Kirshenbaum G, Rhone DF. Extramedullary plasmacytoma of the breast with serum monoclonal protein: a case report and review of the literature. *Am J Clin Pathol*. 1985 Feb;83(2):230-2. PMID:3919437
- 1025.** Kizy S, Huang JL, Marmorstein N, et al. of the 21-gene recurrence score in patients with invasive lobular carcinoma of the breast. *Breast Cancer Res Treat*. 2005 Oct;165(3):757-63. PMID:16264795
- 1026.** Klein ME, Dabbs DJ, Shaukat A, et al. Prediction of the Oncotype DX recurrence score by pathology-generated equation: a study by linear regression analysis. *Mod Pathol*. 2005 May;26(5):658-64. PMID:15913840
- 1027.** Knezevich SR, Gamell LL, Pritchard K, et al. ETV6-NTRK3 gene fusions establish a histogenetic link between mesoblastic nephroma and fibrosarcoma. *Cancer Res*. 2015;55(22):5046-8. PMID:26233077
- 1028.** Knezevich SR, McFadden JE, Pritchard K, et al. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. *Nat Genet*. 2016 Feb;18(2):184-7. PMID:26427558
- 1029.** Knijnenburg TA, Wang L, Zeng J, et al. MT, et al. Genomic and molecular analysis of DNA damage repair deficiency across the Cancer Genome Atlas. *Cell Res*. 2016;26(3):239-254.e6. PMID:26967854
- 1030.** Knoop AS, Lænkholm A, Hansen MB, et al. Estrogen receptor, progesterone receptor, HER2 status and HER3 expression are associated with responsiveness to adjuvant chemotherapy in postmenopausal high-risk breast cancer patients enrolled in the DBCG-10 trial. *Eur J Cancer*. 2014 May;50(9):1500-7. PMID:24675287
- 1031.** Kocjan G, Bourgoin C, Fassina A, et al. The role of breast FNAC in diagnostic and clinical management: a survey of current practice. *Cytopathology*. 2008 Dec;19(12):661-7. PMID:18821945
- 1032.** Kocyigit C, Santas S, Çatış E, et al. mutation in human androgen receptor causing partial androgen insensitivity in a patient presenting with gynecomastia at puberty. *J Clin Res Pediatr Endocrinol*. 2012 Jun;5(2):232-5. PMID:23076752
- 1033.** Koehl RH, Snyder RE, et al. The use of specimen targeting to detect small carcinomas not found on pathologic examination. *CA Cancer J Clin*. 2014 Jan-Feb;64(1):2-10. PMID:24553731

1034. Koenig C, Tavassoli FA. Mucinous cystadenocarcinoma of the breast. *Am J Surg Pathol*. 1998 Jun;22(6):698–703. PMID:9630176
- 1034A. Koh VCY, Ng CCY, Bay BH, et al. The utility of a targeted gene mutation panel in refining the diagnosis of breast phyllodes tumours. *Pathology*. 2019 Aug;51(5):531–4. PMID:31272781
1035. Koh VCY, Thike AA, Nasir NDM, et al. Size and heterologous elements predict metastases in malignant phyllodes tumours of the breast. *Virchows Arch*. 2018 Apr;472(4):615–21. PMID:29127495
1036. Kollmorgen DR, Varanasi JS, Edge SB, et al. Paget's disease of the breast: a 33-year experience. *J Am Coll Surg*. 1998 Aug;187(2):171–7. PMID:9704964
1037. Komaki K, Sakamoto G, Sugano H, et al. Mucinous carcinoma of the breast in Japan. A prognostic analysis based on morphologic features. *Cancer*. 1988 Mar 1;61(5):989–96. PMID:2827884
1038. Kondi-Pafitis A, Kairi-Vassilatou E, Grapsa D, et al. A large benign vascular neoplasm of the male breast. A case report and review of the literature. *Eur J Gynaecol Oncol*. 2005;26(4):454–6. PMID:1612203
1039. Kondis-Pafitis A, Psychogios J, Spanidou-Carvouni H, et al. Clinicopathological study of vascular tumors of the breast: a series of ten patients with a long follow-up. *Eur J Gynaecol Oncol*. 2004;25(3):324–6. PMID:15171310
1040. Korhonen T, Huhtala H, Holl K. A comparison of the biological and clinical features of invasive lobular and ductal carcinomas of the breast. *Breast Cancer Res Treat*. 2004 May;85(1):23–9. PMID:15039595
1041. Korhonen T, Kuukasjärvi T, Huhtala H, et al. The impact of lobular and ductal breast cancer histology on the metastatic behavior and long term survival of breast cancer patients. *Breast*. 2013 Dec;22(6):1119–24. PMID:23863867
1042. Kornegoor R, Moelans CB, Verschuur-Maes AH, et al. Oncogene amplification in male breast cancer: analysis by multiplex ligation-dependent probe amplification. *Breast Cancer Res Treat*. 2012 Aug;135(1):49–58. PMID:22527098
1043. Kornegoor R, Moelans CB, Verschuur-Maes AH, et al. Promoter hypermethylation in male breast cancer: analysis by multiplex ligation-dependent probe amplification. *Breast Cancer Res*. 2012 Jul 5;14(4):R101. PMID:22765268
1044. Kornegoor R, van Diest PJ, Buerger H, et al. Tracing differences between male and female breast cancer: both diseases own a different biology. *Histopathology*. 2015 Dec;67(6):888–97. PMID:25941088
1045. Kornegoor R, Verschuur-Maes AH, Buerger H, et al. Fibrotic focus and hypoxia in male breast cancer. *Mod Pathol*. 2012 Oct;25(10):1397–404. PMID:22684218
1046. Kornegoor R, Verschuur-Maes AH, Buerger H, et al. Immunophenotyping of male breast cancer. *Histopathology*. 2012 Dec;61(6):1145–55. PMID:22958056
1047. Kornegoor R, Verschuur-Maes AH, Buerger H, et al. Molecular subtyping of male breast cancer by immunohistochemistry. *Mod Pathol*. 2012 Mar;25(3):398–404. PMID:22056953
1048. Kornegoor R, Verschuur-Maes AH, Buerger H, et al. The 3-layered ductal epithelium in gynecomastia. *Am J Surg Pathol*. 2012 May;36(5):762–8. PMID:22314184
1049. Korolczuk A, Amarowicz M, Bałk K, et al. Adenomyoepithelioma of the breast with late pulmonary metastases - case report and review of the literature. *J Cardiothorac Surg*. 2016 Aug 4;11(1):121. PMID:27487934
1050. Kothari AS, Beechey-Newman N, Hamed H, et al. Paget disease of the nipple: a multifocal manifestation of higher-risk disease. *Cancer*. 2002 Jul 1;95(1):1–7. PMID:12115309
1051. Kotsopoulos J, Lubinski J, Lynch HT, et al. Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiol Biomarkers Prev*. 2012 Jul;21(7):1089–96. PMID:22564781
1052. Koufopoulos N, Goudeli C, Syrios J, et al. Mucinous cystadenocarcinoma of the breast: the challenge of diagnosing a rare entity. *Rare Tumors*. 2017 Oct 3;9(3):7016. PMID:29081926
1053. Kovács A, Máthé G, Mattsson J, et al. ALK-positive inflammatory myofibroblastic tumor of the nipple during pregnancy—an unusual presentation of a rare disease. *Breast J*. 2015 May-Jun;21(3):297–302. PMID:25772857
1054. Kovári B, Báthori Á, Cséni G. CD10 immunohistochemical expression in apocrine lesions of the breast. *Pathobiology*. 2015;82(6):259–63. PMID:26562027
1055. Kovárová M, Kubis M. Primary tumours of the heart. *Acta Univ Palacki Olomuc Fac Med*. 1987;117:409–12. PMID:2977705
1056. Kraft S, Fletcher CD. Atypical intradermal smooth muscle neoplasms: clinicopathologic analysis of 84 cases and a reappraisal of cutaneous "leiomyosarcoma". *Am J Surg Pathol*. 2011 Apr;35(4):599–607. PMID:21358302
1057. Krammer J, Pinker-Domenig K, Robson ME, et al. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Res Treat*. 2017 Jun;163(3):565–71. PMID:28343309
1058. Krausz T, Jenkins D, Grontoft O, et al. Secretory carcinoma of the breast in adults: emphasis on late recurrence and metastasis. *Histopathology*. 1989 Jan;14(1):25–36. PMID:2925177
1059. Krecke KN, Gisvold JJ. Invasive lobular carcinoma of the breast: mammographic findings and extent of disease at diagnosis in 184 patients. *AJR Am J Roentgenol*. 1993 Nov;161(5):957–60. PMID:8273634
1060. Kriege M, Hollestelle A, Jager A, et al. Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy. *Br J Cancer*. 2014 Aug 26;111(5):1004–13. PMID:24918820
1061. Krings G, Bean GR, Chen YY. Fibroepithelial lesions: the WHO spectrum. *Semin Diagn Pathol*. 2017 Sep;34(5):438–52. PMID:28688536
1062. Krings G, Chen YY. Genomic profiling of metaplastic breast carcinomas reveals genetic heterogeneity and relationship to ductal carcinoma. *Mod Pathol*. 2018 Nov;31(11):1661–74. PMID:29946183
1063. Krings G, Joseph NM, Bean GR, et al. Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas. *Mod Pathol*. 2017 Aug;30(8):1086–99. PMID:28548128
1064. Krings G, McIntire P, Shin SJ. Myofibroblastic, fibroblastic and myoid lesions of the breast. *Semin Diagn Pathol*. 2017 Sep;34(5):427–37. PMID:28751104
1065. Krop I, Ismail N, Stearns V. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice focused update guideline summary. *J Oncol Pract*. 2017 Nov;13(11):763–6. PMID:28696818
1066. Kryvenko ON, Chitale DA, VanEgmond EM, et al. Angiolipoma of the female breast: clinicopathological correlation of 52 cases. *Int J Surg Pathol*. 2011 Feb;19(1):35–43. PMID:21087987
1067. Ku J, Campbell C, Bennett I. Leiomyoma of the nipple. *Breast J*. 2006 Jul-Aug;12(4):377–80. PMID:16848853
1068. Kuba MG, Lester SC, Giess CS, et al. Fibromatosis of the breast: diagnostic accuracy of core needle biopsy. *Am J Clin Pathol*. 2017 Sep 1;148(3):243–50. PMID:28821190
1069. Kuchenbaecker KB, McGuffog L, Barrowdale D, et al. Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers. *J Natl Cancer Inst*. 2017 Jul 1;110(7):djw302. PMID:28376175
1070. Kuchenbaecker KB, Neuhausen SL, Robson M, et al. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Res*. 2014 Dec 31;16(6):3416. PMID:25919761
1071. Kucukyaybek BB, Yigit S, Sarı AA, et al. Primary mucinous cystadenocarcinoma of the breast with amplification of the HER2 gene confirmed by FISH - case report and review of the literature. *Pol J Pathol*. 2014 Mar;65(1):70–3. PMID:25119013
1072. Kuijper A, Buerger H, Simon R, et al. Analysis of the progression of fibroepithelial tumours of the breast by PCR-based clonality assay. *J Pathol*. 2002 Aug;197(5):575–81. PMID:12210075
1073. Kuijper A, Mommers EC, van der Wall E, et al. Histopathology of fibroadenoma of the breast. *Am J Clin Pathol*. 2001 May;115(5):736–42. PMID:11345838
1074. Kulkarni N, Pezzi CM, Greif JM, et al. Rare breast cancer: 933 adenoid cystic carcinomas from the National Cancer Data Base. *Ann Surg Oncol*. 2013 Jul;20(7):2236–41. PMID:23456318
1075. Kulshreshtha B, Arpita A, Rajesh PT, et al. Adolescent gynecomastia is associated with a high incidence of obesity, dysglycemia, and family background of diabetes mellitus. *Indian J Endocrinol Metab*. 2017 Jan-Feb;21(1):160–4. PMID:28217517
1076. Kumar E, Patel NR, Demicco EG, et al. Cutaneous nodular fasciitis with genetic analysis: a case series. *J Cutan Pathol*. 2016 Dec;43(12):1143–9. PMID:27866647
1077. Kumar H, Narasimha A, Bhaskaran, et al. Concurrent lactating adenoma and infiltrating ductal carcinoma: a case report. *J Clin Diagn Res*. 2015 Aug;9(8):ED14–5. PMID:26435957
1078. Kundu UR, Guo M, Landon G, et al. Fine-needle aspiration cytology of sclerosing adenosis of the breast: a retrospective review of cytologic features in conjunction with corresponding histologic features and radiologic findings. *Am J Clin Pathol*. 2012 Jul;138(1):96–102. PMID:22706864
1079. Kuo F, Lally K, Lewis M, et al. Granular cell tumour in male breast mimicking breast carcinoma. *BMJ Case Rep*. 2019 Mar 5;12(3):e227805. PMID:30842135
1080. Kurebayashi J, Izuo M, Ishida T, et al. Two cases of lipid-secreting carcinoma of the breast: case reports with an electron microscopic study. *Jpn J Clin Oncol*. 1988 Sep;18(3):249–54. PMID:3045374
1081. Kurozumi S, Matsumoto H, Hayashi Y, et al. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index. *BMC Cancer*. 2017 May 22;17(1):354. PMID:28532429
1082. Kwasi AB, Groothuis-Oudshoorn KC, Grandjean I, et al. Histological type is not an independent prognostic factor for the risk pattern of breast cancer recurrences. *Breast Cancer Res Treat*. 2012 Aug;135(1):271–80. PMID:22810087
1083. La Vecchia C, Parazzini F, Franceschi S, et al. Risk factors for benign breast disease and their relation with breast cancer risk. Pooled information from epidemiologic studies. *Tumori*. 1985 Apr 30;71(2):167–78. PMID:4002347
1084. Lack EE, Worsham GF, Callihan MD, et al. Granular cell tumor: a clinicopathologic study of 110 patients. *J Surg Oncol*. 1980;13(4):301–16. PMID:6246310
1085. Lacle MM, Kornegoor R, Moelans CB, et al. Analysis of copy number changes on chromosome 16q in male breast cancer by multiplex ligation-dependent probe amplification. *Mod Pathol*. 2013 Nov;26(11):1461–7. PMID:23743929
1086. Lacle MM, Moelans CB, Kornegoor R, et al. Chromosome 17 copy number changes in male breast cancer. *Cell Oncol (Dordr)*. 2015 Jun;38(3):237–45. PMID:25906114
1087. Lacle MM, van der Pol C, Witkamp A, et al. Prognostic value of mitotic index and Bcl2 expression in male breast cancer. *PLoS One*. 2013;8(4):e60138. PMID:23573235
1088. Lacle MM, van Diest PJ, Goldschmeding R, et al. Expression of connective tissue growth factor in male breast cancer: clinicopathologic correlations and prognostic value. *PLoS One*. 2015 Mar 4;10(3):e0118957. PMID:25738829
1089. Lacroix-Triki M, Geyer FC, Lambros MB, et al. β-catenin/Wnt signalling pathway in fibromatoses, metaplastic carcinomas and phyllodes tumours of the breast. *Mod Pathol*. 2010 Nov;23(11):1438–48. PMID:20693983
1090. Lacroix-Triki M, Lambros MB, Geyer FC, et al. Absence of microsatellite instability in mucinous carcinomas of the breast. *Int J Clin Exp Pathol*. 2010 Nov 27;4(1):22–31. PMID:21228925
1091. Lacroix-Triki M, Suarez PH, MacKay A, et al. Mucinous carcinoma of the breast is genetically distinct from invasive ductal carcinomas of no special type. *J Pathol*. 2010 Nov;222(3):282–98. PMID:20815046
1092. Laé M, Fréneau P, Sastre-Garau X, et al. Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum. *Mod Pathol*. 2009 Feb;22(2):291–8. PMID:19011601
1093. Laé M, La Rosa P, Mandel J, et al. Whole-genome profiling helps to classify phyllodes tumours of the breast. *J Clin Pathol*. 2016 Dec;69(12):1081–7. PMID:27207013
1094. Lahat G, Lazar A, Lev D. Sarcoma epidemiology and etiology: potential environmental and genetic factors. *Surg Clin North Am*. 2008 Jun;88(3):451–81, v. PMID:18514694
1095. Lai R, Weiss LM, Chang KL, et al. Frequency of CD43 expression in non-Hodgkin lymphoma. A survey of 742 cases and further characterization of rare CD43+ follicular lymphomas. *Am J Clin Pathol*. 1999 Apr;111(4):488–94. PMID:10191768
1096. Lakhani SR, Chaggar R, Davies S, et al. Genetic alterations in 'normal' luminal and myoepithelial cells of the breast. *J Pathol*. 1999 Dec;189(4):496–503. PMID:10629549
1097. Lakhani SR, Collins N, Stratton MR, et al. Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. *J Clin Pathol*. 1995 Jul;48(7):611–5. PMID:7560165
1098. Lakhani SR, Ellis IO, Schnitt SJ, et al., editors. WHO classification of tumours of the breast. Lyon (France): International Agency for Research on Cancer; 2012. (WHO classification of tumours series, 4th ed.; vol. 4). <http://publications.iarc.fr/14>
1099. Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers

- involving BRCA1 and BRCA2 mutations. *J Natl Cancer Inst.* 1998 Aug 5;90(15):1138–45. PMID:9701363
- 1100.** Lakhani SR, O'Hare MJ. The mammary myoepithelial cell—Cinderella or ugly sister? *Breast Cancer Res.* 2001;3(1):1–4. PMID:11250738
- 1101.** Lakhani SR, Slack DN, Hamoudi RA, et al. Detection of allelic imbalance indicates that a proportion of mammary hyperplasia of usual type are clonal, neoplastic proliferations. *Lab Invest.* 1996 Jan;74(1):129–35. PMID:8569175
- 1102.** Lale S, Kure K, Lingamfelter D. Challenges to diagnose metaplastic carcinoma of the breast through cytologic methods: an eight-case series. *Diagn Pathol.* 2011 Jan 18;6:7. PMID:21244696
- 1102A.** Laloo F, Varley J, Ellis D, et al. Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. *Lancet.* 2003 Mar 29;361(9363):1101–2. PMID:12672316
- 1103.** Lamb J, McGoogan E. Fine needle aspiration cytology of breast in invasive carcinoma of tubular type and in radial scar/complex sclerosing lesions. *Cytopathology.* 1994 Feb;5(1):17–26. PMID:8173027
- 1104.** Lamb LR, Bahl M, Hughes KS, et al. Pathologic upgrade rates of high-risk breast lesions on digital two-dimensional vs tomosynthesis mammography. *J Am Coll Surg.* 2018 May;226(5):858–67. PMID:29410346
- 1105.** Lambertini M, Santoro L, Del Mastro L, et al. Reproductive behaviors and risk of developing breast cancer according to tumor subtype: a systematic review and meta-analysis of epidemiological studies. *Cancer Treat Rev.* 2016 Sep;49:65–76. PMID:27529149
- 1106.** Lambird PA, Shelley WM. The spatial distribution of lobular *in situ* mammary carcinoma. Implications for size and site of breast biopsy. *JAMA.* 1969 Oct 27;210(4):689–93. PMID:5394401
- 1107.** Lammie GA, Millis RR. Ductal adenoma of the breast—a review of fifteen cases. *Hum Pathol.* 1989 Sep;20(9):903–8. PMID:2550351
- 1108.** Lamovec J, Bracko M. Metastatic pattern of infiltrating lobular carcinoma of the breast: an autopsy study. *J Surg Oncol.* 1991 Sep;48(1):28–33. PMID:1653879
- 1109.** Lamovec J, Jancar J. Primary malignant lymphoma of the breast. Lymphoma of the mucosa-associated lymphoid tissue. *Cancer.* 1987 Dec 15;60(12):3033–41. PMID:3315180
- 1110.** Lamovec J, Us-Krasovec M, Zidar A, et al. Adenoid cystic carcinoma of the breast: a histologic, cytologic, and immunohistochemical study. *Semin Diagn Pathol.* 1989 May;6(2):153–64. PMID:2474845
- 1111.** Landrum ML, Ornstein DL. Hypertrophic osteoarthropathy associated with metastatic phyllodes tumor. *Am J Clin Oncol.* 2003 Apr;26(2):146–50. PMID:12714885
- 1112.** Langeveld D, Jansen M, de Boer DV, et al. Aberrant intestinal stem cell lineage dynamics in Peutz-Jeghers syndrome and familial adenomatous polyposis consistent with protracted clonal evolution in the crypt. *Gut.* 2012 Jun;61(6):839–46. PMID:21940722
- 1113.** Langlands F, Cornford E, Rakha E, et al. Imaging overview of metaplastic carcinomas of the breast: a large study of 71 cases. *Br J Radiol.* 2016 Aug;89(1064):20140644. PMID:27245135
- 1114.** Lanng C, Eriksen BØ, Hoffmann J. Lipoma of the breast: a diagnostic dilemma. *Breast.* 2004 Oct;13(5):408–11. PMID:15454196
- 1115.** Lapid O, van Wingerden JJ, Perlmuter L. Tamoxifen therapy for the management of pubertal gynecomastia: a systematic review. *J Pediatr Endocrinol Metab.* 2013;26(9–10):803–7. PMID:23729603
- 1116.** Larson PS, de las Morenas A, Cerda SR, et al. Quantitative analysis of allele imbalance supports atypical ductal hyperplasia lesions as direct breast cancer precursors. *J Pathol.* 2006 Jul;209(3):307–16. PMID:16604511
- 1117.** Laskin WB, Fetisch JF, Lasota J, et al. Benign epithelioid peripheral nerve sheath tumors of the soft tissues: clinicopathologic spectrum of 33 cases. *Am J Surg Pathol.* 2005 Jan;29(1):39–51. PMID:15613855
- 1118.** Laucirica R, Bentz JS, Khalbuss WE, et al. Performance characteristics of mucinous (colloid) carcinoma of the breast in fine-needle aspirates: observations from the College of American Pathologists Interlaboratory Comparison Program in Nongynecologic Cytopathology. *Arch Pathol Lab Med.* 2011 Dec;135(12):1533–8. PMID:22129179
- 1118A.** Laurent E, Begueret H, Bonhomme B, et al. SOX10, GATA3, GCDFP15, androgen receptor, and gammaglobin for the differential diagnosis between triple-negative breast cancer and TTF1-negative lung adenocarcinoma. *Am J Surg Pathol.* 2019 Mar;43(3):293–302. PMID:30628926
- 1118B.** Lavigne M, Menet E, Tille JC, et al. Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast. *Mod Pathol.* 2018 Jan;31(1):68–82. PMID:28884749
- 1119.** Lavoué V, Fritel X, Antoine M, et al. Clinical practice guidelines from the French College of Gynecologists and Obstetricians (CNGOF): benign breast tumors - short text. *Eur J Obstet Gynecol Reprod Biol.* 2016 May;200:16–23. PMID:26967341
- 1120.** Lawrence K, Kar S, McCue K, et al. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. *Nat Commun.* 2016 Sep 7;7:12675. PMID:27601076
- 1121.** Lazar AJ, Tuvin D, Hajibashi S, et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. *Am J Pathol.* 2008 Nov;173(5):1518–27. PMID:18832571
- 1122.** Le BH, Boyer PJ, Lewis JE, et al. Granular cell tumor: immunohistochemical assessment of inhibin-alpha, protein gene product 9.5, S100 protein, CD68, and Ki-67 proliferative index with clinical correlation. *Arch Pathol Lab Med.* 2004 Jul;128(7):771–5. PMID:15214825
- 1123.** Le Gal M, Ollivier L, Asselain B, et al. Mammographic features of 455 invasive lobular carcinomas. *Radiology.* 1992 Dec;185(3):705–8. PMID:1438749
- 1124.** Le Guellec S, Soubeyran I, Rochaix P, et al. CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics. *Mod Pathol.* 2012 Dec;25(12):1551–8. PMID:22766794
- 1125.** Leal C, Costa I, Fonseca D, et al. Intracystic (encysted) papillary carcinoma of the breast: a clinical, pathological, and immunohistochemical study. *Hum Pathol.* 1998 Oct;29(10):1097–104. PMID:9781648
- 1126.** Lechner MG, Megiel C, Church CH, et al. Survival signals and targets for therapy in breast implant-associated ALK-anaplastic large cell lymphoma. *Clin Cancer Res.* 2012 Sep 1;18(17):4549–59. PMID:22791880
- 1127.** Lecuit T, Yap AS. E-cadherin junctions as active mechanical integrators in tissue dynamics. *Nat Cell Biol.* 2015 May;17(5):533–9. PMID:25925582
- 1128.** Lee AH. The histological diagnosis of metastases to the breast from extramammary malignancies. *J Clin Pathol.* 2007 Dec;60(12):1333–41. PMID:18042689
- 1129.** Lee AH. Use of immunohistochemistry in the diagnosis of problematic breast lesions. *J Clin Pathol.* 2013 Jun;66(6):471–7. PMID:23486609
- 1130.** Lee C, Boughey J. Case report of a synchronous nipple adenoma and breast carcinoma with current multi-modality radiologic imaging. *Breast J.* 2016 Jan-Feb;22(1):105–10. PMID:26548327
- 1131.** Lee EK, Kook SH, Kwag HJ, et al. Schwannoma of the breast showing massive exophytic growth: a case report. *Breast.* 2006 Aug;15(4):562–6. PMID:16844378
- 1132.** Lee HW, Kim TE, Cho SY, et al. Invasive Paget disease of the breast: 20 years of experience at a single institution. *Hum Pathol.* 2014 Dec;45(12):2480–7. PMID:25288235
- 1133.** Lee JEA, Li N, Rowley SM, et al. Molecular analysis of PALB2-associated breast cancers. *J Pathol.* 2018 May;245(1):53–60. PMID:29431189
- 1134.** Lee JH, Kim SH, Kang BJ, et al. Ultrasonographic features of benign adenomyoepithelioma of the breast. *Korean J Radiol.* 2010 Sep-Oct;11(5):522–7. PMID:20808695
- 1135.** Lee JY, Schizas M, Geyer FC, et al. Lobular carcinomas *in situ* display intralesion genetic heterogeneity and clonal evolution in the progression to invasive lobular carcinoma. *Clin Cancer Res.* 2019 Jan 15;25(2):674–86. PMID:30185420
- 1136.** Lee SH, Park JM, Kook SH, et al. Metastatic tumors to the breast: mammographic and ultrasonographic findings. *J Ultrasound Med.* 2000 Apr;19(4):257–62. PMID:10759349
- 1137.** Lee YS, Filie A, Arthur D, et al. Breast implant-associated anaplastic large cell lymphoma in a patient with Li-Fraumeni syndrome. *Histopathology.* 2015 Dec;67(6):925–7. PMID:25974645
- 1138.** Leekha N, Muralee M, Mathews A, et al. Pleomorphic adenoma of breast—a case report and review of literature. *Indian J Surg Oncol.* 2014 Jun;5(2):152–4. PMID:25114471
- 1139.** Lefkowitz M, Lefkowitz W, Wargotz ES. Intraductal (intracystic) papillary carcinoma of the breast and its variants: a clinicopathological study of 77 cases. *Hum Pathol.* 1994 Aug;25(8):802–9. PMID:8056421
- 1140.** Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *J Clin Invest.* 2011 Jul;121(7):2750–67. PMID:21633166
- 1140A.** Lehmann BD, Jovanović B, Chen X, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. *PLoS One.* 2016 Jun 16;11(6):e0157368. PMID:27310713
- 1141.** Lehmann U, Streichert T, Otto B, et al. Identification of differentially expressed microRNAs in human male breast cancer. *BMC Cancer.* 2010 Mar 23;10:109. PMID:20331864
- 1142.** Lehmann-Che J, Hamy AS, Porcher R, et al. Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15. *Breast Cancer Res.* 2013 May 11;15(3):R37. PMID:23663520
- 1143.** Leibl S, Regitnig P, Moinfar F. Flat epithelial atypia (DIN 1a, atypical columnar change): an underdiagnosed entity very frequently coexisting with lobular neoplasia. *Histopathology.* 2007 Jun;50(7):859–65. PMID:17543075
- 1144.** Leithner A, Gapp M, Radl R, et al. Immunohistochemical analysis of desmoid tumours. *J Clin Pathol.* 2005 Nov;58(11):1152–6. PMID:16254103
- 1145.** Lempiäinen H, Halazonetis TD. Emerging common themes in regulation of PIK3Cs. *EMBO J.* 2009 Oct 21;28(20):5565–76. PMID:19779456
- 1146.** Lenze D, Leoncini L, Hummel M, et al. The different epidemiologic subtypes of Burkitt lymphoma share a homogenous mRNA profile distinct from diffuse large B-cell lymphoma. *Leukemia.* 2011 Dec;25(12):2167–76. PMID:21701491
- 1147.** Lepe M, Kalife ET, Ou J, et al. Loss of p120 immunostaining pattern in micropapillary carcinoma of the breast: additional unequivocal evidence of polarity. *Histopathology.* 2017 Apr;70(4):522–30. PMID:27862202
- 1148.** Leroy B, Ballinger ML, Barron-Wallace S, et al. Recommended guidelines for quality control, and reporting of TP53 mutations in clinical practice. *Cancer Res.* 2015 Jul;75(16):1250–60. PMID:26254861
- 1149.** Leroy B, Fournier JL, Ishioke C, et al. The TP53 website: an integrative centre for the TP53 mutation database and TP53 mutant analysis. *Nucleic Acids Res.* 2013 Jan;41(Database issue):D116–22. PMID:23161690
- 1150.** Lerwill MF. Current practical application of diagnostic immunohistochemistry in breast pathology. *Am J Surg Pathol.* 2013 Aug;28(8):1076–91. PMID:23520116
- 1151.** Lesley T, Péro G, Largay M, et al. RNA sequencing validation of the Clinical INdex in SARComas prognostic significance. *Cancer.* 2016 Apr;157:104–11. PMID:26940200
- 1152.** Lesser ML, Rosen PP, Kornblith BL. Multicentricity and bilaterality in invasive breast carcinoma. *Surgery.* 1982 Feb;91(2):339–44. PMID:6777027
- 1153.** Lesueur C, Diergaarde B, Oosterom M, et al. Genome-wide association analysis identifies new susceptibility loci for breast and pharyngeal cancer. *Nat Genet.* 2010 Dec;42(12):1544–50. PMID:21074945
- 1154.** Lester SC, Bose S, Chen X, et al. Protocol for the examination of specimens from patients with ductal carcinoma *in situ* of the breast. *Arch Pathol Lab Med.* 2000 Jan;133(1):15–25. PMID:10623730
- 1155.** Lester SC, Bose S, Chen X, et al. Protocol for the examination of specimens from patients with invasive carcinoma of the breast. *Arch Pathol Lab Med.* 2009 Oct;133(10):1338–42. PMID:19792042
- 1156.** Lester SC, Bose S, Chen X, et al. Protocol for the examination of specimens from patients with invasive carcinoma of the breast. *Arch Pathol Lab Med.* 2009 Oct;133(10):1338–42. PMID:19792042
- 1157.** Lesueur GC, Brown RW, Bostick-Bruton G, et al. Incidence of periblobular hemangioma in female breast. *Arch Pathol Lab Med.* 2000 Jun;127(6):308–10. PMID:10877585
- 1158.** Leucci E, Cocco M, Orsi R, et al. MYC translocation-negative classical Hodgkin lymphoma cases: an alternative pathogenetic mechanism involving mRNA deregulation. *J Pathol.* 2008 Dec;215(4):533–40. PMID:18802929
- 1159.** Leung AKC, Leung AAC, Giardina T, et al. Genomic instability in infants, children, and adolescents. *Genet Pat Endocr Metab Immune Disord.* 2017;10(2):127–37. PMID:28261521
- 1160.** Levi Z, Baris HN, Kedar I, et al. BRAF mutation-positive Cowden syndrome: participating in an active surveillance program. *Clin Transl Gastroenterol.* 2011 Nov;2(11):e0005. PMID:22328744
- 1161.** Levy A, Lang AE. Ataxia-telangiectasia: review of movement disorders, clinical features, and genotype correlations. *Neurogenetics.* 2008 Aug;9(3):123–47. PMID:24436738
- 1162.** Levy-Lahad E, Catane R, Eisenberg E, et al. Founder *BRCA1* and *BRCA2* mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian and in breast-ovarian cancer families. *J Hum Genet.* 1997 May;42(5):353–60. PMID:9155155

- PMID:9150153
1163. Lew M, Pang JC, Jing X, et al. Young investigator challenge: the utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions. *Cancer Cytopathol.* 2015 Oct;123(10):576–81. PMID:26465236
1164. Lewis JT, Hartmann LC, Vierkant RA, et al. An analysis of breast cancer risk in women with single, multiple, and atypical papilloma. *Am J Surg Pathol.* 2006 Jun;30(6):665–72. PMID:16723843
1165. Li CI. Risk of mortality by histologic type of breast cancer in the United States. *Horn Cancer.* 2010 Jun;1(3):156–65. PMID:21761358
1166. Li CI, Anderson BO, Daling JR, et al. Changing incidence of lobular carcinoma in situ of the breast. *Breast Cancer Res Treat.* 2002 Oct;75(3):259–68. PMID:12353815
1167. Li CI, Anderson BO, Daling JR, et al. Trends in incidence rates of invasive lobular and ductal breast carcinoma. *JAMA.* 2003 Mar 19;289(11):1421–4. PMID:12636465
1168. Li CI, Anderson BO, Porter P, et al. Changing incidence rate of invasive lobular breast carcinoma among older women. *Cancer.* 2000 Jun 1;88(11):2561–9. PMID:10861434
1169. Li CI, Chlebowski RT, Freiberg M, et al. Alcohol consumption and risk of postmenopausal breast cancer by subtype: the Women's Health Initiative Observational Study. *J Natl Cancer Inst.* 2010 Sep 22;102(18):1422–31. PMID:20733117
1170. Li CI, Daling JR, Malone KE. Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001. *Cancer Epidemiol Biomarkers Prev.* 2005 Apr;14(4):1008–11. PMID:15824180
1171. Li CI, Daling JR, Malone KE, et al. Relationship between established breast cancer risk factors and risk of seven different histologic types of invasive breast cancer. *Cancer Epidemiol Biomarkers Prev.* 2006 May;15(5):946–54. PMID:16702375
1172. Li CI, Malone KE, Saltzman BS, et al. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988–2001. *Cancer.* 2006 May 15;106(10):2104–12. PMID:16604564
1173. Li CI, Moe RE, Daling JR. Risk of mortality by histologic type of breast cancer among women aged 50 to 79 years. *Arch Intern Med.* 2003 Oct 13;163(18):2149–53. PMID:14557212
1174. Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast cancer. *Br J Cancer.* 2005 Oct 31;93(9):1046–52. PMID:16175185
1175. Li CI, Weiss NS, Stanford JL, et al. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. *Cancer.* 2000 Jun 1;88(11):2570–7. PMID:10861435
1176. Li D, Deng J, He H, et al. Primary breast diffuse large B-cell lymphoma shows an activated B-cell-like phenotype. *Ann Diagn Pathol.* 2012 Oct;16(5):335–43. PMID:22569408
1177. Li D, Xiao X, Yang W, et al. Secretory breast carcinoma: a clinicopathological and immunophenotypic study of 15 cases with a review of the literature. *Mod Pathol.* 2012 Apr;25(4):567–75. PMID:22157932
1178. Li H, Sun X, Miller E, et al. BMI, reproductive factors, and breast cancer molecular subtypes: a case-control study and meta-analysis. *J Epidemiol.* 2017 Apr;27(4):143–51. PMID:28142040
1179. Li J, Meeks H, Feng BJ, et al. Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families. *J Med Genet.* 2016 Jan;53(1):34–42. PMID:26534844
1180. Li M, Du J, Wang LJ, et al. A case of nipple adenoma detected by sonography. *Chin Med J (Engl).* 2016 Oct 5;129(19):2386–7. PMID:27647201
1181. Li N, Wang X, Zhang H, et al. Young male breast cancer, a small crowd, the survival, and prognosis? A population-based study. *Medicine (Baltimore).* 2018 Oct;97(40):e12686. PMID:30290658
1182. Li W, Han Y, Wang C, et al. Precise pathologic diagnosis and individualized treatment improve the outcomes of invasive micropapillary carcinoma of the breast: a 12-year prospective clinical study. *Mod Pathol.* 2018 Jun;31(6):956–64. PMID:29403084
1183. Li X, Peng J, Zhang Z, et al. Mammary mucinous cystadenocarcinoma. *Breast J.* 2012 May-Jun;18(3):282–3. PMID:22489551
1184. Li X, Xu Y, Ye H, et al. Encapsulated papillary carcinoma of the breast: a clinicopathological study of 49 cases. *Curr Probl Cancer.* 2018 May-Jun;42(3):291–301. PMID:29731165
1185. Li Y, Zhang S, Wei X, et al. The clinical features and management of women with ductal carcinoma in situ with microinvasion: a retrospective cohort study. *Int J Surg.* 2015 Jul;19:91–4. PMID:26013173
1186. Li YF, Lv MH, Chen LF, et al. Giant lipoma of the breast: a case report and review of the literature. *Clin Breast Cancer.* 2011 Dec;11(6):420–2. PMID:21729672
1187. Lian D, Cheah E, Tan PH, et al. Phyllodes tumour with intraductal growth: a rare cause of nipple discharge. *Histopathology.* 2007 Apr;50(5):666–9. PMID:17394506
1188. Liang M, Zhang Y, Sun C, et al. Association between CHEK2*1100delC and breast cancer: a systematic review and meta-analysis. *Mol Diagn Ther.* 2018 Aug;22(4):397–407. PMID:29909568
1189. Liao HY, Zhang WW, Sun JY, et al. The clinicopathological features and survival outcomes of different histological subtypes in triple-negative breast cancer. *J Cancer.* 2018 Jan 1;9(2):296–303. PMID:29344276
1190. Liu JY, Lee YH, Tsai JH, et al. Frequent PIK3CA activating mutations in nipple adenomas. *Histopathology.* 2017 Jan;70(2):195–202. PMID:27441415
1191. Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. *Nat Genet.* 1997 May;16(1):64–7. PMID:9140396
1192. Liberman L, Sama M, Susnik B, et al. Lobular carcinoma in situ at percutaneous breast biopsy: surgical biopsy findings. *AJR Am J Roentgenol.* 1999 Aug;173(2):291–9. PMID:10430122
1193. Lien HC, Chen YL, Juang YL, et al. Frequent alterations of HER2 through mutation, amplification, or overexpression in pleomorphic lobular carcinoma of the breast. *Breast Cancer Res Treat.* 2015 Apr;150(2):447–55. PMID:25773929
1194. Lien HC, Huang CS, Yang YW, et al. Mutational analysis of MED12 exon 2 in a spectrum of fibroepithelial tumours of the breast: implications for pathogenesis and histogenesis. *Histopathology.* 2016 Feb;68(3):433–41. PMID:26109290
1195. Lien HC, Lin CW, Mao TL, et al. p53 overexpression and mutation in metaplastic carcinoma of the breast: genetic evidence for a monoclonal origin of both the carcinomatous and the heterogeneous sarcomatous components. *J Pathol.* 2004 Oct;204(2):131–9. PMID:15376261
1196. Ligouri G, Cantile M, Cerrone M, et al. Breast MALT lymphomas: a clinicopathological and cytogenetic study of 9 cases. *Oncol Rep.* 2012 Oct;28(4):1211–6. PMID:22842723
1197. Lim HS, Kuzmial CM, Jeong SI, et al. Invasive micropapillary carcinoma of the breast: MR imaging findings. *Korean J Radiol.* 2013 Jul-Aug;14(4):551–8. PMID:23901311
1198. Lim J, Govindarajulu S, Sahu A, et al. Multiple Step-section Frozen Section sentinel lymph node biopsy—a review of 717 patients. *Breast.* 2013 Oct;22(5):639–42. PMID:23953247
1199. Lim SZ, Selvarajan S, Thike AA, et al. Breast sarcomas and malignant phyllodes tumours: comparison of clinicopathological features, treatment strategies, prognostic factors and outcomes. *Breast Cancer Res Treat.* 2016 Sep;159(2):229–44. PMID:27541020
1200. Lim WK, Ong CK, Tan J, et al. Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma. *Nat Genet.* 2014 Aug;46(8):877–80. PMID:25038752
1201. Lim-Co RY, Gisser SD. Unusual variant of lipid-rich mammary carcinoma. *Arch Pathol Lab Med.* 1978 Apr;102(4):193–5. PMID:580713
1202. Limite G, Di Micco R, Esposito E, et al. Acinic cell carcinoma of the breast: review of the literature. *Int J Surg.* 2014;12 Suppl 1:S35–9. PMID:24859406
1203. Limite G, Di Micco R, Esposito E, et al. The first case of acinic cell carcinoma of the breast within a fibroadenoma: case report. *Int J Surg.* 2014;12 Suppl 1:S232–5. PMID:24859396
1204. Lin FdeM, Pincerato KM, Bacchi CE, et al. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity. *J Clin Pathol.* 2012 Jan;65(1):64–8. PMID:22039288
1205. Lin WY, Camp NJ, Ghousaini M, et al. Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. *Hum Mol Genet.* 2015 Jan 1;24(1):285–98. PMID:25168388
1206. Lin X, Yan C, Gao Y, et al. Genetic variants at 9p21.3 are associated with risk of esophageal squamous cell carcinoma in a Chinese population. *Cancer Sci.* 2017 Feb;108(2):250–5. PMID:27960044
1207. Lindström S, Thompson DJ, Paterson AD, et al. Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk. *Nat Commun.* 2014 Oct 24;5:5303. PMID:25342443
1208. Lininger RA, Park WS, Man YG, et al. LOH at 16p13 is a novel chromosomal alteration detected in benign and malignant microdissected papillary neoplasms of the breast. *Hum Pathol.* 1998 Oct;29(10):1113–8. PMID:9781650
1209. Lips EH, Mukhtar RA, Yau C, et al. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. *Breast Cancer Res Treat.* 2012 Nov;136(1):35–43. PMID:22961065
1210. Lipska A, Kowtal P, Sarin R. Novel germline STK11 variants and breast cancer phenotype identified in an Indian cohort of Peutz-Jeghers syndrome. *Hum Mol Genet.* 2019 Jun 1;28(11):1885–93. PMID:30698938
1211. Liu C, Chang H, Li XH, et al. Network meta-analysis on the effects of DNA damage response-related gene mutations on overall survival of breast cancer based on TCGA database. *J Cell Biochem.* 2017 Dec;118(12):4728–34. PMID:28513990
1212. Liu F, Yang M, Li Z, et al. Invasive micropapillary mucinous carcinoma of the breast is associated with poor prognosis. *Breast Cancer Res Treat.* 2015 Jun;151(2):443–51. PMID:25953688
1213. Liu GF, Yang Q, Hafty BG, et al. Clinical-pathologic features and long-term outcomes of tubular carcinoma of the breast compared with invasive ductal carcinoma treated with breast conservation therapy. *Int J Radiat Oncol Biol Phys.* 2009 Dec 1;75(5):1304–8. PMID:19386432
1214. Liu H, Tan H, Cheng Y, et al. Imaging findings in mucinous breast carcinoma and correlating factors. *Eur J Radiol.* 2011 Dec;80(3):706–12. PMID:20615642
1215. Liu J, Jia W, Zeng Y, et al. Adolescent male adenoid cystic breast carcinoma. *Am Surg.* 2012 May;78(5):E288–9. PMID:22691333
1216. Liu J, Liu X, Feng X, et al. C-kit overexpression correlates with KIT gene copy numbers increases in phyllodes tumors of the breast. *Breast Cancer Res Treat.* 2015 Jan;149(2):395–401. PMID:25534827
1217. Liu L, Chi YY, Wang AA, et al. Marital status and survival of patients with hormone receptor-positive male breast cancer: a Surveillance, Epidemiology, and End Results (SEER) population-based study. *Med Sci Monit.* 2018 May 24;24:3425–41. PMID:29795054
1218. Liu N, Johnson KJ, Ma CX. Male breast cancer: an updated Surveillance, Epidemiology, and End Results data analysis. *Clin Breast Cancer.* 2018 Oct;18(5):e997–1002. PMID:30007834
1219. Liu SY, Joseph NM, Ravindranathan A, et al. Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity. *Mod Pathol.* 2016 Sep;29(9):1012–27. PMID:27255162
1220. Liu X, Wu H, Teng L, et al. High-grade encapsulated papillary carcinoma of the breast is clinicopathologically distinct from low/intermediate-grade neoplasms in Chinese patients. *Histol Histopathol.* 2019 Feb;34(2):137–47. PMID:30004109
1221. Liu XY, Jiang YZ, Liu YR, et al. Clinicopathological characteristics and survival outcomes of invasive cribriform carcinoma of breast: a SEER population-based study. *Medicine (Baltimore).* 2015 Aug;94(31):e1309. PMID:26252312
1222. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. *Mod Pathol.* 2006 Feb;19(2):264–71. PMID:16341146
1223. Lloyd J, Flanagan AM. Mammary and extramammary Paget's disease. *J Clin Pathol.* 2000 Oct;53(10):742–9. PMID:11064666
- 1223A. Lloyd-Lewis B, Harris OB, Watson CJ, et al. Mammary stem cells: premise, properties, and perspectives. *Trends Cell Biol.* 2017 Aug;27(8):556–67. PMID:28487183
1224. Lodding P, Kindblom LG, Angervall L, et al. Cellular schwannoma. A clinicopathologic study of 29 cases. *Virchows Arch A Pathol Anat Histopathol.* 1990;416(3):237–48. PMID:2105560
1225. Loghavi S, Khouri JD. Unusual breast mass: lymphoma with crystal-storing histiocytosis. *Blood.* 2015 Apr 9;125(15):2445. PMID:26038772
1226. Loghavi S, Medeiros LJ, Javadi S, et al. Breast implant-associated anaplastic large cell lymphoma with bone marrow involvement. *Aesthet Surg J.* 2018 Jun 13;38(7):NP 92–6. PMID:29635424
1227. Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive

- for trastuzumab benefit in early breast cancer: results from the FinHER trial. *Ann Oncol*. 2014 Aug;25(8):1544–50. PMID:24608200
- 1228.** Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. *J Clin Oncol*. 2013 Mar 1;31(7):860–7. PMID:23341518
- 1229.** Loibl S, Volz C, Mau C, et al. Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma. *Breast Cancer Res Treat*. 2014 Feb;144(1):153–62. PMID:24504379
- 1230.** Luke BN, Md Nasir ND, Thike AA, et al. Genetics and genomics of breast fibroadenomas. *J Clin Pathol*. 2018 May;71(5):381–7. PMID:29248888
- 1231.** Londero V, Zuiani C, Linda A, et al. Lobular neoplasia: core needle breast biopsy underestimation of malignancy in relation to radiologic and pathologic features. *Breast*. 2008 Dec;17(6):623–30. PMID:18619840
- 1232.** Long J, Cai Q, Sung H, et al. Genome-wide association study in east Asians identifies novel susceptibility loci for breast cancer. *PLoS Genet*. 2012;8(2):e1002532. PMID:22383897
- 1233.** Long J, Zhang B, Signorello LB, et al. Evaluating genome-wide association study-identified breast cancer risk variants in African-American women. *PLoS One*. 2013 Apr 8;8(4):e65830. PMID:23593120
- 1234.** Loose JH, Patchesky AS, Hollander IJ, et al. Adenomyoepithelioma of the breast. A spectrum of biologic behavior. *Am J Surg Pathol*. 1992 Sep;16(9):868–76. PMID:1384377
- 1235.** Lopes S, Vide J, Moreira E, et al. Paget disease of the male breast. *Dermatol Online J*. 2017 Apr 15;23(4):13030/qt0t89d5dg. PMID:28541881
- 1236.** López-Bonet E, Alonso-Ruano M, Barraza G, et al. Solid neuroendocrine breast carcinomas: incidence, clinicopathological features and immunohistochemical profiling. *Oncol Rep*. 2008 Dec;20(6):1369–74. PMID:19020716
- 1237.** Lopez-Garcia MA, Geyer FC, Lacroix-Triki M, et al. Breast cancer precursors revisited: molecular features and progression pathways. *Histopathology*. 2010 Aug;57(2):171–92. PMID:20500230
- 1238.** Lopez-Garcia MA, Geyer FC, Natrajan R, et al. Transcriptomic analysis of tubular carcinomas of the breast reveals similarities and differences with molecular subtype-matched ductal and lobular carcinomas. *J Pathol*. 2010 Sep;222(1):64–75. PMID:20593406
- 1239.** López-Urrutia E, Salazar-Rojas V, Brito-Elias L, et al. BRCA mutations: Is everything said? *Breast Cancer Res Treat*. 2019 Jan;173(1):49–54. PMID:30293211
- 1240.** Louwman MW, Vriezen M, van Beek MW, et al. Uncommon breast tumors in perspective: incidence, treatment and survival in the Netherlands. *Int J Cancer*. 2007 Jul 1;121(1):127–35. PMID:17330844
- 1241.** Love C, Sun Z, Jiménez D, et al. The genetic landscape of mutations in Burkitt lymphoma. *Nat Genet*. 2012 Dec;44(12):1321–5. PMID:23143597
- 1242.** Lovly CM, Gupta A, Lipson D, et al. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. *Cancer Discov*. 2014 Aug;4(8):889–95. PMID:24875859
- 1243.** Lozada JR, Basili T, Pareja F, et al. Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (solid papillary carcinomas with reverse polarity) harbour recurrent mutations affecting IDH2 and PIK3CA: a validation cohort. *Histopathology*. 2018 Aug;73(2):339–44. PMID:29603332
- 1244.** Lozada JR, Burke KA, Maguire A, et al. Myxoid fibroadenomas differ from conventional fibroadenomas: a hypothesis-generating study. *Histopathology*. 2017 Oct;71(4):626–34. PMID:28513873
- 1245.** Lu HM, Li S, Black MH, et al. Association of breast and ovarian cancers with predisposition genes identified by large-scale sequencing. *JAMA Oncol*. 2019 Jan 1;5(1):51–7. PMID:30128536
- 1246.** Lu YJ, Osin P, Lakhani SR, et al. Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia. *Cancer Res*. 1998 Oct 15;58(20):4721–7. PMID:9788628
- 1247.** Lüchtrath H, Moll R. Mucoepidermoid mammary carcinoma. Immunohistochemical and biochemical analyses of intermediate filaments. *Virchows Arch A Pathol Anat Histopathol*. 1989;416(2):105–13. PMID:2480681
- 1248.** Ludmir EB, Milgrom SA, Pinnix CC, et al. Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure. *Leuk Lymphoma*. 2018 Dec;59(12):2896–903. PMID:29697005
- 1249.** Lui PC, Lau PP, Tse GM, et al. Fine needle aspiration cytology of invasive micropapillary carcinoma of the breast. *Pathology*. 2007 Aug;39(4):401–5. PMID:17676481
- 1250.** Luini A, Aguilar M, Gatti G, et al. Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature. *Breast Cancer Res Treat*. 2007 Mar;101(3):349–53. PMID:17009109
- 1251.** Luk PP, Wykes J, Selinger CL, et al. Diagnostic and prognostic utility of mastermind-like 2 (MAML2) gene rearrangement detection by fluorescent *in situ* hybridization (FISH) in mucoepidermoid carcinoma of the salivary glands. *Oral Surg Oral Med Oral Pathol Oral Radiol*. 2016 May;121(5):530–41. PMID:27068311
- 1252.** Luna-Moré S, Casquero S, Pérez-Mellado A, et al. Importance of estrogen receptors for the behavior of invasive micropapillary carcinoma of the breast. Review of 68 cases with follow-up of 54. *Pathol Res Pract*. 2000;196(1):35–9. PMID:10674270
- 1253.** Luna-Moré S, Gonzalez B, Acedo C, et al. Invasive micropapillary carcinoma of the breast. A new special type of invasive mammary carcinoma. *Pathol Res Pract*. 1994 Aug;190(7):668–74. PMID:7808965
- 1254.** Luo J, Margolis KL, Wactawski-Wende J, et al. Association of active and passive smoking with risk of breast cancer among postmenopausal women: a prospective cohort study. *BMJ*. 2011 Mar 1;342:d1016. PMID:21363864
- 1255.** Ly D, Forman D, Ferlay J, et al. An international comparison of male and female breast cancer incidence rates. *Int J Cancer*. 2013 Apr 15;132(8):1918–26. PMID:22987302
- 1256.** Lyle PL, Bridge JA, Simpson JF, et al. Liposarcomatous differentiation in malignant phyllodes tumours is unassociated with MDM2 or CDK4 amplification. *Histopathology*. 2016 Jun;68(7):1040–5. PMID:26542423
- 1257.** Lyons TG, Robson ME. Resurrection of PARP inhibitors in breast cancer. *J Natl Compr Canc Netw*. 2018 Sep;16(9):1150–6. PMID:30181424
- 1258.** Ma CX, Bose R, Gao F, et al. Neratinib efficacy and circulating tumor DNA detection of HER2 mutations in HER2 nonamplified metastatic breast cancer. *Clin Cancer Res*. 2017 Oct 1;23(19):5687–95. PMID:28679771
- 1258A.** Ma X, Han Y, Fan Y, et al. Clinicopathologic characteristics and prognosis of glycogen-rich clear cell carcinoma of the breast. *Breast J*. 2014 Mar-Apr;20(2):166–73. PMID:24400866
- 1259.** Ma XJ, Dahia S, Richardson E, et al. Gene expression profiling of the tumor microenvironment during breast cancer progression. *Breast Cancer Res*. 2009;11(1):R7. PMID:19187537
- 1260.** Ma XJ, Salunga R, Tugge JT, et al. Gene expression profiles of human breast cancer progression. *Proc Natl Acad Sci U S A*. 2003 May 13;100(10):5974–9. PMID:12714683
- 1261.** MacGrogan G, Tavassoli FA. Central atypical papillomas of the breast: a clinicopathological study of 119 cases. *Virchows Arch*. 2003 Nov;443(5):609–17. PMID:14680220
- 1263.** MacPherson G, Healey CS, Teare MD, et al. Association of a common variant of the CASP8 gene with reduced risk of breast cancer. *J Natl Cancer Inst*. 2004 Dec 15;96(24):1866–9. PMID:15601643
- 1264.** Madanikia SA, Bergner A, Ye X, et al. Increased risk of breast cancer in women with NF1. *Am J Med Genet A*. 2012 Dec;158A(12):3056–60. PMID:23165953
- 1265.** Magnusson M, Beath K, Cootier R, et al. The epidemiology of breast implant-associated anaplastic large cell lymphoma in Australia and New Zealand confirms the highest risk for grade 4 surface breast implants. *Plast Reconstr Surg*. 2019 May;143(5):1285–92. PMID:30789476
- 1266.** Magrath I. Epidemiology: clues to the pathogenesis of Burkitt lymphoma. *Br J Haematol*. 2012 Mar;156(6):744–56. PMID:22260300
- 1267.** Magro G. Differential diagnosis of benign spindle cell lesions. *Surg Pathol Clin*. 2018 Mar;11(1):91–121. PMID:29413661
- 1268.** Magro G. Mammary myofibroblastoma: a tumor with a wide morphologic spectrum. *Arch Pathol Lab Med*. 2008 Nov;132(11):1813–20. PMID:18976021
- 1269.** Magro G. Mammary myofibroblastoma: an update with emphasis on the most diagnostically challenging variants. *Histol Histopathol*. 2016 Jan;31(1):1–23. PMID:26328916
- 1270.** Magro G, Angelico G, Righi A, et al. Utility of STAT6 and 13q14 deletion in the classification of the benign spindle cell stromal tumors of the breast. *Hum Pathol*. 2018 Nov;81:55–64. PMID:29940288
- 1271.** Magro G, Bisceglia M, Michal M, et al. Spindle cell lipoma-like tumor, solitary fibrous tumor and myofibroblastoma of the breast: a clinicopathological analysis of 13 cases in favor of a unifying histogenetic concept. *Virchows Arch*. 2002 Mar;440(3):249–60. PMID:11889594
- 1272.** Magro G, Michal M, Bisceglia M. Benign spindle cell tumors of the mammary stroma: diagnostic criteria, classification, and histogenesis. *Pathol Res Pract*. 2001;197(7):453–66. PMID:11482575
- 1273.** Magro G, Righi A, Casorzo L, et al. Mammary and vaginal myofibroblastomas are genetically related lesions: fluorescence *in situ* hybridization analysis shows deletion of 13q14 region. *Hum Pathol*. 2012 Nov;43(11):1887–93. PMID:22575260
- 1274.** Mahoney MC, Robinson-Smith TM, Shaughnessy EA. Lobular neoplasia at 11-gauge vacuum-assisted stereotactic biopsy: correlation with surgical excisional biopsy and mammographic follow-up. *AJR Am J Roentgenol*. 2006 Oct;187(4):949–54. PMID:16985141
- 1275.** Maia T, Amendoeira I. Breast sebaceous carcinoma-a rare entity. *Clinicopathological description of two cases and brief review*. *Virchows Arch*. 2018 May;472(5):577–83. PMID:29556777
- 1276.** Maiorano E, Regan MM, Van Den Berg M, et al. Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials. *Breast Cancer Res Treat*. 2010 May;121(2):317–27. PMID:19280340
- 1277.** Makhoul HR, Sabin LH. Inflammatory myofibroblastic tumors (inflammatory pseudotumors) of the gastrointestinal tract: how closely are they related to inflammatory bowel polyps? *Hum Pathol*. 2002 Mar;33(3):357–62. PMID:11979371
- 1278.** Makretsov N. Now, later or never? multicenter randomized controlled trials for surgery necessary after atypical breast biopsy results in mammographic screening settings? *Int J Surg Oncol*. 2015;2015:1–10. PMID:25977821
- 1279.** Makretsov N, He M, Hayes N, et al. A fluorescence *in situ* hybridization assay for ETV6-NTRK3 fusion gene in secretory breast carcinoma. *Genes Chromosomes Cancer*. 2004 Jun;40(2):152–7. PMID:15101046
- 1280.** Malberger E, Yerushalmi R, Tamari M, et al. Diagnosis of fibroadenoma in breast tissue aspirates devoid of typical stroma. *Acta Cytol*. 1997 Sep-Oct;41(5):1483–8. PMID:9327000
- 1281.** Malcolm TI, Hodson DL, Watson EA, et al. Challenging perspectives on the cellular origins of lymphoma. *Open Biol*. 2016 Sep;6(9):160232. PMID:27683157
- 1282.** Malkin D. Li-Fraumeni syndrome. *Br J Cancer*. 2011 Apr;104(2):475–84. PMID:21446200
- 1283.** Malkin D, Li FP, Strong LC, et al. Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasias. *Science*. 1990 Nov 30;250(4991):1671–4. PMID:1778757
- 1284.** Maluf HM, Koerner FC. Solitary fibrous carcinoma of the breast. A form of mesenchymal carcinoma with endocrine differentiation frequently associated with mucinous carcinoma. *Am J Surg Pathol*. 1995 Nov;19(11):1221–6. PMID:7573685
- 1285.** Man S, Ellis IO, Sibley K, et al. High levels of allele loss at the FNT1 locus in genes in non-comedo ductal carcinomas and grade I tubular invasive breast carcinomas. *Cancer Res*. 1996 Dec 1;56(24):5973–8. PMID:8968105
- 1286.** Mandelker D, Zhang L, Kamei T, et al. Mutation detection in patients with breast cancer by universal sequencing of 12 genes related to cancer risk. *Guideline-based germline testing*. *J Am Med Genet Soc*. 2018 Sep;5:318(9):825–35. PMID:29530362
- 1287.** Manders JB, Kuerer HM, Smith BL, et al. Clinical utility of the 12-gene OBCS score in impact on radiotherapy recommendations in patients with ductal carcinoma in situ. *Ann Oncol*. 2017 Mar;28(3):660–6. PMID:27870000
- 1288.** Manipadam MT, Jacob A, Rajesh J. Giant lactating adenoma of the breast. *J Surg Case Rep*. 2010 Nov;2010:1–3. PMID:24946360
- 1289.** Mann RM, Kuhl CK, Kline WM, et al. Breast MRI: guidelines from the American Society of Breast Imaging. *Eur Radiol*. 2007 Jul;18(7):1307–18. PMID:17835250
- 1290.** Manner J, Radlwimmer B, Horwitz P, et al. MYC high level gene amplification is a distinctive feature of angiogenesis in irradiation or chronic lymphocytic leukemia. *Am J Pathol*. 2010 Jan;176(1):34–8. PMID:20040000
- 1291.** Mantilla JG, Koenigsmark T, Reznick M, et al. Core biopsy of vascular neoplasms

- of the breast: pathologic features, imaging, and clinical findings. *Am J Surg Pathol.* 2016 Oct;40(10):1424–34. PMID:27340752
- 1292.** Marchese C, Montero M, Torrini M, et al. Granular cell tumor in a PHTS patient with a novel germline PTEN mutation. *Am J Med Genet A.* 2003 Jul 15;120A(2):286–8. PMID:12833416
- 1293.** Marchiò C, Geyer FC, Ng CK, et al. The genetic landscape of breast carcinomas with neuroendocrine differentiation. *J Pathol.* 2017 Feb;241(3):405–19. PMID:27925203
- 1294.** Marchiò C, Iravani M, Natrajan R, et al. Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. *J Pathol.* 2008 Aug;215(4):398–410. PMID:18484683
- 1295.** Marchiò C, Iravani M, Natrajan R, et al. Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components. *J Pathol.* 2009 Jul;218(3):301–15. PMID:19479727
- 1296.** Marchiò C, Pietribiasi F, Castiglione R, et al. “Giants in a microcosm”: multinucleated giant cells populating an invasive micropapillary carcinoma of the breast. *Int J Surg Pathol.* 2015 Dec;23(8):654–5. PMID:26370736
- 1297.** Marian C, Boila A, Soanca D, et al. Malignant transformation of adenomyoepithelioma of the breast by a monophasic population: a report of two cases and review of literature. *APMIS.* 2013 Apr;121(4):272–9. PMID:23030630
- 1298.** Mariño-Enriquez A, Dal Cin P. ALK as a paradigm of oncogenic promiscuity: different mechanisms of activation and different fusion partners drive tumors of different lineages. *Cancer Genet.* 2013 Nov;206(11):357–73. PMID:24091028
- 1299.** Mariño-Enriquez A, Fletcher CD, Dal Cin P, et al. Dedifferentiated liposarcoma with “homologous” lipoblastic (pleomorphic liposarcoma-like) differentiation: clinicopathologic and molecular analysis of a series suggesting revised diagnostic criteria. *Am J Surg Pathol.* 2010 Aug;34(8):1122–31. PMID:20588177
- 1300.** Maritz RM, Michelow PM. Cytological criteria to distinguish phyllodes tumour of the breast from fibroadenoma. *Acta Cytol.* 2017;61(6):418–24. PMID:28738381
- 1300A.** Markopoulos C, Mantas D, Philipidis T, et al. Glycogen-rich clear cell carcinoma of the breast. *World J Surg Oncol.* 2008 Apr 29;6:44. PMID:18442419
- 1301.** Marshall LM, Hunter DJ, Connolly JL, et al. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. *Cancer Epidemiol Biomarkers Prev.* 1997 May;6(5):297–301. PMID:9149887
- 1302.** Martin RW 3rd, Neldner KH, Boyd AS, et al. Multiple cutaneous granular cell tumors and neurofibromatosis in childhood. A case report and review of the literature. *Arch Dermatol.* 1990 Aug;126(8):1051–6. PMID:2166484
- 1303.** Martinelli G, Ryan G, Seymour JF, et al. Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group. *Ann Oncol.* 2009 Dec;20(12):1993–9. PMID:19570964
- 1304.** Martinelli G, Ryan G. Primary breast lymphoma. In: Cavalli F, Stein H, Zucchetto E, editors. *Extranodal lymphomas: pathology and management.* London (UK): Informa; 2008. pp. 168–73.
- 1305.** Martinez V, Azzopardi JG. Invasive lobular carcinoma of the breast: incidence and variants. *Histopathology.* 1979 Nov;3(6):467–8. PMID:229072
- 1306.** Marucci G, Betts CM, Golouh R, et al. Toker cells are probably precursors of Paget cell carcinoma: a morphological and ultrastructural description. *Virchows Arch.* 2002 Aug;441(2):117–23. PMID:12189500
- 1307.** Marzullo F, Zito FA, Marzullo A, et al. Infiltrating cribriform carcinoma of the breast. A clinico-pathologic and immunohistochemical study of 5 cases. *Eur J Gynaecol Oncol.* 1996;17(3):228–31. PMID:8780923
- 1308.** Masciarelli S, Dillon DA, Rath M, et al. Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. *Breast Cancer Res Treat.* 2012 Jun;133(3):1125–30. PMID:22392042
- 1309.** Masood S, Davis C, Kubik MJ. Changing the term “breast tumor resembling the tall cell variant of papillary thyroid carcinoma” to “tall cell variant of papillary breast carcinoma”. *Adv Anat Pathol.* 2012 Mar;19(2):108–10. PMID:22313838
- 1310.** Mastracci TL, Shadde A, Colby SM, et al. Genomic alterations in lobular neoplasia: a microarray comparative genomic hybridization signature for early neoplastic proliferation in the breast. *Genes Chromosomes Cancer.* 2006 Nov;45(11):1007–17. PMID:16897748
- 1311.** Mastracci TL, Tjan S, Bane AL, et al. E-cadherin alterations in atypical lobular hyperplasia and lobular carcinoma in situ of the breast. *Mod Pathol.* 2005 Jun;18(6):741–51. PMID:15696125
- 1312.** Mastrangelo G, Coindre JM, Ducimetière F, et al. Incidence of soft tissue sarcoma and beyond: a population-based prospective study in 3 European regions. *Cancer.* 2012 Nov 1;118(21):5339–48. PMID:22517534
- 1313.** Mastropasqua MG, Maiorano E, Pruneri G, et al. Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast. *Mod Pathol.* 2005 Oct;18(10):1277–82. PMID:15846389
- 1314.** Masuda H, Baggerly KA, Wang Y, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. *Clin Cancer Res.* 2013 Oct 1;19(19):5533–40. PMID:23948975
- 1315.** Matoso A, Easley SE, Gnepp DR, et al. Salivary gland acinar-like differentiation of the breast. *Histopathology.* 2009 Jan;54(2):262–3. PMID:19207954
- 1316.** Matsubayashi RN, Adachi A, Yasumori K, et al. Adenoma of the nipple: correlation of magnetic resonance imaging findings with histologic features. *J Comput Assist Tomogr.* 2006 Jan-Feb;30(1):148–50. PMID:16365591
- 1317.** Mattia AR, Ferry JA, Harris NL. Breast lymphoma. A B-cell spectrum including the low grade B-cell lymphoma of mucosa associated lymphoid tissue. *Am J Surg Pathol.* 1993 Jun;17(6):574–87. PMID:8333556
- 1318.** Mattoch IW, Robbins JB, Kempson RL, et al. Post-radiotherapy vascular proliferations in mammary skin: a clinicopathologic study of 11 cases. *J Am Acad Dermatol.* 2007 Jul;57(1):126–33. PMID:17572278
- 1319.** Mavaddat N, Barrowdale D, Andrusil IL, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *Cancer Epidemiol Biomarkers Prev.* 2012 Jan;21(1):134–47. PMID:22144499
- 1320.** Mavaddat N, Peacock S, Frost D, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. *J Natl Cancer Inst.* 2013 Jun 5;105(11):812–22. PMID:23628597
- 1321.** Mavaddat N, Pharaoh PD, Michailidou K, et al. Prediction of breast cancer risk based on profiling with common genetic variants. *J Natl Cancer Inst.* 2015 Apr 8;107(5):djv036. PMID:25855707
- 1322.** Maxwell AJ, Clements K, Dodwell DJ, et al. The radiological features, diagnosis and management of screen-detected lobular neoplasia of the breast: findings from the Sloane Project. *Breast.* 2016 Jun;27:109–15. PMID:27060553
- 1323.** Maxwell AJ, Clements K, Hilton B, et al. Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ. *Eur J Surg Oncol.* 2018 Apr;44(4):429–35. PMID:29398324
- 1324.** Mazzella FM, Sieber SC, Braza F. Ductal carcinoma of male breast with prominent lipid-rich component. *Pathology.* 1995 Jul;27(3):280–3. PMID:8532397
- 1325.** Mazzola E, Cheng SC, Parmigiani G. The penetrance of ductal carcinoma in situ among BRCA1 and BRCA2 mutation carriers. *Breast Cancer Res Treat.* 2013 Jan;137(1):315–8. PMID:23184082
- 1326.** Mbulaiteye SM, Anderson WF, Ferlay J, et al. Pediatric, elderly, and emerging adult-onset peaks in Burkitt’s lymphoma incidence diagnosed in four continents, excluding Africa. *Am J Hematol.* 2012 Jun;87(6):573–8. PMID:22488262
- 1327.** McBoyle MF, Razek HA, Carter JL, et al. Tubular carcinoma of the breast: an institutional review. *Am Surg.* 1997 Jul;63(7):639–44, discussion 644–5. PMID:9202540
- 1328.** McCart Reed AE, Kalaw E, Nones K, et al. Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implications. *J Pathol.* 2019 Feb;247(2):214–27. PMID:30350370
- 1329.** McCart Reed AE, Kutashovic JR, Nones K, et al. Mixed ductal-lobular carcinomas: evidence for progression from ductal to lobular morphology. *J Pathol.* 2018 Apr;244(4):460–8. PMID:29344954
- 1330.** McClatchey AI. Neurofibromatosis. *Annu Rev Pathol.* 2007;2:191–216. PMID:18039098
- 1331.** McCullar B, Pandey M, Yaghmour G, et al. Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung. *Breast Cancer Res Treat.* 2016 Jul;158(1):195–202. PMID:27329168
- 1332.** McDermott KM, Crocker PR, Harris A, et al. Overexpression of MUC1 reconfigures the binding properties of tumor cells. *Int J Cancer.* 2001 Dec 15;94(6):783–91. PMID:11745478
- 1333.** McDivitt RW, Boyce W, Gersell D. Tubular carcinoma of the breast. Clinical and pathological observations concerning 135 cases. *Am J Surg Pathol.* 1982 Jul;6(5):401–11. PMID:6289683
- 1334.** McDivitt RW, Stewart FW. Breast carcinoma in children. *JAMA.* 1966 Jan 31;195(5):388–90. PMID:4285563
- 1335.** McGowan TS, Cummings BJ, O’Sullivan B, et al. An analysis of 78 breast sarcoma patients without distant metastases at presentation. *Int J Radiat Oncol Biol Phys.* 2000 Jan 15;46(2):383–90. PMID:10661345
- 1336.** McKeever K, Shepherd CW, Crawford H, et al. An epidemiological, clinical and genetic survey of neurofibromatosis type 1 in children under sixteen years of age. *Ulster Med J.* 2008 Sep;77(3):160–3. PMID:18956796
- 1337.** McKinnon PJ. ATM and ataxiatelangiectasia. *EMBO Rep.* 2004 Aug;5(8):772–6. PMID:15289825
- 1338.** McLaren BK, Smith J, Schuyler PA, et al. Adenomyoepithelioma: clinical, histologic, and immunohistologic evaluation of a series of related lesions. *Am J Surg Pathol.* 2005 Oct;29(10):1294–9. PMID:16160470
- 1339.** Meares AL, Frank RD, Degnim AC, et al. Mucocele-like lesions of the breast: a clinical outcome and histologic analysis of 102 cases. *Hum Pathol.* 2016 Mar;49:33–8. PMID:26826407
- 1340.** Meattini I, Pezzulla D, Saieva C, et al. Triple negative apocrine carcinomas as a distinct subtype of triple negative breast cancer: a case-control study. *Clin Breast Cancer.* 2018 Oct;18(5):e773–80. PMID:29573977
- 1341.** Meijers-Heijboer H, van den Ouwehand A, Klijn J, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. *Nat Genet.* 2002 May;31(1):55–9. PMID:11967536
- 1342.** Meiss AE, Thomas M, Modesitt SC, et al. Clinicopathologic characterization of breast carcinomas in patients with non-BRCA germline mutations: results from a single institution’s high-risk population. *Hum Pathol.* 2018 Dec;82:20–31. PMID:29958926
- 1343.** Mekhail Y, Prather A, Hanna C, et al. Focal angiomyomatosis of the breast with MRI and histologic features. *Radiol Case Rep.* 2017 Mar 18;12(2):219–22. PMID:28491155
- 1344.** Melchor L, Benitez J. The complex genetic landscape of familial breast cancer. *Hum Genet.* 2013 Aug;132(8):845–63. PMID:23552954
- 1345.** Melhem-Bertrandt A, Bojadzieva J, Ready KJ, et al. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. *Cancer.* 2012 Feb 15;118(4):908–13. PMID:21761402
- 1346.** Menen RS, Ganesan N, Bevers T, et al. Long-term safety of observation in selected women following core biopsy diagnosis of atypical ductal hyperplasia. *Ann Surg Oncol.* 2017 Jan;24(1):70–6. PMID:27573525
- 1347.** Menes TS, Rosenberg R, Balch S, et al. Upgrade of high-risk breast lesions detected on mammography in the Breast Cancer Surveillance Consortium. *Am J Surg.* 2014 Jan;207(1):24–31. PMID:24112677
- 1348.** Menet E, Becette V, Briffod M. Cytologic diagnosis of lobular carcinoma of the breast: experience with 555 patients in the Rene Huguener Cancer Center. *Cancer.* 2008 Apr 25;114(2):111–7. PMID:18300231
- 1349.** Menthé G, Meyer P, Huber O, et al. [Liver transplantation. Preliminary results in the district University Hospital of Geneva]. *Schweiz Med Wochenschr.* 1990 Jul 21;120(29):1037–44. French. PMID:2374894
- 1350.** Mentzel T, Kiss K. Reduced H3K27me3 expression in radiation-associated angiosarcoma of the breast. *Virchows Arch.* 2018 Mar;472(3):361–8. PMID:28983701
- 1351.** Mentzel T, Schildhaus HU, Palmedo G, et al. Postradiation cutaneous angiosarcoma after treatment of breast carcinoma is characterized by MYC amplification in contrast to atypical vascular lesions after radiotherapy and control cases: clinicopathological, immunohistochemical and molecular analysis of 66 cases. *Mod Pathol.* 2012 Jan;25(1):75–85. PMID:21909081
- 1352.** Mercado CL, Toth HK, Axelrod D, et al. Fine-needle aspiration biopsy of benign adenomyoepithelioma of the breast: radiologic and pathologic correlation in four cases. *Diagn Cytopathol.* 2007 Nov;35(11):690–4. PMID:17924402
- 1353.** Merchant NB, Lewis JJ, Woodruff JM, et al. Extremity and trunk desmoid tumors: a multifactorial analysis of outcome. *Cancer.* 1999 Nov 15;86(10):2045–52. PMID:10570430
- 1354.** Merino MJ. Plasmacytoma of the breast. *Arch Pathol Lab Med.* 1984 Aug;108(8):676–8. PMID:6378141
- 1355.** Mersch J, Jackson MA, Park M, et al. Erratum to: Mersch J, Jackson MA, Park M, Negeen D, Peterson SK, Singletary C, Arun BK and Litton JK. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. *Cancer.* 2015;121:269–275. *Cancer.*

- 2015 Jul;121(14):2474–5. PMID:26132389
- 1356.** Mester J, Eng C. When overgrowth bumps into cancer: the PTEN-opathies. *Am J Med Genet C Semin Med Genet*. 2013 May;163C(2):114–21. PMID:23613428
- 1357.** Mesurolle B, Sygal V, Lalonde L, et al. Sonographic and mammographic appearances of breast hemangioma. *AJR Am J Roentgenol*. 2008 Jul;191(1):W17–22. PMID:18562711
- 1358.** Metovic J, Gallino C, Zanon E, et al. Eccrine spiradenoma of the nipple: case report, differential diagnosis and literature review. *Histol Histopathol*. 2019 Aug;34(8):909–15. PMID:30806477
- 1359.** Metzger-Filho O, Michiels S, Bertucci F, et al. Genomic grade adds prognostic value in invasive lobular carcinoma. *Ann Oncol*. 2013 Feb;24(2):377–84. PMID:23028037
- 1360.** Metzger-Filho O, Tutt A, de Azambuja E, et al. Dissecting the heterogeneity of triple-negative breast cancer. *J Clin Oncol*. 2012 May 20;30(15):1879–87. PMID:22454417
- 1361.** Meyer A, Dörk T, Sohn C, et al. Breast cancer in patients carrying a germline CHEK2 mutation: outcome after breast conserving surgery and adjuvant radiotherapy. *Radiother Oncol*. 2007 Mar;82(3):349–53. PMID:17250914
- 1362.** Meyer KB, O'Reilly M, Michailidou K, et al. Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. *Am J Hum Genet*. 2013 Dec 5;93(6):1046–60. PMID:24290378
- 1363.** Michailidou K, Beesley J, Lindstrom S, et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. *Nat Genet*. 2015 Apr;47(4):373–80. PMID:25751625
- 1364.** Michailidou K, Hall P, Gonzalez-Neira A, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. *Nat Genet*. 2013 Apr;45(4):353–61, e1–2. PMID:23535729
- 1365.** Michailidou K, Lindström S, Dennis J, et al. Association analysis identifies 65 new breast cancer risk loci. *Nature*. 2017 Nov 2;551(7678):92–4. PMID:29059683
- 1366.** Michal M, Baumruk L, Burger J, et al. Adenomyoepithelioma of the breast with undifferentiated carcinoma component. *Histopathology*. 1994 Mar;24(3):274–6. PMID:7515373
- 1367.** Michaut M, Chin SF, Majewski I, et al. Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer. *Sci Rep*. 2016 Jan 5;6:18517. PMID:26729235
- 1368.** Middleton LP, Grant S, Stephens T, et al. Lobular carcinoma in situ diagnosed by core needle biopsy: When should it be excised? *Mod Pathol*. 2003 Feb;16(2):120–9. PMID:12591964
- 1369.** Middleton LP, Palacios DM, Bryant BR, et al. Pleomorphic lobular carcinoma: morphology, immunohistochemistry, and molecular analysis. *Am J Surg Pathol*. 2000 Dec;24(12):1650–6. PMID:11117786
- 1370.** Miettinen M. Immunoreactivity for cytokeratin and epithelial membrane antigen in leiomyosarcoma. *Arch Pathol Lab Med*. 1988 Jun;112(6):637–40. PMID:2454091
- 1371.** Miettinen M, McCue PA, Sarlomo-Rikala M, et al. Sox10—a marker for not only schwannian and melanocytic neoplasms but also myoepithelial cell tumors of soft tissue: a systematic analysis of 5134 tumors. *Am J Surg Pathol*. 2015 Jun;39(6):826–35. PMID:25724000
- 1372.** Miettinen MM, Antonescu CR, Fletcher CDM, et al. Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1—a consensus overview. *Hum Pathol*. 2017 Sep;67:1–10. PMID:28551330
- 1373.** Milanezi MF, Saggiorno FP, Zanati SG, et al. Pseudoangiomatous hyperplasia of mammary stroma associated with gynaecomastia. *J Clin Pathol*. 1998 Mar;51(3):204–6. PMID:9659260
- 1374.** Miles RR, Arnold S, Cairo MS. Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia. *Br J Haematol*. 2012 Mar;156(6):730–43. PMID:22260323
- 1375.** Miller MC, Johnson P, Kim S, et al. Tubular adenomas of the breast: a rare diagnosis. *BMJ Case Rep*. 2018 Aug 27;2018. PMID:30150335
- 1376.** Mills AME, E Gottlieb C, M Wendroth S, et al. Pure apocrine carcinomas represent a clinicopathologically distinct androgen receptor-positive subset of triple-negative breast cancers. *Am J Surg Pathol*. 2016 Aug;40(8):1109–16. PMID:27259012
- 1377.** Mills MN, Yang GQ, Oliver DE, et al. Histologic heterogeneity of triple negative breast cancer: a National Cancer Centre Database analysis. *Eur J Cancer*. 2018 Jul;98:48–58. PMID:29870876
- 1378.** Milne RL, Antoniou AC. Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers. *Ann Oncol*. 2011 Jan;22 Suppl 1:i11–7. PMID:21285145
- 1379.** Milne RL, Burwinkel B, Michailidou K, et al. Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. *Hum Mol Genet*. 2014 Nov 15;23(22):6096–111. PMID:24943594
- 1380.** Milne RL, Kuchenbaecker KB, Michailidou K, et al. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nat Genet*. 2017 Dec;49(12):1767–78. PMID:29058716
- 1381.** Minami S, Matsuo S, Azuma T, et al. Parenchymal leiomyoma of the breast: a case report with special reference to magnetic resonance imaging findings and an update review of literature. *Breast Cancer*. 2011 Jul;18(3):231–6. PMID:21416339
- 1382.** Miranda RN, Aladily TN, Prince HM, et al. Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. *J Clin Oncol*. 2014 Jan 10;32(2):114–20. PMID:24323027
- 1383.** Miremadi A, Pinder SE, Lee AH, et al. Neuroendocrine differentiation and prognosis in breast adenocarcinoma. *Histopathology*. 2002 Mar;40(3):215–22. PMID:11895486
- 1384.** Mirza IA, Shahab N. Small cell carcinoma of the breast. *Semin Oncol*. 2007 Feb;34(1):64–6. PMID:17270668
- 1385.** Mishima C, Kagara N, Tanei T, et al. Mutational analysis of MED12 in fibroadenomas and phyllodes tumors of the breast by means of targeted next-generation sequencing. *Breast Cancer Res Treat*. 2015 Jul;152(2):305–12. PMID:26093648
- 1386.** Mitchell JS, Li N, Weinhold N, et al. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. *Nat Commun*. 2016 Jul 1;7:12050. PMID:27363682
- 1387.** Mitnick JS, Gianutsos R, Pollack AH, et al. Tubular carcinoma of the breast: sensitivity of diagnostic techniques and correlation with histopathology. *AJR Am J Roentgenol*. 1999 Feb;172(2):319–23. PMID:9930775
- 1388.** Mito JK, Mitra D, Barysauskas CM, et al. A comparison of outcomes and prognostic features for radiation-associated angiosarcoma of the breast and other radiation-associated sarcomas. *Int J Radiat Oncol Biol Phys*. 2019 Jun 1;104(2):425–35. PMID:30703514
- 1389.** Moelans CB, de Wegers RA, Monsuur HN, et al. Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study. *Cell Oncol (Dordr)*. 2011 Oct;34(5):475–82. PMID:21547576
- 1390.** Moelans CB, Verschuer-Maes AH, van Diest PJ. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer. *J Pathol*. 2011 Oct;225(2):222–31. PMID:21710692
- 1391.** Mogal H, Brown DR, Isom S, et al. Intracystic papillary carcinoma of the breast: a SEER database analysis of implications for therapy. *Breast*. 2016 Jun;27:87–92. PMID:27057453
- 1392.** Mohammadi A, Rosa M. Carcinoma of the breast with choriocarcinomatous features. *Arch Pathol Lab Med*. 2011 Sep;135(9):1097–100. PMID:21877993
- 1393.** Mohanty SK, Kim SA, DeLair DF, et al. Comparison of metastatic neuroendocrine neoplasms to the breast and primary invasive mammary carcinomas with neuroendocrine differentiation. *Mod Pathol*. 2016 Aug;29(8):788–98. PMID:27125358
- 1394.** Mohsin SK, Weiss H, Havighurst T, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. *Mod Pathol*. 2004 Dec;17(12):1545–54. PMID:15272277
- 1395.** Moinfar F. Flat ductal intraepithelial neoplasia of the breast: evolution of Azzopardi's "clinging" concept. *Semin Diagn Pathol*. 2010 Feb;27(1):37–48. PMID:20306829
- 1396.** Moinfar F, Man YG, Arnould L, et al. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. *Cancer Res*. 2000 May 1;60(9):2562–6. PMID:10811140
- 1397.** Moinfar F, Man YG, Brathauer GL, et al. Genetic abnormalities in mammary ductal intraepithelial neoplasia-flat type ("clinging ductal carcinoma in situ"): a simulator of normal mammary epithelium. *Cancer*. 2000 May 1;88(9):2072–81. PMID:10813719
- 1398.** Mokbel K. Grading of infiltrating lobular carcinoma. *Eur J Surg Oncol*. 2001 Sep;27(6):609–10. PMID:11520101
- 1399.** Moll R, Mitze M, Frixi UH, et al. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. *Am J Pathol*. 1993 Dec;143(6):1731–42. PMID:8256859
- 1400.** Moll UM, Chumas J. Morphologic effects of neoadjuvant chemotherapy in locally advanced breast cancer. *Pathol Res Pract*. 1997;193(3):187–96. PMID:9198104
- 1401.** Molland JG, Donnellan M, Janu NC, et al. Infiltrating lobular carcinoma—a comparison of diagnosis, management and outcome with infiltrating duct carcinoma. *Breast*. 2004 Oct;13(5):389–96. PMID:15454194
- 1402.** Möller P, Hagen AI, Apold J, et al. Genetic epidemiology of BRCA mutations—family history detects less than 50% of the mutation carriers. *Eur J Cancer*. 2007 Jul;43(11):1713–7. PMID:17574839
- 1403.** Möller P, Seppälä T, Bernstein I, et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the Prospective Lynch Syndrome Database. *Gut*. 2017 Mar;66(3):464–72. PMID:26657901
- 1404.** Möller P, Seppälä T, Bernstein I, et al. Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the Prospective Lynch Syndrome Database. *Gut*. 2017 Sep;66(9):1657–64. PMID:27261338
- 1405.** Möller P, Seppälä TT, Bernstein I, et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: report from the Prospective Lynch Syndrome Database. *Gut*. 2018 Jul;67(7):1384–91. PMID:28754778
- 1406.** Molyneux EM, Rochford R, Griffin B, et al. Burkitt's lymphoma. *Lancet*. 2012 Mar 31;379(9822):1234–44. PMID:22333447
- 1407.** Montagna E, Maisonneuve P, Roman N, et al. Heterogeneity of triple-negative breast cancer: histologic subtyping to improve the outcome. *Clin Breast Cancer*. 2001 Feb;13(1):31–9. PMID:13989574
- 1408.** Monteiro JC, Ferguson KM, Nelson JA, et al. Ectopic production of human chorionic gonadotrophin-like material by breast cancer. *Cancer*. 1984 Feb 15;53(4):857–62. PMID:6692294
- 1409.** Montgomery E, Torbenson MS, Krasnik M, et al. Beta-catenin immunohistochemistry separates mesenteric fibromatosis from gastrointestinal stromal tumor and desmoid mesenteritis. *Am J Surg Pathol*. 2003 Oct;26(10):1296–301. PMID:14561044
- 1410.** Montgomery ND, Bianchi ED, Demore N, et al. Bilateral symmetrical adenomas of the nipple: case report and immunohistochemical characterization of a tumor mimicking malignancy. *Am J Clin Pathol*. 2014 May;141(5):727–31. PMID:24713747
- 1411.** Moo TA, Alabdulkareem A, Tan S, et al. Association between recurrence and re-excision for close and positive margins versus observation in patients with phyllodes tumors. *Ann Surg Oncol*. 2010 Oct;24(10):3088–92. PMID:20757227
- 1412.** Mooney KL, Bassett LW, Aguirre JI, et al. Upgrade rates of high-risk breast cancer diagnosed on core needle biopsy: institution experience and literature review. *Mod Pathol*. 2016 Dec;29(12):1477–84. PMID:27538687
- 1413.** Moore KH, Thaler HT, Tan S, et al. Immunohistochemically detected HER2 in the sentinel lymph nodes of patients with breast carcinoma: biologic metastasis or artifact? *Cancer*. 2004 Mar 1;101(5):1012–7. PMID:14983487
- 1414.** Moran MS, Schnitt SJ, Giuliano AR, et al. Society of Surgical Oncologists and the Society for Radiation Oncology joint guideline on margins for breast surgery with whole-breast irradiation in I and II invasive breast cancer. *Int J Radiat Oncol Biol Phys*. 2014 Mar 1;90(3):660–70. PMID:24521674
- 1415.** Morandi L, Pession A, Manzoni S, et al. Intraepidermal cells of Paget's carcinoma of the breast can be genetically different from the underlying carcinoma. *Hum Pathol*. 2002 Dec;34(12):1321–30. PMID:12459185
- 1415A.** Morita M, Yamaguchi R, Tanaka T, et al. Two progressive pathways of breast carcinoma: low-grade luminal pathway and high-grade HER2 pathway based on tumour-infiltrating lymphocytes. *J Clin Oncol*. 2016 Oct;34(30):890–8. PMID:27033239
- 1416.** Moritani S, Ichihara S, Yamamoto T, et al. Uniqueness of ductal carcinoma in situ of the breast concurrent with mastectomy and wide local excision: implications from a detailed histopathological study of 50 cases. *Surg Pathol*. 2013 Sep;44(9):1129–36. PMID:23829486
- 1417.** Moritani S, Ichihara S, Yamamoto T, et al. Immunohistochemical expression of myoepithelial markers in adenocarcinoma of the breast: a unique paradoxical pattern of high-molecular weight vimentin. *Virchows Arch*. 2015 Feb;467(2):241–50. PMID:25616020

- PMID:25479938
- 1418.** Moritani S, Kushima R, Sugihara H, et al. Availability of CD10 immunohistochemistry as a marker of breast myoepithelial cells on paraffin sections. *Mod Pathol.* 2002 Apr;15(4):397–405. PMID:11950913
- 1419.** Moritz AW, Wiedenhofer JF, Profit AP, et al. Breast adenomyoepithelioma and adenomyoepithelioma with carcinoma (malignant adenomyoepithelioma) with associated breast malignancies: a case series emphasizing histologic, radiologic, and clinical correlation. *Breast.* 2016 Oct;29:132–9. PMID:27494340
- 1420.** Moriya T, Sakamoto K, Sasano H, et al. Immunohistochemical analysis of Ki-67, p53, p21, and p27 in benign and malignant apocrine lesions of the breast: its correlation to histologic findings in 43 cases. *Mod Pathol.* 2000 Jan;13(1):13–8. PMID:10658905
- 1421.** Morrogh M, Andrade VP, Giri D, et al. Cadherin-catenin complex dissociation in lobular neoplasia of the breast. *Breast Cancer Res Treat.* 2012 Apr;132(2):641–52. PMID:22080244
- 1422.** Morrow M, Berger D, Thelmo W. Diffuse cystic angiomatosis of the breast. *Cancer.* 1988 Dec 1;62(11):2392–6. PMID:3179956
- 1423.** Morrow M, Van Zee KJ, Solin LJ, et al. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. *J Clin Oncol.* 2016 Nov 20;34(33):4040–6. PMID:27528719
- 1424.** Moy L, Slanetz PJ, Moore R, et al. Specificity of mammography and US in the evaluation of a palpable abnormality: retrospective review. *Radiology.* 2002 Oct;225(1):176–81. PMID:12355002
- 1425.** Mulligan AM, O'Malley FP. Metastatic potential of encapsulated (intracystic) papillary carcinoma of the breast: a report of 2 cases with axillary lymph node micrometastases. *Int J Surg Pathol.* 2007 Apr;15(2):143–7. PMID:17478767
- 1426.** Mulligan S, Hu P, Murphy A, et al. Variations in MALT1 gene disruptions detected by FISH in 109 MALT lymphomas occurring in different primary sites. *J Assoc Genet Technol.* 2011;37(2):76–9. PMID:21654070
- 1427.** Mullooly M, Khodr ZG, Dallal CM, et al. Epidemiologic risk factors for in situ and invasive breast cancers among postmenopausal women in the National Institutes of Health-AARP Diet and Health Study. *Am J Epidemiol.* 2017 Dec 15;186(12):1329–40. PMID:28637226
- 1428.** Mun SH, Ko EY, Han BK, et al. Secretory carcinoma of the breast: sonographic features. *J Ultrasound Med.* 2008 Jun;27(6):947–54. PMID:18499854
- 1429.** Mundo L, Ambrosio MR, Picciolini M, et al. Unveiling another missing piece in EBV-driven lymphomagenesis: EBV-encoded microRNAs expression in EBER-negative Burkitt lymphoma cases. *Front Microbiol.* 2017 Mar 1;8:229. PMID:28298901
- 1430.** Murakami A, Kawachi K, Sasaki T, et al. Sebaceous carcinoma of the breast. *Pathol Int.* 2009 Mar;59(3):188–92. PMID:19261098
- 1431.** Muranen TA, Blomqvist C, Dörk T, et al. Patient survival and tumor characteristics associated with CHEK2;p.I157T - findings from the Breast Cancer Association Consortium. *Breast Cancer Res.* 2016 Oct 3;18(1):98. PMID:27716369
- 1432.** Muranen TA, Greco D, Blomqvist C, et al. Genetic modifiers of CHEK2*1100delC-associated breast cancer risk. *Genet Med.* 2017 May 19(5):599–603. PMID:27711073
- 1433.** Muranen TA, Greco D, Fagerholm R, et al. Breast tumors from CHEK2 1100delC-mutation carriers: genomic landscape and clinical implications. *Breast Cancer Res.* 2011 Sep 20;13(5):R90. PMID:21542898
- 1434.** Murat A, Kansiz F, Kabakus N, et al. Neurofibroma of the breast in a boy with neurofibromatosis type 1. *Clin Imaging.* 2004 Nov-Dec;28(6):415–7. PMID:15531141
- 1435.** Murphy SB, Hustu HO. A randomized trial of combined modality therapy of childhood non-Hodgkin's lymphoma. *Cancer.* 1980 Feb 15;45(4):630–7. PMID:6986967
- 1436.** Murray MP, Luedtke C, Liberman L, et al. Classic lobular carcinoma in situ and atypical lobular hyperplasia at percutaneous breast core biopsy: outcomes of prospective excision. *Cancer.* 2013 Mar 1;119(5):1073–9. PMID:23132235
- 1437.** Myhre-Jensen O. A consecutive 7-year series of 1331 benign soft tissue tumours. Clinicopathologic data. Comparison with sarcomas. *Acta Orthop Scand.* 1981 Jun;52(3):287–93. PMID:7282321
- 1438.** Nadelman CM, Leslie KO, Fishbein MC. "Benign," metastasizing adenomyoepithelioma of the breast: a report of 2 cases. *Arch Pathol Lab Med.* 2006 Sep;130(9):1349–53. PMID:16948523
- 1439.** Nagao T, Kinoshita T, Hojo T, et al. The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics. *Breast.* 2012 Jun;21(3):289–95. PMID:22277312
- 1440.** Nagar H, Marmor S, Hammar B. Haemangiomas of the breast in children. *Eur J Surg.* 1992 Sep;158(9):503–5. PMID:1358220
- 1441.** Nagata Y, Yoshioka M, Uramoto H, et al. Malignant melanoma of the nipple: a case report. *J Breast Cancer.* 2018 Mar;21(1):96–101. PMID:29628990
- 1442.** Nagel JH, Peeters JK, Smid M, et al. Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes. *Breast Cancer Res Treat.* 2012 Apr;132(2):439–48. PMID:21614566
- 1443.** Nagi C, Bleiweiss I, Jaffer S. Epithelial displacement in breast lesions: a papillary phenomenon. *Arch Pathol Lab Med.* 2005 Nov;129(11):1465–9. PMID:16253028
- 1444.** Nagi CS, O'Donnell JE, Tismenetsky M, et al. Lobular neoplasia on core needle biopsy does not require excision. *Cancer.* 2008 May 15;112(10):2152–8. PMID:18348299
- 1445.** Nakagawa S, Miki Y, Miyashita M, et al. Tumor microenvironment in invasive lobular carcinoma: possible therapeutic targets. *Breast Cancer Res Treat.* 2016 Jan;155(1):65–75. PMID:26715212
- 1446.** Nakai T, Ichihara S, Kada A, et al. The unique luminal staining pattern of cytokeratin 5/6 in adenoid cystic carcinoma of the breast may aid in differentiating it from its mimickers. *Virchows Arch.* 2016 Aug;469(2):213–22. PMID:27240462
- 1447.** Nakhlis F, Gilmore L, Gelman R, et al. Incidence of adjacent synchronous invasive carcinoma and/or ductal carcinoma in-situ in patients with lobular neoplasia on core biopsy: results from a prospective multi-institutional registry (TBCRC 020). *Ann Surg Oncol.* 2016 Mar;23(3):722–8. PMID:26542585
- 1448.** Nakhlis F, Harrison BT, Giess CS, et al. Evaluating the rate of upgrade to invasive breast cancer and/or ductal carcinoma in situ following a core biopsy diagnosis of non-classic lobular carcinoma in situ. *Ann Surg Oncol.* 2019 Jan;26(1):55–61. PMID:30362065
- 1449.** Nakken S, Hovig E, Møller P, editors. Prospective Lynch Syndrome Database [Internet]. Edinburgh (UK): European Hereditary Tumour Group & Middlesex (UK);
- International Society for Gastrointestinal Hereditary Tumours; 2019. Available from <http://www.icsarisk.org>.
- 1450.** Nalwa A, Nath D, Suri V, et al. Myeloid sarcoma of the breast in an aleukemic patient: a rare entity in an uncommon location. *Malays J Pathol.* 2015 Apr;37(1):63–6. PMID:25890617
- 1451.** Nangal JK, Kapoor A, Narayan S, et al. A case of CD68 negative histiocytic sarcoma of axilla masquerading as metastatic breast cancer. *J Surg Case Rep.* 2014 Jul 16;2014(7):rju071. PMID:25031040
- 1452.** Narend KN, Ibrahim HA, Lazzi S, et al. Diagnosis of Burkitt lymphoma using an algorithmic approach—applicable in both resource-poor and resource-rich countries. *Br J Haematol.* 2011 Sep;154(6):770–6. PMID:21718280
- 1453.** Nard SA. Modifiers of risk of hereditary breast cancer. *Oncogene.* 2006 Sep 25;25(43):5832–6. PMID:16998497
- 1454.** Nard SA, Huzarski T, Gronwald J, et al. Predictors of survival for breast cancer patients with a BRCA1 mutation. *Breast Cancer Res Treat.* 2018 Apr;168(2):513–21. PMID:29247441
- 1455.** Narula HS, Carlson HE. Gynaecomastia-pathophysiology, diagnosis and treatment. *Nat Rev Endocrinol.* 2014 Nov;10(11):684–98. PMID:25112235
- 1456.** Nascimento AF, Raut CP, Fletcher CD. Primary angiosarcoma of the breast: clinicopathologic analysis of 49 cases, suggesting that grade is not prognostic. *Am J Surg Pathol.* 2008 Dec;32(12):1896–904. PMID:18813119
- 1457.** Nascimento AG, Karas M, Rosen PP, et al. Leiomyoma of the nipple. *Am J Surg Pathol.* 1979 Apr;3(2):151–4. PMID:532847
- 1458.** Näslund-Koch C, Nordestgaard BG, Bojesen SE. Increased risk for other cancers in addition to breast cancer for CHEK2*1100delC heterozygotes estimated from the Copenhagen General Population Study. *J Clin Oncol.* 2016 Apr 10;34(11):1208–16. PMID:26884562
- 1459.** Nasrallah MP, Nasrallah IM, Yu GH. Fine-needle aspiration of superficial myxoid neurofibroma in the region of the breast. *Diagn Cytopathol.* 2015 May;43(5):427–31. PMID:25722038
- 1460.** Nassar A. Core needle biopsy versus fine needle aspiration biopsy in breast—a historical perspective and opportunities in the modern era. *Diagn Cytopathol.* 2011 May;39(5):380–8. PMID:20949457
- 1461.** Nassar A, Conners AL, Celik B, et al. Radial scar/complex sclerosing lesions: a clinicopathologic correlation study from a single institution. *Ann Diagn Pathol.* 2015 Feb;19(1):24–8. PMID:25578683
- 1462.** Nassar A, Visscher DW, Degnim AC, et al. Complex fibroadenoma and breast cancer risk: a Mayo Clinic Benign Breast Disease Cohort study. *Breast Cancer Res Treat.* 2015 Sep;153(2):397–405. PMID:26264469
- 1463.** Nassar H. Carcinomas with micropapillary morphology: clinical significance and current concepts. *Adv Anat Pathol.* 2004 Nov;11(6):297–303. PMID:15505530
- 1464.** Nassar H, Elieff MP, Kronz JD, et al. Pseudoangiomatous stromal hyperplasia (PASH) of the breast with foci of morphologic malignancy: a case of PASH with malignant transformation? *Int J Surg Pathol.* 2010 Dec;18(6):564–9. PMID:18611932
- 1465.** Nassar H, Pansare V, Zhang H, et al. Pathogenesis of invasive micropapillary carcinoma: role of MUC1 glycoprotein. *Mod Pathol.* 2004 Sep;17(9):1045–50. PMID:15154007
- 1466.** Nassar H, Qureshi H, Adsay NV, et al. Clinicopathologic analysis of solid papillary carcinoma of the breast and associated invasive carcinomas. *Am J Surg Pathol.* 2006 Apr;30(4):501–7. PMID:16625097
- 1467.** Nassif S, Ozdemirli M. EBV-positive low-grade marginal zone lymphoma in the breast with massive amyloid deposition arising in a heart transplant patient: a report of an unusual case. *Pediatr Transplant.* 2013 Sep;17(6):E141–5. PMID:23773403
- 1468.** National Comprehensive Cancer Network (NCCN). Genetic/familial high-risk assessment: breast and ovarian. Plymouth Meeting (PA): NCCN; 2018 [accessed 2018 Nov 4]. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx.
- 1469.** National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): breast cancer. Version 1.2018. Fort Washington (PA): NCCN; 2018 [accessed 2018 Nov 1]. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx.
- 1470.** Natrajan R, Lambros MB, Geyer FC, et al. Loss of 16q in high grade breast cancer is associated with estrogen receptor status: evidence for progression in tumors with a luminal phenotype? *Genes Chromosomes Cancer.* 2009 Apr;48(4):351–65. PMID:19156836
- 1471.** Natrajan R, Wilkerson PM, Marchiò C, et al. Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. *J Pathol.* 2014 Apr;232(5):553–65. PMID:24395524
- 1472.** Natsiopoulos I, Liapis T, Demiri E, et al. Diffuse breast angiomatosis with involvement of overlying skin: a case report. *Clin Breast Cancer.* 2016 Feb;16(1):e7–10. PMID:26456034
- 1473.** Nayak A, Bleiweiss IJ, Dumoff K, et al. Mucinous cystadenocarcinoma of the breast: report of 2 cases including one with long-term local recurrence. *Int J Surg Pathol.* 2018 Dec;26(8):749–57. PMID:29745281
- 1474.** Nayar R, Zhuang Z, Merino MJ, et al. Loss of heterozygosity on chromosome 11q13 in lobular lesions of the breast using tissue microdissection and polymerase chain reaction. *Hum Pathol.* 1997 Mar;28(3):277–82. PMID:9042790
- 1475.** Neal L, Sandhu NP, Hieken TJ, et al. Diagnosis and management of benign, atypical, and indeterminate breast lesions detected on core needle biopsy. *Mayo Clin Proc.* 2014 Apr;89(4):536–47. PMID:24684875
- 1476.** Negahban S, Ahmadi N, Oryan A, et al. Primary bilateral Burkitt lymphoma of the lactating breast: a case report and review of the literature. *Mol Diagn Ther.* 2010 Aug 1;14(4):243–50. PMID:20799767
- 1477.** Nelen MR, Kremer H, Konings IB, et al. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. *Eur J Hum Genet.* 1999 Apr;7(3):267–73. PMID:10234502
- 1478.** Nelen MR, Padberg GW, Peeters EA, et al. Localization of the gene for Cowden disease to chromosome 10q22–23. *Nat Genet.* 1996 May;13(1):114–6. PMID:8673088
- 1479.** Nelson ER, Sharma R, Argani P, et al. Utility of Sox10 labeling in metastatic breast carcinomas. *Hum Pathol.* 2017 Sep;67:205–10. PMID:28843711
- 1480.** Nelson RA, Guye ML, Luu T, et al. Survival outcomes of metaplastic breast cancer patients: results from a US population-based analysis. *Ann Surg Oncol.* 2015 Jan;22(1):24–31. PMID:25012264
- 1481.** Neuhaus T, Hess T. Bilateral extramedullary plasmacytoma of the breast. *Breast J.* 2014 May-Jun;20(3):315–8. PMID:24673829
- 1482.** Neuman HB, Brogi E, Ebrahim A, et al.

- Desmoid tumors (fibromatoses) of the breast: a 25-year experience. *Ann Surg Oncol.* 2008 Jan;15(1):274–80. PMID:17896146
- 1483.** Neuman JF. Evaluation and treatment of gynecomastia. *Am Fam Physician.* 1997 Apr;55(5):1835–44, 1849–50. PMID:9105209
- 1484.** Neuville A, Chibon F, Coidre JM. Grading of soft tissue sarcomas: from histological to molecular assessment. *Pathology.* 2014 Feb;46(2):113–20. PMID:24378389
- 1485.** Nevanlinna H, Bartek J. The CHEK2 gene and inherited breast cancer susceptibility. *Oncogene.* 2006 Sep 25;25(43):5912–9. PMID:16998506
- 1486.** Newcomb PA, Trentham-Dietz A, Hampton JM, et al. Late age at first full term birth is strongly associated with lobular breast cancer. *Cancer.* 2011 May 1;117(9):1946–56. PMID:21509772
- 1487.** Newman PL, Fletcher CD. Smooth muscle tumours of the external genitalia: clinicopathological analysis of a series. *Histopathology.* 1991 Jun;18(6):523–9. PMID:1879812
- 1488.** Newman W. Lobular carcinoma of the female breast. Report of 73 cases. *Ann Surg.* 1966 Aug;164(2):305–14. PMID:5915941
- 1489.** Ng CKY, Piscuoglio S, Geyer FC, et al. The landscape of somatic genetic alterations in metaplastic breast carcinomas. *Clin Cancer Res.* 2017 Jul 15;23(14):3859–70. PMID:28153863
- 1490.** Ng WK. Fine needle aspiration cytology of invasive cribriform carcinoma of the breast with osteoclastlike giant cells: a case report. *Acta Cytol.* 2001 Jul-Aug;45(4):593–8. PMID:11480724
- 1491.** Ng WK. Fine-needle aspiration cytology findings of an uncommon micropapillary variant of pure mucinous carcinoma of the breast: review of patients over an 8-year period. *Cancer.* 2002 Oct 25;96(5):280–8. PMID:12378595
- 1492.** Ngeow J, Sesock K, Eng C. Clinical implications for germline PTEN spectrum disorders. *Endocrinol Metab Clin North Am.* 2017 Jun;46(2):503–17. PMID:28476234
- 1493.** Ngoma T, Addo M, Durosinni M, et al. Treatment of Burkitt lymphoma in equatorial Africa using a simple three-drug combination followed by a salvage regimen for patients with persistent or recurrent disease. *Br J Haematol.* 2012 Sep;158(6):749–62. PMID:22844968
- 1494.** Nguyen B, Veys I, Leduc S, et al. Genomic, transcriptomic, epigenetic, and immune profiling of mucinous breast cancer. *J Natl Cancer Inst.* 2019 Feb 21;djz023. PMID:30789657
- 1495.** Nguyen CV, Falcón-Escobedo R, Hunt KK, et al. Pleomorphic ductal carcinoma of the breast: predictors of decreased overall survival. *Am J Surg Pathol.* 2010 Apr;34(4):486–93. PMID:20154588
- 1496.** Nguyen GK, Neifer R. Aspiration biopsy cytology of secretory carcinoma of the breast. *Diagn Cytopathol.* 1987 Sep;3(3):234–7. PMID:2822366
- 1497.** Ni M, Chen Y, Lim E, et al. Targeting androgen receptor in estrogen receptor-negative breast cancer. *Cancer Cell.* 2011 Jul 12;20(1):119–31. PMID:21741601
- 1498.** Ni Y, Zbuk KM, Sadler T, et al. Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes. *Am J Hum Genet.* 2008 Aug;83(2):261–8. PMID:18678321
- 1499.** Ni YB, Tsang JYS, Shao MM, et al. GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer. *Breast Cancer Res Treat.* 2018 May;169(1):25–32. PMID:29340880
- 1500.** Nichols KE, Malkin D. Genotype versus phenotype: the yin and yang of germline TP53 mutations in Li-Fraumeni syndrome. *J Clin Oncol.* 2015 Jul 20;33(21):2331–3. PMID:26101242
- 1501.** Nicholson S, Hanby A, Clements K, et al. Variations in the management of the axilla in screen-detected ductal carcinoma in situ: evidence from the UK NHS breast screening programme audit of screen detected DCIS. *Eur J Surg Oncol.* 2015 Jan;41(1):86–93. PMID:25441934
- 1502.** Nicolas MM, Wu Y, Middleton LP, et al. Loss of myoepithelium is variable in solid papillary carcinoma of the breast. *Histopathology.* 2007 Nov;51(5):657–65. PMID:17927587
- 1503.** Nicolis GL, Modlinger RS, Gabrilove JL. A study of the histopathology of human gynecomastia. *J Clin Endocrinol Metab.* 1971 Feb;32(2):173–8. PMID:5539033
- 1504.** Niell B, Specht M, Gerade B, et al. Is excisional biopsy required after a breast core biopsy yields lobular neoplasia? *AJR Am J Roentgenol.* 2012 Oct;199(4):929–35. PMID:22997389
- 1505.** Nielsen TO, Parker JS, Leung S, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. *Clin Cancer Res.* 2010 Nov 1;16(21):5222–32. PMID:20837693
- 1506.** Nigro DM, Organ CH Jr. Fibroadenoma of the female breast. Some epidemiologic surprises. *Postgrad Med.* 1976 May;59(5):113–7. PMID:177964
- 1507.** Nik-Zainal S, Davies H, Staaf J, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. *Nature.* 2016 Jun 2;534(7605):47–54. PMID:27135926
- 1508.** Nindrea RD, Harahap WA, Aryandono T, et al. Association of BRCA1 promoter methylation with breast cancer in Asia: a meta-analysis. *Asian Pac J Cancer Prev.* 2018 Apr 25;19(4):885–9. PMID:29693332
- 1509.** Nishimura R, Tan PH, Thike AA, et al. Utility of the Singapore nomogram for predicting recurrence-free survival in Japanese women with breast phyllodes tumours. *J Clin Pathol.* 2014 Aug;67(8):748–50. PMID:24811489
- 1510.** Nishizaki T, Chew K, Chu L, et al. Genetic alterations in lobular breast cancer by comparative genomic hybridization. *Int J Cancer.* 1997 Oct 21;74(5):513–7. PMID:9355973
- 1511.** Nobukawa B, Fujii H, Hirai S, et al. Breast carcinoma diverging to aberrant melanocytic differentiation: a case report with histopathologic and loss of heterozygosity analyses. *Am J Surg Pathol.* 1999 Oct;23(10):1280–7. PMID:10524531
- 1512.** Noel JC, Van Geertryden J, Engohan-Aloge C. Angiolipoma of the breast in a male: a case report and review of the literature. *Int J Surg Pathol.* 2011 Dec;19(6):813–6. PMID:20034977
- 1513.** Noguchi S, Motomura K, Inaji H, et al. Clonal analysis of solitary intraductal papilloma of the breast by means of polymerase chain reaction. *Am J Pathol.* 1994 Jun;144(6):1320–5. PMID:7911274
- 1514.** Noguchi S, Yokouchi H, Aihara T, et al. Progression of fibroadenoma to phyllodes tumor demonstrated by clonal analysis. *Cancer.* 1995 Nov 15;76(10):1779–85. PMID:8625047
- 1515.** Nolan E, Savas P, Policheni AN, et al. Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. *Sci Transl Med.* 2017 Jun 7;9(393):eaal4922. PMID:28592566
- 1516.** Nonaka D, Chiriboga L, Rubin BP. Sox10: a pan-schwannian and melanocytic marker. *Am J Surg Pathol.* 2008 Sep;32(9):1291–9. PMID:18636017
- 1517.** Nonaka D, Chiriboga L, Soslow RA. Expression of Pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. *Am J Surg Pathol.* 2008 Oct;32(10):1566–71. PMID:18724243
- 1518.** Nones K, Johnson J, Newell F, et al. Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers. *Ann Oncol.* 2019 May 15;mdz132. PMID:31090900
- 1519.** Nordenskjöld A, Fohlin H, Fornander T, et al. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer. *Breast Cancer Res Treat.* 2016 Nov;160(2):313–22. PMID:27722840
- 1520.** Norris HJ, Taylor HB. Prognosis of mucinous (gelatinous) carcinoma of the breast. *Cancer.* 1965 Jul;18:879–85. PMID:14308235
- 1521.** Northridge ME, Rhoads GG, Wartenberg D, et al. The importance of histologic type on breast cancer survival. *J Clin Epidemiol.* 1997 Mar;50(3):283–90. PMID:9120527
- 1522.** Noske A, Schwabe M, Pahl S, et al. Report of a metaplastic carcinoma of the breast with multi-directional differentiation: an adenoid cystic carcinoma, a spindle cell carcinoma and melanoma. *Virchows Arch.* 2008 May;452(5):575–9. PMID:18283489
- 1523.** Nuttall FQ, Warrier RS, Gannon MC. Gynecomastia and drugs: a critical evaluation of the literature. *Eur J Clin Pharmacol.* 2015 May;71(5):569–78. PMID:25827472
- 1524.** Oakley GJ 3rd, Tubbs RR, Crowe J, et al. HER-2 amplification in tubular carcinoma of the breast. *Am J Clin Pathol.* 2006 Jul;126(1):55–8. PMID:16753605
- 1525.** Oba T, Ono M, Iesato A, et al. Lipid-rich carcinoma of the breast that is strongly positive for estrogen receptor: a case report and literature review. *Onco Targets Ther.* 2016 Mar 18;9:1641–6. PMID:27051299
- 1526.** Oberman HA. Hamartomas and hamartoma variants of the breast. *Semin Diagn Pathol.* 1989 May;6(2):135–45. PMID:2669070
- 1527.** Oberman HA. Metaplastic carcinoma of the breast. A clinicopathologic study of 29 patients. *Am J Surg Pathol.* 1987 Dec;11(12):918–29. PMID:2825549
- 1528.** Oberman HA. Secretory carcinoma of the breast in adults. *Am J Surg Pathol.* 1980 Oct;4(5):465–70. PMID:7435774
- 1529.** Obiorah IE, Ozdemirli M. Myeloid sarcoma with megakaryoblastic differentiation presenting as a breast mass. *Hematol Oncol Stem Cell Ther.* 2018 Sep;11(3):178–82. PMID:29684340
- 1530.** O'Connell P, Pekkel V, Fuqua SA, et al. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. *J Natl Cancer Inst.* 1998 May 6;90(9):697–703. PMID:9586667
- 1531.** O'Connor IF, Shembekar MV, Shousha S. Breast carcinoma developing in patients on hormone replacement therapy: a histological and immunohistological study. *J Clin Pathol.* 1998 Dec;51(12):935–8. PMID:10070338
- 1532.** Odashiro AN, Odashiro Miji LN, Odashiro DN, et al. Mammary myofibroblastoma: report of two cases with fine-needle aspiration cytology and review of the cytology literature. *Diagn Cytopathol.* 2004 Jun;30(6):406–10. PMID:15176028
- 1533.** Ogwang MD, Bhatia K, Biggar RJ, et al. Incidence and geographic distribution of endemic Burkitt lymphoma in northern Uganda revisited. *Int J Cancer.* 2008 Dec 1;123(11):2658–63. PMID:18767045
- 1534.** Oh M, McBride A, Yun S, et al. BRCA1 and BRCA2 gene mutations and colorectal cancer risk: systematic review and meta-analysis. *J Natl Cancer Inst.* 2018 Mar 1;110(11):1178–89. PMID:30380096
- 1535.** Ohashi R, Matsubara M, Watanabe T, et al. Pleomorphic lobular carcinoma of the breast: a comparison of cytopathological features with other lobular carcinoma variants. *Cytopathology.* 2017 Apr;28(2):122–31. PMID:27489086
- 1536.** Ohta M, Mori M, Kawada T, et al. Collagenous spherulosis associated with adenomyoepithelioma of the breast: a report. *Acta Cytol.* 2010 May-Jun;54(3):394–9. PMID:20518417
- 1537.** Ohta T, Abe R, Kimijima I, et al. Intraductal extension of primary invasive breast carcinoma treated by breast-conserving surgery. Computer graphic three-dimensional reconstruction of the mammary duct–tumor systems. *Cancer.* 1995 Jul 17;75(1):123–40. PMID:8630874
- 1538.** Ohuchi N. Breast-conserving surgery for invasive cancer: a principle based on segmental anatomy. *Tohoku J Exp Med.* 1999 Jun;188(2):103–18. PMID:10526872
- 1539.** Ohuchi N. Breast-conserving surgery for invasive cancer: a principle based on segmental anatomy. *Tohoku J Exp Med.* 1999 Jun;188(2):103–18. PMID:10526872
- 1540.** Ohuchi N, Abe R, Kasai M. Positive cancerous change of intraductal carcinoma of the breast. A 3-D reconstruction study of 25 cases. *Cancer.* 1984 Aug 15;54(4):555–61. PMID:6331624
- 1541.** Ohuchi N, Furuta A, Mori S. Management of ductal carcinoma in situ with non-discharge. Intraductal spreading of carcinoma as an unfavorable pathologic factor for breast-conserving surgery. *Cancer.* 1994 May 15;74(4):1294–302. PMID:8055451
- 1542.** Oishi N, Brody GS, Ketterling PP, et al. Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. *Blood.* 2001 Aug 2;132(5):544–7. PMID:29921815
- 1543.** Oiwa M, Endo T, Ichihara S, et al. Sclerosing adenosis as a predictor of cancer bilaterality and multicentricity. *Am J Pathol.* 2015 Jul;147(1):71–8. PMID:25990000
- 1544.** Oka H, Shiozaki H, Kobayashi T, et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues: its relationship to metastasis. *Cancer Res.* 1993 Apr 1;53(7):1696–701. PMID:8453544
- 1545.** Okada K, Suzuki Y, Saito Y, et al. The cases of ductal adenoma of the breast. *Cancer.* 2006;113(4):354–9. PMID:17146381
- 1546.** Oliveira C, Sousa S, Pinheiro P, et al. Quantification of epigenetic and genetic changes in CDH1 during hereditary diffuse-gastrointestinal syndrome progression. *Gastroenterology.* 2006 Jun;136(7):2137–48. PMID:16926290
- 1547.** Olivier M, Goldgar DE, Sodha S, et al. Li-Fraumeni and related syndromes: comparison between tumor type, family structure, and TP53 genotype. *Cancer Res.* 2003 Mar 15;63(20):6643–50. PMID:14583457
- 1548.** Olivier M, Hollstein M, Hamid R, et al. TP53 mutations in human cancers: mutational consequences, and clinical use. *Curr Opin Harv Perspect Biol.* 2010 Jan;21(1):1–10. PMID:20182602
- 1549.** O'Malley FP, Bane A. An update on apocrine lesions of the breast. *Histopathology.* 2008 Jan;52(1):3–10. PMID:18174742
- 1550.** O'Malley FP, Bane AL. The spectrum of apocrine lesions of the breast. *Adv Anat Pathol.* 2004 Jan;11(1):1–9. PMID:14576766
- 1551.** O'Malley FP, Mohsin SK, Bache S, et al. Interobserver reproducibility in the diagnosis of flat epithelial atypia of the breast. *Mod Pathol.* 2006 Feb;19(2):172–9. PMID:16424892
- 1552.** Omar L, Pfeiffer CM, Kulkarni S, et al. Granular cell tumor in a premenstrual breast. *Clin Imaging.* 2018 Nov-Dec;55:10–14. PMID:30241035
- 1553.** O'Neil M, Madan R, Tawfik DI, et al. Lobular carcinoma in situ/typical lobular carcinoma: a meta-analysis. *J Natl Cancer Inst.* 2018 Mar 1;110(11):1178–89. PMID:30380096

- hyperplasia on breast needle biopsies: Does it warrant surgical excisional biopsy? A study of 27 cases. *Ann Diagn Pathol.* 2010 Aug;14(4):251–5. PMID:20637429
- 1554.** Onnis A, De Falco G, Antonicelli G, et al. Alteration of microRNAs regulated by c-Myc in Burkitt lymphoma. *PLoS One.* 2010 Sep 24;5(9):e12960. PMID:20930934
- 1555.** Ono M, Yoshikawa K, Yamaguchi T, et al. A case of breast cancer coexisting with florid papillomatosis of the nipple. *Breast Cancer.* 1998 Jun 30;5(1):87–91. PMID:11091632
- 1556.** Organ CH Jr, Organ BC. Fibroadenoma of the female breast: a critical clinical assessment. *J Natl Med Assoc.* 1983 Jul;75(7):701–4. PMID:6887274
- 1557.** Orguc S, Akin M, Aydogdu I, et al. Bilateral plasmacytoma of the breast. *Breast J.* 2018 Mar;24(2):210–1. PMID:28805290
- 1558.** Orloff MS, Eng C. Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome. *Oncogene.* 2008 Sep 18;27(41):5387–97. PMID:18794875
- 1559.** Orr N, Dudbridge F, Dryden N, et al. Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. *Hum Mol Genet.* 2015 May 15;24(10):2966–84. PMID:25652398
- 1560.** Orvieto E, Maiorano E, Bottiglieri L, et al. Clinicopathologic characteristics of invasive lobular carcinoma of the breast: results of an analysis of 530 cases from a single institution. *Cancer.* 2008 Oct 1;113(7):1511–20. PMID:18704988
- 1561.** Ozarzleski L, Casella D, Criscenti V, et al. Microinvasive breast cancer: pathological parameters, cancer subtypes distribution, and correlation with axillary lymph nodes invasion. Results of a large single-institution series. *Breast Cancer.* 2016 Jul;23(4):640–8. PMID:25981971
- 1562.** Osborn G, Wilton F, Stevens G, et al. A review of needle core biopsy diagnosed radial scars in the Welsh Breast Screening Programme. *Ann R Coll Surg Engl.* 2011 Mar;93(2):123–6. PMID:21073820
- 1563.** O’Shea R, Clarke R, Berkley E, et al. Next generation sequencing is informing phenotype: a TP53 example. *Fam Cancer.* 2018 Jan;17(1):123–8. PMID:28509937
- 1564.** Oshida K, Miyachi M, Yamamoto N, et al. Phyllodes tumor arising in ectopic breast tissue of the axilla. *Breast Cancer.* 2003;10(1):82–4. PMID:12525768
- 1564A.** O’Sullivan CC, Swain SM. Pertuzumab: evolving therapeutic strategies in the management of HER2-overexpressing breast cancer. *Expert Opin Biol Ther.* 2013 May;13(5):779–90. PMID:23530718
- 1565.** Otsuki Y, Yamada M, Shimizu S, et al. Solid-papillary carcinoma of the breast: clinicopathological study of 20 cases. *Pathol Int.* 2007 Jul;57(7):421–9. PMID:17587241
- 1566.** Ozaki S, Mizukami Y, Kawahara E. Cytologic features of nipple adenoma: a report of four cases of adenoma of the nipple. *Diagn Cytopathol.* 2015 Aug;43(8):664–8. PMID:26011103
- 1567.** Ozerdem U, McNiff JM, Tavassoli FA. Cytokeratin 7-negative mammary Paget’s disease: a diagnostic pitfall. *Pathol Res Pract.* 2016 Apr;212(4):279–81. PMID:26944832
- 1568.** Ozerdem U, Swistel A, Antonio LB, et al. Invasive Paget disease of the nipple: a brief review of the literature and report of the first case with axillary nodal metastases. *Int J Surg Pathol.* 2014 Sep;22(6):566–9. PMID:24583835
- 1569.** Paciolas T, Seth R, Orellana C, et al. Malignant phyllodes tumor of the breast presenting with hypoglycemia: a case report and literature review. *Cancer Manag Res.* 2014 Dec 8;6:467–73. PMID:25525388
- 1570.** Padmore RF, Lara JF, Ackerman DJ, et al. Primary combined malignant melanoma and ductal carcinoma of the breast. A report of two cases. *Cancer.* 1996 Dec 15;78(12):2515–25. PMID:895260
- 1571.** Pagani A, Sapino A, Eusebi V, et al. PIP/GCDFP-15 gene expression and apocrine differentiation in carcinomas of the breast. *Virchows Arch.* 1994;425(5):459–65. PMID:7850069
- 1572.** Page DL. Apocrine carcinomas of the breast. *Breast.* 2005 Feb;14(1):1–2. PMID:15695073
- 1573.** Page DL, Dixon JM, Anderson TJ, et al. Invasive cribriform carcinoma of the breast. *Histopathology.* 1983 Jul;7(4):525–36. PMID:6884999
- 1574.** Page DL, Dupont WD, Rogers LW. Ductal involvement by cells of atypical lobular hyperplasia in the breast: a long-term follow-up study of cancer risk. *Hum Pathol.* 1988 Feb;19(2):201–7. PMID:3343034
- 1575.** Page DL, Dupont WD, Rogers LW, et al. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. *Cancer.* 1985 Jun 1;55(11):2698–708. PMID:2986821
- 1576.** Page DL, Kidd TE Jr, Dupont WD, et al. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. *Hum Pathol.* 1991 Dec;22(12):1232–9. PMID:1748429
- 1577.** Page DL, Salhaney KE, Jensen RA, et al. Subsequent breast carcinoma risk after biopsy with atypia in a breast papilloma. *Cancer.* 1996 Jul 15;78(2):258–66. PMID:8674001
- 1578.** Page DL, Schuyler PA, Dupont WD, et al. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. *Lancet.* 2003 Jan 11;361(9352):125–9. PMID:12531579
- 1579.** Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. *N Engl J Med.* 2004 Dec 30;351(27):2817–26. PMID:15591335
- 1580.** Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. *J Clin Oncol.* 2006 Aug 10;24(23):3726–34. PMID:16720680
- 1581.** Pairoler K, Fernandes H, Cs J, et al. Fine needle aspiration cytology of male breast lesions - a retrospective study over a six year period. *J Clin Diagn Res.* 2014 Oct;8(10):FC13–5. PMID:25478347
- 1582.** Palacios J, Benito N, Pizarro A, et al. Anomalous expression of P-cadherin in breast carcinoma. Correlation with E-cadherin expression and pathological features. *Am J Pathol.* 1995 Mar;146(3):605–12. PMID:7534041
- 1583.** Palacios J, Sarrió D, García-Macias MC, et al. Frequent E-cadherin gene inactivation by loss of heterozygosity in pleomorphic lobular carcinoma of the breast. *Mod Pathol.* 2003 Jul;16(7):674–8. PMID:12861063
- 1584.** Palazzo JP, Hyslop T. Hyperplastic ductal and lobular lesions and carcinomas in situ of the breast: reproducibility of current diagnostic criteria among community- and academic-based pathologists. *Breast J.* 1998 Jul;4(4):230–7. PMID:21223441
- 1585.** Palermo MH, Pinto MB, Zanetti JS, et al. Primary mucoepidermoid carcinoma of the breast: a case report with immunohistochemical analysis and comparison with salivary gland mucoepidermoid carcinomas. *Pol J Pathol.* 2013 Oct;64(3):210–5. PMID:24166608
- 1586.** Palogiannis P, Cossu A, Palmieri G, et al. Breast nodular fasciitis: a comprehensive review. *Breast Care (Basel).* 2016 Aug;11(4):270–4. PMID:27721715
- 1587.** Palli D, Galli M, Bianchi S, et al. Reproducibility of histological diagnosis of breast lesions: results of a panel in Italy. *Eur J Cancer.* 1996 Apr;32(A4):603–7. PMID:8695260
- 1588.** Pallis L, Wilking N, Cedermark B, et al. Receptors for estrogen and progesterone in breast carcinoma in situ. *Anticancer Res.* 1992 Nov-Dec;12(6B):2113–5. PMID:1295456
- 1589.** Panagopoulos I, Gorunova L, Bjerkehegen B, et al. The recurrent chromosomal translocation t(12;18) (q14–15;q21–21) causes the fusion gene HMGA2-SETBP1 and HMGA2 expression in lipoma and osteochondromatoma. *Int J Oncol.* 2015 Sep;47(3):884–90. PMID:26202160
- 1590.** Panagopoulos I, Höglund M, Mertens F, et al. Fusion of the EWS and CHOP genes in myxoid liposarcoma. *Oncogene.* 1996 Feb 1;12(3):489–94. PMID:8637704
- 1591.** Pang JM, Deb S, Takano EA, et al. Methylation profiling of ductal carcinoma in situ and its relationship to histopathological features. *Breast Cancer Res.* 2014 Oct 21;16(5):423. PMID:25331261
- 1592.** Pang JM, Gorringe KL, Wong SQ, et al. Appraisal of the technologies and review of the genomic landscape of ductal carcinoma in situ of the breast. *Breast Cancer Res.* 2015 Jun 16;17(8):80. PMID:26078038
- 1593.** Pant I, Kaur G, Joshi SC, et al. Myxoid liposarcoma of the breast in a 25-year-old female as a diagnostic pitfall in fine needle aspiration cytology: report of a rare case. *Diagn Cytopathol.* 2008 Sep;36(9):674–7. PMID:18677756
- 1594.** Pantziarka P. Li Fraumeni syndrome, cancer and senescence: a new hypothesis. *Cancer Cell Int.* 2013 Apr 15;13(1):35. PMID:23587008
- 1595.** Papachristou DN, Kinne D, Ashikari R, et al. Melanoma of the nipple and areola. *Br J Surg.* 1979 Apr;66(4):287–8. PMID:455001
- 1596.** Papadatos G, Rangan AM, Psarianos T, et al. Probability of axillary node involvement in patients with tubular carcinoma of the breast. *Br J Surg.* 2001 Jun;88(6):860–4. PMID:11412259
- 1597.** Papalas JA, Wylie JD, Dash RC. Recurrence risk and margin status in granular cell tumors of the breast: a clinicopathologic study of 13 patients. *Arch Pathol Lab Med.* 2011 Jul;135(7):890–5. PMID:21732779
- 1598.** Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer.* 2012 Mar 22;12(4):252–64. PMID:22437870
- 1599.** Pareja F, Brandes AH, Basili T, et al. Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors. *Nat Commun.* 2018 Aug 30;9(1):3533. PMID:30166553
- 1600.** Pareja F, Corben AD, Brennan SB, et al. Breast intraductal papillomas without atypia in radiologic-pathologic concordant core-needle biopsies: rate of upgrade to carcinoma at excision. *Cancer.* 2016 Sep 15;122(18):2819–27. PMID:27315013
- 1601.** Pareja F, Geyer FC, Kumar R, et al. Phyllodes tumors with and without fibroadenoma-like areas display distinct genomic features and may evolve through distinct pathways. *NPJ Breast Cancer.* 2017 Oct 12;3:40. PMID:29043292
- 1602.** Pareja F, Lee JY, Brown DN, et al. The genomic landscape of mucinous breast cancer. *J Natl Cancer Inst.* 2019 Jul;111(7):737–41. PMID:30649385
- 1603.** Parham DM, Fisher C. Angiosarcomas of the breast developing post radiotherapy. *Histopathology.* 1997 Aug;31(2):189–95. PMID:9279573
- 1604.** Parise CA, Bauer KR, Caggiano V. Variation in breast cancer subtypes with age and race/ethnicity. *Crit Rev Oncol Hematol.* 2010 Oct;76(1):44–52. PMID:19800812
- 1605.** Park B, Hopper JL, Win AK, et al. Reproductive factors as risk modifiers of breast cancer in BRCA mutation carriers and high-risk non-carriers. *Oncotarget.* 2017 Oct 31;8(60):102110–8. PMID:29254229
- 1606.** Park JS, Lee ST, Han JW, et al. Difference in risk of breast and ovarian cancer according to putative functional domain regions in Korean BRCA1/2 mutation carriers. *Clin Breast Cancer.* 2018 Oct;18(5):362–373.e1. PMID:29673794
- 1607.** Park S, Koo JS, Kim MS, et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. *Breast.* 2012 Feb;21(1):50–7. PMID:21865043
- 1608.** Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. *J Clin Oncol.* 2009 Mar 10;27(8):1160–7. PMID:19204204
- 1609.** Pasquale-Styles MA, Milikowski C. Three-millimeter apocrine adenoma in a man: a case report and review of the literature. *Arch Pathol Lab Med.* 2003 Nov;127(11):1498–500. PMID:14567753
- 1610.** Pasquali P, Freites-Martinez A, Fortuño A. Nipple adenoma: new images and cryosurgery treatment. *Breast J.* 2016 Sep;22(5):584–5. PMID:27345934
- 1611.** Pastorello RG, D’Almeida Costa F, Osório CABT, et al. Breast implant-associated anaplastic large cell lymphoma in a Li-Fraumeni patient: a case report. *Diagn Pathol.* 2018 Jan 25;13(1):10. PMID:29370815
- 1612.** Patel A, D’Alfonso T, Cheng E, et al. Sentinel lymph nodes in classic invasive lobular carcinoma of the breast: cytokeratin immunostain ensures detection, and precise determination of extent, of involvement. *Am J Surg Pathol.* 2017 Nov;41(11):1499–505. PMID:28877063
- 1613.** Paterakos M, Watkin WG, Edgerton SM, et al. Invasive micropapillary carcinoma of the breast: a prognostic study. *Hum Pathol.* 1999 Dec;30(12):1459–63. PMID:10667424
- 1614.** Pathmanathan N, Renthawa J, French JR, et al. Intraoperative sentinel lymph node assessment in breast cancer: a comparison of rapid diagnostic method based on CK19 mRNA expression and imprint cytology. *ANZ J Surg.* 2014 Oct;84(10):730–4. PMID:24899463
- 1615.** Patil T, Bernard B. Complications of androgen deprivation therapy in men with prostate cancer. *Oncology (Williston Park).* 2018 Sep 15;32(9):470–4, CV3. PMID:30248169
- 1616.** Patton KT, Deyrup AT, Weiss SW. Atypical vascular lesions after surgery and radiation of the breast: a clinicopathologic study of 32 cases analyzing histologic heterogeneity and association with angiosarcoma. *Am J Surg Pathol.* 2008 Jun;32(6):943–50. PMID:18551753
- 1617.** Patwardhan UM, Vu MT, Soballe PW. Multiple schwannomas in a patient with gynecomastia. *Breast J.* 2017 May;23(3):360–2. PMID:27988983
- 1618.** Patzelt M, Zarubova L, Kleiner P, et al. Anaplastic large-cell lymphoma associated with breast implants: a case report of a transgender female. *Aesthetic Plast Surg.* 2018 Apr;42(2):451–5. PMID:29101436
- 1619.** Paul Wright G, Davis AT, Koehler TJ, et al. Hormone receptor status does not affect prognosis in metaplastic breast cancer: a population-based analysis with comparison to infiltrating ductal and lobular carcinomas. *Ann Surg Oncol.* 2014 Oct;21(11):3497–503. PMID:24838367
- 1620.** Pauwels P, Sciot R, Croiset F, et al.

- Myofibroblastoma of the breast: genetic link with spindle cell lipoma. *J Pathol.* 2000 Jul;191(3):282–5. PMID:10878550
- 1621.** Peiro G, Bernstein BA, Connolly JL, et al. The influence of infiltrating lobular carcinoma on the outcome of patients treated with breast-conserving surgery and radiation therapy. *Breast Cancer Res Treat.* 2000 Jan;59(1):49–54. PMID:10752679
- 1622.** Peña A, Shah SS, Fazio RT, et al. Multivariate model to identify women at low risk of cancer upgrade after a core needle biopsy diagnosis of atypical ductal hyperplasia. *Breast Cancer Res Treat.* 2017 Jul;164(2):295–304. PMID:28474262
- 1623.** Penault-Llorca F, Radosevic-Robin N. Biomarkers of residual disease after neoadjuvant therapy for breast cancer. *Nat Rev Clin Oncol.* 2016 Aug;13(8):487–503. PMID:26856744
- 1624.** Penkert J, Schmidt G, Hofmann W, et al. Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity. *Breast Cancer Res.* 2018 Aug 7;20(1):87. PMID:30086788
- 1625.** Pereira B, Chin SF, Rueda OM, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. *Nat Commun.* 2016 May 10;7:11479. PMID:27161491
- 1626.** Pereira H, Pinder SE, Sibbering DM, et al. Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. *Histopathology.* 1995 Sep;27(3):219–26. PMID:8522285
- 1626A.** Perez AA, Balabram D, Salles Mde A, et al. Ductal carcinoma in situ of the breast: correlation between histopathological features and age of patients. *Diagn Pathol.* 2014 Dec 3;9:227. PMID:25471940
- 1627.** Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. *J Clin Oncol.* 2014 Nov 20;32(33):3744–52. PMID:25332249
- 1628.** Perez-Montiel MD, Plaza JA, Dominguez-Malagon H, et al. Differential expression of smooth muscle myosin, smooth muscle actin, h-caldesmon, and calponin in the diagnosis of myofibroblastic and smooth muscle lesions of skin and soft tissue. *Am J Dermatopathol.* 2006 Apr;28(2):105–11. PMID:16625070
- 1629.** Perlman S, Becker-Catania S, Gatti RA. Ataxia-telangiectasia: diagnosis and treatment. *Semin Pediatr Neurol.* 2003 Sep;10(3):173–82. PMID:14653405
- 1630.** Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. *Nature.* 2000 Aug 17;406(6797):747–52. PMID:10963602
- 1631.** Perry A, Roth KA, Banerjee R, et al. NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors. *Am J Pathol.* 2001 Jul;159(1):57–61. PMID:11438454
- 1632.** Persson F, Andrén Y, Winnes M, et al. High-resolution genomic profiling of adenomas and carcinomas of the salivary glands reveals amplification, rearrangement, and fusion of HMGA2. *Genes Chromosomes Cancer.* 2009 Jan;48(1):69–82. PMID:18828159
- 1633.** Pestalozzi BC, Zahrieh D, Mallon E, et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. *J Clin Oncol.* 2008 Jun 20;26(18):3006–14. PMID:18458044
- 1634.** Peters GN, Wolff M, Haagensen CD. Tubular carcinoma of the breast. Clinical pathologic correlations based on 100 cases. *Ann Surg.* 1981 Feb;193(2):138–49. PMID:7469549
- 1635.** Petersson F, Ivan D, Kazakov DV, et al. Pigmented Paget disease—a diagnostic pitfall mimicking melanoma. *Am J Dermatopathol.* 2009 May;31(3):223–6. PMID:19384061
- 1636.** Petersson F, Pang B, Thambo TP, et al. Mucinous cystadenocarcinoma of the breast with amplification of the HER2-gene confirmed by FISH: the first case reported. *Hum Pathol.* 2010 Jun;41(6):910–3. PMID:20338619
- 1637.** Petrelli F, Barni S. Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: a meta-analysis of published trials including 1,764 lobular breast cancer. *Breast Cancer Res Treat.* 2013 Nov;142(2):227–35. PMID:24177758
- 1638.** Petridis C, Brook MN, Shah V, et al. Genetic predisposition to ductal carcinoma in situ of the breast. *Breast Cancer Res.* 2016 Feb 17;18(1):22. PMID:26884359
- 1639.** Petridis C, Shinomiya I, Kohut K, et al. Germline CDH1 mutations in bilateral lobular carcinoma in situ. *Br J Cancer.* 2014 Feb 18;110(4):1053–7. PMID:24366306
- 1640.** Pettinato G, Manivel CJ, Panico L, et al. Invasive micropapillary carcinoma of the breast: clinicopathologic study of 62 cases of a poorly recognized variant with highly aggressive behavior. *Am J Clin Pathol.* 2004 Jun;121(6):857–66. PMID:15198358
- 1641.** Pétursson HI, Kovács A, Mattsson J, et al. Evaluation of intraoperative touch imprint cytology on axillary sentinel lymph nodes in invasive breast carcinomas, a retrospective study of 1227 patients comparing sensitivity in the different tumor subtypes. *PLoS One.* 2018 Apr 12;13(4):e0195560. PMID:29649327
- 1642.** Pfaff CL, Parra EJ, Bonilla C, et al. Population structure in admixed populations: effect of admixture dynamics on the pattern of linkage disequilibrium. *Am J Hum Genet.* 2001 Jan;68(1):198–207. PMID:11112661
- 1643.** Philip J, Harris WG, Rustage JH. Radiography of breast biopsy specimens. *Br J Surg.* 1982 Mar;69(3):126–7. PMID:7066650
- 1644.** Phillips SR, A'Hern R, Thomas JM. Aggressive fibromatosis of the abdominal wall, limbs and limb girdles. *Br J Surg.* 2004 Dec;91(12):1624–9. PMID:15505878
- 1645.** Philpott C, Tovell H, Frayling IM, et al. The NF1 somatic mutational landscape in sporadic human cancers. *Hum Genomics.* 2017 Jun 21;11(1):13. PMID:28637487
- 1646.** Piccaluga PP, De Falco G, Kustagi M, et al. Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes. *Blood.* 2011 Mar 31;117(13):3596–608. PMID:21245480
- 1647.** Piccaluga PP, Navari M, De Falco G, et al. Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas. *Oncotarget.* 2016 Jan 5;7(1):224–40. PMID:26325594
- 1648.** Pickett JL, Chou A, Andrici JA, et al. Inflammatory myofibroblastic tumors of the female genital tract are under-recognized: a low threshold for ALK immunohistochemistry is required. *Am J Surg Pathol.* 2017 Oct;41(10):1433–42. PMID:28731868
- 1649.** Picouleau E, Denis M, Lavoue V, et al. Atypical hyperplasia of the breast: the black hole of routine breast cancer screening. *Anticancer Res.* 2012 Dec;32(12):5441–6. PMID:23225449
- 1650.** Pilarski R, Burt R, Kohlman W, et al. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. *J Natl Cancer Inst.* 2013 Nov 6;105(21):1607–16. PMID:24136893
- 1651.** Pimiento JM, Gadgil PV, Santillan AA, et al. Phyllodes tumors: race-related differences. *J Am Coll Surg.* 2011 Oct;213(4):537–42. PMID:21856184
- 1652.** Pinder SE, Reis-Filho JS. Non-operative breast pathology: columnar cell lesions. *J Clin Pathol.* 2007 Dec;60(12):1307–12. PMID:17182657
- 1653.** Pirie A, Guo Q, Kraft P, et al. Common germline polymorphisms associated with breast cancer-specific survival. *Breast Cancer Res.* 2015 Apr 22;17:58. PMID:25897948
- 1654.** Pisano ED, Fajardo LL, Tsimikas J, et al. Rate of insufficient samples for fine-needle aspiration for nonpalpable breast lesions in a multicenter clinical trial: the Radiologic Diagnostic Oncology Group 5 Study. *The RDOG Investigators.* *Cancer.* 1998 Feb 15;82(4):679–88. PMID:9477100
- 1655.** Piscuoglio S, Geyer FC, Burke KA, et al. Massively parallel sequencing analysis of synchronous fibroepithelial lesions supports the concept of progression from fibroadenoma to phyllodes tumor. *NPJ Breast Cancer.* 2016 Nov 16;2:16035. PMID:28721388
- 1656.** Piscuoglio S, Hodz Z, Katabi N, et al. Are acinic cell carcinomas of the breast and salivary glands distinct diseases? *Histopathology.* 2015 Oct;67(4):529–37. PMID:25688711
- 1657.** Piscuoglio S, Murray M, Fusco N, et al. MED12 somatic mutations in fibroadenomas and phyllodes tumours of the breast. *Histopathology.* 2015 Nov;67(5):719–29. PMID:25855048
- 1658.** Piscuoglio S, Ng CK, Martelotto LG, et al. Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast. *Mol Oncol.* 2014 Dec;8(8):1588–602. PMID:25041824
- 1659.** Piscuoglio S, Ng CK, Murray M, et al. Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression. *J Pathol.* 2016 Mar;238(4):508–18. PMID:26832993
- 1660.** Piscuoglio S, Ng CK, Murray MP, et al. The genomic landscape of male breast cancers. *Clin Cancer Res.* 2016 Aug 15;22(16):4045–56. PMID:26960396
- 1661.** Piscuoglio S, Ng CKY, Geyer FC, et al. Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast. *NPJ Breast Cancer.* 2017 Dec 1;3:48. PMID:29214215
- 1662.** Pitanguy I, Torres E, Salgado F, et al. Breast pathology and reduction mammoplasty. *Plast Reconstr Surg.* 2005 Mar;115(3):729–34, discussion 735. PMID:15731670
- 1663.** Pitino A, Squillaci S, Spairani C, et al. Tall cell variant of papillary breast carcinoma: an additional case with review of the literature. *Pathologica.* 2017 Sep;109(3):162–7. PMID:29154377
- 1664.** Podetta M, D'Ambrosio G, Ferrari A, et al. Low-grade fibromatosis-like spindle cell metaplastic carcinoma: a basal-like tumor with a favorable clinical outcome. Report of two cases. *Tumori.* 2009 Mar-Apr;95(2):264–7. PMID:19579879
- 1665.** Poling JS, Yonescu R, Subhawong AP, et al. MYB labeling by immunohistochemistry is more sensitive and specific for breast adenoid cystic carcinoma than MYB labeling by FISH. *Am J Surg Pathol.* 2017 Jul;41(7):973–9. PMID:28498281
- 1666.** Popnikolov NK, Cavone SM, Schultz PM, et al. Diagnostic utility of p75 neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells. *Mod Pathol.* 2006 Dec;19(12):1535–41. PMID:16258511
- 1667.** Porter PL, Garcia R, Moe R, et al. C-erbB-2 oncogene protein in *in situ* and invasive lobular breast neoplasia. *Cancer.* 1991 Jul 15;68(2):331–4. PMID:1676930
- 1668.** Posner MC, Shiu MH, Newsome JL, et al. The desmoid tumor. Not a benign disease. *Am J Surg.* 1989 Feb;147(2):191–6. PMID:2515947
- 1669.** Pouysségur J, Pastan I. Mutants of mouse fibroblasts altered in the synthesis of cell surface glycoproteins. Preliminary evidence for a defect in the acetylation of glucosamine 6-phosphate. *J Biol Chem.* 1981 Mar 10;252(6):1639–46. PMID:7038733
- 1670.** Powell CM, Cranor ML, Rosen PP. Multinucleated stromal giant cells in mammary fibroepithelial neoplasms. A study of 11 patients. *Arch Pathol Lab Med.* 1994 Sep;118(9):970–4. PMID:8080361
- 1671.** Powell CM, Cranor ML, Rosen PP. Pseudoangiomatous stromal hyperplasia (PASH). A mammary stromal tumor with myofibroblastic differentiation. *Am J Surg Pathol.* 1995 Mar;19(3):270–7. PMID:7792020
- 1672.** Powell CM, Rosen PP. Histologic differentiation in cystosarcoma phylloides: a study of 14 cases. *Am J Surg Pathol.* 1995 Jul;18(7):720–7. PMID:8017566
- 1673.** Prasad ML, Osborne MP, Grignon DJ. Microinvasive carcinoma (T1mic) of the breast: clinicopathologic profile of 21 cases. *Am J Surg Pathol.* 2000 Mar;24(3):422–8. PMID:10730203
- 1674.** Prat A, Parker JS, Karginova A, et al. Phenotypic and molecular characteristics of the claudin-low intrinsic subtype of breast cancer. *Breast Cancer Res.* 2010 Dec;12(12):R113. PMID:20813035
- 1675.** Prescott RJ, Eyden BP, Ross NL. Sebaceous differentiation in a breast carcinoma with ductal, myoepithelial and squamous elements. *Histopathology.* 1995 Aug;21(2):181–4. PMID:1324221
- 1676.** Pritchett M, Summerour P, McNeese M, et al. Male breast cancer in a multicenter panel testing cohort: insights and unexpected results. *Breast Cancer Res Treat.* 2007 Feb;161(3):575–86. PMID:28000555
- 1677.** Provenzano E, Bossuyt A, Van Den Berg G, et al. Standardization of postmenopausal evaluation and reporting of postmenopausal specimens in clinical trials of breast cancer: recommendations from an international group. *Mod Pathol.* 2015 Sep;28(9):1253–62. PMID:26205180
- 1678.** Pruneri G, Masullo M, Romeo E, et al. Follicular dendritic cell sarcoma of the breast. *Virchows Arch.* 2002 Aug;440(2):193–7. PMID:12189511
- 1679.** Puri S, Mohindoo S, Bhattacharya S, et al. Collagenous spherulosis: an atypical cytological finding in breast lesion. *Cancer.* 2015 Nov 30;125(22):2668–73. PMID:26661973
- 1680.** Purrington KS, Visscher DM, McNeese M, et al. Genes associated with histopathologic features of triple negative breast cancer and molecular subtypes. *Breast Cancer Res Treat.* 2016 May;157(1):117–31. PMID:27083102
- 1681.** Qian F, Wang S, Mittelman J, et al. Height and body mass index as modifiable risk factors of breast cancer risk in BRCA1 carriers: a Mendelian randomization study. *Natl Cancer Inst.* 2019 Apr 1;111(7):725–33. PMID:30312457
- 1682.** Quesada AE, Medeiros LI, D'Amico MV, et al. Breast implant-associated large cell lymphoma: a review. *Mod Pathol.* 2019 Feb;32(2):166–88. PMID:30354441
- 1683.** Quincey C, Raitt N, Bell J, et al. Intracytoplasmic lumina—a useful diagnostic feature of adenocarcinomas. *Histopathology.* 1991 Jul;19(1):83–7. PMID:1515947

1684. Quinn CM, Ostrowski JL. Cytological and architectural heterogeneity in ductal carcinoma *in situ* of the breast. *J Clin Pathol.* 1997 Jul;50(7):596–9. PMID:9306942
1685. Rabban JT, Sgroi DC. Sclerosing lesions of the breast. *Semin Diagn Pathol.* 2004 Feb;21(1):42–7. PMID:15074558
1686. Rabban JT, Swain RS, Zaloudek CJ, et al. Immunophenotypic overlap between adenoid cystic carcinoma and collagenous spherulosis of the breast: potential diagnostic pitfalls using myoepithelial markers. *Mod Pathol.* 2006 Oct;19(10):1351–7. PMID:16810311
1687. Rabbitte TH, Forster A, Larson R, et al. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation (12;16) in malignant liposarcoma. *Nat Genet.* 1993 Jun;4(2):175–80. PMID:7503811
1688. Racz JM, Degen AC. When does atypical ductal hyperplasia require surgical excision? *Surg Oncol Clin N Am.* 2018 Jan;27(1):23–32. PMID:29132563
1689. Radhi JM. Immunohistochemical analysis of pleomorphic lobular carcinoma: higher expression of p53 and chromogranin and lower expression of ER and PgR. *Histopathology.* 2000 Feb;36(2):156–60. PMID:10672061
1690. Ragazzi M, de Biasi D, Bettà CM, et al. Oncocytic carcinoma of the breast: frequency, morphology and follow-up. *Hum Pathol.* 2011 Feb;42(2):166–75. PMID:21111455
1691. Rageth CJ, O'Flynn EA, Comstock C, et al. First International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). *Breast Cancer Res Treat.* 2016 Sep;159(2):203–13. PMID:27522516
1692. Rageth CJ, Rubenov R, Bronz C, et al. Atypical ductal hyperplasia and the risk of underestimation: tissue sampling method, multifocality, and associated calcification significantly influence the diagnostic upgrade rate based on subsequent surgical specimens. *Breast Cancer.* 2019 Jul;26(4):452–8. PMID:30591993
1693. Rahman N, Seal S, Thompson D, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. *Nat Genet.* 2007 Feb;39(2):165–7. PMID:17200668
1694. Rahmani S, Turton P, Shaaban A, et al. Overview of gynecomastia in the modern era and the Leeds Gynaecomastia Investigation algorithm. *Breast J.* 2011 May-Jun;17(3):246–55. PMID:21477170
1695. Rainey JJ, Omenah D, Sumba PO, et al. Spatial clustering of endemic Burkitt's lymphoma in high-risk regions of Kenya. *Int J Cancer.* 2007 Jan 1;120(1):121–7. PMID:17019706
1696. Raj SD, Sahani VG, Adrada BE, et al. Pseudoangiomatous stromal hyperplasia of the breast: multimodality review with pathologic correlation. *Curr Probl Diagn Radiol.* 2017 Mar-Apr;46(2):130–5. PMID:26949063
1697. Rakha EA, Aleskandarany M, El-Sayed ME, et al. The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. *Eur J Cancer.* 2009 Jul;45(10):1780–7. PMID:19286369
1698. Rakha EA, Aleskandarany MA, Lee AH, et al. An approach to the diagnosis of spindle cell lesions of the breast. *Histopathology.* 2016 Jan;68(1):33–44. PMID:26768028
1699. Rakha EA, Aleskandarany MA, Samaka RM, et al. Pleomorphic adenoma-like tumour of the breast. *Histopathology.* 2016 Feb;68(3):405–10. PMID:26096183
1700. Rakha EA, Badve S, Eusebi V, et al. Breast lesions of uncertain malignant nature and limited metastatic potential: proposals to improve their recognition and clinical management. *Histopathology.* 2016 Jan;68(1):45–56. PMID:26348644
1701. Rakha EA, Coimbra ND, Hodi Z, et al. Immunoprofile of metaplastic carcinomas of the breast. *Histopathology.* 2017 May;70(6):975–85. PMID:28029685
1702. Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. *Cancer.* 2007 Jan 1;109(1):25–32. PMID:17147672
1703. Rakha EA, El-Sayed ME, Lee AH, et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. *J Clin Oncol.* 2008 Jul 1;26(19):3153–8. PMID:18490649
1704. Rakha EA, El-Sayed ME, Menon S, et al. Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast. *Breast Cancer Res Treat.* 2008 Sep;111(1):121–7. PMID:17929165
1705. Rakha EA, El-Sayed ME, Powe DG, et al. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. *Eur J Cancer.* 2008 Jan;44(1):73–83. PMID:18035533
1706. Rakha EA, Gandhi N, Climent F, et al. Encapsulated papillary carcinoma of the breast: an invasive tumor with excellent prognosis. *Am J Surg Pathol.* 2011 Aug;35(8):1093–103. PMID:21753694
1707. Rakha EA, Ho BC, Naik V, et al. Outcome of breast lesions diagnosed as lesion of uncertain malignant potential (B3) or suspicious of malignancy (B4) on needle core biopsy, including detailed review of epithelial atypia. *Histopathology.* 2011 Mar;58(4):626–32. PMID:21371081
1708. Rakha EA, Lee AH, Evans AJ, et al. Tubular carcinoma of the breast: further evidence to support its excellent prognosis. *J Clin Oncol.* 2010 Jan 1;28(1):99–104. PMID:19917872
1709. Rakha EA, Lee AH, Jenkins JA, et al. Characterization and outcome of breast needle core biopsy diagnoses of lesions of uncertain malignant potential (B3) in abnormalities detected by mammographic screening. *Int J Cancer.* 2011 Sep 15;129(6):1417–24. PMID:21128240
1710. Rakha EA, Martin S, Lee AH, et al. The prognostic significance of lymphovascular invasion in invasive breast carcinoma. *Cancer.* 2012 Aug 1;118(15):3670–80. PMID:22180017
1711. Rakha EA, Miligy IM, Gorringe KL, et al. Invasion in breast lesions: the role of the epithelial-stroma barrier. *Histopathology.* 2018 Jun;72(7):1075–83. PMID:29197112
1712. Rakha EA, Patel A, Powe DG, et al. Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast. *Am J Surg Pathol.* 2010 Oct;34(10):1472–9. PMID:20871222
1713. Rakha EA, Putti TC, Abd El-Rehim DM, et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. *J Pathol.* 2006 Mar;208(4):495–506. PMID:16429394
1714. Rakha EA, Reis-Filho JS, Baehner F, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. *Breast Cancer Res.* 2010;12(4):207. PMID:20804570
1715. Rakha EA, Shaaban AM, Haider SA, et al. Outcome of pure mucocele-like lesions diagnosed on breast core biopsy. *Histopathology.* 2013 May;62(6):894–8. PMID:23402386
1716. Rakha EA, Tan PH, Varga Z, et al. Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study. *Br J Cancer.* 2015 Jan 20;112(2):283–9. PMID:25422911
1717. Rakha EA, van Deurzen CH, Paish EC, et al. Pleomorphic lobular carcinoma of the breast: Is it a prognostically significant pathological subtype independent of histological grade? *Mod Pathol.* 2013 Apr;26(4):496–501. PMID:23238630
1718. Rakha EA, Varga Z, Elsheik S, et al. High-grade encapsulated papillary carcinoma of the breast: an under-recognized entity. *Histopathology.* 2015 Apr;66(5):740–6. PMID:25382726
1719. Ramachandra S, Machin L, Ashley S, et al. Immunohistochemical distribution of c-erbB-2 in *in situ* breast carcinoma—a detailed morphological analysis. *J Pathol.* 1990 May;161(7):7–14. PMID:1973459
1720. Ramljak V, Sarcević B, Vrdoljak DV, et al. Fine needle aspiration cytology in diagnosing rare breast carcinoma—two case reports. *Coll Antropol.* 2010 Mar;34(1):201–5. PMID:20432752
1721. Ranade A, Batra R, Sandhu G, et al. Clinicopathological evaluation of 100 cases of mucinous carcinoma of breast with emphasis on axillary staging and special reference to a micropapillary pattern. *J Clin Pathol.* 2010 Dec;63(12):1043–7. PMID:20962055
1722. Rao P, Lahat G, Arnold C, et al. Angiosarcoma: a tissue microarray study with diagnostic implications. *Am J Dermatopathol.* 2013 Jun;35(4):432–7. PMID:23689692
1723. Rao P, Shousha S. Male nipple adenoma with DCIS followed 9 years later by invasive carcinoma. *Breast J.* 2010 May-Jun;16(3):317–8. PMID:20408826
1724. Rao VK, Weiss SW. Angiomyomatosis of soft tissue. An analysis of the histologic features and clinical outcome in 51 cases. *Am J Surg Pathol.* 1992 Aug;16(8):764–71. PMID:1497117
1725. Raphael M, Gentilhomme O, Tullez M, et al. Histopathologic features of high-grade non-Hodgkin's lymphomas in acquired immunodeficiency syndrome. *Arch Pathol Lab Med.* 1991 Jan;115(1):15–20. PMID:1987908
1726. Rasbridge SA, Gillett CE, Sampson SA, et al. Epithelial (E-) and placental (P-) cadherin cell adhesion molecule expression in breast carcinoma. *J Pathol.* 1993 Feb;169(2):245–50. PMID:8383197
1727. Rasbridge SA, Millis RR. Adenomyoepithelioma of the breast with malignant features. *Virchows Arch.* 1998 Feb;432(2):123–30. PMID:9504856
1728. Rasmussen BB, Rose C, Christensen IB. Prognostic factors in primary mucinous breast carcinoma. *Am J Clin Pathol.* 1987 Feb;87(2):155–60. PMID:3028120
1729. Rasmussen BB, Rose C, Thorpe SM, et al. Argyrophilic cells in 202 human mucinous breast carcinomas: Relation to histopathologic and clinical factors. *Am J Clin Pathol.* 1985 Dec;84(6):737–40. PMID:2416216
1730. Rathod J, Taori K, Disawal A, et al. A rare case of male primary breast lymphoma. *J Breast Cancer.* 2011 Dec;14(4):333–6. PMID:22323922
1731. Raut CP, Miceli R, Strauss DC, et al. External validation of a multi-institutional retroperitoneal sarcoma nomogram. *Cancer.* 2016 May 1;122(9):1417–24. PMID:26916507
1732. Rebbeck TR, Friebel TM, Friedman E, et al. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. *Hum Mutat.* 2018 May;39(5):593–620. PMID:29446198
1733. Rebbeck TR, Mitra N, Wan F, et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. *JAMA.* 2015 Apr 7;313(13):1347–61. PMID:25849179
1734. Recine MA, Deavers MT, Middleton LP, et al. Serous carcinoma of the ovary and peritoneum with metastases to the breast and axillary lymph nodes: a potential pitfall. *Am J Surg Pathol.* 2004 Dec;28(12):1646–51. PMID:15577686
1735. Reeves GK, Beral V, Green J, et al. Hormonal therapy for menopause and breast cancer risk by histological type: a cohort study and meta-analysis. *Lancet Oncol.* 2006 Nov;7(11):910–8. PMID:17081916
1736. Reeves GK, Pirie K, Green J, et al. Reproductive factors and specific histological types of breast cancer: prospective study and meta-analysis. *Br J Cancer.* 2009 Feb 10;100(3):538–44. PMID:19190634
1737. Regan MM, Francis PA, Pagani O, et al. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials. *J Clin Oncol.* 2016 Jul 1;34(19):2221–31. PMID:27044936
1738. Reid S, Schindler D, Hanenberg H, et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. *Nat Genet.* 2007 Feb;39(2):162–4. PMID:17200671
1739. Reinhardt F, Mathys B, Reinecke P, et al. Magnetic resonance imaging findings of high-grade ductal carcinoma *in situ* of the male breast: a case report. *SAGE Open Med Case Rep.* 2018 Jun 12;6:X18781727. PMID:29977557
1740. Reis-Filho JS, Faoro LN, Gasparetto EL, et al. Mammary epithelioid myofibroblastoma arising in bilateral gynecomastia: case report with immunohistochemical profile. *Int J Surg Pathol.* 2001 Oct;9(4):331–4. PMID:12574852
1741. Reis-Filho JS, Fulford LG, Crebassa B, et al. Collagenous spherulosis in an adenomyoepithelioma of the breast. *J Clin Pathol.* 2004 Jan;57(1):83–6. PMID:14693844
1742. Reis-Filho JS, Fulford LG, Lakhani SR, et al. Pathologic quiz case: a 62-year-old woman with a 4.5-cm nodule in the right breast. Lipid-rich breast carcinoma. *Arch Pathol Lab Med.* 2003 Sep;127(9):e396–8. PMID:12951994
1743. Reis-Filho JS, Lakhani SR. The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesions. *Breast Cancer Res.* 2003;5(6):313–9. PMID:14580249
1744. Reis-Filho JS, Milanezi F, Carvalho S, et al. Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic *in situ* hybridization analysis. *Breast Cancer Res.* 2005;7(6):R1028–35. PMID:16280056
1745. Reis-Filho JS, Milanezi F, Steele D, et al. Metaplastic breast carcinomas are basal-like tumours. *Histopathology.* 2006 Jul;49(1):10–21. PMID:16842242
1746. Reis-Filho JS, Natrajan R, Vatcheva R, et al. Is acinic cell carcinoma a variant of secretory carcinoma? A FISH study using ETV6 'split apart' probes. *Histopathology.* 2008 Jun;52(7):840–6. PMID:18462362
1747. Reis-Filho JS, Pinheiro C, Lambros MB, et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. *J Pathol.* 2006 Aug;209(4):445–53. PMID:16739104
1748. Reis-Filho JS, Simpson PT, Jones C, et al. Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. *J Pathol.* 2005 Sep;207(1):1–13. PMID:15957152
1749. Rekhtman N, Pietanza MC, Hellmann MD, et al. Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets. *Clin Cancer Res.*

- 2016 Jul 15;22(14):3618–29. PMID:26960398
- 1750.** Renault AL, Mebirouk N, Fuhrmann L, et al. Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers. *Breast Cancer Res.* 2018 Apr 17;20(1):28. PMID:29665859
- 1751.** Renaux-Petel M, Charbonnier F, Théry JC, et al. Contribution of de novo and mosaic TP53 mutations to Li-Fraumeni syndrome. *J Med Genet.* 2018 Mar;55(3):173–80. PMID:29070607
- 1752.** Rendi MH, Dintzis SM, Lehman CD, et al. Lobular in-situ neoplasia on breast core needle biopsy: imaging indication and pathologic extent can identify which patients require excisional biopsy. *Ann Surg Oncol.* 2012 Mar;19(3):914–21. PMID:21861212
- 1753.** Renshaw AA, Derhagopian RP, Martinez P, et al. Lobular neoplasia in breast core needle biopsy specimens is associated with a low risk of ductal carcinoma in situ or invasive carcinoma on subsequent excision. *Am J Clin Pathol.* 2006 Aug;126(2):310–3. PMID:16891208
- 1754.** Requena L, Kutzner H, Mentzel T, et al. Benign vascular proliferations in irradiated skin. *Am J Surg Pathol.* 2002 Mar;26(3):328–37. PMID:11859204
- 1755.** Resetkova E, Sahin A, Ayala AG, et al. Breast carcinoma with choriocarcinomatous features. *Ann Diagn Pathol.* 2004 Apr;8(2):74–9. PMID:15060884
- 1756.** Reusche R, Winocour S, Degnim A, et al. Diffuse dermal angiomyomatosis of the breast: a series of 22 cases from a single institution. *Gland Surg.* 2015 Dec;4(6):554–60. PMID:26645009
- 1757.** Reynolds RD, Pajak TF, Greenberg BR, et al. Lung cancer as a second primary. *Cancer.* 1978 Dec;42(6):2887–93. PMID:215300
- 1758.** Ribelles N, Santonja A, Pajares B, et al. The seed and soil hypothesis revisited: current state of knowledge of inherited genes on prognosis in breast cancer. *Cancer Treat Rev.* 2014 Mar;40(2):293–9. PMID:24112814
- 1759.** Ribrag V, Bibeau F, El Weshi A, et al. Primary breast lymphoma: a report of 20 cases. *Br J Haematol.* 2001 Nov;115(2):253–6. PMID:11703318
- 1760.** Richter J, Schlesner M, Hoffmann S, et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. *Nat Genet.* 2012 Dec;44(12):1316–20. PMID:23143595
- 1761.** Rieger-Johnson DL, Gleeson FC, Roberts M, et al. Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients. *Hered Cancer Clin Pract.* 2010 Jun 17;8(1):6. PMID:20565722
- 1762.** Riener MO, Nikolopoulos E, Herr A, et al. Microarray comparative genomic hybridization analysis of tubular breast carcinoma shows recurrent loss of the CDH13 locus on 16q. *Hum Pathol.* 2008 Nov;39(11):1621–9. PMID:18656243
- 1763.** Righi A, Lenzi M, Morandi L, et al. Adenoid cystic carcinoma of the breast associated with invasive duct carcinoma: a case report. *Int J Surg Pathol.* 2011 Apr;19(2):230–4. PMID:19233861
- 1764.** Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. *Mod Pathol.* 2018 Dec;31(12):1770–86. PMID:30140036
- 1765.** Ripamonti CB, Colombo M, Mondini P, et al. First description of an acinic cell carcinoma of the breast in a BRCA1 mutation carrier: a case report. *BMC Cancer.* 2013 Feb 1;13:46. PMID:23374397
- 1766.** Rissanen T, Tikkakoski T, Autio AL, et al. Ultrasonography of invasive lobular breast carcinoma. *Acta Radiol.* 1998 May;39(3):285–91. PMID:9571945
- 1767.** Rivandi M, Martens JWM, Hollestelle A. Elucidating the underlying functional mechanisms of breast cancer susceptibility through post-GWAS analyses. *Front Genet.* 2018 Aug 2;9:280. PMID:30116257
- 1768.** Rizzolo P, Silvestri V, Tommasi S, et al. Male breast cancer: genetics, epigenetics, and ethical aspects. *Ann Oncol.* 2013 Nov;24 Suppl 8:vii75–82. PMID:24131976
- 1769.** Ro JY, Silva EG, Gallagher HS. Adenoid cystic carcinoma of the breast. *Hum Pathol.* 1987 Dec;18(12):1276–81. PMID:2824330
- 1770.** Robbe P, Popitsch N, Knight SJL, et al. Clinical whole-genome sequencing from routine formalin-fixed, paraffin-embedded specimens: pilot study for the 100,000 Genomes Project. *Genet Med.* 2018 Oct;20(10):1196–205. PMID:29388947
- 1771.** Robbiani DF, Deroubaix S, Feldhahn N, et al. Plasmodium infection promotes genomic instability and AID-dependent B cell lymphoma. *Cell.* 2015 Aug 13;162(4):727–37. PMID:26276629
- 1772.** Robens J, Goldstein L, Gown AM, et al. Thyroid transcription factor-1 expression in breast carcinomas. *Am J Surg Pathol.* 2010 Dec;34(12):1881–5. PMID:21107096
- 1773.** Roberts NJ, Jiao Y, Yu J, et al. ATM mutations in patients with hereditary pancreatic cancer. *Cancer Discov.* 2012 Jan;2(1):41–6. PMID:22585167
- 1773A.** Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. *N Engl J Med.* 2017 Aug 10;377(6):523–33. PMID:28578601
- 1773B.** Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. *Ann Oncol.* 2019 Apr 1;30(4):558–66. PMID:30689707
- 1774.** Roden AC, Macon WR, Keeney GL, et al. Seroma-associated primary anaplastic large-cell lymphoma adjacent to breast implants: an indolent T-cell lymphoproliferative disorder. *Mod Pathol.* 2008 Apr;21(4):455–63. PMID:18223553
- 1776.** Rogers D, Karki C, Bartlett C, et al. The motor disorders of mental handicap. An overlap with the motor disorders of severe psychiatric illness. *Br J Psychiatry.* 1991 Jan;158:97–102. PMID:205458
- 1777.** Rohayem J, Nieschlag E, Zitzmann M, et al. Testicular function during puberty and young adulthood in patients with Klinefelter's syndrome with and without spermatozoa in seminal fluid. *Andrology.* 2016 Nov;4(6):1178–86. PMID:27611179
- 1778.** Rohen C, Caselitz J, Stern C, et al. A hamartoma of the breast with an aberration of 12q mapped to the MAR region by fluorescence in situ hybridization. *Cancer Genet Cytogenet.* 1995 Oct 1;84(1):82–4. PMID:749740
- 1779.** Roithmann S, Toledo M, Tourani JM, et al. HIV-associated non-Hodgkin's lymphomas: clinical characteristics and outcome. The experience of the French Registry of HIV-Associated Tumors. *Ann Oncol.* 1991 Apr;2(4):289–95. PMID:1868025
- 1780.** Rombouts AJM, Huising J, Hugen N, et al. Assessment of radiotherapy-associated angiosarcoma after breast cancer treatment in a Dutch population-based study. *JAMA Oncol.* 2019 Feb 1;5(2):267–9. PMID:30676608
- 1780A.** Romero P, Benhamo V, Deniziatu G, et al. Medullary breast carcinoma, a triple-negative breast cancer associated with BCLG overexpression. *Am J Pathol.* 2018 Oct;188(10):2378–91. PMID:30075151
- 1781.** Roncaroli F, Lamovic J, Zidar A, et al. Acinic cell-like carcinoma of the breast. *Virchows Arch.* 1996 Sep;429(1):69–74. PMID:8865856
- 1782.** Rosa M, Masood S. Cytomorphology of male breast lesions: diagnostic pitfalls and clinical implications. *Diagn Cytopathol.* 2012 Feb;40(2):179–84. PMID:22246937
- 1783.** Rosa M, Mohammadi A, Masood S. Lobular carcinoma of the breast with extracellular mucin: new variant of mucin-producing carcinomas? *Pathol Int.* 2009 Jun;59(6):405–9. PMID:19490472
- 1784.** Rosai J. Borderline epithelial lesions of the breast. *Am J Surg Pathol.* 1991 Mar;15(3):209–21. PMID:1847606
- 1785.** Rosen PP. Adenomyoepithelioma of the breast. *Hum Pathol.* 1987 Dec;18(12):1232–7. PMID:2824328
- 1786.** Rosen PP. Syringomatous adenoma of the nipple. *Am J Surg Pathol.* 1983 Dec;7(8):739–45. PMID:6660349
- 1787.** Rosen PP. Vascular tumors of the breast. III. Angiomyomatosis. *Am J Surg Pathol.* 1985 Sep;9(9):652–8. PMID:4051097
- 1788.** Rosen PP. Vascular tumors of the breast. V. Nonparenchymal hemangiomas of mammary subcutaneous tissues. *Am J Surg Pathol.* 1985 Oct;9(10):723–9. PMID:4061730
- 1789.** Rosen PP, Caicco JA. Florid papillomatosis of the nipple. A study of 51 patients, including nine with mammary carcinoma. *Am J Surg Pathol.* 1986 Feb;10(2):87–101. PMID:3006526
- 1790.** Rosen PP, Cranor ML. Secretory carcinoma of the breast. *Arch Pathol Lab Med.* 1991 Feb;115(2):141–4. PMID:1992979
- 1791.** Rosen PP, editor. *Rosen's breast pathology.* 3rd ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2008.
- 1792.** Rosen PP, Ernsberger D. Mammary fibromatosis. A benign spindle-cell tumor with significant risk for local recurrence. *Cancer.* 1989 Apr 1;63(7):1363–9. PMID:2920364
- 1793.** Rosen PP, Jozefczyk MA, Boram LH. Vascular tumors of the breast. IV. The venous hemangioma. *Am J Surg Pathol.* 1985 Sep;9(9):659–65. PMID:4051098
- 1794.** Rosen PP, Kimmel M, Ernsberger D. Mammary angiосарcoma. The prognostic significance of tumor differentiation. *Cancer.* 1988 Nov 15;62(10):2145–51. PMID:3179927
- 1795.** Rosen PP, Kosloff C, Lieberman PH, et al. Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients with average follow-up of 24 years. *Am J Surg Pathol.* 1978 Sep;2(3):225–51. PMID:210682
- 1796.** Rosen PP, Ridolfi RL. The periblobular hemangioma. A benign microscopic vascular lesion of the breast. *Am J Clin Pathol.* 1977 Jul;68(1):21–3. PMID:868802
- 1797.** Rosen PP, Senie R, Schottenfeld D, et al. Noninvasive breast carcinoma: frequency of unsuspected invasion and implications for treatment. *Ann Surg.* 1979 Mar;189(3):377–82. PMID:218506
- 1798.** Rosenbohm A, Hirsch S, Volk AE, et al. The metabolic and endocrine characteristics in spinal and bulbar muscular atrophy. *J Neurol.* 2018 May;265(5):1026–36. PMID:29464380
- 1799.** Rosolen A, Perkins SL, Pinkerton CR, et al. Revised international pediatric non-Hodgkin lymphoma staging system. *J Clin Oncol.* 2015 Jun 20;33(18):2112–8. PMID:25940716
- 1800.** Ross DS, Giri DD, Akram MM, et al. Fibroepithelial lesions in the breast of adolescent females: a clinicopathological study of 54 cases. *Breast J.* 2017 Mar;23(2):182–92. PMID:28299887
- 1801.** Ross DS, Hoda SA. Microinvasive (T1mic) lobular carcinoma of the breast: clinicopathologic profile of 16 cases. *J Surg Pathol.* 2011 May;124(5):709–11. PMID:21415700
- 1802.** Ross JS, Gay LM, Wang K, et al. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: an emerging opportunity for HER2 targeted therapies. *Cancer.* 2011 May;124(17):2654–62. PMID:22784056
- 1803.** Rosso R, Scelsi M, Camewell L. Mammary cell traumatic neuroma: a lesion occurring in mastectomy scars. *Arch Pathol Lab Med.* 1984 May;124(5):709–11. PMID:6782582
- 1804.** Rossouw JE, Anderson GL, Phillips RL, et al. Risks and benefits of estrogen/progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. *2002 Jul 17;288(3):321–33.* PMID:12173534
- 1805.** Rothblum-Ovitt C, Wright J, Greif MA, et al. Ataxia telangiectasia and the Orphanet J Rare Dis. 2016 Nov 20;7(1):16. PMID:27884168
- 1806.** Rowe JJ, Cheah AL, Chua BC. Lipomatous tumors of the breast: a contemporary review. *Semin Diagn Pathol.* 2017 Sep;34(5):453–61. PMID:28752200
- 1807.** Royal College of Pathologists. London (UK): Royal College of Pathologists; 2019. Cancer datasets and tissue pathways. Available from: <https://www.rcpath.org/profession/guidelines/cancer-datasets/tissue-pathways.html>.
- 1808.** Rozan S, Vincent-Salomon A, et al. No significant predictive value of p53 or p53 expression regarding primary chemotherapy or radiotherapy for cancer. *Int J Cancer.* 1998 Feb 20;76(4):535–40. PMID:9495354
- 1809.** Rudas M, Neumayer R, Gruber A, et al. p53 protein expression, cell proliferation, steroid hormone receptors induction and in situ carcinomas of the breast. *Eur J Cancer.* 1997 Jan;33(1):39–44. PMID:9030570
- 1810.** Ruddy KJ, Winer EP, et al. Risk factors, biology, diagnosis, and survivorship. *Ann Oncol.* 2013 Jun;24(6):143–53. PMID:23425944
- 1811.** Ruffolo EF, Koerner RJ, et al. Metaplastic carcinoma of the breast: a rare form of melanocytic differentiation. *World J Surg.* 1995 Jun;19(6):592–6. PMID:9195577
- 1812.** Rugo HS, Olopade OI, et al. Adaptive randomization of letrozole versus tamoxifen treatment in breast cancer. *N Engl J Med.* 2007 Jul 7;357(1):23–34. PMID:17404647
- 1813.** Rungra S, Kleer CG, et al. Carcinomas of the breast: diagnosis and new translational insights. *Am J Pathol.* 2012 Aug;181(2):333–40. PMID:22849737
- 1814.** Ryan G, Martinelli G, et al. Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcome of a study by the International Lymphoma Study Group. *Am J Clin Pathol.* 2000 Feb;153(2):233–41. PMID:10702294
- 1815.** Saad RS, Richmond L, et al. Fine-needle aspiration biopsy of breast adenomyoepithelioma: a positive pitfall and presence of cytoplasmic inclusions. *Diagn Cytopathol.* 2000 Nov;24(11):1005–9. PMID:11074817
- 1816.** Sadanaga N, Okada S, et al. Clinical characteristics of small cell carcinoma of the breast. *Oncol Rep.* 2008 Apr;20(4):1037–42. PMID:18357385
- 1817.** Saglam A, Can B, et al. Lactating adenoma and immunoadenocarcinoma of the breast in a woman. *J Clin Pathol.* 2005 Jan;58(1):103–5.

PMID:15623491

1818. Sahin S, Karatas F, Erdem GU, et al. Invasive pleomorphic lobular histology is an adverse prognostic factor on survival in patients with breast cancer. *Am Surg.* 2017 Apr 1;83(4):359–64. PMID:28424130
1819. Sahoo S, Green I, Rosen PP. Bilateral Paget disease of the nipple associated with lobular carcinoma in situ. *Arch Pathol Lab Med.* 2002 Jan;126(1):90–2. PMID:11800657
1820. Said SM, Visscher DW, Nassar A, et al. Flat epithelial atypia and risk of breast cancer: a Mayo cohort study. *Cancer.* 2015 May 15;121(10):1548–55. PMID:25639678
1821. Sai-Giridhar P, Al-Ramadhan S, George D, et al. A multicentre validation of Metasin: a molecular assay for the intraoperative assessment of sentinel lymph nodes from breast cancer patients. *Histopathology.* 2016 May;68(6):875–87. PMID:26383172
1822. Saimura M, Anan K, Mitsuyama S, et al. Ductal carcinoma in situ arising in tubular adenoma of the breast. *Breast Cancer.* 2015 Jul;22(4):428–31. PMID:22700460
1823. Saito T, Ryu M, Fukumura Y, et al. A case of myxoid liposarcoma of the breast. *Int J Clin Exp Pathol.* 2013 Jun 15;6(7):1432–6. PMID:23826427
1824. Sakharpe A, Lahat G, Gulamhusein T, et al. Epithelioid sarcoma and unclassified sarcoma with epithelioid features: clinicopathological variables, molecular markers, and a new experimental model. *Oncologist.* 2011;16(4):512–22. PMID:2135725
1825. Sakr RA, Schizas M, Carniello JV, et al. Targeted capture massively parallel sequencing analysis of LCIS and invasive lobular cancer: repertoire of somatic genetic alterations and clonal relationships. *Mol Oncol.* 2016 Feb;10(2):360–70. PMID:26643573
1826. Sakuma T, Mimura A, Tanigawa N, et al. Fine needle aspiration cytology of acinic cell carcinoma of the breast. *Cytopathology.* 2013 Dec;24(6):403–5. PMID:22734799
1827. Sakuma T, Mori M, Kokubo C, et al. Cytology of breast pleomorphic adenoma associated with extensive apocrine metaplasia. *Diagn Cytopathol.* 2018 Jan;46(1):56–8. PMID:28994509
1828. Salemis NS. Florid papillomatosis of the nipple: a rare presentation and review of the literature. *Breast Dis.* 2015;35(2):153–6. PMID:25585841
1829. Salemis NS, Gemenetzis G, Karagiouzis G, et al. Tubular adenoma of the breast: a rare presentation and review of the literature. *J Clin Med Res.* 2012 Feb;4(1):64–7. PMID:22383931
1830. Salgado R, Denkert C, Campbell C, et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial. *JAMA Oncol.* 2015 Jul;1(4):448–54. PMID:26181252
1831. Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. *Ann Oncol.* 2015 Feb;26(2):259–71. PMID:25214542
1832. Salhany KE, Page DL. Fine-needle aspiration of mammary lobular carcinoma in situ and atypical lobular hyperplasia. *Am J Clin Pathol.* 1989 Jul;92(1):22–6. PMID:2750704
1833. Samani NJ, Erdmann J, Hall AS, et al. Genomewide association analysis of coronary artery disease. *N Engl J Med.* 2007 Aug 2;357(5):443–53. PMID:17634449
1834. Sander S, Calado DP, Srinivasan L, et al. Synergy between PI3K signaling and MYC

- in Burkitt lymphomagenesis. *Cancer Cell.* 2012 Aug 14;22(2):167–79. PMID:22897848
1836. Sanders MA, Brock JE, Harrison BT, et al. Nipple-invasive primary carcinomas: clinical, imaging, and pathologic features of breast carcinomas originating in the nipple. *Arch Pathol Lab Med.* 2018 May;142(5):598–605. PMID:29431468
1837. Sanders MA, Dominici L, Denison C, et al. Paget disease of the breast with invasion from nipple skin into the dermis: an unusual type of skin invasion not associated with an adverse outcome. *Arch Pathol Lab Med.* 2013 Jan;137(1):72–6. PMID:23276177
1838. Sanders ME, Schuyler PA, Simpson JF, et al. Continued observation of the natural history of low-grade ductal carcinoma in situ reaffirms proclivity for local recurrence even after more than 30 years of follow-up. *Mod Pathol.* 2015 May;28(5):662–9. PMID:25502729
1839. Sandison AT. Metastatic tumours in the breast. *Br J Surg.* 1959 Jul;47:54–8. PMID:14441414
1840. Sangi AR, Shrestha B, Yang G, et al. The novel marker GATA3 is significantly more sensitive than traditional markers mammaglobin and GCDFP15 for identifying breast cancer in surgical and cytology specimens of metastatic and matched primary tumors. *Appl Immunohistochem Mol Morphol.* 2016 Apr;24(4):229–37. PMID:25906123
1841. Sapino A, Papotti M, Pietribiasi F, et al. Diagnostic cytological features of neuroendocrine differentiated carcinoma of the breast. *Virchows Arch.* 1998 Sep;433(3):217–22. PMID:9769124
1842. Sapino A, Papotti M, Righi L, et al. Clinical significance of neuroendocrine carcinoma of the breast. *Ann Oncol.* 2001;12 Suppl 2:S115–7. PMID:11762336
1843. Sapino A, Righi L, Cassoni P, et al. Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women. *Mod Pathol.* 2001 Aug;14(8):768–76. PMID:11504836
1844. Sapino A, Righi L, Cassoni P, et al. Expression of the neuroendocrine phenotype in carcinomas of the breast. *Semin Diagn Pathol.* 2000 May;17(2):127–37. PMID:10839613
1845. Sapino A, Roepman P, Linn SC, et al. MammaPrint molecular diagnostics on formalin-fixed, paraffin-embedded tissue. *J Mol Diagn.* 2014 Mar;16(2):190–7. PMID:24378251
1846. Sarrió D, Moreno-Bueno G, Hardisson D, et al. Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. *Int J Cancer.* 2003 Aug 20;106(2):208–15. PMID:12800196
1847. Sarrió D, Pérez-Mies B, Hardisson D, et al. Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. *Oncogene.* 2004 Apr 22;23(19):3272–83. PMID:15077190
1848. Castre-Garau X, Jouve M, Asselain B, et al. Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. *Cancer.* 1996 Jan 1;77(1):113–20. PMID:8630916
1849. Satou A, Asano N, Nakazawa A, et al. Epstein-Barr virus (EBV)-positive sporadic Burkitt lymphoma: an age-related lymphoproliferative disorder? *Am J Surg Pathol.* 2015 Feb;39(2):227–35. PMID:25231330
1850. Sau P, Solis J, Lupton GP, et al. Pigmented breast carcinoma. A clinical and histopathologic simulator of malignant melanoma. *Arch Dermatol.* 1989 Apr;125(4):536–9. PMID:2930211
1851. Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. *Science.* 1995 Jun 23;268(5218):1749–53. PMID:7792600
1852. Sawhney N, Garrahan N, Douglas-Jones AG, et al. Epithelial-stromal interactions in tumors. A morphologic study of fibroepithelial tumors of the breast. *Cancer.* 1992 Oct 15;70(8):2115–20. PMID:1327488
1853. Sawyer E, Roylance R, Petridis C, et al. Genetic predisposition to in situ and invasive lobular carcinoma of the breast. *PLoS Genet.* 2014 Apr 17;10(4):e1004285. PMID:24743323
1854. Sawyer EJ, Hanby AM, Poulsom R, et al. Beta-catenin abnormalities and associated insulin-like growth factor overexpression are important in phyllodes tumours and fibroadenomas of the breast. *J Pathol.* 2003 Aug;200(5):627–32. PMID:12898599
1855. Sawyer EJ, Hanby AM, Rowan AJ, et al. The Wnt pathway, epithelial-stromal interactions, and malignant progression in phyllodes tumours. *J Pathol.* 2002 Apr;196(4):437–44. PMID:11920740
1856. Sawyer S, Mitchell G, McKinley J, et al. A role for common genomic variants in the assessment of familial breast cancer. *J Clin Oncol.* 2012 Dec 10;30(35):4330–6. PMID:23109704
1857. Scheffzek K, Ahmadian MR, Wiesmüller L, et al. Structural analysis of the GAP-related domain from neurofibromin and its implications. *EMBO J.* 1998 Aug 3;17(15):4313–27. PMID:9687500
1858. Scheffel K, Van Goethem M, Kersschot E, et al. Preoperative breast MRI in patients with invasive lobular breast cancer. *Eur Radiol.* 2004 Jul;14(7):1209–16. PMID:15024602
1859. Schmidt P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. *N Engl J Med.* 2018 Nov 29;379(22):2108–21. PMID:30345906
1860. Schmidt MK, Hogervorst F, van Hien R, et al. Age- and tumor subtype-specific breast cancer risk estimates for CHEK2*1100delC carriers. *J Clin Oncol.* 2016 Aug 10;34(23):2750–60. PMID:27269948
1861. Schmidt MK, Tollenaar RA, de Kemp SR, et al. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. *J Clin Oncol.* 2007 Jan 1;25(1):64–9. PMID:17132695
1862. Schmitt FC, Reis-Filho JS. Oncogenes, granules and breast cancer: What has c-myc to do with apocrine changes? *Breast.* 2002 Dec;11(6):463–5. PMID:14965710
1863. Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. *Nature.* 2012 Oct 4;490(7418):116–20. PMID:22885699
1864. Schnitt SJ. Benign breast disease and breast cancer risk: morphology and beyond. *Am J Surg Pathol.* 2003 Jun;27(6):836–41. PMID:12766590
1865. Schnitt SJ. Clinging carcinoma: an American perspective. *Semin Diagn Pathol.* 2010 Feb;27(1):31–6. PMID:20306828
1866. Schnitt SJ. Spindle cell lesions of the breast. *Surg Pathol Clin.* 2009 Jun;2(2):375–90. PMID:26838327
1867. Schnitt SJ, Connolly JL. Processing and evaluation of breast excision specimens. A clinically oriented approach. *Am J Clin Pathol.* 1992 Jul;98(1):125–37. PMID:1615916
1868. Schnitt SJ, Connolly JL, Tavassoli FA, et al. Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria. *Am J Surg Pathol.* 1992 Dec;16(12):1133–43. PMID:1463092
1869. Schnitt SJ, Morrow M. Lobular carcinoma in situ: current concepts and controversies. *Semin Diagn Pathol.* 1999 Aug;16(3):209–23. PMID:10490198
1870. Schnitt SJ, Vincent-Salomon A. Columnar cell lesions of the breast. *Adv Anat Pathol.* 2003 May;10(3):113–24. PMID:12717115
1871. Schoenmakers EF, Wanschura S, Mols R, et al. Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. *Nat Genet.* 1995 Aug;10(4):436–44. PMID:7670494
1872. Scholtens R, Kreuz M, Klapper W, et al. Detection of genomic aberrations in molecularly defined Burkitt's lymphoma by array-based, high resolution, single nucleotide polymorphism analysis. *Haematologica.* 2010 Dec;95(12):2047–55. PMID:20823134
1873. Schon K, Tischkowitz M. Clinical implications of germline mutations in breast cancer: TP53. *Breast Cancer Res Treat.* 2018 Jan;167(2):417–23. PMID:29039119
1874. Schoolmeester JK, Lastra RR. Granular cell tumors overexpress TFE3 without corollary gene rearrangement. *Hum Pathol.* 2015 Aug;46(8):1242–3. PMID:26009539
1875. Schoolmeester JK, Moyer AM, Goodenberger ML, et al. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2. *Hum Pathol.* 2017 Dec;70:14–26. PMID:28709830
1876. Schrader KA, Masciarelli S, Boyd N, et al. Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. *J Med Genet.* 2011 Jan;48(1):64–8. PMID:20921021
1877. Schrader KA, Nelson TN, De Luca A, et al. Multiple granular cell tumors are an associated feature of LEOPARD syndrome caused by mutation in PTPN11. *Clin Genet.* 2009 Feb;75(2):185–9. PMID:19054014
1878. Schrager CA, Schneider D, Gruener AC, et al. Clinical and pathological features of breast disease in Cowden's syndrome: an underrecognized syndrome with an increased risk of breast cancer. *Hum Pathol.* 1998 Jan;29(1):47–53. PMID:9445133
1879. Schroeder MC, Rastogi P, Geyer CE Jr, et al. Early and locally advanced metaplastic breast cancer: presentation and survival by receptor status in Surveillance, Epidemiology, and End Results (SEER) 2010–2014. *Oncologist.* 2018 Apr;23(4):481–8. PMID:2930212
1880. Schwartz GF, Patchefsky AS, Finklestein SD, et al. Nonpalpable in situ ductal carcinoma of the breast. Predictors of multicentricity and microinvasion and implications for treatment. *Arch Surg.* 1989 Jan;124(1):29–32. PMID:2535928
1881. Schwenther L, Kurzeder C, Kreienberg R, et al. Focus on haematogenous dissemination of the malignant cystosarcoma phyllodes: institutional experience. *Arch Gynecol Obstet.* 2011 Mar;283(3):591–6. PMID:21069366
1882. Scoggins M, Krishnamurthy S, Santiago L, et al. Lobular carcinoma in situ of the breast: clinical, radiological, and pathological correlation. *Acad Radiol.* 2013 Apr;20(4):463–70. PMID:23498988
1883. Scolyer RA, McKenzie PR, Ahmed D, et al. Can phyllodes tumours of the breast be distinguished from fibroadenomas using fine needle aspiration cytology? *Pathology.* 2001 Nov;33(4):437–43. PMID:11827409
1884. Scopsi L, Andreola S, Pilotti S, et al. Mucinous carcinoma of the breast. A clinicopathologic, histochemical, and

- immunocytochemical study with special reference to neuroendocrine differentiation. *Am J Surg Pathol.* 1994 Jul;18(7):702–11. PMID:8017565
1885. Screening & Immunisations Team, NHS Digital. NHS Breast Screening Programme: England 2016–17. Leeds (UK): Health and Social Care Information Centre; 2018 Jan 31 [updated 2018 Apr 4, cited 2018 Oct 11]. Available from: https://files.digital.nhs.uk/pdf/m/f/breast_screening_programme_england_2016-17_-report_v2.pdf.
1886. Sebastiani C, Gennaro L, Brogi E, et al. Benign vascular lesions of the breast diagnosed by core needle biopsy do not require excision. *Histopathology.* 2017 Nov;71(5):795–804. PMID:28644513
1887. Seethala RR, Hunt JL, Baloch ZW, et al. Adenoid cystic carcinoma with high-grade transformation: a report of 11 cases and a review of the literature. *Am J Surg Pathol.* 2007 Nov;31(11):1683–94. PMID:18059225
1888. Seifert G. Are adenomyoepithelioma of the breast and epithelial-myoepithelial carcinoma of the salivary glands identical tumours? *Virchows Arch.* 1998 Sep;433(3):285–8. PMID:9769134
1889. Sek P, Zawrocki A, Biernat W, et al. HER2 molecular subtype is a dominant subtype of mammary Paget's cells. An immunohistochemical study. *Histopathology.* 2010 Oct;57(4):564–71. PMID:20955381
1890. Sekimizu M, Yoshida A, Mitani S, et al. Frequent mutations of genes encoding vacuolar H⁺-ATPase components in granular cell tumors. *Genes Chromosomes Cancer.* 2019 Jun;58(6):373–80. PMID:30597645
1891. Selim AG, El-Ayat G, Naase M, et al. C-myc oncogene expression and gene amplification in apocrine metaplasia and apocrine change within sclerosing adenosis of the breast. *Breast.* 2002 Dec;11(6):466–72. PMID:14965711
1892. Selim AG, El-Ayat G, Wells CA, c-erbB2 oncogene expression, gene amplification, and chromosome 17 aneusomy in apocrine adenosis of the breast. *J Pathol.* 2000 Jun;191(2):138–42. PMID:10861572
1893. Selim AG, Ryan A, El-Ayat GA, et al. Loss of heterozygosity and allelic imbalance in apocrine adenosis of the breast. *Cancer Detect Prev.* 2001;25(3):262–7. PMID:11425268
1894. Selinko VL, Middleton LP, Dempsey PJ. Role of sonography in diagnosing and staging invasive lobular carcinoma. *J Clin Ultrasound.* 2004 Sep;32(7):323–32. PMID:15293298
1895. Seminoğlu OO, Goldacre MJ. Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neurofibromatosis: population-based record-linkage study. *Br J Cancer.* 2013 Jan 15;108(1):193–8. PMID:23257896
1896. Sengupta S, Pal S, Biswas BK, et al. Evaluation of clinic-radio-pathological features of tubular adenoma of breast: a study of ten cases with histopathological differential diagnosis. *Iran J Pathol.* 2015 Winter;10(1):17–22. PMID:26516321
1897. Sengupta S, Pal S, Biswas BK, et al. Preoperative diagnosis of tubular adenoma of breast - 10 years of experience. *N Am J Med Sci.* 2014 May;6(5):219–23. PMID:24926447
1898. Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2015 Sep;26 Suppl 5:v8–30. PMID:26314782
1899. Senkus E, Kyriakides S, Penault-Llorca F, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2013 Oct;24 Suppl 6:v17–23. PMID:23970019
1900. Sentani K, Tashiro T, Uraoka N, et al. Primary mammary mucinous cystadenocarcinoma: cytological and histological findings. *Diagn Cytopathol.* 2012 Jul;40(7):624–8. PMID:21472867
1901. Seo IS, Min KW. Postirradiation epithelioid angiosarcoma of the breast: a case report with immunohistochemical and electron microscopic study. *Ultrastruct Pathol.* 2003 May-Jun;27(3):197–203. PMID:12775509
1902. Seong M, Ko EY, Han BK, et al. Radiologic findings of primary mucinous cystadenocarcinoma of the breast: a report of two cases and a literature review. *J Breast Cancer.* 2016 Sep;19(3):330–3. PMID:27721884
1903. Severson TM, Zwart W. A review of estrogen receptor/androgen receptor genomics in male breast cancer. *Endocr Relat Cancer.* 2017 Mar;24(3):R27–34. PMID:28062545
1904. Sevim Y, Kocaay AF, Eker T, et al. Breast hamartoma: a clinicopathologic analysis of 27 cases and a literature review. *Clinics (Sao Paulo).* 2014 Aug;69(8):515–23. PMID:25141109
1905. Shaaban AM, Ball GR, Brannan RA, et al. A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences. *Breast Cancer Res Treat.* 2012 Jun;133(3):949–58. PMID:22094935
1906. Shabaik A, Lin G, Peterson M, et al. Reliability of Her2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma. *Diagn Cytopathol.* 2011 May;39(5):328–32. PMID:21488175
1907. Shah V, Nowinski S, Levi D, et al. PIK3CA mutations are common in lobular carcinoma *in situ*, but are not a biomarker of progression. *Breast Cancer Res.* 2017 Jan 17;19(1):7. PMID:28095868
1908. Shah-Khan MG, Geiger XJ, Reynolds C, et al. Long-term follow-up of lobular neoplasia (atypical lobular hyperplasia/lobular carcinoma *in situ*) diagnosed on core needle biopsy. *Ann Surg Oncol.* 2012 Oct;19(10):3131–8. PMID:22847124
1909. Shakya R, Reid LJ, Reczek CR, et al. BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity. *Science.* 2011 Oct 28;334(6055):525–8. PMID:22034435
1910. Shamir ER, Chen YY, Chu T, et al. Pleomorphic and florid lobular carcinoma *in situ* variants of the breast: a clinicopathologic study of 85 cases with and without invasive carcinoma from a single academic center. *Am J Surg Pathol.* 2019 Mar;43(3):399–408. PMID:30489319
1911. Sharif S, Moran A, Huson SM, et al. Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. *J Med Genet.* 2007 Aug;44(8):481–4. PMID:17369502
1912. Sharma-Oates A, Shaaban AM, Tomlinson I, et al. Heterogeneity of germline variants in high risk breast and ovarian cancer susceptibility genes in India. *Precis Clin Med.* 2018 Sep;1(2):75–87. doi:10.1093/pcmed/pby010.
1913. Sheffield BS, Kos Z, Asheh-Aburaya K, et al. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor. *Breast Cancer Res Treat.* 2016 Feb;155(3):483–90. PMID:26846986
1914. Shehata BM, Fishman I, Collings MH, et al. Pseudoangiomatous stromal hyperplasia of the breast in pediatric patients: an underrecognized entity. *Pediatr Dev Pathol.* 2009 Nov-Dec;12(6):450–4. PMID:19606909
1915. Sher T, Hennessy BT, Valero V, et al. Primary angiosarcomas of the breast. *Cancer.* 2007 Jul 1;110(1):173–8. PMID:17541936
1916. Sheth NA, Saruiya JN, Ranadive KJ, et al. Ectopic production of human chorionic gonadotrophin by human breast tumours. *Br J Cancer.* 1974 Dec;30(6):566–70. PMID:4374964
1917. Shi P, Wang M, Zhang Q, et al. Lipid-rich carcinoma of the breast. A clinicopathological study of 49 cases. *Tumori.* 2008 May-Jun;94(3):342–6. PMID:18705401
1918. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. *Nat Rev Cancer.* 2003 Mar;3(3):155–68. PMID:12612651
1919. Shimao K, Haga S, Shimizu T, et al. Acinic cell adenocarcinoma arising in the breast of a young male: a clinicopathological, immunohistochemical and ultrastructural study. *Breast Cancer.* 1998 Jun 30;5(1):77–81. PMID:11091630
1920. Shin C, Low I, Ng D, et al. USP6 gene rearrangement in nodular fasciitis and histological mimics. *Histopathology.* 2016 Nov;69(5):784–91. PMID:27271298
1921. Shin HJ, Kim HH, Kim SM, et al. Pure and mixed tubular carcinoma of the breast: mammographic and sonographic differential features. *Korean J Radiol.* 2007 Mar-Apr;8(2):103–10. PMID:17420627
1922. Shin SJ, DeLellis RA, Ying L, et al. Small cell carcinoma of the breast: a clinicopathologic and immunohistochemical study of nine patients. *Am J Surg Pathol.* 2000 Sep;24(9):1231–8. PMID:10976697
1923. Shin SJ, Kanomata N, Rosen PP. Mammary carcinoma with prominent cytoplasmic lipofuscin granules mimicking melanocytic differentiation. *Histopathology.* 2000 Nov;37(5):456–9. PMID:11119128
1924. Shin SJ, Lal A, De Vries S, et al. Florid lobular carcinoma *in situ*: molecular profiling and comparison to classic lobular carcinoma *in situ* and pleomorphic lobular carcinoma *in situ*. *Hum Pathol.* 2013 Oct;44(10):1998–2009. PMID:23809857
1925. Shin SJ, Rosen PP. Excisional biopsy should be performed if lobular carcinoma *in situ* is seen on needle core biopsy. *Arch Pathol Lab Med.* 2002 Jun;126(6):697–701. PMID:12033958
1926. Shin SJ, Rosen PP. Solid variant of mammary adenoid cystic carcinoma with basaloid features: a study of nine cases. *Am J Surg Pathol.* 2002 Apr;26(4):413–20. PMID:11914618
1927. Shin SJ, Sheikh FS, Allenby PA, et al. Invasive secretory (juvenile) carcinoma arising in ectopic breast tissue of the axilla. *Arch Pathol Lab Med.* 2001 Oct;125(10):1372–4. PMID:11570920
1928. Shin SJ, Simpson PT, Da Silva L, et al. Molecular evidence for progression of microglandular adenosis (MGA) to invasive carcinoma. *Am J Surg Pathol.* 2009 Apr;33(4):496–504. PMID:19047897
1929. Shintaku M, Yamamoto Y, Kono F, et al. Chondrolioma of the breast as a rare variant of myofibroblastoma: an immunohistochemical study of two cases. *Virchows Arch.* 2017 Oct;471(4):531–5. PMID:28653201
1930. Shirah BH, Shirah HA. Incidental unilateral and bilateral ductal carcinoma *in situ* encountered in the surgical management of young male gynecomastia. *Breast Dis.* 2016 Jul 28;36(2–3):103–10. PMID:27612041
1931. Shirley SE, Duncan ND, Escoffery CT, et al. Angiomatosis of the breast in a male child. A case report with immunohistochemical analysis. *West Indian Med J.* 2002 Dec;51(4):254–6. PMID:12632645
1932. Shousha S. Glandular Paget disease of the nipple. *Histopathology.* 2007 May;50(6):812–4. PMID:17376174
1933. Shousha S, Backhouse CM, Alagham-Zadeh J, et al. Alveolar variant of invasive lobular carcinoma of the breast. A tumor rich in estrogen receptors. *Am J Clin Pathol.* 1996 Jan;85(1):1–5. PMID:9040412
1934. Shousha S, Schoenfeld A, Moss J, et al. Light and electron microscopic study of an invasive cribriform carcinoma with extensive microcalcification developing in a breast with silicone augmentation. *Ultrastruct Pathol.* 1994 Sep-Oct;18(5):519–23. PMID:7810003
1935. Shousha S, Tisdall M, Simnett HD. Paget's disease of the nipple occurring after conservative surgery for ductal carcinoma *in situ* of the breast. *Histopathology.* 2004 Oct;45(4):416–8. PMID:15469484
1936. Shukla N, Roberts SS, Bakri MO, et al. Successful targeted therapy of refractory pediatric ETV6-NTRK3 fusion-positive secretory breast carcinoma. *JCO Precis Oncol.* 2017;2017. PMID:29623306
1937. Siddiqui A, Couch FJ, Chen GK, et al. Meta-analysis of genome-wide association studies of breast cancer identifies two susceptibility loci at 6q14 and 20q11. *Hum Mol Genet.* 2012 Dec 15;21(24):5571–PMID:22976474
1938. Siddiqui NH, Cabay RJ, Salem F. Fine-needle aspiration biopsy of a case of breast carcinoma with choriocarcinomatous features. *Diagn Cytopathol.* 2006 Oct;34(10):594–7. PMID:16955470
1939. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin.* 2016 Jan-Feb;66(1):7–30. PMID:26742998
1940. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. *CA Cancer J Clin.* 2017 Jan;67(1):7–30. PMID:28055103
1941. Silver SA, Tavassoli FA. Papillary carcinoma of the breast: clinicopathologic analysis of 26 cases of an unusual high-grade phenotype of ductal carcinoma. *Histopathology.* 2000 Jun;36(6):505–14. PMID:10849302
1942. Silverman EM, Oberman HA. Mammary neoplasms in the breast. *Surg Gynecol Obstet.* 1974 Jan;138(1):26–8. PMID:4809000
1943. Silverman JF, Masood S, Dickey BS, et al. Can FNA biopsy separate atypical hyperplasia, carcinoma *in situ*, and invasive carcinoma of the breast? Cytodiagnostic criteria and limitations in diagnosis. *Diagn Cytopathol.* 1993 Dec;9(6):705–23. PMID:8143551
1944. Silverstein MJ, Lewinsky BS, Werner JR, et al. Infiltrating lobular carcinoma: is it different from infiltrating duct carcinoma? *Cancer.* 1994 Mar 15;73(6):1670–4. PMID:8156495
1945. Silverstein MJ, Waisman JR, Gershenson D, et al. Intraductal carcinoma of the breast (cases). Clinical factors influencing treatment choice. *Cancer.* 1990 Jul 1;65(1):100–4. PMID:2162238
1946. Silvestri V, Barrowdale D, Naylor AM, et al. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology. *Consortium of Investigators of Modifiers of BRCA1/2.* *Breast Cancer Res.* 2016 Feb;18(1):15. PMID:26857456
1947. Simha MR, Doctor VM, Udawatta TE. Mixed tumour of salivary gland type of breast. *Indian J Cancer.* 1992 Mar;25(1):104–7. PMID:1328037
1948. Simpson J, Page D. Lobular neoplasia. In: Elston CW, Ellis IO, editors. *The breast.* London (UK): Churchill Livingstone; 1995 (Systematic pathology series, 3rd ed., vol. 10)
1949. Simpson PT, Gale T, Fulford LG, et al.

- al. The diagnosis and management of pre-invasive breast disease: pathology of atypical lobular hyperplasia and lobular carcinoma in situ. *Breast Cancer Res.* 2003;5(5):258–62. PMID:12927036
1950. Simpson PT, Gale T, Reis-Filho JS, et al. Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis. *Am J Surg Pathol.* 2005 Jun;29(6):734–46. PMID:15897740
1951. Simpson PT, Reis-Filho JS, Lambros MB, et al. Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas. *J Pathol.* 2008 Jul;215(3):231–44. PMID:18473330
1952. Simpson RH, Cope N, Skálová A, et al. Malignant adenomyoepithelioma of the breast with mixed osteogenic, spindle cell, and carcinomatous differentiation. *Am J Surg Pathol.* 1998 May;22(5):631–6. PMID:9591734
1953. Singh K, Diaz-Gomez B, Wang Y, et al. Invasive lobular carcinoma with extracellular mucin: not all mucinous mammary carcinomas are ductal! *Int J Surg Pathol.* 2019 Feb;27(1):55–8. PMID:30032676
1954. Singletary SE. Surgical margins in patients with early-stage breast cancer treated with breast conservation therapy. *Am J Surg.* 2002 Nov;184(5):383–93. PMID:12433599
1955. Siponen E, Hukkinen K, Heikkilä P, et al. Surgical treatment in Paget's disease of the breast. *Am J Surg.* 2010 Aug;200(2):241–6. PMID:20678619
1956. Siriaungkul S, Tavassoli FA. Invasive micropapillary carcinoma of the breast. *Mod Pathol.* 1993 Nov;6(6):660–2. PMID:8302807
1957. Skálová A, Vanecek T, Sima R, et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. *Am J Surg Pathol.* 2010 May;34(5):599–608. PMID:20410810
1958. Sklar-Levy M, Sella T, Alweiss T, et al. Incidence and management of complex fibroadenomas. *AJR Am J Roentgenol.* 2008 Jan;190(1):214–8. PMID:18094314
1959. Skubitz KM. Biology and treatment of aggressive fibromatosis or desmoid tumor. *Mayo Clin Proc.* 2017 Jun;92(6):947–64. PMID:28578783
1960. Sloane JP, Amendoeira I, Apostolikas N, et al. Consistency achieved by 23 European pathologists from 12 countries in diagnosing breast disease and reporting prognostic features of carcinomas. *Virchows Arch.* 1999 Jan;434(1):3–10. PMID:10071228
1961. Sloane JP, Amendoeira I, Apostolikas N, et al. Consistency achieved by 23 European pathologists in categorizing ductal carcinoma in situ of the breast using five classifications. *Hum Pathol.* 1998 Oct;29(10):1056–62. PMID:9781641
1962. Slodkowska E, Nofech-Mozes S, Xu B, et al. Fibroepithelial lesions of the breast: a comprehensive morphological and outcome analysis of a large series. *Mod Pathol.* 2018 Jul;31(7):1073–84. PMID:29449684
1964. Smith-Warner SA, Spiegelman D, Yaun SS, et al. Alcohol and breast cancer in women: a pooled analysis of cohort studies. *JAMA.* 1998 Feb 18;279(7):535–40. PMID:9480365
1965. Snead GM, Duncan LD. Quantifying the extent of invasive carcinoma and margin status in partial mastectomy cases having a gross lesion: Is a defined tissue processing protocol needed? *Am J Clin Pathol.* 2011 Nov;136(5):747–53. PMID:22031313
1966. Sneige N, Wang J, Baker BA, et al. Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases. *Mod Pathol.* 2002 Oct;15(10):1044–50. PMID:12379750
1967. Sneige N, Yaziji H, Mandavilli SR, et al. Low-grade (fibromatosis-like) spindle cell carcinoma of the breast. *Am J Surg Pathol.* 2001 Aug;25(8):1009–16. PMID:11474284
1968. Soenderstrup IMH, Laenkholm AV, Jensen MB, et al. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG. *Acta Oncol.* 2018 Jan;57(1):95–101. PMID:29164974
1969. Sohn VY, Arthurs ZM, Kim FS, et al. Lobular neoplasia: Is surgical excision warranted? *Am Surg.* 2008 Feb;74(2):172–7. PMID:18306873
1970. Sohn VY, Causey MW, Steele SR, et al. The treatment of radial scars in the modern era—surgical excision is not required. *Am Surg.* 2010 May;76(5):522–5. PMID:20506884
1971. Soliman NA, Yussif SM. Ki-67 as a prognostic marker according to breast cancer molecular subtype. *Cancer Biol Med.* 2016 Dec;13(4):496–504. PMID:28154782
1972. Solin LJ, Gray R, Hughes LL, et al. Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study. *J Clin Oncol.* 2015 Nov 20;33(33):3938–44. PMID:26371148
1973. Solorzano CC, Middleton LP, Hunt KK, et al. Treatment and outcome of patients with intracystic papillary carcinoma of the breast. *Am J Surg.* 2002 Oct;184(4):364–8. PMID:12383904
1974. Sønderstrup IMH, Jensen MB, Ejlersen B, et al. Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer. *Acta Oncol.* 2019 Mar;58(3):363–70. PMID:30614364
1975. Sonderstrup IMH, Jensen MR, Ejlersen B, et al. Subtypes in BRCA-mutated breast cancer. *Hum Pathol.* 2019 Feb;84:192–201. PMID:30342055
1976. Soo MS, Rosen EL, Baker JA, et al. Negative predictive value of sonography with mammography in patients with palpable breast lesions. *AJR Am J Roentgenol.* 2001 Nov;177(5):1167–70. PMID:11641195
1977. Soomro S, Shousha S, Taylor P, et al. c-erbB-2 expression in different histological types of invasive breast carcinoma. *J Clin Pathol.* 1991 Mar;44(3):211–4. PMID:1672872
1978. Sopik V, Sun P, Narod SA. Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ. *Breast Cancer Res Treat.* 2018 Feb;167(3):787–95. PMID:29119353
1979. Sorrell AD, Espenschied CR, Culver JO, et al. Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome: current status of clinical applications and future directions. *Mol Diagn Ther.* 2013 Feb;17(1):31–47. PMID:23355100
1980. Southey MC, Goldgar DE, Winquist R, et al. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. *J Med Genet.* 2016 Dec;53(12):800–11. PMID:27595995
1981. Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. *N Engl J Med.* 2018 Jul 12;379(2):111–21. PMID:29860917
1982. Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. *N Engl J Med.* 2015 Nov 19;373(21):2005–14. PMID:26412349
1983. Speirs V, Shaaban AM. The rising incidence of male breast cancer. *Breast Cancer Res Treat.* 2009 May;115(2):429–30. PMID:18478326
1984. Spillane AJ, Thomas JM, Fisher C. Epithelioid sarcoma: the clinicopathological complexities of this rare soft tissue sarcoma. *Ann Surg Oncol.* 2000 Apr;7(3):218–25. PMID:10791853
1985. Spurdle AB, Couch FJ, Parsons MT, et al. Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. *Breast Cancer Res.* 2014 Dec 23;16(6):3419. PMID:25857409
1986. Sreekantaiah C, Karakousis CP, Leong SP, et al. Cytogenetic findings in liposarcoma correlate with histopathologic subtypes. *Cancer.* 1992 May;65(10):2484–95. PMID:1568170
1987. Srivastava S, Zou ZQ, Pirollo K, et al. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. *Nature.* 1990 Dec 20–27;348(6303):747–9. PMID:2259385
1988. Stacey SN, Manolescu A, Sulem P, et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. *Nat Genet.* 2008 Jun;40(6):703–6. PMID:18438407
1989. Stacey SN, Manolescu A, Sulem P, et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. *Nat Genet.* 2007 Jul;39(7):865–9. PMID:17529974
1990. Stafyla V, Kotsopoulos N, Grigoriades K, et al. Lobular carcinoma in situ of the breast within a fibroadenoma. A case report. *Gynecol Oncol.* 2004 Aug;94(2):572–4. PMID:15297206
1991. Stålahammer G, Rosin G, Fredriksson I, et al. Low concordance of biomarkers in histopathological and cytological material from breast cancer. *Histopathology.* 2014 Jun;64(7):971–80. PMID:24320941
1992. Stankovic T, Kidd AM, Sutcliffe A, et al. ATM mutations and phenotypes in ataxiatelangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. *Am J Hum Genet.* 1998 Feb;62(2):334–45. PMID:9463314
1993. Stephens PJ, Tarpey PS, Davies H, et al. The landscape of cancer genes and mutational processes in breast cancer. *Nature.* 2012 May 16;486(7403):400–4. PMID:22722201
1994. Stewart RL, Caron JE, Gulbahce EH, et al. HER2 immunohistochemical and fluorescence in situ hybridization discordances in invasive breast carcinoma with micropapillary features. *Mod Pathol.* 2017 Nov;30(11):1561–6. PMID:28752841
1995. Stone J, Thompson DJ, Dos Santos Silva I, et al. Novel associations between common breast cancer susceptibility variants and risk-predicting mammographic density measures. *Cancer Res.* 2015 Jun 15;75(12):2457–67. PMID:25862352
1996. Stone JP, Hartley RL, Temple-Oberle C. Breast cancer in transgender patients: a systematic review. Part 2: female to male. *Eur J Surg Oncol.* 2018 Oct;44(10):1463–8. PMID:30037639
1997. Stoppa-Lyonnet D. The biological effects and clinical implications of BRCA mutations: Where do we go from here? *Eur J Hum Genet.* 2016 Sep;24 Suppl 1:S3–9. PMID:27514841
1998. Stracke TH, Usui T, Petri JH. Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. *DNA Repair (Amst).* 2009 Sep 2;8(9):1047–54. PMID:19473886
1999. Stratton ME, Glas AM, Hannemann J, et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. *Breast Cancer Res Treat.* 2010 Feb;119(3):551–8. PMID:19214742
2000. Stuebs F, Heidemann S, Caliebe A, et al. CDH1 mutation screen in a BRCA1/2-negative familial breast/ovarian cancer cohort. *Arch Gynecol Obstet.* 2018 Jan;297(1):147–52. PMID:28993866
2001. Stutz JA, Evans AJ, Pinder S, et al. The radiological appearances of invasive cribriform carcinoma of the breast. *Clin Radiol.* 1994 Oct;49(10):693–5. PMID:7955831
2002. Su Y, Swift M. Outcomes of adjuvant radiation therapy for breast cancer in women with ataxia-telangiectasia mutations. *JAMA.* 2001 Nov 14;286(18):2233–4. PMID:11710885
2003. Subhawong AP, Subhawong TK, Khouri N, et al. Incidental minimal atypical lobular hyperplasia on core needle biopsy: correlation with findings on follow-up excision. *Am J Surg Pathol.* 2010 Jun;34(6):822–8. PMID:20431477
2004. Sullivan ME, Khan SA, Sullu Y, et al. Lobular carcinoma in situ variants in breast cores: potential for misdiagnosis, upgrade rates at surgical excision, and practical implications. *Arch Pathol Lab Med.* 2010 Jul;134(7):1024–8. PMID:20586632
2005. Sullivan SG, Hussain R, Threlfall T, et al. The incidence of cancer in people with intellectual disabilities. *Cancer Causes Control.* 2004 Dec;15(10):1021–5. PMID:15801486
2006. Sun HF, Zhao Y, Gao SP, et al. Clinicopathological characteristics and survival outcomes of male breast cancer according to race: a SEER population-based study. *Oncotarget.* 2017 May 26;8(41):69680–90. PMID:29050233
2007. Sung HJ, Maeng YI, Kim MK, et al. Breast carcinoma with choriocarcinomatous features: a case report. *J Breast Cancer.* 2013 Sep;16(3):349–53. PMID:24155767
2008. Surov A, Holzhausen HJ, Ruschke K, et al. Breast plasmacytoma. *Acta Radiol.* 2010 Jun;51(5):498–504. PMID:20429767
2009. Suryawanshi A, Middleton T, Ganda K. An unusual presentation of X-linked adrenoleukodystrophy. *Endocrinol Diabetes Metab Case Rep.* 2015;2015:150098. PMID:26609365
2010. Susnik B, Day D, Abeln E, et al. Surgical outcomes of lobular neoplasia diagnosed in core biopsy: prospective study of 316 cases. *Clin Breast Cancer.* 2016 Dec;16(6):507–13. PMID:27425222
2011. Sutton B, Davison S, Feldman M, et al. Mucocoele-like lesions diagnosed on breast core biopsy: assessment of upgrade rate and need for surgical excision. *Am J Clin Pathol.* 2012 Dec;138(6):783–8. PMID:23161710
2012. Sutton T, Farinola M, Johnson N, et al. Atypical ductal hyperplasia: clinicopathologic factors are not predictive of upgrade after excisional biopsy. *Am J Surg.* 2019 May;217(5):848–50. PMID:30611396
2013. Suzuki R, Orsini N, Mignone L, et al. Alcohol intake and risk of breast cancer defined by estrogen and progesterone receptor status—a meta-analysis of epidemiological studies. *Int J Cancer.* 2008 Apr 15;122(8):1832–41. PMID:18067133
2014. Švajdler M, Baník P, Poliaková K, et al. Sebaceous carcinoma of the breast: report of four cases and review of the literature. *Pol J Pathol.* 2015 Jun;66(2):142–8. PMID:26247527
2015. Swisher EM, Lin KK, Oza AM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. *Lancet Oncol.* 2017 Jan;18(1):75–87. PMID:27908594
2016. Sy SM, Huen MS, Zhu Y, et al. PALB2 regulates recombinational repair through chromatin association and oligomerization. *J Biol Chem.* 2009 Jul 3;284(27):18302–10. PMID:19423707
2017. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer

- burden to predict survival after neoadjuvant chemotherapy. *J Clin Oncol.* 2007 Oct 1;25(28):4414–22. PMID:17785706
- 2018.** Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. *Am J Gastroenterol.* 2015 Feb;110(2):223–62, quiz 263. PMID:25645574
- 2019.** Szabo J, Garcia D, Ciomek N, et al. Spuriously aggressive features of a lactating adenoma prompting repeated biopsies. *Radiol Case Rep.* 2017 Feb 24;12(2):215–8. PMID:28491154
- 2020.** Szychta P, Westfal B, Maciejczyk R, et al. Intraoperative diagnosis of sentinel lymph node metastases in breast cancer treatment with one-step nucleic acid amplification assay (OSNA). *Arch Med Sci.* 2016 Dec 1;12(6):1239–46. PMID:27904514
- 2021.** Tadros AB, Wen HY, Morrow M. Breast cancers of special histologic subtypes are biologically diverse. *Ann Surg Oncol.* 2018 Oct;25(11):3158–64. PMID:30094484
- 2022.** Tait R, Pinder SE, Ellis IO, et al. Adenomyoepithelioma of the breast: a case report and literature review. *J BUON.* 2005 Jul-Sep;10(3):393–5. PMID:17357195
- 2023.** Tajima S, Koda K, Ishii Y, et al. A case of matrix-producing metaplastic carcinoma of the breast exhibiting similarities to pleomorphic adenoma on fine-needle aspiration cytology. *Int J Clin Exp Pathol.* 2015 Nov 1;8(11):15333–7. PMID:26823890
- 2024.** Talman ML, Jensen MB, Rank F. Invasive lobular breast cancer. Prognostic significance of histological malignancy grading. *Acta Oncol.* 2007;46(6):803–9. PMID:17653904
- 2025.** Talwalkar SS, Miranda RN, Valbuena JR, et al. Lymphomas involving the breast: a study of 106 cases comparing localized and disseminated neoplasms. *Am J Surg Pathol.* 2008 Sep;32(9):1299–309. PMID:18636016
- 2026.** Talwalkar SS, Valbuena JR, Abruzzo LV, et al. MALT1 gene rearrangements and NF-kappaB activation involving p65 and p50 are absent or rare in primary MALT lymphomas of the breast. *Mod Pathol.* 2006 Nov;19(11):1402–8. PMID:16917511
- 2027.** Tamimi RM, Baer HJ, Marotti J, et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. *Breast Cancer Res.* 2008;10(4):R67. PMID:18681955
- 2028.** Tamura G, Monma N, Suzuki Y, et al. Adenomyoepithelioma (myoepithelioma) of the breast in a male. *Hum Pathol.* 1993 Jun;24(6):678–81. PMID:8389319
- 2029.** Tan BY, Acs G, Apple SK, et al. Phyllodes tumours of the breast: a consensus review. *Histopathology.* 2016 Jan;68(1):5–21. PMID:26768026
- 2030.** Tan BY, Tan PH. A diagnostic approach to fibroepithelial breast lesions. *Surg Pathol Clin.* 2018 Mar;11(1):17–42. PMID:29413655
- 2031.** Tan EY, Tan PH, Yong WS, et al. Recurrent phyllodes tumours of the breast: pathological features and clinical implications. *ANZ J Surg.* 2006 Jun;76(6):476–80. PMID:16768772
- 2032.** Tan H, Zhang S, Liu H, et al. Imaging findings in phyllodes tumors of the breast. *Eur J Radiol.* 2012 Jan;81(1):e62–9. PMID:21353414
- 2033.** Tan J, Ong CK, Lim WK, et al. Genomic landscapes of breast fibroepithelial tumors. *Nat Genet.* 2015 Nov;47(11):1341–5. PMID:26437033
- 2034.** Tan MH, Mester J, Peterson C, et al. A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. *Am J Hum Genet.* 2011 Jan 7;88(1):42–56. PMID:21194675
- 2035.** Tan MH, Mester JL, Ngeow J, et al. Lifetime cancer risks in individuals with germline PTEN mutations. *Clin Cancer Res.* 2012 Jan 15;18(2):400–7. PMID:22252256
- 2036.** Tan PH, Ellis IO. Myoepithelial and epithelial-myoepithelial, mesenchymal and fibroepithelial breast lesions: updates from the WHO Classification of Tumours of the Breast 2012. *J Clin Pathol.* 2013 Jun;66(6):465–70. PMID:23533258
- 2037.** Tan PH, Harada O, Thike AA, et al. Histiocytoid breast carcinoma: an enigmatic lobular entity. *J Clin Pathol.* 2011 Aug;64(8):654–9. PMID:21398688
- 2038.** Tan PH, Jayabaskar T, Chuah KL, et al. Phyllodes tumors of the breast: the role of pathologic parameters. *Am J Clin Pathol.* 2005 Apr;123(4):529–40. PMID:15743740
- 2039.** Tan PH, Jayabaskar T, Yip G, et al. p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: a tissue microarray study. *Mod Pathol.* 2005 Dec;18(12):1527–34. PMID:16258510
- 2040.** Tan PH, Schnitt SJ, van de Vijver MJ, et al. Papillary and neuroendocrine breast lesions: the WHO stance. *Histopathology.* 2015 May;66(6):761–70. PMID:24845113
- 2041.** Tan PH, Thike AA, Tan WJ, et al. Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins. *J Clin Pathol.* 2012 Jan;65(1):69–76. PMID:22049216
- 2042.** Tan PH, Tse GM, Bay BH. Mucinous breast lesions: diagnostic challenges. *J Clin Pathol.* 2008 Jan;61(1):11–9. PMID:17873114
- 2043.** Tan WJ, Cimia I, Choudhury Y, et al. A five-gene reverse transcription-PCR assay for pre-operative classification of breast fibroepithelial lesions. *Breast Cancer Res.* 2016 Mar 9;18(1):31. PMID:26961242
- 2044.** Tan WJ, Thike AA, Bay BH, et al. Immunohistochemical expression of homeoproteins Six1 and Pax3 in breast phyllodes tumours correlates with histological grade and clinical outcome. *Histopathology.* 2014 May;64(6):807–17. PMID:24438019
- 2045.** Tan WJ, Thike AA, Tan SY, et al. CD117 expression in breast phyllodes tumors correlates with adverse pathologic parameters and reduced survival. *Mod Pathol.* 2015 Mar;28(3):352–8. PMID:25216225
- 2046.** Tanaka K, Imoto S, Wada N, et al. Invasive apocrine carcinoma of the breast: clinicopathologic features of 57 patients. *Breast J.* 2008 Mar-Apr;14(2):164–8. PMID:18248561
- 2047.** Tanaka N, Ueno T, Takama Y, et al. Fibroadenoma in adolescent females after living donor liver transplantation. *Pediatr Transplant.* 2017 Sep;21(6):e12947. PMID:28556594
- 2048.** Tang F, Wei B, Tian Z, et al. Invasive mammary carcinoma with neuroendocrine differentiation: histological features and diagnostic challenges. *Histopathology.* 2011 Jul;59(1):106–15. PMID:21668471
- 2049.** Tang SL, Yang JQ, Du ZG, et al. Clinicopathologic study of invasive micropapillary carcinoma of the breast. *Oncotarget.* 2017 Jun 27;8(26):42455–65. PMID:28418916
- 2050.** Taniguchi K, Takata K, Chuang SS, et al. Frequent MYD88 L265P and CD79B mutations in primary breast diffuse large B-cell lymphoma. *Am J Surg Pathol.* 2016 Mar;40(3):324–34. PMID:26752547
- 2051.** Tao L, Gomez SL, Keegan TH, et al. Breast cancer mortality in African-American and non-Hispanic white women by molecular subtype and stage at diagnosis: a population-based study. *Cancer Epidemiol Biomarkers Prev.* 2015 Jul;24(7):1039–45. PMID:25969506
- 2052.** Tao L, Schwab RB, San Miguel Y, et al. Breast cancer mortality in older and younger patients in California. *Cancer Epidemiol Biomarkers Prev.* 2019 Feb;28(2):303–10. PMID:30333222
- 2053.** Tavassoli FA. Myoepithelial lesions of the breast. Myoepitheliosis, adenomyoepithelioma, and myoepithelial carcinoma. *Am J Surg Pathol.* 1991 Jun;15(6):554–68. PMID:1709559
- 2054.** Tavassoli FA, editor. *Pathology of the breast.* 2nd ed. Stamford (CT): Appleton & Lange; 1999.
- 2055.** Tavassoli FA, Eusebi V. Tumors of the mammary gland. Washington, DC: American Registry of Pathology; 2009. (AFIP atlas of tumor pathology, series 4; fascicle 10).
- 2056.** Tavassoli FA, Norris HJ. A comparison of the results of long-term follow-up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast. *Cancer.* 1990 Feb 1;65(3):518–29. PMID:2297643
- 2057.** Tavassoli FA, Norris HJ. Breast carcinoma with osteoclast-like giant cells. *Arch Pathol Lab Med.* 1986 Jul;110(7):636–9. PMID:3013119
- 2058.** Tavassoli FA, Norris HJ. Mammary adenoid cystic carcinoma with sebaceous differentiation. A morphologic study of the cell types. *Arch Pathol Lab Med.* 1986 Nov;110(11):1045–53. PMID:3022669
- 2059.** Tavassoli FA, Norris HJ. Secretory carcinoma of the breast. *Cancer.* 1980 May 1;45(9):2404–13. PMID:6445777
- 2060.** Tavtigian SV, Oefner PJ, Babikyan D, et al. Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. *Am J Hum Genet.* 2009 Oct;85(4):427–46. PMID:19781682
- 2061.** Tawasli J, Go EM, Tsang JY, et al. Associations of epithelial c-kit expression in phyllodes tumours of the breast. *J Clin Pathol.* 2015 Oct;68(10):808–11. PMID:26056158
- 2062.** Tay TK, Chang KT, Thike AA, et al. Paediatric fibroepithelial lesions revisited: pathological insights. *J Clin Pathol.* 2015 Aug;68(8):633–41. PMID:25998513
- 2063.** Tay TKY, Guan P, Loke BN, et al. Molecular insights into paediatric breast fibroepithelial tumours. *Histopathology.* 2018 Nov;73(5):809–18. PMID:29969836
- 2064.** Taylor AM, Lam Z, Last JI, et al. Ataxia telangiectasia: more variation at clinical and cellular levels. *Clin Genet.* 2015 Mar;87(3):199–208. PMID:25040471
- 2065.** Tejpar S, Nollet F, Li C, et al. Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). *Oncogene.* 1999 Nov 11;18(47):6615–20. PMID:10597266
- 2066.** Telesinghe PU, Anthony PP. Primary lymphoma of the breast. *Histopathology.* 1985 Mar;9(3):297–307. PMID:3922871
- 2067.** Teng CY, Diego EJ. Case report of a large lactating adenoma with rapid antepartum enlargement. *Int J Surg Case Rep.* 2016;20:127–9. PMID:26855073
- 2068.** Teo ZL, Provenzano E, Dite GS, et al. Tumour morphology predicts PALB2 germline mutation status. *Br J Cancer.* 2013 Jul 9;109(1):154–63. PMID:23787919
- 2069.** Terada T. Ductal adenoma of the breast: immunohistochemistry of two cases. *Pathol Int.* 2008 Dec;58(12):801–5. PMID:19067857
- 2070.** Tessier Cloutier B, Costa FD, Tazelaar HD, et al. Aberrant expression of neuroendocrine markers in angiomyxoma: a potential diagnostic pitfall. *Hum Pathol.* 2014 Aug;45(8):1618–24. PMID:24846674
- 2071.** The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. *Blood.* 1997 Jun 1;89(11):3909–18. PMID:9166827
- 2072.** Thomas A, Link BK, Altekruse S, et al. Primary breast lymphoma in the United States: 1975–2013. *J Natl Cancer Inst.* 2017 Jun 1;109(6):djw294. PMID:28376147
- 2073.** Thomas G, Jacobs KB, Kraft P, et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 1q24.1 (RAD51L1). *Nat Genet.* 2009 May;41(5):579–84. PMID:19330030
- 2074.** Thomas JS, Julian HS, Green RL, et al. Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring. *Histopathology.* 2007 Aug;51(2):219–26. PMID:17650216
- 2075.** Thompson AM, Clements K, Cheung S, et al. Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project. *Europ J Cancer.* 2018 Sep;101:210–9. PMID:30052488
- 2076.** Thompson D, Duedal S, Kimer J, et al. Cancer risks and mortality in heterozygous ATM mutation carriers. *J Natl Cancer Inst.* 2015 Jun 1;97(11):813–22. PMID:15928302
- 2077.** Thompson D, Easton DF, Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers. *J Natl Cancer Inst.* 2002 Sep 18;94(18):1358–65. PMID:12257288
- 2079.** Thompson S, Kaplan SS, Popoff RL Jr, et al. Solitary neurofibroma of the breast. *Radiol Case Rep.* 2015 Dec 7;7(4):462. PMID:27330588
- 2080.** Thor AD, Eng C, Devries S, et al. Invasive micropapillary carcinoma of the breast is associated with chromosome 8 abnormalities detected by comparative genomic hybridization. *Hum Pathol.* 2002 Jun;33(6):528–31. PMID:12152162
- 2081.** Tierney RJ, Shannon-Lowe C, Fitzsimmons L, et al. Unexpected patterns of Epstein-Barr virus transcription revealed by a high throughput PCR array for absolute quantification of viral mRNA. *Virology.* 2015 Jan 1;474:117–30. PMID:25463610
- 2082.** Tilve A, Mallo R, Pérez A, et al. Breast hemangiomas: correlation between imaging and pathologic findings. *J Clin Ultrasound.* 2011 Oct;40(8):512–7. PMID:22434703
- 2083.** Tischkowitz M, Xia B. PALEO/FANCI recombining cancer and Fanconi anemia. *Cancer Res.* 2010 Oct 1;70(19):7354–61. PMID:20858716
- 2084.** Tiulipakov A, Kalintchenko N, Semenova T, et al. A potential rearrangement between CYP19 and TRPM7 genes on chromosome 15q21.2 as a cause of aromatase excess syndrome. *J Clin Endocrinol Metab.* 2003 Jul;119(7):4184–90. PMID:15811932
- 2085.** Tjalma WA, Verslegers IO, De Looscher PA, et al. Low and high grade mucinous carcinomas of the breast. *Eur J Gynaecol Oncol.* 2002;23(5):423–5. PMID:12440215
- 2086.** To T, Wall C, Baines CJ, et al. Carcinoma in situ a precursor lesion of invasive breast cancer? *Int J Cancer.* 2014 Dec 1;135(7):1646–52. PMID:24615647
- 2087.** Tognon C, Garnett M, Kenward E, et al. The chimeric protein tyrosine kinase ET6-NTRK3 requires both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation. *Cancer Res.* 2011 Dec 15;61(24):8909–16. PMID:11751416
- 2088.** Tognon C, Knezevich SR, Hutmacher D, et al. Expression of the ET6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. *Cancer Cell.* 2010 Nov;2(5):367–76. PMID:12450792
- 2089.** Toi PC, Neelaiyah S, Dharampal Singh, et al. Evaluation of estrogen and progesterone receptors and Her-2 expression with fine-needle aspirates of patients with carcinoma. *J Cytol.* 2018 Oct-Dec;35(4):229–34.

- PMID:30498294
- 2090.** Toikkanen S, Kujari H. Pure and mixed mucinous carcinomas of the breast: a clinicopathologic analysis of 61 cases with long-term follow-up. *Hum Pathol.* 1989 Aug;20(8):758–64. PMID:2545592
- 2091.** Toikkanen S, Pylkkänen L, Joensuu H. Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma. *Br J Cancer.* 1997;76(9):1234–40. PMID:9365176
- 2092.** Toker C. Clear cells of the nipple epidermis. *Cancer.* 1970 Mar;25(3):601–10. PMID:4313654
- 2093.** Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomatosis and papillary renal cell cancer. *Nat Genet.* 2002 Apr;30(4):406–10. PMID:11865300
- 2094.** Torres-Mora J, Dry S, Li X, et al. Malignant melanotic schwannian tumor: a clinicopathologic, immunohistochemical, and gene expression profiling study of 40 cases, with a proposal for the reclassification of “melanotic schwannoma”. *Am J Surg Pathol.* 2014 Jan;38(1):94–105. PMID:24145644
- 2095.** Tosi AL, Ragazzi M, Ascoli S, et al. Breast tumor resembling the tall cell variant of papillary thyroid carcinoma: report of 4 cases with evidence of malignant potential. *Int J Surg Pathol.* 2007 Jan;15(1):14–9. PMID:17172492
- 2096.** Toss A, Grandi G, Cagnacci A, et al. The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation. *Oncotarget.* 2017 Feb 7;8(6):9144–54. PMID:27880720
- 2097.** Toss MS, Billingham K, Egbuniwe IU, et al. Breast tumours resembling the tall cell variant of thyroid papillary carcinoma: Are they part of the papillary carcinoma spectrum or a distinct entity? *Pathobiology.* 2019;86(2-3):83–91. PMID:30308500
- 2098.** Toss MS, Pinder SE, Green AR, et al. Breast conservation in ductal carcinoma in situ (DCIS): What defines optimal margins? *Histopathology.* 2017 Apr;70(5):681–92. PMID:28000325
- 2099.** Tozbikian G, Brogi E, Vallejo CE, et al. Atypical ductal hyperplasia bordering on ductal carcinoma in situ. *Int J Surg Pathol.* 2017 Apr;25(2):100–7. PMID:27481892
- 2099A.** Tozbikian GH, Zynger DL. A combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple-negative breast cancer. *Hum Pathol.* 2019 Mar;85:221–7. PMID:30468800
- 2100.** Tramm T, Kim JY, Tavassoli FA. Diminished number or complete loss of myoepithelial cells associated with metaplastic and neoplastic apocrine lesions of the breast. *Am J Surg Pathol.* 2011 Feb;35(2):202–11. PMID:21263240
- 2101.** Trentham-Dietz A, Newcomb PA, Storer BE, et al. Risk factors for carcinoma in situ of the breast. *Cancer Epidemiol Biomarkers Prev.* 2000 Jul;9(7):697–703. PMID:10919740
- 2102.** Trojani M, De Mascarel I, Coquet M, et al. [Osteoclastic type giant cell carcinoma of the breast]. *Ann Pathol.* 1989;9(3):189–94. French. PMID:2757703
- 2103.** Trovik CS, Bauer HC, Alvegård TA, et al. Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically-treated patients from the Scandinavian Sarcoma Group Register. *Eur J Cancer.* 2000 Apr;36(6):710–6. PMID:10762742
- 2104.** Troxell ML. Merkel cell carcinoma, melanoma, metastatic mimics of breast cancer. *Semin Diagn Pathol.* 2017 Sep;34(5):479–95. PMID:28645508
- 2105.** Troxell ML. Reversed MUC1/EMA polarity in both mucinous and micropapillary breast carcinoma. *Hum Pathol.* 2014 Feb;45(2):432–4. PMID:24439232
- 2106.** Troxell ML, Levine J, Beadling C, et al. High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast. *Mod Pathol.* 2010 Jan;23(1):27–37. PMID:19898424
- 2107.** Troxell ML, Masek M, Sibley RK. Immunohistochemical staining of papillary breast lesions. *Appl Immunohistochem Mol Morphol.* 2007 Jun;15(2):145–53. PMID:17525625
- 2108.** Tsai ML, Lillemoe TJ, Finkelstein MJ, et al. Utility of Oncotype DX risk assessment in patients with invasive lobular carcinoma. *Clin Breast Cancer.* 2016 Feb;16(1):45–50. PMID:26385397
- 2109.** Tsang JY, Mendoza P, Lam CC, et al. Involvement of α- and β-catenins and E-cadherin in the development of mammary phyllodes tumours. *Histopathology.* 2012 Oct;61(4):667–74. PMID:22571452
- 2110.** Tsang JY, Mendoza P, Putti TC, et al. E-cadherin expression in the epithelial components of mammary phyllodes tumors. *Hum Pathol.* 2012 Dec;43(12):2117–23. PMID:22820000
- 2111.** Tsang JYS, Hui YK, Lee MA, et al. Association of clinicopathological features and prognosis of TERT alterations in phyllodes tumor of breast. *Sci Rep.* 2018 Mar 1;8(1):3881. PMID:29497099
- 2112.** Tsang WY, Chan JK. Endocrine ductal carcinoma in situ (E-DCIS) of the breast: a form of low-grade DCIS with distinctive clinicopathologic and biologic characteristics. *Am J Surg Pathol.* 1996 Aug;20(8):921–43. PMID:8712293
- 2113.** Tse GM, Law BK, Chan KF, et al. Multinucleated stromal giant cells in mammary phyllodes tumours. *Pathology.* 2001 May;33(2):153–6. PMID:11358046
- 2114.** Tse GM, Law BK, Ma TK, et al. Hamartoma of the breast: a clinicopathological review. *J Clin Pathol.* 2002 Dec;55(12):951–4. PMID:12461066
- 2115.** Tse GM, Ma TK, Lui PC, et al. Fine needle aspiration cytology of papillary lesions of the breast: How accurate is the diagnosis? *J Clin Pathol.* 2008 Aug;61(8):945–9. PMID:18552172
- 2116.** Tse GM, Ma TK, Pang LM, et al. Fine needle aspiration cytologic features of mammary phyllodes tumors. *Acta Cytol.* 2002 Sep-Oct;46(5):855–63. PMID:12365219
- 2117.** Tse GM, Tan PH. Diagnosing breast lesions by fine needle aspiration cytology or core biopsy: Which is better? *Breast Cancer Res Treat.* 2010 Aug;123(1):1–8. PMID:20526738
- 2118.** Tseng WH, Martinez SR. Metaplastic breast cancer: To radiate or not to radiate? *Ann Surg Oncol.* 2011 Jan;18(1):94–103. PMID:20585866
- 2119.** Tsubura A, Hatano T, Murata A, et al. Breast carcinoma in patients receiving neuroleptic therapy. Morphologic and clinicopathologic features of thirteen cases. *Acta Pathol Jpn.* 1992 Jul;42(7):494–9. PMID:1357916
- 2120.** Turashvili G, Brogi E, Morrow M, et al. The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis. *Breast Cancer Res Treat.* 2017 Aug;165(1):65–76. PMID:28577081
- 2121.** Turnbull C, Ahmed S, Morrison J, et al. Genome-wide association study identifies five new breast cancer susceptibility loci. *Nat Genet.* 2010 Jun;42(6):504–7. PMID:20453838
- 2122.** Tuttle R, Kane JM 3rd. Biopsy techniques for soft tissue and bowel sarcomas. *J Surg Oncol.* 2015 Apr;111(5):504–12. PMID:25663366
- 2123.** Uchida N, Yokoo H, Kuwano H. Schwannoma of the breast: report of a case. *Surg Today.* 2005;35(3):238–42. PMID:15772796
- 2124.** Uchida T, Ishii M, Motomiya Y. Fibroadenoma associated with gynaecomastia in an adult man. Case report. *Scand J Plast Reconstr Surg Hand Surg.* 1993 Dec;27(4):327–9. PMID:8159950
- 2125.** Udder MS, Ahmed S, Healey CS, et al. Fine scale mapping of the breast cancer 16q12 locus. *Hum Mol Genet.* 2010 Jun 15;19(12):2507–15. PMID:20332101
- 2126.** Ueng SH, Mezzetti T, Tavassoli FA. Papillary neoplasms of the breast: a review. *Arch Pathol Lab Med.* 2009 Jun;133(6):893–907. PMID:19492881
- 2127.** UICC [Internet]. Geneva (Switzerland): Union for International Cancer Control; 2019. TNM Publications and Resources; updated 2019 Feb 4. Available from: <https://www.uicc.org/resources/tnm/publications-resources>.
- 2128.** University of Pittsburgh Department of Pathology [Internet]. Pittsburgh (PA): University of Pittsburgh Medical Center; 2018. Estimating tumor volume reduction in the breast after neoadjuvant (a.k.a. pre-operative) therapy - Magee method. Available from: <https://path.upmc.edu/onlineTools/ptrv.html>.
- 2128B.** University of Texas MD Anderson Cancer Center [Internet]. Houston (TX): University of Texas MD Anderson Cancer Center; 2019. Residual cancer burden calculator. Available from: <http://www3.mdanderson.org/app/medcalc/index.cfm?pagename=jconvert>.
- 2129.** Upadhyaya M. Neurofibromatosis type 1: diagnosis and recent advances. *Expert Opin Med Diagn.* 2010 Jul;4(4):307–22. PMID:23496147
- 2130.** Upasham SP, VinodKiri M, Sudhamani S. One more common tumor in an uncommon location: squamous cell carcinoma on nipple areola complex. *Indian J Cancer.* 2014 July-September;51(3):376–7. PMID:25494146
- 2131.** Ustün M, Berner A, Davidson B, et al. Fine-needle aspiration cytology of lobular carcinoma in situ. *Diagn Cytopathol.* 2002 Jul;27(1):22–6. PMID:12112810
- 2132.** Usitalo E, Kallioniemi RA, Kurki S, et al. Breast cancer in neurofibromatosis type 1: overrepresentation of unfavourable prognostic factors. *Br J Cancer.* 2017 Jan 17;116(2):211–7. PMID:27931045
- 2133.** Uziel T, Savitsky K, Platzter M, et al. Genomic organization of the ATM gene. *Genomics.* 1996 Apr 15;33(2):317–20. PMID:8660985
- 2134.** Seema V, Kalyani R, Srinivasa Murthy V. Multinucleate giant cells in FNAC of benign breast lesions: its significance. *J Clin Diagn Res.* 2014 Dec;8(12):FC01–4. PMID:25653953
- 2135.** Vainio H, Kaaks R, Bianchini F. Weight control and physical activity in cancer prevention: international evaluation of the evidence. *Eur J Cancer Prev.* 2002 Aug;11 Suppl 2:S94–100. PMID:12570341
- 2136.** Valbuena JR, Admirand JH, Gualco G, et al. Myeloid sarcoma involving the breast. *Arch Pathol Lab Med.* 2005 Jan;129(1):32–8. PMID:15628906
- 2137.** Valdez JM, Nichols KE, Kesserwan C, Li-Fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition. *Br J Haematol.* 2017 Feb;176(4):539–52. PMID:27984644
- 2138.** Valero MG, Raut CP, Lotfi P, et al. Atypical lipomatous tumor of the breast. *J Clin Oncol.* 2011 Nov 1;29(31):766–8. PMID:2193120
- 2139.** Validire P, Capovilla M, Asselain B, et al. Primary breast non-Hodgkin's lymphoma: a large single center study of initial characteristics, natural history, and prognostic factors. *Am J Hematol.* 2009 Mar;84(3):133–9. PMID:19199367
- 2140.** van Broekhoven DL, Verhoef C, Grünhagen DJ, et al. Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis. *Ann Surg Oncol.* 2015 May;22(5):1464–70. PMID:25341748
- 2141.** van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. *N Engl J Med.* 2002 Dec 19;347(25):1999–2009. PMID:12490681
- 2142.** van den Broek AJ, Schmidt MK, van 't Veer LJ, et al. Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: What's the evidence? A systematic review with meta-analysis. *PLoS One.* 2015 Mar 27;10(3):e0120189. PMID:25816289
- 2143.** Van den Eynden GG, Colpaert CG, Couvelard A, et al. A fibrotic focus is a prognostic factor and a surrogate marker for hypoxia and (lymph)angiogenesis in breast cancer: review of the literature and proposal on the criteria of evaluation. *Histopathology.* 2007 Oct;51(4):440–51. PMID:17593207
- 2144.** van den Munckhof P, Christiaans I, Kenter SB, et al. Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falk cerebri. *Neurogenetics.* 2012 Feb;13(1):1–7. PMID:22038540
- 2145.** van der Pol CC, Lacle MM, Witkamp AJ, et al. Prognostic models in male breast cancer. *Breast Cancer Res Treat.* 2016 Nov;160(2):339–46. PMID:27671991
- 2145A.** van der Post RS, Bult P, Vogelaar IP, et al. HNF4A immunohistochemistry facilitates distinction between primary and metastatic breast and gastric carcinoma. *Virchows Arch.* 2014 Jun;464(6):673–9. PMID:24711169
- 2145B.** van der Post RS, Vogelaar IP, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. *J Med Genet.* 2015 Jun;52(6):361–74. PMID:25979631
- 2146.** van Deurzen CH, Bult P, de Boer M, et al. Morphometry of isolated tumor cells in breast cancer sentinel lymph nodes: metastases or displacement? *Am J Surg Pathol.* 2009 Jan;33(1):106–10. PMID:18852675
- 2147.** van Deurzen CH, de Bruin PC, Koelemij R, et al. Isolated tumor cells in breast cancer sentinel lymph nodes: displacement or metastases? An immunohistochemical study. *Hum Pathol.* 2009 Jun;40(6):778–82. PMID:19200573
- 2148.** van Deurzen CH, Lee AH, Gill MS, et al. Metaplastic breast carcinoma: tumour histogenesis or dedifferentiation? *J Pathol.* 2011 Aug;224(4):434–7. PMID:21462188
- 2149.** Van Hoeven KH, Drudis T, Cranor ML, et al. Low-grade adenosquamous carcinoma of the breast. A clinicopathologic study of 32 cases with ultrastructural analysis. *Am J Surg Pathol.* 1993 Mar;17(3):248–58. PMID:8434705
- 2150.** van Lier MG, Westerman AM, Wagner A, et al. High cancer risk and increased mortality in patients with Peutz-Jeghers syndrome. *Gut.* 2011 Feb;60(2):141–7. PMID:21205875
- 2151.** van Maaren MC, Lagendijk M, Tilanus-Linthorst MMA, et al. Breast cancer-related deaths according to grade in ductal carcinoma

- in situ*: a Dutch population-based study on patients diagnosed between 1999 and 2012. *Eur J Cancer*. 2018 Sep;101:134–42. PMID:30058817
- 2152.** van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. *Nature*. 2002 Jan 31;415(6871):530–6. PMID:11823860
- 2153.** Vandenbussche CJ, Khouri N, Sbaity E, et al. Borderline atypical ductal hyperplasia/low-grade ductal carcinoma *in situ* on breast needle core biopsy should be managed conservatively. *Am J Surg Pathol*. 2013 Jun;37(6):913–23. PMID:23598968
- 2154.** van der Groep P, van der Wall E, van Diest PJ. Pathology of hereditary breast cancer. *Cell Oncol (Dordr)*. 2011 Apr;34(2):71–88. PMID:21336636
- 2155.** Varga Z, Kolb SA, Flury R, et al. Sebaceous carcinoma of the breast. *Pathol Int*. 2000 Jan;50(1):63–6. PMID:10692180
- 2156.** Varga Z, Robl C, Spycher M, et al. Metaplastic lipid-rich carcinoma of the breast. *Pathol Int*. 1998 Nov;48(11):912–6. PMID:9832063
- 2157.** Varga Z, Theurillat JP, Filonenko V, et al. Preferential nuclear and cytoplasmic NY-BR-1 protein expression in primary breast cancer and lymph node metastases. *Clin Cancer Res*. 2006 May 1;12(9):2745–51. PMID:16675566
- 2158.** Varga Z, Zhao J, Ohlschlegel C, et al. Preferential HER-2/neu overexpression and/or amplification in aggressive histological subtypes of invasive breast cancer. *Histopathology*. 2004 Apr;44(4):332–8. PMID:15049898
- 2159.** Vargas AC, Lakhani SR, Simpson PT. Pleomorphic lobular carcinomas of the breast: molecular pathology and clinical impact. *Future Oncol*. 2009 Mar;5(2):233–43. PMID:19284381
- 2160.** Varley JM. Germline TP53 mutations and Li-Fraumeni syndrome. *Hum Mutat*. 2003 Mar;21(3):313–20. PMID:12619118
- 2161.** Venable JG, Schwartz AM, Silverberg SG. Infiltrating cribriform carcinoma of the breast: a distinctive clinicopathologic entity. *Hum Pathol*. 1990 Mar;21(3):333–8. PMID:2312110
- 2162.** Vengoechea J, Tallo C. A germline deletion of 9p21.3 presenting as familial melanoma, astrocytoma and breast cancer: clinical and genetic counselling challenges. *J Med Genet*. 2017 Oct;54(10):682–4. PMID:28754699
- 2163.** Ventura K, Cangiarella J, Lee I, et al. Aspiration biopsy of mammary lesions with abundant extracellular mucinous material. Review of 43 cases with surgical follow-up. *Am J Clin Pathol*. 2003 Aug;120(2):194–202. PMID:12931549
- 2164.** Vera-Badillo FE, Templeton AJ, de Gouveia P, et al. Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. *J Natl Cancer Inst*. 2014 Jan;106(1):dj319. PMID:24273215
- 2165.** Vereide DT, Seto E, Chiu YF, et al. Epstein-Barr virus maintains lymphomas via its miRNAs. *Oncogene*. 2014 Mar 6;33(10):1258–64. PMID:23503461
- 2166.** Vergne M, Musella A, Gulotta E, et al. Paget's disease of the male breast: case report and a point of view from actual literature. *G Chir*. 2018 Mar-Apr;39(2):114–7. PMID:29694313
- 2167.** Verghen MM, Last JI, Hogervorst FB, et al. Presence of ATM protein and residual kinase activity correlates with the phenotype in ataxia-telangiectasia: a genotype-phenotype study. *Hum Mutat*. 2012 Mar;33(3):561–71. PMID:22213089
- 2168.** Vermeulen MA, Doobar SC, van Deurzen CHM, et al. Copy number profiling of oncogenes in ductal carcinoma *in situ* of the male breast. *Endocr Relat Cancer*. 2018 Mar;25(3):173–84. PMID:29203614
- 2169.** Vermeulen MA, Slabets L, Cardoso F, et al. Pathological characterisation of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. *Eur J Cancer*. 2017 Sep;82:219–27. PMID:28292559
- 2170.** Verschoor AJ, Cleton-Jansen AM, Wijers-Koster P, et al. Radiation-induced sarcomas occurring in desmoid-type fibromatosis are not always derived from the primary tumor. *Am J Surg Pathol*. 2015 Dec;39(12):1701–7. PMID:26414222
- 2171.** Verschuur-Maes AH, de Bruin PC, van Diest PJ. Epigenetic progression of columnar cell lesions of the breast to invasive breast cancer. *Breast Cancer Res Treat*. 2012 Dec;136(3):705–15. PMID:23104224
- 2172.** Verschuur-Maes AH, Kornegoor R, de Bruin PC, et al. Do columnar cell lesions exist in the male breast? *Histopathology*. 2014 May;64(6):818–25. PMID:24267518
- 2173.** Verschuur-Maes AH, Moelans CB, de Bruin PC, et al. Analysis of gene copy number alterations by multiplex ligation-dependent probe amplification in columnar cell lesions of the breast. *Cell Oncol (Dordr)*. 2014 Apr;37(2):147–54. PMID:24692099
- 2174.** Viale G, Rotmensz N, Maisonneuve P, et al. Lack of prognostic significance of "classic" lobular breast carcinoma: a matched, single institution series. *Breast Cancer Res Treat*. 2009 Sep;117(1):211–4. PMID:18629634
- 2175.** Vieira CC, Mercado CL, Cangiarella JF, et al. Microinvasive ductal carcinoma *in situ*: clinical presentation, imaging features, pathologic findings, and outcome. *Eur J Radiol*. 2010 Jan;73(1):102–7. PMID:19026501
- 2176.** Vielli P, Validire P, Kheirallah S, et al. Paget's disease of the nipple without clinically and radiologically detectable breast tumor. *Histochemical and immunohistochemical study of 44 cases*. *Pathol Res Pract*. 1993 Mar;189(2):150–5. PMID:8391688
- 2176A.** Vincent-Salomon A, Gruel N, Lucchesi C, et al. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. *Breast Cancer Res*. 2007;9(2):R24. PMID:17417968
- 2177.** Vincent-Salomon A, Lucchesi C, Gruel N, et al. Integrated genomic and transcriptomic analysis of ductal carcinoma *in situ* of the breast. *Clin Cancer Res*. 2008 Apr 1;14(7):1956–65. PMID:18381933
- 2178.** Vingiani A, Maisonneuve P, Dell'orto P, et al. The clinical relevance of micropapillary carcinoma of the breast: a case-control study. *Histopathology*. 2013 Aug;63(2):217–24. PMID:23763700
- 2179.** Virk RK, Khan A. Pseudoangiomatous stromal hyperplasia: an overview. *Arch Pathol Lab Med*. 2010 Jul;134(7):1070–4. PMID:20586640
- 2180.** Virnig BA, Tuttle TM, Shamliyan T, et al. Ductal carcinoma *in situ* of the breast: a systematic review of incidence, treatment, and outcomes. *J Natl Cancer Inst*. 2010 Feb 3;102(3):170–8. PMID:20071685
- 2181.** Visscher DW, Nassar A, Degnim AC, et al. Sclerosing adenosis and risk of breast cancer. *Breast Cancer Res Treat*. 2014 Feb;144(1):205–12. PMID:24510013
- 2181A.** Visvader JE, Stigl J. Mammary stem cells and the differentiation hierarchy: current status and perspectives. *Genes Dev*. 2014 Jun 1;28(11):1143–58. PMID:24888586
- 2182.** Viswanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol*. 2013 Aug 10;31(23):2942–62. PMID:23835710
- 2183.** Viswanathan K, McMillen B, Cheng E, et al. Juvenile papillomatosis (Swiss-cheese disease) of breast in an adult male with sequential diagnoses of ipsilateral intraductal, invasive, and widely metastatic carcinoma: a case report and review of the disease in males. *Int J Surg Pathol*. 2017 Sep;25(6):536–42. PMID:28420303
- 2184.** Vladescu T, Klijjanenko J, Caillaud JM, et al. Fine-needle sampling in malignant phyllodes tumors: clinicopathologic study of 22 cases seen at the Institut Curie. *Diagn Cytopathol*. 2004 Aug;31(2):71–6. PMID:15282716
- 2185.** Vo T, Xing Y, Meric-Bernstam F, et al. Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. *Am J Surg*. 2007 Oct;194(4):527–31. PMID:17826073
- 2186.** Vo TN, Meric-Bernstam F, Yi M, et al. Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma. *Am J Surg*. 2006 Oct;192(4):552–5. PMID:16978974
- 2187.** Vogel WH. Li-Fraumeni syndrome. *J Adv Pract Oncol*. 2017 Nov-Dec;8(7):742–6. PMID:30333936
- 2188.** Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. *Nature*. 2000 Nov 16;408(6810):307–10. PMID:11099028
- 2189.** Volckmar AL, Leichsenring J, Flechtenmacher C, et al. Tubular, lactating, and ductal adenomas are devoid of MED12 exon2 mutations, and ductal adenomas show recurrent mutations in GNAS and the PI3K-AKT pathway. *Genes Chromosomes Cancer*. 2017 Jan;56(1):11–7. PMID:27438523
- 2190.** von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. *J Clin Oncol*. 2012 May 20;30(15):1796–804. PMID:22508812
- 2191.** Vorburger SA, Xing Y, Hunt KK, et al. Angiosarcoma of the breast. *Cancer*. 2005 Dec 15;104(12):2682–8. PMID:16288486
- 2192.** Vos CB, Cleton-Jansen AM, Berx G, et al. E-cadherin inactivation in lobular carcinoma *in situ* of the breast: an early event in tumorigenesis. *Br J Cancer*. 1997;76(9):1131–3. PMID:9365159
- 2193.** Vos S, Elias SG, van der Groep P, et al. Comprehensive proteomic profiling-derived immunohistochemistry-based prediction models for BRCA1 and BRCA2 germline mutation-related breast carcinomas. *Am J Surg Pathol*. 2018 Sep;42(9):1262–72. PMID:29979200
- 2194.** Vos S, Moelans CB, van Diest PJ. BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers. *Breast Cancer Res*. 2017 May 31;19(1):64. PMID:28569220
- 2195.** Vos S, van Diest PJ, Ausems MG, et al. Ethical considerations for modern molecular pathology. *J Pathol*. 2018 Dec;246(4):405–14. PMID:30125358
- 2196.** Vos S, van Diest PJ, Moelans CB. A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: mutually exclusive, or not? *Crit Rev Oncol Hematol*. 2018 Jul;127:29–41. PMID:29891109
- 2197.** Vourtsi A, Zervoudis S, Pafiti A, et al. Male breast hemangioma—a rare entity: a case report and review of the literature. *Breast*. 2006 May-Jun;12(3):260–2. PMID:16684325
- 2198.** Voz ML, Aström AK, Kas K, et al. The recurrent translocation t(5;8)(p13;q12) in pleomorphic adenomas results in upregulation of PLAG1 gene expression under control of the LIFR promoter. *Oncogene*. Mar;16(11):1409–16. PMID:9525740
- 2199.** Vranic S, Feldman R, Gatalica Z. Apocrine carcinoma of the breast: a brief update on the molecular features and targetable biomarkers. *Bosn J Basic Med Sci*. 2017 Feb 21;17(1):1–11. PMID:28027454
- 2200.** Vranic S, Marchiò C, Castellano L, et al. Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast. *Hum Pathol*. 2015 Sep;46(9):1381–9. PMID:26208846
- 2201.** Vranic S, Schmitt F, Sapino A, et al. Apocrine carcinoma of the breast: a comprehensive review. *Histol Histopathol*. 2011 Nov;28(11):1393–409. PMID:23771415
- 2202.** Vranic S, Tawfik O, Palazzo JJ, et al. EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. *Mod Pathol*. 2010 May;23(5):644–53. PMID:20204795
- 2203.** Wachter DL, Wachter PW, Fassina PA, et al. Characterization of molecular subtypes of Paget disease of the breast: immunohistochemistry and *in situ* hybridization. *Arch Pathol Lab Med*. 2019 Feb;143(2):238–43. PMID:30124327
- 2204.** Wagner N, Schmidt S, Yerlikaya E, et al. Superficial papillary adenomatosis of the nose: a rare disease diagnosed by sonography and histopathologically confirmed by preserving total excision. *J Ultrasound Med*. 2013 Feb;32(2):373–4. PMID:23341397
- 2204A.** Wahl GM, Spike BT. Cell state plasticity, stem cells, EMT, and the generation of tumoral heterogeneity. *NPJ Breast Cancer*. 2017 Apr 19;3:14. PMID:28494654
- 2205.** Wahner-Roedler DL, Sebo TJ, Gennari L. Hamartomas of the breast: clinical, radiologic, and pathologic manifestations. *Breast J*. 2006 Mar-Apr;7(2):101–5. PMID:16328316
- 2206.** Waldman FM, Hwang ES, Ezzell J, et al. Genomic alterations in tubular breast carcinomas. *Hum Pathol*. 2001 Feb;32(2):223–6. PMID:11230710
- 2207.** Walford N, ten Velden J. Histologic breast carcinoma: an apocrine variant of lobular carcinoma. *Histopathology*. 1998 May;14(5):515–22. PMID:972346
- 2208.** Walker GV, Smith GL, Perkins C, et al. Population-based analysis of primary breast cancer with axillary lymph node metastasis. *Cancer*. 2010 Sep 1;115(17):4030–6. PMID:20564117
- 2209.** Walker L, Thompson D, Easton D, et al. A prospective study of neurofibromatosis 1 cancer incidence in the UK. *Br J Cancer*. 2008 Jul 17;95(2):233–8. PMID:18786042
- 2210.** Wallden B, Storhoff J, Nielsen T, et al. Development and verification of the Prosigna breast cancer gene signature assay. *BMC Med Genomics*. 2015 Aug;8:10. PMID:26297356
- 2211.** Walsh MM, Bleiweiss IL. Micropapillary carcinoma of the breast: cases of an underrecognized entity. *Pathol*. 2001 Jun;32(6):583–9. PMID:11407770
- 2212.** Walters LL, Pang JC, Zhao L, et al. Ductal carcinoma *in situ* with distorting sclerosing core biopsy may be predictive of upstage excision. *Histopathology*. 2015 Mar;66(3):554–6. PMID:25231210
- 2213.** Wang C, Wang X, Ma R. Diagnostic and surgical treatment of nipple adenoma. *Adv Surg*. 2015 Jun;85(6):444–7. PMID:26075700
- 2214.** Wang F, Jia Y, Tong Z. Comparison of the clinical and prognostic features of primary breast sarcomas and malignant mixed tumor. *Jpn J Clin Oncol*. 2015 Feb;45(2):146–52. PMID:25387733
- 2215.** Wang J, Wei B, Albarash CT, et al. Invasive neuroendocrine carcinoma of the breast: a population-based study from the

- Surveillance, Epidemiology and End Results (SEER) database. *BMC Cancer*. 2014 Mar 4;14:147. PMID:24589259
- 2216.** Wang P, Yu XM. A primary nipple lymphoma diagnosed by a modified fine-needle aspiration method. *Diagn Cytopathol*. 2012 Aug;40(8):719–23. PMID:22988573
- 2217.** Wang SS, Deapen D, Voutsinas J, et al. Breast implants and anaplastic large cell lymphomas among females in the California Teachers Study cohort. *Br J Haematol*. 2016 Aug;174(3):480–3. PMID:26456010
- 2218.** Wang W, Ding J, Yang W, et al. MRI characteristics of intraductal papilloma. *Acta Radiol*. 2015 Mar;56(3):276–83. PMID:24696194
- 2219.** Wang W, Zhu W, Du F, et al. The demographic features, clinicopathological characteristics and cancer-specific outcomes for patients with microinvasive breast cancer: a SEER database analysis. *Sci Rep*. 2017 Feb 6;7:42045. PMID:28165014
- 2220.** Wang X, Levin AM, Smolinski SE, et al. Breast cancer and other neoplasms in women with neurofibromatosis type 1: a retrospective review of cases in the Detroit metropolitan area. *Am J Med Genet A*. 2012 Dec;158A(12):3061–4. PMID:22965642
- 2221.** Wang Y, Dai B, Ye D. CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis. *Int J Clin Exp Med*. 2015 Sep 15;8(9):15708–15. PMID:26629066
- 2222.** Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. *J Natl Cancer Inst*. 2011 Mar 16;103(6):478–88. PMID:21398619
- 2223.** Waraya M, Hayashi K, Oshida S, et al. [A case report of ipsilateral nipple skin recurrence]. *Gan To Kagaku Ryoho*. 2017 Nov;44(12):1595–7. Japanese. PMID:29394713
- 2224.** Ward BA, McKhann CF, Ravikumar TS. Ten-year follow-up of breast carcinoma in situ in Connecticut. *Arch Surg*. 1992 Dec;127(12):1392–5. PMID:1365682
- 2225.** Ward EM, DeSantis CE, Lin CC, et al. Cancer statistics: breast cancer in situ. *CA Cancer J Clin*. 2015 Nov-Dec;65(6):481–95. PMID:26431342
- 2226.** Wargotz ES, Deos PH, Norris HJ. Metaplastic carcinomas of the breast. II. Spindle cell carcinoma. *Hum Pathol*. 1989 Aug;20(8):732–40. PMID:2473024
- 2227.** Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. I. Matrix-producing carcinoma. *Hum Pathol*. 1989 Jul;20(7):628–35. PMID:2544506
- 2228.** Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. III. Carcinosarcoma. *Cancer*. 1989 Oct 1;64(7):1490–9. PMID:2776108
- 2229.** Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. IV. Squamous cell carcinoma of ductal origin. *Cancer*. 1990 Jan 15;65(2):272–6. PMID:2153044
- 2230.** Wargotz ES, Norris HJ, Austin RM, et al. Fibromatosis of the breast. A clinical and pathological study of 28 cases. *Am J Surg Pathol*. 1987 Jan;11(1):38–45. PMID:3789257
- 2231.** Wargotz ES, Weiss SW, Norris HJ. Myofibroblastoma of the breast. Sixteen cases of a distinctive benign mesenchymal tumor. *Am J Surg Pathol*. 1987 Jul;11(7):493–502. PMID:3037930
- 2232.** Warner ET, Tamimi RM, Hughes ME, et al. Racial and ethnic differences in breast cancer survival: mediating effect of tumor characteristics and sociodemographic and treatment factors. *J Clin Oncol*. 2015 Jul 10;33(20):2254–61. PMID:25964252
- 2233.** Warner NE. Lobular carcinoma of the breast. *Cancer*. 1969 Apr;23(4):840–6. PMID:5775975
- 2234.** Watanabe Y, Anan K, Saimura M, et al. Upstaging to invasive ductal carcinoma after mastectomy for ductal carcinoma in situ: predictive factors and role of sentinel lymph node biopsy. *Breast Cancer*. 2018 Nov;25(6):663–70. PMID:29786772
- 2235.** Watermann DO, Tempfer C, Heifler LA, et al. Ultrasound morphology of invasive lobular breast cancer is different compared with other types of breast cancer. *Ultrasound Med Biol*. 2005 Feb;31(2):167–74. PMID:15708454
- 2236.** Waters EA, McNeel TS, Stevens WM, et al. Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. *Breast Cancer Res Treat*. 2012 Jul;134(2):875–80. PMID:22622807
- 2237.** Weaver DL, Rosenberg RD, Barlow WE, et al. Pathologic findings from the Breast Cancer Surveillance Consortium: population-based outcomes in women undergoing biopsy after screening mammography. *Cancer*. 2006 Feb 15;106(4):732–42. PMID:16411214
- 2238.** Weaver J, Downs-Kelly E, Goldblum JR, et al. Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms. *Mod Pathol*. 2008 Aug;21(8):943–9. PMID:18500263
- 2239.** Weaver MG, Abdul-Karim FW, al-Kaisi N. Mucinous lesions of the breast. A pathological continuum. *Pathol Res Pract*. 1993 Sep;189(8):873–6. PMID:8302709
- 2240.** Wechselberger G, Schoeller T, Pizakater H. Juvenile fibroadenoma of the breast. *Surgery*. 2002 Jul;132(1):106–7. PMID:12110805
- 2241.** Wei S. Papillary lesions of the breast: an update. *Arch Pathol Lab Med*. 2016 Jul;140(7):628–43. PMID:27362568
- 2242.** Weidner N, Levine JD. Spindle-cell adenomyoepithelioma of the breast. A microscopic, ultrastructural, and immunocytochemical study. *Cancer*. 1988 Oct 15;62(8):1561–7. PMID:2844382
- 2243.** Weidner N, Semple JP. Pleomorphic variant of invasive lobular carcinoma of the breast. *Hum Pathol*. 1992 Oct;23(10):1167–71. PMID:1398644
- 2244.** Weigelt B, Bi R, Kumar R, et al. The landscape of somatic genetic alterations in breast cancers from ATM germline mutation carriers. *J Natl Cancer Inst*. 2018 Sep 1;110(9):1030–4. PMID:29506079
- 2245.** Weigelt B, Eberle C, Cowell CF, et al. Metaplastic breast carcinoma: more than a special type. *Nat Rev Cancer*. 2014 Mar;14(3):147–8. PMID:25688406
- 2246.** Weigelt B, Geyer FC, Horlings HM, et al. Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type. *Mod Pathol*. 2009 Nov;22(11):1401–14. PMID:19633645
- 2247.** Weigelt B, Geyer FC, Natrajan R, et al. The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type. *J Pathol*. 2010 Jan;220(1):45–57. PMID:19877120
- 2248.** Weigelt B, Geyer FC, Reis-Filho JS. Histological types of breast cancer: How special are they? *Mol Oncol*. 2010 Jun;4(3):192–208. PMID:20452298
- 2249.** Weigelt B, Horlings HM, Kreike B, et al. Refinement of breast cancer classification by molecular characterization of histological special types. *J Pathol*. 2008 Oct;216(2):141–50. PMID:18720457
- 2250.** Weigelt B, Kreike B, Reis-Filho JS. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. *Breast Cancer Res Treat*. 2009 Sep;117(2):273–80. PMID:18815879
- 2251.** Weigelt B, Ng CK, Shen R, et al. Metaplastic breast carcinomas display genomic and transcriptomic heterogeneity [corrected]. *Mod Pathol*. 2015 Mar;28(3):340–51. PMID:25412848
- 2252.** Weischer M, Bojesen SE, Ellervik C, et al. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. *J Clin Oncol*. 2008 Feb 1;26(4):542–8. PMID:18172190
- 2253.** Weischer M, Nordestgaard BG, Pharoah P, et al. CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. *J Clin Oncol*. 2012 Dec 10;30(35):4308–16. PMID:23109706
- 2254.** Weisman PS, Ng CK, Brogi E, et al. Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology. *Mod Pathol*. 2016 May;29(5):476–88. PMID:26939876
- 2255.** Weiss HA, Brinton LA, Brogan D, et al. Epidemiology of in situ and invasive breast cancer in women aged under 45. *Br J Cancer*. 1996 May;73(10):1298–305. PMID:8630296
- 2256.** Weiss JB, Do WS, Forte DM, et al. Is bigger better? Twenty-year institutional experience of atypical ductal hyperplasia discovered by core needle biopsy. *Am J Surg*. 2019 May;217(5):906–9. PMID:30771862
- 2257.** Weitzel JN, Pooler PA, Mohammed R, et al. A unique case of breast carcinoma producing pancreatic-type isomylase. *Gastroenterology*. 1988 Feb;94(2):519–20. PMID:2446952
- 2258.** Wellcome Sanger Institute [Internet]. Hinxton (UK): Wellcome Sanger Institute, Genome Research Limited; 2018. Catalogue Of Somatic Mutations In Cancer (COSMIC); cited 2018 Oct 18. Available from: <https://cancer.sanger.ac.uk/cosmic>.
- 2259.** Wells CA, Ferguson DJ. Ultrastructural and immunocytochemical study of a case of invasive cribriform breast carcinoma. *J Clin Pathol*. 1988 Jan;41(1):17–20. PMID:3343375
- 2259A.** Wells CA, McGregor IL, Makunura CN, et al. Apocrine adenosis: a precursor of aggressive breast cancer? *J Clin Pathol*. 1995 Aug;48(8):737–42. PMID:7560201
- 2260.** Wen HY, Brogi E. Lobular carcinoma in situ. *Surg Pathol Clin*. 2018 Mar;11(1):123–45. PMID:29413653
- 2261.** Wen X, Cheng W. Nonmalignant breast papillary lesions at core-needle biopsy: a meta-analysis of underestimation and influencing factors. *Ann Surg Oncol*. 2013 Jan;20(1):94–101. PMID:22878621
- 2262.** Wen YH, Weigelt B, Reis-Filho JS. Microglandular adenosis: a non-obligate precursor of triple-negative breast cancer? *Histol Histopathol*. 2013 Sep;28(9):1099–108. PMID:23584829
- 2263.** Wendroth SM, Mentrikoski MJ, Wick MR. GATA3 expression in morphologic subtypes of breast carcinoma: a comparison with gross cystic disease fluid protein 15 and gammaglobulin. *Ann Diagn Pathol*. 2015 Feb;19(1):6–9. PMID:25544392
- 2264.** Werling RW, Hwang H, Yaziji H, et al. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain. *Am J Surg Pathol*. 2003 Jan;27(1):82–90. PMID:12502930
- 2265.** Wesseling J, van der Valk SW, Vos HL, et al. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. *J Cell Biol*. 1995 Apr;129(1):255–65. PMID:7698991
- 2266.** Wesseling J, van der Valk SW, Hilkens J. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. *Mol Biol Cell*. 1996 Apr;7(4):565–77. PMID:8730100
- 2267.** Weston VJ, Oldrieve CE, Skowronski A, et al. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. *Blood*. 2010 Nov 25;116(22):4578–87. PMID:20739657
- 2268.** Westra WH, Lewis JS Jr. Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Oropharynx. *Head Neck Pathol*. 2017 Mar;11(1):41–7. PMID:28247229
- 2269.** White SR, Auguste LJ, Guo H, et al. Periductal stromal sarcoma of the breast with liposarcomatous differentiation: a case report with 10-year follow-up and literature review. *Int J Surg Pathol*. 2015 May;23(3):221–4. PMID:25614463
- 2270.** White W, Shiu MH, Rosenblum MK, et al. Cellular schwannoma. A clinicopathologic study of 57 patients and 58 tumors. *Cancer*. 1990 Sep 15;66(6):1266–75. PMID:2400975
- 2270A.** WHO Classification of Tumours Editorial Board. Digestive system tumours. Lyon (France): International Agency for Research on Cancer; 2019. (WHO classification of tumours series, 5th ed.; vol. 1). <http://publications.iarc.fr/579>
- 2271.** Williams KE, Amin A, Hill J, et al. Radiologic and pathologic features associated with upgrade of atypical ductal hyperplasia at surgical excision. *Acad Radiol*. 2019 Jul;26(7):893–9. PMID:30318287
- 2272.** Williams LA, Pankratz N, Lane J, et al. Klinefelter syndrome in males with germ cell tumors: a report from the Children's Oncology Group. *Cancer*. 2018 Oct 1;124(19):3900–8. PMID:30291793
- 2273.** Williams RF, Fernandez-Pineda I, Gosain A. Pediatric sarcomas. *Surg Clin North Am*. 2016 Oct;96(5):1107–25. PMID:27542645
- 2274.** Williams SA, Ehlers RA 2nd, Hunt KK, et al. Metastases to the breast from nonbreast solid neoplasms: presentation and determinants of survival. *Cancer*. 2007 Aug 15;110(4):731–7. PMID:17582626
- 2275.** Wilsher M, McKessar M, Mak C. Phyllodes tumour of the nipple presenting with nipple discharge. *Pathology*. 2014 Aug;46(5):455–7. PMID:24977745
- 2276.** Wilsher MJ, Owens TW, Alcock RJ. Next generation sequencing of the nidus of early (adenosquamous proliferation rich) radial sclerosing lesions of the breast reveals evidence for a neoplastic precursor lesion. *J Pathol Clin Res*. 2017 Mar 20;3(2):115–22. PMID:28451460
- 2277.** Wilson CH, Griffith CD, Shrimarkar J, et al. Gynaecomastia, neurofibromatosis and breast cancer. *Breast*. 2004 Feb;13(1):77–9. PMID:14759722
- 2278.** Wilson JR, Bateman AC, Hanson H, et al. A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. *J Med Genet*. 2010 Nov;47(11):771–4. PMID:20805372
- 2279.** Wilson PC, Chagpar AB, Cicek AF, et al. Breast cancer histopathology is predictive of low-risk Oncotype DX recurrence score. *Breast*. 2018 Nov;24(6):976–80. PMID:30230117
- 2280.** Winchester DJ, Chang HR, Graves TA, et al. A comparative analysis of lobular and ductal carcinoma of the breast: presentation, treatment, and outcomes. *J Am Coll Surg*. 1998 Apr;186(4):416–22. PMID:9544955
- 2281.** Winham SJ, Mehner C, Heinzen EP, et al.

- NanoString-based breast cancer risk prediction for women with sclerosing adenosis. *Breast Cancer Res Treat.* 2017 Nov;166(2):641–50. PMID:28798985
- 2282.** Wiseman C, Liao KT. Primary lymphoma of the breast. *Cancer.* 1972 Jun;29(6):1705–12. PMID:4555557
- 2283.** Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. *Arch Pathol Lab Med.* 2014 Feb;138(2):241–56. PMID:24099077
- 2284.** Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. *J Clin Oncol.* 2018 Jul 10;36(20):2105–22. PMID:29846104
- 2285.** Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. *Arch Pathol Lab Med.* 2018 Nov;142(11):1364–82. PMID:29846104
- 2286.** Wolfram D, Rabensteiner E, Grundtman C, et al. T regulatory cells and TH17 cells in peri-silicone implant capsular fibrosis. *Plast Reconstr Surg.* 2012 Feb;129(2):327e–37e. PMID:22286447
- 2287.** Wong AY, Salisbury E, Bilous M. Recent developments in stereotactic breast biopsy methodologies: an update for the surgical pathologist. *Adv Anat Pathol.* 2000 Jan;7(1):26–35. PMID:10640199
- 2288.** Wong LK, Kereke AR, Wright AE, et al. Microcystic adnexal carcinoma of the nipple. *Wounds.* 2018 Jun;30(6):E65–7. PMID:30059333
- 2289.** Wong SM, Freedman RA, Sagara Y, et al. The effect of Paget disease on axillary lymph node metastases and survival in invasive ductal carcinoma. *Cancer.* 2015 Dec 15;121(24):4333–40. PMID:26376021
- 2290.** Wong WW, Schild SE, Halyard MY, et al. Primary non-Hodgkin lymphoma of the breast: the Mayo Clinic experience. *J Surg Oncol.* 2002 May;80(1):19–25, discussion 26. PMID:11967901
- 2291.** Wong YN, Jack RH, Mak V, et al. The epidemiology and survival of extrapulmonary small cell carcinoma in South East England, 1970–2004. *BMC Cancer.* 2009 Jun 29;9:209. PMID:19563623
- 2292.** Woodard AH, Yu J, Dabbs DJ, et al. NY-BR-1 and PAX8 immunoreactivity in breast, gynecologic tract, and other CK7+ carcinomas: potential use for determining site of origin. *Am J Clin Pathol.* 2011 Sep;136(3):428–35. PMID:21846919
- 2293.** Work ME, Andrusis IL, John EM, et al. Risk factors for uncommon histologic subtypes of breast cancer using centralized pathology review in the Breast Cancer Family Registry. *Breast Cancer Res Treat.* 2012 Aug;134(3):1209–20. PMID:22527103
- 2294.** Worsham MJ, Abrams J, Raju U, et al. Breast cancer incidence in a cohort of women with benign breast disease from a multiethnic, primary health care population. *Breast J.* 2007 Mar-Apr;13(2):115–21. PMID:17319851
- 2295.** Wrba F, Ellinger A, Reiner G, et al. Ultrastructural and immunohistochemical characteristics of lipid-rich carcinoma of the breast. *Virchows Arch A Pathol Anat Histopathol.* 1988;413(5):381–5. PMID:2845641
- 2296.** Wright DH. Burkitt's lymphoma: a review of the pathology, immunology, and possible etiologic factors. *Pathol Annu.* 1971;6:337–63. PMID:4342309
- 2297.** Wu CC, Shete S, Amos CI, et al. Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome. *Cancer Res.* 2006 Aug 15;66(16):8287–92. PMID:16912210
- 2298.** Wu Y, Zhang N, Yang Q. The prognosis of invasive micropapillary carcinoma compared with invasive ductal carcinoma in the breast: a meta-analysis. *BMC Cancer.* 2017 Dec 11;17(1):839. PMID:29228910
- 2299.** Wynveen CA, Nehhozina T, Akram M, et al. Intracystic papillary carcinoma of the breast: an *in situ* or invasive tumor? Results of immunohistochemical analysis and clinical follow-up. *Am J Surg Pathol.* 2011 Jan;35(1):1–14. PMID:21084964
- 2300.** Wyszynski A, Hong CC, Lam K, et al. An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. *Hum Mol Genet.* 2016 Sep 1;25(17):3863–76. PMID:27402876
- 2301.** Xia B, Dorsman JC, Ameziane N, et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. *Nat Genet.* 2007 Feb;39(2):159–61. PMID:17200672
- 2302.** Xia B, Sheng Q, Nakanishi K, et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. *Mol Cell.* 2006 Jun 23;22(6):719–29. PMID:16793542
- 2303.** Xie ZM, Li LS, Laquet C, et al. Germline mutations of the E-cadherin gene in families with inherited invasive lobular breast carcinoma but no diffuse gastric cancer. *Cancer.* 2011 Jul 15;117(14):3112–7. PMID:21271559
- 2304.** Xu S, Cao X. Interleukin-17 and its expanding biological functions. *Cell Mol Immunol.* 2010 May;7(3):164–74. PMID:20383173
- 2305.** Xu X, Bi R, Shui R, et al. Micropapillary pattern in pure mucinous carcinoma of the breast - Does it matter or not? *Histopathology.* 2019 Jan;74(2):248–55. PMID:30066338
- 2306.** Yahara T, Yamaguchi R, Yokoyama G, et al. Adenomyoepithelioma of the breast diagnosed by a mammotome biopsy: report of a case. *Surg Today.* 2008;38(2):144–6. PMID:18239872
- 2307.** Yamada M, Otsuki Y, Shimizu S, et al. Cytological study of 20 cases of solid-papillary carcinoma of the breast. *Diagn Cytopathol.* 2007 Jul;35(7):417–22. PMID:17580353
- 2308.** Yamaguchi R, Horii R, Maeda I, et al. Clinicopathologic study of 53 metaplastic breast carcinomas: their elements and prognostic implications. *Hum Pathol.* 2010 May;41(5):679–85. PMID:20153509
- 2309.** Yamaguchi R, Horii R, Maki K, et al. Carcinoma in a solitary intraductal papilloma of the breast. *Pathol Int.* 2009 Mar;59(3):185–7. PMID:19261097
- 2310.** Yamaguchi R, Tanaka M, Kondo K, et al. Characteristic morphology of invasive micropapillary carcinoma of the breast: an immunohistochemical analysis. *Jpn J Clin Oncol.* 2010 Aug;40(8):781–7. PMID:20444748
- 2311.** Yamamoto H, Yoshida A, Taguchi K, et al. ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours. *Histopathology.* 2016 Jul;69(1):72–83. PMID:26647767
- 2312.** Yang M, Moriya T, Oguma M, et al. Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases. *Pathol Int.* 2003 Jul;53(7):422–8. PMID:12828606
- 2313.** Yang WT, Hennessy BT, Dryden MJ, et al. Mammary angiiosarcomas: imaging findings in 24 patients. *Radiology.* 2007 Mar;242(3):725–34. PMID:17325063
- 2314.** Yang XR, Chang-Claude J, Goode EL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. *J Natl Cancer Inst.* 2011 Feb 2;103(3):250–63. PMID:21191117
- 2315.** Yang Y, Wang Y, He J, et al. Malignant adenomyoepithelioma combined with adenoid cystic carcinoma of the breast: a case report and literature review. *Diagn Pathol.* 2014 Jul 23;9:148. PMID:25056281
- 2316.** Yap J, Chuba PJ, Thomas R, et al. Sarcoma as a second malignancy after treatment for breast cancer. *Int J Radiat Oncol Biol Phys.* 2002 Apr 1;52(5):1231–7. PMID:11955733
- 2317.** Yap YS, Munusamy P, Lim C, et al. Breast cancer in women with neurofibromatosis type 1 (NF1): a comprehensive case series with molecular insights into its aggressive phenotype. *Breast Cancer Res Treat.* 2018 Oct;171(3):719–35. PMID:29926297
- 2318.** Yaziji H, Gow AM, Sneige N. Detection of stromal invasion in breast cancer: the myoepithelial markers. *Adv Anat Pathol.* 2000 Mar;7(2):100–9. PMID:10721417
- 2319.** Yeong J, Thike AA, Young Ng CC, et al. A genetic mutation panel for differentiating malignant phyllodes tumour from metaplastic breast carcinoma. *Pathology.* 2017 Dec;49(7):786–9. PMID:29066183
- 2320.** Yiannakopoulou E. Etiology of familial breast cancer with undetected BRCA1 and BRCA2 mutations: clinical implications. *Cell Oncol (Dordr).* 2014 Feb;37(1):1–8. PMID:24306927
- 2321.** Yilmaz E, Sal S, Lebe B. Differentiation of phyllodes tumors versus fibroadenomas. *Acta Radiol.* 2002 Jan;43(1):34–9. PMID:11972459
- 2322.** Yilmaz R, Akkavak G, Ozgur E, et al. Myofibroblastoma of the breast: ultrasonography, mammography, and magnetic resonance imaging features with pathologic correlation. *Ultrasound Q.* 2018 Jun;34(2):99–102. PMID:29420368
- 2323.** Yilmaz R, Bayramoglu Z, Emirkici S, et al. MR imaging features of tubular carcinoma: preliminary experience in twelve masses. *Eur J Breast Health.* 2018 Jan 1;14(1):39–45. PMID:29322118
- 2324.** Yin M, Wang W, Drabick JJ, et al. Prognosis and treatment of non-metastatic primary and secondary breast angiosarcoma: a comparative study. *BMC Cancer.* 2017 Apr 27;17(1):295. PMID:28449661
- 2325.** Yokouchi M, Nagano S, Kijima Y, et al. Solitary breast metastasis from myxoid liposarcoma. *BMC Cancer.* 2014 Jul 4;14:482. PMID:24994066
- 2326.** Yoo JL, Woo OH, Kim YK, et al. Can MR imaging contribute in characterizing well-circumscribed breast carcinomas? *Radiographics.* 2010 Oct;30(6):1689–702. PMID:21071383
- 2327.** Yoo SJ, Lee DS, Oh HS, et al. Male breast adenoid cystic carcinoma. *Case Rep Oncol.* 2013 Oct 12;6(3):514–9. PMID:24403896
- 2328.** Yoon JY, Chitale D. Adenomyoepithelioma of the breast: a brief diagnostic review. *Arch Pathol Lab Med.* 2013 May;137(5):725–9. PMID:23627458
- 2329.** Yoshida M, Ogawa R, Yoshida H, et al. TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast. *Br J Cancer.* 2015 Oct 20;113(8):1244–8. PMID:26355235
- 2330.** Yoshida S, Nakamura N, Sasaki Y, et al. Primary breast diffuse large B-cell lymphoma shows a non-germinal center B-cell phenotype. *Mod Pathol.* 2005 Mar;18(3):398–405. PMID:15492762
- 2331.** Young RH, Clement PB, et al. Adenomyoepithelioma of the breast. A report of three cases and review of the literature. *Am J Clin Pathol.* 1988 Mar;89(3):308–14. PMID:2831705
- 2332.** Young RJ, Natukunda A, Litte S, et al. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials. *Eur J Cancer.* 2014 Dec;50(18):3178–85. PMID:25459395
- 2333.** Yu BH, Tang SX, Xu XL, et al. Breast carcinoma in sclerosing adenosis: a clinicopathological and immunophenotypic analysis on 206 lesions. *J Clin Pathol.* 2016 Jun;71(6):546–53. PMID:29436376
- 2334.** Yu J, Bhargava R, Dabbs DJ. Invasive lobular carcinoma with extracellular mucus production and HER-2 overexpression: a case report and further case studies. *Diagn Pathol.* 2010 Jun 15;5:36. PMID:20550696
- 2335.** Yu JI, Choi DH, Park W, et al. Differences in prognostic factors and patterns of failure between invasive micropapillary carcinoma and invasive ductal carcinoma of the breast: matched case-control study. *Breast.* 2010 Jun;19(3):231–7. PMID:20304650
- 2336.** Yu SN, Li J, Wong SI, et al. Atypical aspirates of the breast: a dilemma in current cytology practice. *J Clin Pathol.* 2017 Dec;70(12):1024–32. PMID:28554890
- 2337.** Yu XF, Yang HJ, Yu Y, et al. A prognostic analysis of male breast cancer (NEC) compared with post-menopausal female breast cancer (FBC). *PLoS One.* 2015 Aug 27;10(8):e0136670. PMID:26313461
- 2338.** Yun SU, Choi BB, Shu KS, et al. Imaging findings of invasive micropapillary carcinoma of the breast. *J Breast Cancer.* 2011 Mar;15(1):57–64. PMID:22493629
- 2339.** Zafrani B, Aubriot MH, Mourad E, et al. High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determinations: prospective study of 793 cases. *Histopathology.* 2000 Dec;37(6):536–45. PMID:1122436
- 2340.** Zagars GK, Ballo MT, Petersen PA, et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: analysis of 1225 patients. *Cancer.* 2003 May 15;97(10):2530–43. PMID:12733153
- 2341.** Zakaria S, Pantvaidya G, Ghosh K, et al. Paget's disease of the breast: accuracy of preoperative assessment. *Breast Cancer Res Treat.* 2007 Apr;102(2):337–42. PMID:17028984
- 2342.** Zandriro F, Calabrese M, Riccio C, et al. Tubular carcinoma of the breast: pathological, clinical, and ultrasonographic findings. A review of the literature. *Radiol Med.* 2006 Sep;111(6):773–82. PMID:16960000
- 2343.** Zarbo RJ, Oberman HA. Adenomyoepithelioma of the breast. *Am J Clin Pathol.* 1983 Dec;7(8):863–70. PMID:6671550
- 2344.** Zardavas D, Te Marvelde L, Minne RL, et al. Tumor PIK3CA genotype and prognosis in early-stage breast cancer: a pooled analysis of individual patient data. *J Clin Oncol.* 2011 Mar;29(10):3030–7. PMID:21361000
- 2345.** Zeggini E, Weedon MN, Lindgren CM, et al. Replication of genome-wide association signals in UK samples reveals new loci for type 2 diabetes. *Science.* 2007 Jun 1;316(5829):1336–41. PMID:17463246
- 2346.** Zekioglu O, Erhan Y, Cimri M, et al. Invasive micropapillary carcinoma of the breast: high incidence of lymph node metastasis with extranodal extension and immunohistochemical profile compared with

- invasive ductal carcinoma. Histopathology. 2004 Jan;44(1):18–23. PMID:14717664
- 2347.** Zhang F, Ma J, Wu J, et al. PALB2 links BRCA1 and BRCA2 in the DNA-damage response. *Curr Biol*. 2009 Mar 24;19(6):524–9. PMID:19268590
- 2348.** Zhang G, Ataya D, L Lebda P, et al. Mucocele-like lesions diagnosed on breast core biopsy: low risk of upgrade and subsequent carcinoma. *Breast J*. 2018 May;24(3):314–8. PMID:29024198
- 2349.** Zhang J, White NM, Schmidt HK, et al. INTEGRATE: gene fusion discovery using whole genome and transcriptome data. *Genome Res*. 2016 Jan;26(1):108–18. PMID:26556708
- 2350.** Zhang LJ, Su Z, Liu X, et al. Peutz-Jeghers syndrome with early onset of preadolescent gynecomastia: a pedigree case report and clinical and molecular genetic analysis. *Am J Transl Res*. 2017 May 15;9(5):2639–44. PMID:28560011
- 2351.** Zhang N, Zhang H, Chen T, et al. Dose invasive apocrine adenocarcinoma has worse prognosis than invasive ductal carcinoma of breast: evidence from SEER database. *Oncotarget*. 2017 Apr 11;8(15):24579–92. PMID:28445946
- 2352.** Zhang X, Chiang HC, Wang Y, et al. Attenuation of RNA polymerase II pausing mitigates BRCA1-associated R-loop accumulation and tumorigenesis. *Nat Commun*. 2017 Jun 26;8:15908. PMID:28649985
- 2353.** Zhang Y, Kleer CG. Phyllodes tumor of the breast: histopathologic features, differential diagnosis, and molecular/genetic updates. *Arch Pathol Lab Med*. 2016 Jul;140(7):665–71. PMID:27362571
- 2354.** Zhang Y, Lv F, Yang Y, et al. Clinicopathological features and prognosis of metaplastic breast carcinoma: experience of a major Chinese cancer center. *PLoS One*. 2015 Jun 26;10(6):e0131409. PMID:26115045
- 2355.** Zhao C, Desouki MM, Florea A, et al. Pathologic findings of follow-up surgical excision for lobular neoplasia on breast core biopsy performed for calcification. *Am J Clin Pathol*. 2012 Jul;138(1):72–8. PMID:22706860
- 2356.** Zhao HD, Wu T, Wang JQ, et al. Primary inflammatory myofibroblastic tumor of the breast with rapid recurrence and metastasis: a case report. *Oncol Lett*. 2013 Jan;5(1):97–100. PMID:23255901
- 2357.** Zhao S, Ma D, Xiao Y, et al. Clinicopathologic features and prognoses of different histologic types of triple-negative breast cancer: a large population-based analysis. *Eur J Surg Oncol*. 2018 Apr;44(4):420–8. PMID:29429597
- 2358.** Zhen DB, Rabe KG, Gallinger S, et al. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. *Genet Med*. 2015 Jul;17(7):569–77. PMID:25356972
- 2359.** Zheng Z, Liebers M, Zhelyazkova B, et al. Anchored multiplex PCR for targeted next-generation sequencing. *Nat Med*. 2014 Dec;20(12):1479–84. PMID:25384085
- 2360.** Zhong E, Scognamiglio T, D’Alfonso T, et al. Breast tumor resembling the tall cell variant of papillary thyroid carcinoma: molecular characterization by next-generation sequencing and histopathological comparison with tall cell papillary carcinoma of thyroid. *Int J Surg Pathol*. 2018 Sep 18:1066896918800779. PMID:30227763
- 2361.** Zhong F, Bi R, Yu B, et al. Carcinoma arising in microglandular adenosis of the breast: triple negative phenotype with variable morphology. *Int J Clin Exp Pathol*. 2014 Aug 15;7(9):6149–56. PMID:25337263
- 2362.** Zhong Q, Peng HL, Zhao X, et al. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. *Clin Cancer Res*. 2015 Jan 21;21(1):211–20. PMID:25348513
- 2363.** Zhou M, Wang X, Jiang L, et al. The diagnostic value of one step nucleic acid amplification (OSNA) in differentiating lymph node metastasis of tumors: a systematic review and meta-analysis. *Int J Surg*. 2018 Aug;56:49–56. PMID:29753955
- 2363A.** Zhou Z, Kinslow CJ, Hibshoosh H, et al. Clinical features, survival and prognostic factors of glycogen-rich clear cell carcinoma (GRCC) of the breast in the U.S. population. *J Clin Med*. 2019 Feb 14;8(2). PMID:30769905
- 2364.** Zhou ZR, Wang CC, Sun XJ, et al. Prognostic factors in breast phyllodes tumors: a nomogram based on a retrospective cohort study of 404 patients. *Cancer Med*. 2018 Apr;7(4):1030–42. PMID:29479819
- 2365.** Zhu D, Qian HS, Han HX, et al. An unusual magnetic resonance imaging of a giant cystic volume of tubular adenoma of the breast. *Breast J*. 2017 Mar;23(2):225–6. PMID:27868357
- 2366.** Zhu J, Ni G, Wang D, et al. Lobulated adenomyoepithelioma: a case report showing immunohistochemical profiles. *Int J Clin Exp Pathol*. 2015 Nov 1;8(11):15407–11. PMID:26823903
- 2367.** Zhu Y, Wu J, Zhang C, et al. BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis. *Oncotarget*. 2016 Oct 25;7(43):70113–27. PMID:27659521
- 2368.** Zimmerman A, Locke FL, Emole J, et al. Recurrent systemic anaplastic lymphoma kinase-negative anaplastic large cell lymphoma presenting as a breast implant-associated lesion. *Cancer Control*. 2015 Jul;22(3):369–73. PMID:26351895
- 2369.** Zucca-Matthes G, Urban C, Vallejo A. Anatomy of the nipple and breast ducts. *Gland Surg*. 2016 Feb;5(1):32–6. PMID:26855906

Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) 274, 293

Breast Cancer Association Consortium (BCAC) 274, 292

breastfeeding 35–36, 84, 271

breast implant-associated anaplastic large cell lymphoma (ALCL) 232, 234, 245–246

bromodipropylene 136

Burkitt lymphoma (BL) 232, 234, 242–244

C

C/EBP 226

CA125 262

cadherin 39, 69–73, 89, 103, 115–118, 120, 129, 138, 149, 137, 151–152, 234–265, 273, 286, 284–285

calponin 14–16, 18, 26, 28, 32, 34, 35, 46, 53, 76, 83, 85, 114, 119, 121, 124–125, 132, 134, 165, 169–170, 173–180, 191, 207, 211, 229, 273

CALCOOCO1 262

calretinin 39, 219

calponin 24, 31, 34, 39, 41, 40–50, 53, 94, 112, 143, 205, 207

calretinin 154